DDI-DrugBank.d577.s0
DDI-DrugBank.d577.s0.e0_DDI-DrugBank.d577.s0.e1 false in elderly patients concurrently receiving certain diuretics , primarily thiazides , an increased incidence of thrombopenia with purpura has been reported .
DDI-DrugBank.d633.s10
DDI-DrugBank.d575.s5
DDI-DrugBank.d575.s5.e0_DDI-DrugBank.d575.s5.e1 true an increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide .
DDI-DrugBank.d572.s30
DDI-DrugBank.d623.s2
DDI-DrugBank.d703.s1
DDI-DrugBank.d668.s3
DDI-DrugBank.d633.s6
DDI-DrugBank.d633.s6.e0_DDI-DrugBank.d633.s6.e1 false when concomitant administration of either of these two drugs with mexiletine is initiated , the dose of mexiletine should be slowly titrated to desired effect .
DDI-DrugBank.d782.s0
DDI-DrugBank.d782.s0.e0_DDI-DrugBank.d782.s0.e1 true vindesine can interact with the drugs of the following categories : - blood dyscrasia : can cause unpredictable myelotoxicity - bone marrow depressants : can cause a predictable dose-related myelotoxicity - radiation therapy : may cause marrow depression - neurotoxic medications : can cause neurologic toxicity - phenytoin : can increase seizure activity
DDI-DrugBank.d782.s0.e3_DDI-DrugBank.d782.s0.e4 false live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - mitomycin-c : may cause shortness of breath and bronchospasm - killed virus vaccines : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0.e3_DDI-DrugBank.d782.s0.e2 false live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - mitomycin-c : may cause shortness of breath and bronchospasm - killed virus vaccines : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0.e3_DDI-DrugBank.d782.s0.e5 false live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - mitomycin-c : may cause shortness of breath and bronchospasm - killed virus vaccines : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0.e3_DDI-DrugBank.d782.s0.e6 false live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - mitomycin-c : may cause shortness of breath and bronchospasm - killed virus vaccines : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0.e4_DDI-DrugBank.d782.s0.e2 false live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - mitomycin-c : may cause shortness of breath and bronchospasm - killed virus vaccines : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0.e4_DDI-DrugBank.d782.s0.e5 false live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - mitomycin-c : may cause shortness of breath and bronchospasm - killed virus vaccines : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0.e4_DDI-DrugBank.d782.s0.e6 false live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - mitomycin-c : may cause shortness of breath and bronchospasm - killed virus vaccines : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0.e2_DDI-DrugBank.d782.s0.e5 false live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - mitomycin-c : may cause shortness of breath and bronchospasm - killed virus vaccines : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0.e2_DDI-DrugBank.d782.s0.e6 false live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - mitomycin-c : may cause shortness of breath and bronchospasm - killed virus vaccines : may decrease patient 's response to the vaccine
DDI-DrugBank.d782.s0.e5_DDI-DrugBank.d782.s0.e6 false live virus vaccines : may potentiate the replication of the vaccine virus , may increase the side effects of the vaccination , and decrease patient 's response to the vaccine - mitomycin-c : may cause shortness of breath and bronchospasm - killed virus vaccines : may decrease patient 's response to the vaccine
DDI-DrugBank.d779.s15
DDI-DrugBank.d780.s0
DDI-DrugBank.d780.s0.e1_DDI-DrugBank.d780.s0.e4 false anticholinesterases : concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride .
DDI-DrugBank.d780.s0.e1_DDI-DrugBank.d780.s0.e0 false anticholinesterases : concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride .
DDI-DrugBank.d780.s0.e1_DDI-DrugBank.d780.s0.e2 true anticholinesterases : concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride .
DDI-DrugBank.d780.s0.e1_DDI-DrugBank.d780.s0.e3 false anticholinesterases : concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride .
DDI-DrugBank.d780.s0.e4_DDI-DrugBank.d780.s0.e0 false anticholinesterases : concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride .
DDI-DrugBank.d780.s0.e4_DDI-DrugBank.d780.s0.e2 false anticholinesterases : concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride .
DDI-DrugBank.d780.s0.e4_DDI-DrugBank.d780.s0.e3 false anticholinesterases : concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride .
DDI-DrugBank.d780.s0.e0_DDI-DrugBank.d780.s0.e2 false anticholinesterases : concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride .
DDI-DrugBank.d780.s0.e0_DDI-DrugBank.d780.s0.e3 false anticholinesterases : concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride .
DDI-DrugBank.d780.s0.e2_DDI-DrugBank.d780.s0.e3 false anticholinesterases : concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride .
DDI-DrugBank.d659.s5
DDI-DrugBank.d572.s27
DDI-DrugBank.d572.s27.e2_DDI-DrugBank.d572.s27.e0 false when zetia is administered with an hmg-coa reductase inhibitor in a woman of childbearing potential , refer to the pregnancy category and package labeling for the hmg-coa reductase inhibitor .
DDI-DrugBank.d572.s27.e2_DDI-DrugBank.d572.s27.e1 false when zetia is administered with an hmg-coa reductase inhibitor in a woman of childbearing potential , refer to the pregnancy category and package labeling for the hmg-coa reductase inhibitor .
DDI-DrugBank.d572.s27.e0_DDI-DrugBank.d572.s27.e1 false when zetia is administered with an hmg-coa reductase inhibitor in a woman of childbearing potential , refer to the pregnancy category and package labeling for the hmg-coa reductase inhibitor .
DDI-DrugBank.d761.s6
DDI-DrugBank.d761.s6.e0_DDI-DrugBank.d761.s6.e1 false glyburide : in 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days , orlistat did not alter the pharmacokinetics or pharmacodynamics ( blood glucose-lowering ) of glyburide .
DDI-DrugBank.d761.s6.e0_DDI-DrugBank.d761.s6.e2 false glyburide : in 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days , orlistat did not alter the pharmacokinetics or pharmacodynamics ( blood glucose-lowering ) of glyburide .
DDI-DrugBank.d761.s6.e0_DDI-DrugBank.d761.s6.e3 false glyburide : in 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days , orlistat did not alter the pharmacokinetics or pharmacodynamics ( blood glucose-lowering ) of glyburide .
DDI-DrugBank.d761.s6.e1_DDI-DrugBank.d761.s6.e2 false glyburide : in 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days , orlistat did not alter the pharmacokinetics or pharmacodynamics ( blood glucose-lowering ) of glyburide .
DDI-DrugBank.d761.s6.e1_DDI-DrugBank.d761.s6.e3 false glyburide : in 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days , orlistat did not alter the pharmacokinetics or pharmacodynamics ( blood glucose-lowering ) of glyburide .
DDI-DrugBank.d761.s6.e2_DDI-DrugBank.d761.s6.e3 false glyburide : in 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days , orlistat did not alter the pharmacokinetics or pharmacodynamics ( blood glucose-lowering ) of glyburide .
DDI-DrugBank.d746.s2
DDI-DrugBank.d709.s4
DDI-DrugBank.d709.s4.e0_DDI-DrugBank.d709.s4.e1 false - cisapride , pimozide : other drugs such as cisapride or pimozide , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials
DDI-DrugBank.d709.s4.e0_DDI-DrugBank.d709.s4.e2 false - cisapride , pimozide : other drugs such as cisapride or pimozide , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials
DDI-DrugBank.d709.s4.e0_DDI-DrugBank.d709.s4.e3 false - cisapride , pimozide : other drugs such as cisapride or pimozide , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials
DDI-DrugBank.d709.s4.e0_DDI-DrugBank.d709.s4.e4 false - cisapride , pimozide : other drugs such as cisapride or pimozide , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials
DDI-DrugBank.d709.s4.e1_DDI-DrugBank.d709.s4.e2 false - cisapride , pimozide : other drugs such as cisapride or pimozide , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials
DDI-DrugBank.d709.s4.e1_DDI-DrugBank.d709.s4.e3 false - cisapride , pimozide : other drugs such as cisapride or pimozide , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials
DDI-DrugBank.d709.s4.e1_DDI-DrugBank.d709.s4.e4 true - cisapride , pimozide : other drugs such as cisapride or pimozide , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials
DDI-DrugBank.d709.s4.e2_DDI-DrugBank.d709.s4.e3 false - cisapride , pimozide : other drugs such as cisapride or pimozide , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials
DDI-DrugBank.d709.s4.e2_DDI-DrugBank.d709.s4.e4 true - cisapride , pimozide : other drugs such as cisapride or pimozide , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials
DDI-DrugBank.d709.s4.e3_DDI-DrugBank.d709.s4.e4 false - cisapride , pimozide : other drugs such as cisapride or pimozide , which are metabolised by hepatic cyp3a isozymes have been associated with qt interval prolongation and/or cardiac arrythmias ( typically torsades de pointe ) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme , including some macrolide antibacterials
DDI-DrugBank.d604.s6
DDI-DrugBank.d752.s1
DDI-DrugBank.d752.s1.e0_DDI-DrugBank.d752.s1.e1 false drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1.e0_DDI-DrugBank.d752.s1.e2 false drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1.e0_DDI-DrugBank.d752.s1.e3 false drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1.e0_DDI-DrugBank.d752.s1.e4 false drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1.e0_DDI-DrugBank.d752.s1.e5 false drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1.e0_DDI-DrugBank.d752.s1.e6 true drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1.e1_DDI-DrugBank.d752.s1.e2 false drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1.e1_DDI-DrugBank.d752.s1.e3 false drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1.e1_DDI-DrugBank.d752.s1.e4 false drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1.e1_DDI-DrugBank.d752.s1.e5 false drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1.e1_DDI-DrugBank.d752.s1.e6 false drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1.e2_DDI-DrugBank.d752.s1.e3 false drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1.e2_DDI-DrugBank.d752.s1.e4 false drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1.e2_DDI-DrugBank.d752.s1.e5 false drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1.e2_DDI-DrugBank.d752.s1.e6 false drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1.e3_DDI-DrugBank.d752.s1.e4 false drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1.e3_DDI-DrugBank.d752.s1.e5 false drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1.e3_DDI-DrugBank.d752.s1.e6 false drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1.e4_DDI-DrugBank.d752.s1.e5 false drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1.e4_DDI-DrugBank.d752.s1.e6 false drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d752.s1.e5_DDI-DrugBank.d752.s1.e6 false drugs such as erythromycin , diltiazem , verapamil , ketoconazole , fluconazole and itraconazole were shown to significantly increase the c max and auc of orally administered midazolam .
DDI-DrugBank.d603.s6
DDI-DrugBank.d668.s5
DDI-DrugBank.d604.s5
DDI-DrugBank.d604.s5.e0_DDI-DrugBank.d604.s5.e1 true john 's wort with hormonal contraceptive agents may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies .
DDI-DrugBank.d775.s7
DDI-DrugBank.d732.s1
DDI-DrugBank.d623.s9
DDI-DrugBank.d769.s3
DDI-DrugBank.d763.s0
DDI-DrugBank.d761.s11
DDI-DrugBank.d761.s11.e0_DDI-DrugBank.d761.s11.e2 false warfarin : in 12 normal-weight subjects , administration of xenical 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics ( both r- and s-enantiomers ) or pharmacodynamics ( prothrombin time and serum factor vii ) .
DDI-DrugBank.d761.s11.e0_DDI-DrugBank.d761.s11.e1 false warfarin : in 12 normal-weight subjects , administration of xenical 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics ( both r- and s-enantiomers ) or pharmacodynamics ( prothrombin time and serum factor vii ) .
DDI-DrugBank.d761.s11.e2_DDI-DrugBank.d761.s11.e1 false warfarin : in 12 normal-weight subjects , administration of xenical 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics ( both r- and s-enantiomers ) or pharmacodynamics ( prothrombin time and serum factor vii ) .
DDI-DrugBank.d739.s6
DDI-DrugBank.d739.s6.e0_DDI-DrugBank.d739.s6.e1 false phenobarbital , which induces hepatic metabolism , decreased the auc of montelukast approximately 40 % following a single 10-mg dose of montelukast .
DDI-DrugBank.d739.s6.e0_DDI-DrugBank.d739.s6.e2 false phenobarbital , which induces hepatic metabolism , decreased the auc of montelukast approximately 40 % following a single 10-mg dose of montelukast .
DDI-DrugBank.d739.s6.e1_DDI-DrugBank.d739.s6.e2 false phenobarbital , which induces hepatic metabolism , decreased the auc of montelukast approximately 40 % following a single 10-mg dose of montelukast .
DDI-DrugBank.d775.s6
DDI-DrugBank.d599.s8
DDI-DrugBank.d773.s3
DDI-DrugBank.d637.s3
DDI-DrugBank.d781.s15
DDI-DrugBank.d781.s15.e1_DDI-DrugBank.d781.s15.e0 false : oral administration of aceon tablets with food does not significantly lower the rate or extent of perindopril absorption relative to the fasted state .
DDI-DrugBank.d717.s0
DDI-DrugBank.d717.s0.e0_DDI-DrugBank.d717.s0.e1 true mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction , leading to an increase in dosage requirements for warfarin .
DDI-DrugBank.d717.s0.e0_DDI-DrugBank.d717.s0.e2 false mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction , leading to an increase in dosage requirements for warfarin .
DDI-DrugBank.d717.s0.e1_DDI-DrugBank.d717.s0.e2 false mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction , leading to an increase in dosage requirements for warfarin .
DDI-DrugBank.d727.s0
DDI-DrugBank.d727.s0.e0_DDI-DrugBank.d727.s0.e1 true zidovudine competitively inhibits the intracellular phosphorylation of stavudine .
DDI-DrugBank.d651.s0
DDI-DrugBank.d651.s0.e0_DDI-DrugBank.d651.s0.e1 true drug interactions : women on oral contraceptives have shown a significant increase in plasma vitamin a levels .
DDI-DrugBank.d597.s6
DDI-DrugBank.d597.s6.e0_DDI-DrugBank.d597.s6.e1 false mobic is not a substitute for aspirin for cardiovascular prophylaxis .
DDI-DrugBank.d577.s5
DDI-DrugBank.d752.s0
DDI-DrugBank.d752.s0.e0_DDI-DrugBank.d752.s0.e1 true drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system ( ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics ) .
DDI-DrugBank.d752.s0.e0_DDI-DrugBank.d752.s0.e2 true drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system ( ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics ) .
DDI-DrugBank.d752.s0.e0_DDI-DrugBank.d752.s0.e3 true drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system ( ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics ) .
DDI-DrugBank.d752.s0.e0_DDI-DrugBank.d752.s0.e4 true drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system ( ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics ) .
DDI-DrugBank.d752.s0.e1_DDI-DrugBank.d752.s0.e2 false drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system ( ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics ) .
DDI-DrugBank.d752.s0.e1_DDI-DrugBank.d752.s0.e3 false drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system ( ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics ) .
DDI-DrugBank.d752.s0.e1_DDI-DrugBank.d752.s0.e4 false drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system ( ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics ) .
DDI-DrugBank.d752.s0.e2_DDI-DrugBank.d752.s0.e3 false drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system ( ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics ) .
DDI-DrugBank.d752.s0.e2_DDI-DrugBank.d752.s0.e4 false drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system ( ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics ) .
DDI-DrugBank.d752.s0.e3_DDI-DrugBank.d752.s0.e4 false drug interactions : inhibitors of cyp3a4 isozymes : caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome p450 3a4 enzyme system ( ie , some drugs in the drug classes of azole antimycotics , protease inhibitors , calcium channel antagonists , and macrolide antibiotics ) .
DDI-DrugBank.d676.s4
DDI-DrugBank.d676.s4.e0_DDI-DrugBank.d676.s4.e1 false no cross-resistance with other chemotherapeutic agents , radiotherapy or steroids has been demonstrated .
DDI-DrugBank.d747.s0
DDI-DrugBank.d747.s0.e2_DDI-DrugBank.d747.s0.e0 false tetracycline , a bacteriostatic antibiotic , may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided .
DDI-DrugBank.d747.s0.e2_DDI-DrugBank.d747.s0.e1 false tetracycline , a bacteriostatic antibiotic , may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided .
DDI-DrugBank.d747.s0.e0_DDI-DrugBank.d747.s0.e1 false tetracycline , a bacteriostatic antibiotic , may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided .
DDI-DrugBank.d622.s1
DDI-DrugBank.d622.s1.e0_DDI-DrugBank.d622.s1.e1 false this is especially true if the total dose of atropine has been large and the administration of pralidoxime has been delayed .
DDI-DrugBank.d776.s1
DDI-DrugBank.d577.s4
DDI-DrugBank.d577.s4.e0_DDI-DrugBank.d577.s4.e1 true at a 1.6-g dose , sulfamethoxazole produced a slight but significant increase in the half-life of phenytoin but did not produce a corresponding decrease in the metabolic clearance rate .
DDI-DrugBank.d603.s1
DDI-DrugBank.d741.s3
DDI-DrugBank.d630.s1
DDI-DrugBank.d630.s1.e1_DDI-DrugBank.d630.s1.e0 false caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors .
DDI-DrugBank.d630.s1.e1_DDI-DrugBank.d630.s1.e2 false caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors .
DDI-DrugBank.d630.s1.e1_DDI-DrugBank.d630.s1.e3 false caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors .
DDI-DrugBank.d630.s1.e0_DDI-DrugBank.d630.s1.e2 false caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors .
DDI-DrugBank.d630.s1.e0_DDI-DrugBank.d630.s1.e3 false caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors .
DDI-DrugBank.d630.s1.e2_DDI-DrugBank.d630.s1.e3 true caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly , as anorexia , tachypnea , lethargy , coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors .
DDI-DrugBank.d680.s2
DDI-DrugBank.d596.s8
DDI-DrugBank.d596.s8.e0_DDI-DrugBank.d596.s8.e1 false use with anticholinergics : because of their mechanism of action , cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications.
DDI-DrugBank.d596.s8.e0_DDI-DrugBank.d596.s8.e2 false use with anticholinergics : because of their mechanism of action , cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications.
DDI-DrugBank.d596.s8.e1_DDI-DrugBank.d596.s8.e2 true use with anticholinergics : because of their mechanism of action , cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications.
DDI-DrugBank.d727.s3
DDI-DrugBank.d671.s0
DDI-DrugBank.d671.s0.e1_DDI-DrugBank.d671.s0.e0 false the interaction of cylert ( pemoline ) with other drugs has not been studied in humans .
DDI-DrugBank.d654.s1
DDI-DrugBank.d654.s1.e0_DDI-DrugBank.d654.s1.e1 false due to low systemic exposure to retapamulin following topical application in patients , dosage adjustments for retapamulin are unnecessary when co-administered with cyp3a4 inhibitors , such as ketoconazole .
DDI-DrugBank.d654.s1.e0_DDI-DrugBank.d654.s1.e2 false due to low systemic exposure to retapamulin following topical application in patients , dosage adjustments for retapamulin are unnecessary when co-administered with cyp3a4 inhibitors , such as ketoconazole .
DDI-DrugBank.d654.s1.e1_DDI-DrugBank.d654.s1.e2 false due to low systemic exposure to retapamulin following topical application in patients , dosage adjustments for retapamulin are unnecessary when co-administered with cyp3a4 inhibitors , such as ketoconazole .
DDI-DrugBank.d578.s1
DDI-DrugBank.d578.s1.e0_DDI-DrugBank.d578.s1.e1 true mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone ;
DDI-DrugBank.d600.s1
DDI-DrugBank.d600.s1.e0_DDI-DrugBank.d600.s1.e2 true concurrent use of alcohol and other cns depression-producing drugs may increase the cns depressant effects of methyprylon or these other medications.
DDI-DrugBank.d600.s1.e0_DDI-DrugBank.d600.s1.e1 false concurrent use of alcohol and other cns depression-producing drugs may increase the cns depressant effects of methyprylon or these other medications.
DDI-DrugBank.d600.s1.e2_DDI-DrugBank.d600.s1.e1 false concurrent use of alcohol and other cns depression-producing drugs may increase the cns depressant effects of methyprylon or these other medications.
DDI-DrugBank.d776.s10
DDI-DrugBank.d776.s10.e0_DDI-DrugBank.d776.s10.e2 false phenytoin : diflucan increases the plasma concentrations of phenytoin .
DDI-DrugBank.d776.s10.e0_DDI-DrugBank.d776.s10.e1 false phenytoin : diflucan increases the plasma concentrations of phenytoin .
DDI-DrugBank.d776.s10.e2_DDI-DrugBank.d776.s10.e1 false phenytoin : diflucan increases the plasma concentrations of phenytoin .
DDI-DrugBank.d735.s0
DDI-DrugBank.d735.s0.e1_DDI-DrugBank.d735.s0.e2 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e1_DDI-DrugBank.d735.s0.e3 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e1_DDI-DrugBank.d735.s0.e4 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e1_DDI-DrugBank.d735.s0.e5 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e1_DDI-DrugBank.d735.s0.e6 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e1_DDI-DrugBank.d735.s0.e7 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e1_DDI-DrugBank.d735.s0.e8 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e1_DDI-DrugBank.d735.s0.e9 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e1_DDI-DrugBank.d735.s0.e0 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e2_DDI-DrugBank.d735.s0.e3 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e2_DDI-DrugBank.d735.s0.e4 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e2_DDI-DrugBank.d735.s0.e5 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e2_DDI-DrugBank.d735.s0.e6 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e2_DDI-DrugBank.d735.s0.e7 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e2_DDI-DrugBank.d735.s0.e8 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e2_DDI-DrugBank.d735.s0.e9 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e2_DDI-DrugBank.d735.s0.e0 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e3_DDI-DrugBank.d735.s0.e4 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e3_DDI-DrugBank.d735.s0.e5 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e3_DDI-DrugBank.d735.s0.e6 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e3_DDI-DrugBank.d735.s0.e7 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e3_DDI-DrugBank.d735.s0.e8 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e3_DDI-DrugBank.d735.s0.e9 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e3_DDI-DrugBank.d735.s0.e0 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e4_DDI-DrugBank.d735.s0.e5 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e4_DDI-DrugBank.d735.s0.e6 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e4_DDI-DrugBank.d735.s0.e7 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e4_DDI-DrugBank.d735.s0.e8 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e4_DDI-DrugBank.d735.s0.e9 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e4_DDI-DrugBank.d735.s0.e0 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e5_DDI-DrugBank.d735.s0.e6 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e5_DDI-DrugBank.d735.s0.e7 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e5_DDI-DrugBank.d735.s0.e8 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e5_DDI-DrugBank.d735.s0.e9 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e5_DDI-DrugBank.d735.s0.e0 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e6_DDI-DrugBank.d735.s0.e7 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e6_DDI-DrugBank.d735.s0.e8 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e6_DDI-DrugBank.d735.s0.e9 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e6_DDI-DrugBank.d735.s0.e0 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e7_DDI-DrugBank.d735.s0.e8 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e7_DDI-DrugBank.d735.s0.e9 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e7_DDI-DrugBank.d735.s0.e0 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e8_DDI-DrugBank.d735.s0.e9 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e8_DDI-DrugBank.d735.s0.e0 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d735.s0.e9_DDI-DrugBank.d735.s0.e0 false a total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between mycamine and mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , sirolimus , nifedipine , fluconazole , ritonavir , and rifampin .
DDI-DrugBank.d666.s2
DDI-DrugBank.d666.s2.e0_DDI-DrugBank.d666.s2.e2 false pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions .
DDI-DrugBank.d666.s2.e0_DDI-DrugBank.d666.s2.e3 false pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions .
DDI-DrugBank.d666.s2.e0_DDI-DrugBank.d666.s2.e4 false pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions .
DDI-DrugBank.d666.s2.e0_DDI-DrugBank.d666.s2.e1 false pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions .
DDI-DrugBank.d666.s2.e2_DDI-DrugBank.d666.s2.e3 false pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions .
DDI-DrugBank.d666.s2.e2_DDI-DrugBank.d666.s2.e4 false pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions .
DDI-DrugBank.d666.s2.e2_DDI-DrugBank.d666.s2.e1 false pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions .
DDI-DrugBank.d666.s2.e3_DDI-DrugBank.d666.s2.e4 false pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions .
DDI-DrugBank.d666.s2.e3_DDI-DrugBank.d666.s2.e1 false pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions .
DDI-DrugBank.d666.s2.e4_DDI-DrugBank.d666.s2.e1 false pindolol has been used with a variety of antihypertensive agents , including hydrochlorothiazide , hydralazine , and guanethidine without unexpected adverse interactions .
DDI-DrugBank.d623.s1
DDI-DrugBank.d623.s1.e0_DDI-DrugBank.d623.s1.e2 false aminoglutethimide administered concomitantly with depo-subq provera 104 may significantly decrease the serum concentrations of mpa .
DDI-DrugBank.d623.s1.e0_DDI-DrugBank.d623.s1.e1 true aminoglutethimide administered concomitantly with depo-subq provera 104 may significantly decrease the serum concentrations of mpa .
DDI-DrugBank.d623.s1.e2_DDI-DrugBank.d623.s1.e1 false aminoglutethimide administered concomitantly with depo-subq provera 104 may significantly decrease the serum concentrations of mpa .
DDI-DrugBank.d579.s0
DDI-DrugBank.d579.s0.e0_DDI-DrugBank.d579.s0.e1 false patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers .
DDI-DrugBank.d579.s0.e0_DDI-DrugBank.d579.s0.e2 true patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers .
DDI-DrugBank.d579.s0.e1_DDI-DrugBank.d579.s0.e2 true patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers .
DDI-DrugBank.d726.s3
DDI-DrugBank.d726.s3.e1_DDI-DrugBank.d726.s3.e2 true drugs that impair intestinal absorption of fat-soluble vitamins , such as cholestyramine , may interfere with the absorption of zemplar capsules .
DDI-DrugBank.d726.s3.e1_DDI-DrugBank.d726.s3.e0 false drugs that impair intestinal absorption of fat-soluble vitamins , such as cholestyramine , may interfere with the absorption of zemplar capsules .
DDI-DrugBank.d726.s3.e2_DDI-DrugBank.d726.s3.e0 false drugs that impair intestinal absorption of fat-soluble vitamins , such as cholestyramine , may interfere with the absorption of zemplar capsules .
DDI-DrugBank.d781.s1
DDI-DrugBank.d781.s1.e1_DDI-DrugBank.d781.s1.e0 false the possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with perindopril .
DDI-DrugBank.d670.s0
DDI-DrugBank.d670.s0.e1_DDI-DrugBank.d670.s0.e0 false potential for invega to affect other drugs paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome p450 isozymes .
DDI-DrugBank.d779.s10
DDI-DrugBank.d659.s6
DDI-DrugBank.d572.s13
DDI-DrugBank.d746.s0
DDI-DrugBank.d746.s0.e0_DDI-DrugBank.d746.s0.e1 false aramine should be used with caution in digitalized patients , since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias .
DDI-DrugBank.d746.s0.e0_DDI-DrugBank.d746.s0.e2 false aramine should be used with caution in digitalized patients , since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias .
DDI-DrugBank.d746.s0.e1_DDI-DrugBank.d746.s0.e2 true aramine should be used with caution in digitalized patients , since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias .
DDI-DrugBank.d639.s6
DDI-DrugBank.d675.s4
DDI-DrugBank.d675.s4.e0_DDI-DrugBank.d675.s4.e1 false less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4.e0_DDI-DrugBank.d675.s4.e2 false less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4.e0_DDI-DrugBank.d675.s4.e3 false less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4.e0_DDI-DrugBank.d675.s4.e4 false less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4.e0_DDI-DrugBank.d675.s4.e5 false less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4.e0_DDI-DrugBank.d675.s4.e6 false less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4.e1_DDI-DrugBank.d675.s4.e2 false less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4.e1_DDI-DrugBank.d675.s4.e3 false less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4.e1_DDI-DrugBank.d675.s4.e4 false less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4.e1_DDI-DrugBank.d675.s4.e5 false less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4.e1_DDI-DrugBank.d675.s4.e6 false less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4.e2_DDI-DrugBank.d675.s4.e3 false less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4.e2_DDI-DrugBank.d675.s4.e4 false less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4.e2_DDI-DrugBank.d675.s4.e5 false less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4.e2_DDI-DrugBank.d675.s4.e6 false less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4.e3_DDI-DrugBank.d675.s4.e4 false less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4.e3_DDI-DrugBank.d675.s4.e5 false less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4.e3_DDI-DrugBank.d675.s4.e6 false less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4.e4_DDI-DrugBank.d675.s4.e5 false less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4.e4_DDI-DrugBank.d675.s4.e6 false less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d675.s4.e5_DDI-DrugBank.d675.s4.e6 false less potent inhibitors include saquinavir , nefazodone , fluconazole , grapefruit juice , fluoxetine , fluvoxamine , zileuton , and clotrimazole .
DDI-DrugBank.d654.s0
DDI-DrugBank.d654.s0.e0_DDI-DrugBank.d654.s0.e1 false co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean auc(0 - 24 ) and cmax by 81 % after topical application of retapamulin ointment , 1 % on the abraded skin of healthy adult males .
DDI-DrugBank.d654.s0.e0_DDI-DrugBank.d654.s0.e2 true co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean auc(0 - 24 ) and cmax by 81 % after topical application of retapamulin ointment , 1 % on the abraded skin of healthy adult males .
DDI-DrugBank.d654.s0.e1_DDI-DrugBank.d654.s0.e2 false co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean auc(0 - 24 ) and cmax by 81 % after topical application of retapamulin ointment , 1 % on the abraded skin of healthy adult males .
DDI-DrugBank.d590.s1
DDI-DrugBank.d590.s1.e0_DDI-DrugBank.d590.s1.e1 false coadministration with aspirin results in a slight decrease in the rate of salicylate absorption that is clinically unimportant .
DDI-DrugBank.d670.s10
DDI-DrugBank.d704.s2
DDI-DrugBank.d704.s2.e0_DDI-DrugBank.d704.s2.e1 false the pharmacokinetic interaction between cimetidine and flomax capsules was investigated .
DDI-DrugBank.d775.s11
DDI-DrugBank.d775.s11.e0_DDI-DrugBank.d775.s11.e1 true the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase .
DDI-DrugBank.d775.s11.e0_DDI-DrugBank.d775.s11.e2 true the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase .
DDI-DrugBank.d775.s11.e0_DDI-DrugBank.d775.s11.e3 true the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase .
DDI-DrugBank.d775.s11.e1_DDI-DrugBank.d775.s11.e2 false the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase .
DDI-DrugBank.d775.s11.e1_DDI-DrugBank.d775.s11.e3 false the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase .
DDI-DrugBank.d775.s11.e2_DDI-DrugBank.d775.s11.e3 false the neuromuscular blocking effect of mivacron may be enhanced by drugs that reduce plasma cholinesterase activity ( e.g. , chronically administered oral contraceptives , glucocorticoids , or certain monoamine oxidase inhibitors ) or by drugs that irreversibly inhibit plasma cholinesterase .
DDI-DrugBank.d775.s11.e5_DDI-DrugBank.d775.s11.e6 false resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine .
DDI-DrugBank.d775.s11.e5_DDI-DrugBank.d775.s11.e4 false resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine .
DDI-DrugBank.d775.s11.e6_DDI-DrugBank.d775.s11.e4 false resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine .
DDI-DrugBank.d700.s0
DDI-DrugBank.d700.s0.e2_DDI-DrugBank.d700.s0.e3 false antacids : absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids ( 30 ml ): the mean cmax and auc(0-t ) values for mpa were 25 % and 37 % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.e2_DDI-DrugBank.d700.s0.e1 false antacids : absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids ( 30 ml ): the mean cmax and auc(0-t ) values for mpa were 25 % and 37 % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.e2_DDI-DrugBank.d700.s0.e5 false antacids : absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids ( 30 ml ): the mean cmax and auc(0-t ) values for mpa were 25 % and 37 % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.e2_DDI-DrugBank.d700.s0.e0 false antacids : absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids ( 30 ml ): the mean cmax and auc(0-t ) values for mpa were 25 % and 37 % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.e2_DDI-DrugBank.d700.s0.e4 false antacids : absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids ( 30 ml ): the mean cmax and auc(0-t ) values for mpa were 25 % and 37 % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.e3_DDI-DrugBank.d700.s0.e1 false antacids : absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids ( 30 ml ): the mean cmax and auc(0-t ) values for mpa were 25 % and 37 % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.e3_DDI-DrugBank.d700.s0.e5 false antacids : absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids ( 30 ml ): the mean cmax and auc(0-t ) values for mpa were 25 % and 37 % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.e3_DDI-DrugBank.d700.s0.e0 false antacids : absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids ( 30 ml ): the mean cmax and auc(0-t ) values for mpa were 25 % and 37 % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.e3_DDI-DrugBank.d700.s0.e4 false antacids : absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids ( 30 ml ): the mean cmax and auc(0-t ) values for mpa were 25 % and 37 % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.e1_DDI-DrugBank.d700.s0.e5 false antacids : absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids ( 30 ml ): the mean cmax and auc(0-t ) values for mpa were 25 % and 37 % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.e1_DDI-DrugBank.d700.s0.e0 false antacids : absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids ( 30 ml ): the mean cmax and auc(0-t ) values for mpa were 25 % and 37 % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.e1_DDI-DrugBank.d700.s0.e4 false antacids : absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids ( 30 ml ): the mean cmax and auc(0-t ) values for mpa were 25 % and 37 % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.e5_DDI-DrugBank.d700.s0.e0 false antacids : absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids ( 30 ml ): the mean cmax and auc(0-t ) values for mpa were 25 % and 37 % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.e5_DDI-DrugBank.d700.s0.e4 false antacids : absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids ( 30 ml ): the mean cmax and auc(0-t ) values for mpa were 25 % and 37 % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d700.s0.e0_DDI-DrugBank.d700.s0.e4 false antacids : absorption of a single dose of myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids ( 30 ml ): the mean cmax and auc(0-t ) values for mpa were 25 % and 37 % lower , respectively , than when myfortic was administered alone under fasting conditions .
DDI-DrugBank.d742.s1
DDI-DrugBank.d605.s0
DDI-DrugBank.d605.s0.e1_DDI-DrugBank.d605.s0.e0 false skelaxin may enhance the effects of alcohol , barbiturates and other cns depressants .
DDI-DrugBank.d605.s0.e1_DDI-DrugBank.d605.s0.e2 false skelaxin may enhance the effects of alcohol , barbiturates and other cns depressants .
DDI-DrugBank.d605.s0.e1_DDI-DrugBank.d605.s0.e3 false skelaxin may enhance the effects of alcohol , barbiturates and other cns depressants .
DDI-DrugBank.d605.s0.e0_DDI-DrugBank.d605.s0.e2 true skelaxin may enhance the effects of alcohol , barbiturates and other cns depressants .
DDI-DrugBank.d605.s0.e0_DDI-DrugBank.d605.s0.e3 true skelaxin may enhance the effects of alcohol , barbiturates and other cns depressants .
DDI-DrugBank.d605.s0.e2_DDI-DrugBank.d605.s0.e3 false skelaxin may enhance the effects of alcohol , barbiturates and other cns depressants .
DDI-DrugBank.d736.s7
DDI-DrugBank.d736.s7.e0_DDI-DrugBank.d736.s7.e1 true thiazides may add to or potentiate the action of other antihypertensive drugs .
DDI-DrugBank.d577.s6
DDI-DrugBank.d577.s6.e1_DDI-DrugBank.d577.s6.e2 false sulfonamides can also displace methotrexate from plasma protein-binding sites , thus increasing free methotrexate concentrations .
DDI-DrugBank.d577.s6.e1_DDI-DrugBank.d577.s6.e0 false sulfonamides can also displace methotrexate from plasma protein-binding sites , thus increasing free methotrexate concentrations .
DDI-DrugBank.d577.s6.e2_DDI-DrugBank.d577.s6.e0 false sulfonamides can also displace methotrexate from plasma protein-binding sites , thus increasing free methotrexate concentrations .
DDI-DrugBank.d752.s8
DDI-DrugBank.d761.s2
DDI-DrugBank.d761.s2.e0_DDI-DrugBank.d761.s2.e3 false digoxin : in 12 normal-weight subjects receiving xenical 120 mg three times a day for 6 days , xenical did not alter the pharmacokinetics of a single dose of digoxin .
DDI-DrugBank.d761.s2.e0_DDI-DrugBank.d761.s2.e1 false digoxin : in 12 normal-weight subjects receiving xenical 120 mg three times a day for 6 days , xenical did not alter the pharmacokinetics of a single dose of digoxin .
DDI-DrugBank.d761.s2.e0_DDI-DrugBank.d761.s2.e2 false digoxin : in 12 normal-weight subjects receiving xenical 120 mg three times a day for 6 days , xenical did not alter the pharmacokinetics of a single dose of digoxin .
DDI-DrugBank.d761.s2.e3_DDI-DrugBank.d761.s2.e1 false digoxin : in 12 normal-weight subjects receiving xenical 120 mg three times a day for 6 days , xenical did not alter the pharmacokinetics of a single dose of digoxin .
DDI-DrugBank.d761.s2.e3_DDI-DrugBank.d761.s2.e2 false digoxin : in 12 normal-weight subjects receiving xenical 120 mg three times a day for 6 days , xenical did not alter the pharmacokinetics of a single dose of digoxin .
DDI-DrugBank.d761.s2.e1_DDI-DrugBank.d761.s2.e2 false digoxin : in 12 normal-weight subjects receiving xenical 120 mg three times a day for 6 days , xenical did not alter the pharmacokinetics of a single dose of digoxin .
DDI-DrugBank.d670.s5
DDI-DrugBank.d721.s1
DDI-DrugBank.d721.s1.e0_DDI-DrugBank.d721.s1.e1 true aspirin may decrease bioavailability of skelid by up to 50 % when taken 2 hours after skelid .
DDI-DrugBank.d721.s1.e0_DDI-DrugBank.d721.s1.e2 false aspirin may decrease bioavailability of skelid by up to 50 % when taken 2 hours after skelid .
DDI-DrugBank.d721.s1.e1_DDI-DrugBank.d721.s1.e2 false aspirin may decrease bioavailability of skelid by up to 50 % when taken 2 hours after skelid .
DDI-DrugBank.d688.s3
DDI-DrugBank.d688.s3.e0_DDI-DrugBank.d688.s3.e1 false the effects of indinavir , zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied .
DDI-DrugBank.d688.s3.e0_DDI-DrugBank.d688.s3.e2 false the effects of indinavir , zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied .
DDI-DrugBank.d688.s3.e0_DDI-DrugBank.d688.s3.e3 false the effects of indinavir , zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied .
DDI-DrugBank.d688.s3.e1_DDI-DrugBank.d688.s3.e2 false the effects of indinavir , zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied .
DDI-DrugBank.d688.s3.e1_DDI-DrugBank.d688.s3.e3 false the effects of indinavir , zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied .
DDI-DrugBank.d688.s3.e2_DDI-DrugBank.d688.s3.e3 false the effects of indinavir , zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied .
DDI-DrugBank.d766.s0
DDI-DrugBank.d766.s0.e0_DDI-DrugBank.d766.s0.e1 false since trimetrexate is metabolized by a p450 enzyme system , drugs that induce or inhibit this drug metabolizing enzyme system may elicit important drug-drug interactions that may alter trimetrexate plasma concentrations .
DDI-DrugBank.d572.s32
DDI-DrugBank.d771.s1
DDI-DrugBank.d771.s1.e0_DDI-DrugBank.d771.s1.e3 true scopolamine should be used with care in patients taking other drugs that are capable of causing cns effects such as sedatives , tranquilizers , or alcohol .
DDI-DrugBank.d771.s1.e0_DDI-DrugBank.d771.s1.e1 true scopolamine should be used with care in patients taking other drugs that are capable of causing cns effects such as sedatives , tranquilizers , or alcohol .
DDI-DrugBank.d771.s1.e0_DDI-DrugBank.d771.s1.e2 true scopolamine should be used with care in patients taking other drugs that are capable of causing cns effects such as sedatives , tranquilizers , or alcohol .
DDI-DrugBank.d771.s1.e3_DDI-DrugBank.d771.s1.e1 false scopolamine should be used with care in patients taking other drugs that are capable of causing cns effects such as sedatives , tranquilizers , or alcohol .
DDI-DrugBank.d771.s1.e3_DDI-DrugBank.d771.s1.e2 false scopolamine should be used with care in patients taking other drugs that are capable of causing cns effects such as sedatives , tranquilizers , or alcohol .
DDI-DrugBank.d771.s1.e1_DDI-DrugBank.d771.s1.e2 false scopolamine should be used with care in patients taking other drugs that are capable of causing cns effects such as sedatives , tranquilizers , or alcohol .
DDI-DrugBank.d744.s1
DDI-DrugBank.d744.s1.e1_DDI-DrugBank.d744.s1.e0 false in clinical studies , patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate igf-i suppression compared with patients not receiving opioids .
DDI-DrugBank.d744.s1.e1_DDI-DrugBank.d744.s1.e2 false in clinical studies , patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate igf-i suppression compared with patients not receiving opioids .
DDI-DrugBank.d744.s1.e0_DDI-DrugBank.d744.s1.e2 false in clinical studies , patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate igf-i suppression compared with patients not receiving opioids .
DDI-DrugBank.d676.s3
DDI-DrugBank.d776.s5
DDI-DrugBank.d776.s5.e0_DDI-DrugBank.d776.s5.e1 true when diflucan is used concomitantly with these or other sulfonylurea oral hypoglycemic agents , blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary .
DDI-DrugBank.d776.s5.e0_DDI-DrugBank.d776.s5.e2 false when diflucan is used concomitantly with these or other sulfonylurea oral hypoglycemic agents , blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary .
DDI-DrugBank.d776.s5.e1_DDI-DrugBank.d776.s5.e2 false when diflucan is used concomitantly with these or other sulfonylurea oral hypoglycemic agents , blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary .
DDI-DrugBank.d645.s2
DDI-DrugBank.d645.s2.e0_DDI-DrugBank.d645.s2.e1 false this may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as tricyclic antidepressants , -blockers , selective serotonin reuptake inhibitors ( ssris ) , and monoamine oxidase inhibitors ( mao-is ) type b , if they have a narrow therapeutic window .
DDI-DrugBank.d645.s2.e0_DDI-DrugBank.d645.s2.e2 false this may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as tricyclic antidepressants , -blockers , selective serotonin reuptake inhibitors ( ssris ) , and monoamine oxidase inhibitors ( mao-is ) type b , if they have a narrow therapeutic window .
DDI-DrugBank.d645.s2.e0_DDI-DrugBank.d645.s2.e3 false this may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as tricyclic antidepressants , -blockers , selective serotonin reuptake inhibitors ( ssris ) , and monoamine oxidase inhibitors ( mao-is ) type b , if they have a narrow therapeutic window .
DDI-DrugBank.d645.s2.e1_DDI-DrugBank.d645.s2.e2 false this may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as tricyclic antidepressants , -blockers , selective serotonin reuptake inhibitors ( ssris ) , and monoamine oxidase inhibitors ( mao-is ) type b , if they have a narrow therapeutic window .
DDI-DrugBank.d645.s2.e1_DDI-DrugBank.d645.s2.e3 false this may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as tricyclic antidepressants , -blockers , selective serotonin reuptake inhibitors ( ssris ) , and monoamine oxidase inhibitors ( mao-is ) type b , if they have a narrow therapeutic window .
DDI-DrugBank.d645.s2.e2_DDI-DrugBank.d645.s2.e3 false this may be of clinical relevance for compounds predominantly metabolized by this enzyme , such as tricyclic antidepressants , -blockers , selective serotonin reuptake inhibitors ( ssris ) , and monoamine oxidase inhibitors ( mao-is ) type b , if they have a narrow therapeutic window .
DDI-DrugBank.d753.s0
DDI-DrugBank.d753.s0.e9_DDI-DrugBank.d753.s0.e0 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e9_DDI-DrugBank.d753.s0.e1 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e9_DDI-DrugBank.d753.s0.e2 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e9_DDI-DrugBank.d753.s0.e3 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e9_DDI-DrugBank.d753.s0.e4 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e9_DDI-DrugBank.d753.s0.e5 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e9_DDI-DrugBank.d753.s0.e6 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e9_DDI-DrugBank.d753.s0.e7 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e9_DDI-DrugBank.d753.s0.e8 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e0_DDI-DrugBank.d753.s0.e1 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e0_DDI-DrugBank.d753.s0.e2 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e0_DDI-DrugBank.d753.s0.e3 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e0_DDI-DrugBank.d753.s0.e4 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e0_DDI-DrugBank.d753.s0.e5 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e0_DDI-DrugBank.d753.s0.e6 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e0_DDI-DrugBank.d753.s0.e7 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e0_DDI-DrugBank.d753.s0.e8 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e1_DDI-DrugBank.d753.s0.e2 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e1_DDI-DrugBank.d753.s0.e3 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e1_DDI-DrugBank.d753.s0.e4 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e1_DDI-DrugBank.d753.s0.e5 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e1_DDI-DrugBank.d753.s0.e6 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e1_DDI-DrugBank.d753.s0.e7 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e1_DDI-DrugBank.d753.s0.e8 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e2_DDI-DrugBank.d753.s0.e3 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e2_DDI-DrugBank.d753.s0.e4 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e2_DDI-DrugBank.d753.s0.e5 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e2_DDI-DrugBank.d753.s0.e6 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e2_DDI-DrugBank.d753.s0.e7 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e2_DDI-DrugBank.d753.s0.e8 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e3_DDI-DrugBank.d753.s0.e4 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e3_DDI-DrugBank.d753.s0.e5 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e3_DDI-DrugBank.d753.s0.e6 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e3_DDI-DrugBank.d753.s0.e7 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e3_DDI-DrugBank.d753.s0.e8 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e4_DDI-DrugBank.d753.s0.e5 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e4_DDI-DrugBank.d753.s0.e6 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e4_DDI-DrugBank.d753.s0.e7 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e4_DDI-DrugBank.d753.s0.e8 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e5_DDI-DrugBank.d753.s0.e6 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e5_DDI-DrugBank.d753.s0.e7 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e5_DDI-DrugBank.d753.s0.e8 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e6_DDI-DrugBank.d753.s0.e7 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e6_DDI-DrugBank.d753.s0.e8 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d753.s0.e7_DDI-DrugBank.d753.s0.e8 false the concomitant use of other cns depressants including sedatives , hypnotics , tranquilizers , general anesthetics , phenothiazines , other opioids , tricyclic antidepressants , monoamine oxidase ( mao ) inhibitors , and alcohol may produce additive cns depressant effects .
DDI-DrugBank.d779.s11
DDI-DrugBank.d761.s5
DDI-DrugBank.d761.s5.e0_DDI-DrugBank.d761.s5.e1 false the effect of orlistat on the absorption of supplemental vitamin d , vitamin a , and nutritionally-derived vitamin k is not known at this time .
DDI-DrugBank.d761.s5.e0_DDI-DrugBank.d761.s5.e2 false the effect of orlistat on the absorption of supplemental vitamin d , vitamin a , and nutritionally-derived vitamin k is not known at this time .
DDI-DrugBank.d761.s5.e0_DDI-DrugBank.d761.s5.e3 false the effect of orlistat on the absorption of supplemental vitamin d , vitamin a , and nutritionally-derived vitamin k is not known at this time .
DDI-DrugBank.d761.s5.e1_DDI-DrugBank.d761.s5.e2 false the effect of orlistat on the absorption of supplemental vitamin d , vitamin a , and nutritionally-derived vitamin k is not known at this time .
DDI-DrugBank.d761.s5.e1_DDI-DrugBank.d761.s5.e3 false the effect of orlistat on the absorption of supplemental vitamin d , vitamin a , and nutritionally-derived vitamin k is not known at this time .
DDI-DrugBank.d761.s5.e2_DDI-DrugBank.d761.s5.e3 false the effect of orlistat on the absorption of supplemental vitamin d , vitamin a , and nutritionally-derived vitamin k is not known at this time .
DDI-DrugBank.d633.s18
DDI-DrugBank.d633.s18.e1_DDI-DrugBank.d633.s18.e2 false theophylline plasma levels returned to pre-mexitil values within 48 hours after discontinuing mexitil
DDI-DrugBank.d633.s18.e1_DDI-DrugBank.d633.s18.e3 true theophylline plasma levels returned to pre-mexitil values within 48 hours after discontinuing mexitil
DDI-DrugBank.d633.s18.e2_DDI-DrugBank.d633.s18.e3 false theophylline plasma levels returned to pre-mexitil values within 48 hours after discontinuing mexitil
DDI-DrugBank.d633.s18.e5_DDI-DrugBank.d633.s18.e6 false if mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18.e5_DDI-DrugBank.d633.s18.e4 false if mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18.e5_DDI-DrugBank.d633.s18.e7 false if mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18.e6_DDI-DrugBank.d633.s18.e4 false if mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18.e6_DDI-DrugBank.d633.s18.e7 false if mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d633.s18.e4_DDI-DrugBank.d633.s18.e7 false if mexitil and theophylline are to be used concurrently , theophylline blood levels should be monitored , particularly when the mexitil dose is changed .
DDI-DrugBank.d713.s5
DDI-DrugBank.d756.s6
DDI-DrugBank.d653.s6
DDI-DrugBank.d653.s6.e0_DDI-DrugBank.d653.s6.e1 true aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia .
DDI-DrugBank.d678.s1
DDI-DrugBank.d678.s1.e1_DDI-DrugBank.d678.s1.e0 false the metabolism of metopirone is accelerated by phenytoin ;
DDI-DrugBank.d726.s1
DDI-DrugBank.d726.s1.e0_DDI-DrugBank.d726.s1.e1 true a multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol auc0-
DDI-DrugBank.d726.s1.e2_DDI-DrugBank.d726.s1.e3 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e2_DDI-DrugBank.d726.s1.e4 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e2_DDI-DrugBank.d726.s1.e5 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e2_DDI-DrugBank.d726.s1.e6 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e2_DDI-DrugBank.d726.s1.e7 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e2_DDI-DrugBank.d726.s1.e8 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e2_DDI-DrugBank.d726.s1.e9 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e3_DDI-DrugBank.d726.s1.e4 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e3_DDI-DrugBank.d726.s1.e5 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e3_DDI-DrugBank.d726.s1.e6 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e3_DDI-DrugBank.d726.s1.e7 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e3_DDI-DrugBank.d726.s1.e8 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e3_DDI-DrugBank.d726.s1.e9 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e4_DDI-DrugBank.d726.s1.e5 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e4_DDI-DrugBank.d726.s1.e6 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e4_DDI-DrugBank.d726.s1.e7 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e4_DDI-DrugBank.d726.s1.e8 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e4_DDI-DrugBank.d726.s1.e9 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e5_DDI-DrugBank.d726.s1.e6 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e5_DDI-DrugBank.d726.s1.e7 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e5_DDI-DrugBank.d726.s1.e8 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e5_DDI-DrugBank.d726.s1.e9 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e6_DDI-DrugBank.d726.s1.e7 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e6_DDI-DrugBank.d726.s1.e8 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e6_DDI-DrugBank.d726.s1.e9 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e7_DDI-DrugBank.d726.s1.e8 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e7_DDI-DrugBank.d726.s1.e9 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d726.s1.e8_DDI-DrugBank.d726.s1.e9 false since paricalcitol is partially metabolized by cyp3a and ketoconazole le is known to be a strong inhibitor of cytochrome p450 3a enzyme , care should be taken while dosing paricalcitol with ketoconazole and other strong p450 3a inhibitors including atazanavir , clarithromycin , indinavir , itraconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin or voriconazole .
DDI-DrugBank.d675.s5
DDI-DrugBank.d640.s4
DDI-DrugBank.d640.s6
DDI-DrugBank.d640.s6.e0_DDI-DrugBank.d640.s6.e1 false lithium : increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with lithium .
DDI-DrugBank.d640.s6.e0_DDI-DrugBank.d640.s6.e2 false lithium : increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with lithium .
DDI-DrugBank.d640.s6.e0_DDI-DrugBank.d640.s6.e4 false lithium : increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with lithium .
DDI-DrugBank.d640.s6.e0_DDI-DrugBank.d640.s6.e3 false lithium : increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with lithium .
DDI-DrugBank.d640.s6.e1_DDI-DrugBank.d640.s6.e2 false lithium : increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with lithium .
DDI-DrugBank.d640.s6.e1_DDI-DrugBank.d640.s6.e4 false lithium : increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with lithium .
DDI-DrugBank.d640.s6.e1_DDI-DrugBank.d640.s6.e3 false lithium : increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with lithium .
DDI-DrugBank.d640.s6.e2_DDI-DrugBank.d640.s6.e4 false lithium : increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with lithium .
DDI-DrugBank.d640.s6.e2_DDI-DrugBank.d640.s6.e3 false lithium : increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with lithium .
DDI-DrugBank.d640.s6.e4_DDI-DrugBank.d640.s6.e3 false lithium : increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ace inhibitors during therapy with lithium .
DDI-DrugBank.d647.s3
DDI-DrugBank.d647.s3.e0_DDI-DrugBank.d647.s3.e1 true the concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity .
DDI-DrugBank.d647.s3.e0_DDI-DrugBank.d647.s3.e2 false the concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity .
DDI-DrugBank.d647.s3.e1_DDI-DrugBank.d647.s3.e2 false the concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity .
DDI-DrugBank.d756.s1
DDI-DrugBank.d756.s1.e0_DDI-DrugBank.d756.s1.e1 false combination with tramadol ( ultram ) is associated with increased risk of seizures .
DDI-DrugBank.d623.s0
DDI-DrugBank.d572.s10
DDI-DrugBank.d572.s10.e0_DDI-DrugBank.d572.s10.e1 true patients who take both ezetimibe and cyclosporine should be carefully monitored .
DDI-DrugBank.d578.s12
DDI-DrugBank.d757.s0
DDI-DrugBank.d757.s0.e0_DDI-DrugBank.d757.s0.e1 false usage with alcohol : due to the potential for increased cns depressants effects , alcohol should be used with caution in patients who are currently receiving pentazocine .
DDI-DrugBank.d757.s0.e0_DDI-DrugBank.d757.s0.e2 false usage with alcohol : due to the potential for increased cns depressants effects , alcohol should be used with caution in patients who are currently receiving pentazocine .
DDI-DrugBank.d757.s0.e1_DDI-DrugBank.d757.s0.e2 true usage with alcohol : due to the potential for increased cns depressants effects , alcohol should be used with caution in patients who are currently receiving pentazocine .
DDI-DrugBank.d638.s2
DDI-DrugBank.d638.s2.e3_DDI-DrugBank.d638.s2.e4 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e3_DDI-DrugBank.d638.s2.e5 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e3_DDI-DrugBank.d638.s2.e6 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e3_DDI-DrugBank.d638.s2.e8 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e3_DDI-DrugBank.d638.s2.e9 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e3_DDI-DrugBank.d638.s2.e0 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e3_DDI-DrugBank.d638.s2.e1 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e3_DDI-DrugBank.d638.s2.e2 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e3_DDI-DrugBank.d638.s2.e7 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e4_DDI-DrugBank.d638.s2.e5 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e4_DDI-DrugBank.d638.s2.e6 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e4_DDI-DrugBank.d638.s2.e8 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e4_DDI-DrugBank.d638.s2.e9 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e4_DDI-DrugBank.d638.s2.e0 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e4_DDI-DrugBank.d638.s2.e1 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e4_DDI-DrugBank.d638.s2.e2 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e4_DDI-DrugBank.d638.s2.e7 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e5_DDI-DrugBank.d638.s2.e6 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e5_DDI-DrugBank.d638.s2.e8 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e5_DDI-DrugBank.d638.s2.e9 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e5_DDI-DrugBank.d638.s2.e0 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e5_DDI-DrugBank.d638.s2.e1 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e5_DDI-DrugBank.d638.s2.e2 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e5_DDI-DrugBank.d638.s2.e7 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e6_DDI-DrugBank.d638.s2.e8 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e6_DDI-DrugBank.d638.s2.e9 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e6_DDI-DrugBank.d638.s2.e0 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e6_DDI-DrugBank.d638.s2.e1 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e6_DDI-DrugBank.d638.s2.e2 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e6_DDI-DrugBank.d638.s2.e7 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e8_DDI-DrugBank.d638.s2.e9 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e8_DDI-DrugBank.d638.s2.e0 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e8_DDI-DrugBank.d638.s2.e1 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e8_DDI-DrugBank.d638.s2.e2 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e8_DDI-DrugBank.d638.s2.e7 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e9_DDI-DrugBank.d638.s2.e0 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e9_DDI-DrugBank.d638.s2.e1 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e9_DDI-DrugBank.d638.s2.e2 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e9_DDI-DrugBank.d638.s2.e7 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e0_DDI-DrugBank.d638.s2.e1 true human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e0_DDI-DrugBank.d638.s2.e2 true human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e0_DDI-DrugBank.d638.s2.e7 true human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e1_DDI-DrugBank.d638.s2.e2 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e1_DDI-DrugBank.d638.s2.e7 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d638.s2.e2_DDI-DrugBank.d638.s2.e7 false human pharmacologic studies have shown that ritalin may inhibit the metabolism of coumarin anticoagulants , anticonvulsants ( phenobarbital , diphenylhydantoin , primidone ) , phenylbutazone , and tricyclic drugs ( imipramine , clomipramine , desipramine ) .
DDI-DrugBank.d675.s2
DDI-DrugBank.d675.s2.e1_DDI-DrugBank.d675.s2.e2 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e1_DDI-DrugBank.d675.s2.e3 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e1_DDI-DrugBank.d675.s2.e6 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e1_DDI-DrugBank.d675.s2.e7 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e1_DDI-DrugBank.d675.s2.e8 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e1_DDI-DrugBank.d675.s2.e9 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e1_DDI-DrugBank.d675.s2.e0 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e1_DDI-DrugBank.d675.s2.e4 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e1_DDI-DrugBank.d675.s2.e4 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e1_DDI-DrugBank.d675.s2.e5 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e2_DDI-DrugBank.d675.s2.e3 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e2_DDI-DrugBank.d675.s2.e6 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e2_DDI-DrugBank.d675.s2.e7 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e2_DDI-DrugBank.d675.s2.e8 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e2_DDI-DrugBank.d675.s2.e9 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e2_DDI-DrugBank.d675.s2.e0 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e2_DDI-DrugBank.d675.s2.e4 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e2_DDI-DrugBank.d675.s2.e4 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e2_DDI-DrugBank.d675.s2.e5 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e3_DDI-DrugBank.d675.s2.e6 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e3_DDI-DrugBank.d675.s2.e7 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e3_DDI-DrugBank.d675.s2.e8 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e3_DDI-DrugBank.d675.s2.e9 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e3_DDI-DrugBank.d675.s2.e0 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e3_DDI-DrugBank.d675.s2.e4 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e3_DDI-DrugBank.d675.s2.e4 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e3_DDI-DrugBank.d675.s2.e5 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e6_DDI-DrugBank.d675.s2.e7 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e6_DDI-DrugBank.d675.s2.e8 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e6_DDI-DrugBank.d675.s2.e9 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e6_DDI-DrugBank.d675.s2.e0 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e6_DDI-DrugBank.d675.s2.e4 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e6_DDI-DrugBank.d675.s2.e4 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e6_DDI-DrugBank.d675.s2.e5 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e7_DDI-DrugBank.d675.s2.e8 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e7_DDI-DrugBank.d675.s2.e9 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e7_DDI-DrugBank.d675.s2.e0 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e7_DDI-DrugBank.d675.s2.e4 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e7_DDI-DrugBank.d675.s2.e4 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e7_DDI-DrugBank.d675.s2.e5 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e8_DDI-DrugBank.d675.s2.e9 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e8_DDI-DrugBank.d675.s2.e0 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e8_DDI-DrugBank.d675.s2.e4 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e8_DDI-DrugBank.d675.s2.e4 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e8_DDI-DrugBank.d675.s2.e5 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e9_DDI-DrugBank.d675.s2.e0 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e9_DDI-DrugBank.d675.s2.e4 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e9_DDI-DrugBank.d675.s2.e4 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e9_DDI-DrugBank.d675.s2.e5 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e0_DDI-DrugBank.d675.s2.e4 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e0_DDI-DrugBank.d675.s2.e4 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e0_DDI-DrugBank.d675.s2.e5 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e4_DDI-DrugBank.d675.s2.e4 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e4_DDI-DrugBank.d675.s2.e5 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d675.s2.e4_DDI-DrugBank.d675.s2.e5 false examples of some of the more potent cyp 3a4 inhibitors include macrolide antibiotics ( e.g. , erythromycin , troleandomycin , clarithromycin ) , hiv protease or reverse transcriptase inhibitors ( e.g. , ritonavir , indinavir , nelfinavir , delavirdine ) or azole antifungals ( e.g. , ketoconazole , itraconazole , voriconazole ) .
DDI-DrugBank.d775.s13
DDI-DrugBank.d775.s13.e1_DDI-DrugBank.d775.s13.e2 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e1_DDI-DrugBank.d775.s13.e4 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e1_DDI-DrugBank.d775.s13.e5 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e1_DDI-DrugBank.d775.s13.e6 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e1_DDI-DrugBank.d775.s13.e7 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e1_DDI-DrugBank.d775.s13.e8 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e1_DDI-DrugBank.d775.s13.e0 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e1_DDI-DrugBank.d775.s13.e3 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e1_DDI-DrugBank.d775.s13.e9 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e2_DDI-DrugBank.d775.s13.e4 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e2_DDI-DrugBank.d775.s13.e5 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e2_DDI-DrugBank.d775.s13.e6 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e2_DDI-DrugBank.d775.s13.e7 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e2_DDI-DrugBank.d775.s13.e8 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e2_DDI-DrugBank.d775.s13.e0 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e2_DDI-DrugBank.d775.s13.e3 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e2_DDI-DrugBank.d775.s13.e9 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e4_DDI-DrugBank.d775.s13.e5 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e4_DDI-DrugBank.d775.s13.e6 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e4_DDI-DrugBank.d775.s13.e7 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e4_DDI-DrugBank.d775.s13.e8 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e4_DDI-DrugBank.d775.s13.e0 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e4_DDI-DrugBank.d775.s13.e3 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e4_DDI-DrugBank.d775.s13.e9 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e5_DDI-DrugBank.d775.s13.e6 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e5_DDI-DrugBank.d775.s13.e7 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e5_DDI-DrugBank.d775.s13.e8 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e5_DDI-DrugBank.d775.s13.e0 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e5_DDI-DrugBank.d775.s13.e3 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e5_DDI-DrugBank.d775.s13.e9 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e6_DDI-DrugBank.d775.s13.e7 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e6_DDI-DrugBank.d775.s13.e8 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e6_DDI-DrugBank.d775.s13.e0 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e6_DDI-DrugBank.d775.s13.e3 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e6_DDI-DrugBank.d775.s13.e9 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e7_DDI-DrugBank.d775.s13.e8 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e7_DDI-DrugBank.d775.s13.e0 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e7_DDI-DrugBank.d775.s13.e3 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e7_DDI-DrugBank.d775.s13.e9 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e8_DDI-DrugBank.d775.s13.e0 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e8_DDI-DrugBank.d775.s13.e3 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e8_DDI-DrugBank.d775.s13.e9 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e0_DDI-DrugBank.d775.s13.e3 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e0_DDI-DrugBank.d775.s13.e9 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d775.s13.e3_DDI-DrugBank.d775.s13.e9 false some drug interactions are : - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin b or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
DDI-DrugBank.d575.s3
DDI-DrugBank.d575.s3.e0_DDI-DrugBank.d575.s3.e1 false there was no change in the plasma kinetics of teniposide when coadministered with methotrexate .
DDI-DrugBank.d725.s3
DDI-DrugBank.d725.s3.e0_DDI-DrugBank.d725.s3.e1 true the pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants .
DDI-DrugBank.d588.s13
DDI-DrugBank.d588.s13.e1_DDI-DrugBank.d588.s13.e0 false anticoagulants : metolazone , as well as other thiazide-like diuretics , may affect the hypoprothrombinemic response to anticoagulants ;
DDI-DrugBank.d588.s13.e1_DDI-DrugBank.d588.s13.e2 false anticoagulants : metolazone , as well as other thiazide-like diuretics , may affect the hypoprothrombinemic response to anticoagulants ;
DDI-DrugBank.d588.s13.e1_DDI-DrugBank.d588.s13.e3 true anticoagulants : metolazone , as well as other thiazide-like diuretics , may affect the hypoprothrombinemic response to anticoagulants ;
DDI-DrugBank.d588.s13.e0_DDI-DrugBank.d588.s13.e2 false anticoagulants : metolazone , as well as other thiazide-like diuretics , may affect the hypoprothrombinemic response to anticoagulants ;
DDI-DrugBank.d588.s13.e0_DDI-DrugBank.d588.s13.e3 false anticoagulants : metolazone , as well as other thiazide-like diuretics , may affect the hypoprothrombinemic response to anticoagulants ;
DDI-DrugBank.d588.s13.e2_DDI-DrugBank.d588.s13.e3 false anticoagulants : metolazone , as well as other thiazide-like diuretics , may affect the hypoprothrombinemic response to anticoagulants ;
DDI-DrugBank.d645.s8
DDI-DrugBank.d645.s8.e0_DDI-DrugBank.d645.s8.e1 false terbinafine clearance is unaffected by cyclosporine .
DDI-DrugBank.d628.s1
DDI-DrugBank.d628.s1.e4_DDI-DrugBank.d628.s1.e5 false and combinations of opioids and sedatives ( eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc . ) .
DDI-DrugBank.d628.s1.e4_DDI-DrugBank.d628.s1.e0 false and combinations of opioids and sedatives ( eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc . ) .
DDI-DrugBank.d628.s1.e4_DDI-DrugBank.d628.s1.e1 false and combinations of opioids and sedatives ( eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc . ) .
DDI-DrugBank.d628.s1.e4_DDI-DrugBank.d628.s1.e2 false and combinations of opioids and sedatives ( eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc . ) .
DDI-DrugBank.d628.s1.e4_DDI-DrugBank.d628.s1.e3 false and combinations of opioids and sedatives ( eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc . ) .
DDI-DrugBank.d628.s1.e5_DDI-DrugBank.d628.s1.e0 false and combinations of opioids and sedatives ( eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc . ) .
DDI-DrugBank.d628.s1.e5_DDI-DrugBank.d628.s1.e1 false and combinations of opioids and sedatives ( eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc . ) .
DDI-DrugBank.d628.s1.e5_DDI-DrugBank.d628.s1.e2 false and combinations of opioids and sedatives ( eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc . ) .
DDI-DrugBank.d628.s1.e5_DDI-DrugBank.d628.s1.e3 false and combinations of opioids and sedatives ( eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc . ) .
DDI-DrugBank.d628.s1.e0_DDI-DrugBank.d628.s1.e1 false and combinations of opioids and sedatives ( eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc . ) .
DDI-DrugBank.d628.s1.e0_DDI-DrugBank.d628.s1.e2 false and combinations of opioids and sedatives ( eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc . ) .
DDI-DrugBank.d628.s1.e0_DDI-DrugBank.d628.s1.e3 false and combinations of opioids and sedatives ( eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc . ) .
DDI-DrugBank.d628.s1.e1_DDI-DrugBank.d628.s1.e2 false and combinations of opioids and sedatives ( eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc . ) .
DDI-DrugBank.d628.s1.e1_DDI-DrugBank.d628.s1.e3 false and combinations of opioids and sedatives ( eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc . ) .
DDI-DrugBank.d628.s1.e2_DDI-DrugBank.d628.s1.e3 false and combinations of opioids and sedatives ( eg , benzodiazepines , barbiturates , chloral hydrate , droperidol , etc . ) .
DDI-DrugBank.d599.s3
DDI-DrugBank.d603.s5
DDI-DrugBank.d603.s5.e2_DDI-DrugBank.d603.s5.e3 false alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine .
DDI-DrugBank.d603.s5.e2_DDI-DrugBank.d603.s5.e4 false alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine .
DDI-DrugBank.d603.s5.e2_DDI-DrugBank.d603.s5.e5 false alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine .
DDI-DrugBank.d603.s5.e2_DDI-DrugBank.d603.s5.e1 false alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine .
DDI-DrugBank.d603.s5.e3_DDI-DrugBank.d603.s5.e4 false alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine .
DDI-DrugBank.d603.s5.e3_DDI-DrugBank.d603.s5.e5 false alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine .
DDI-DrugBank.d603.s5.e3_DDI-DrugBank.d603.s5.e1 false alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine .
DDI-DrugBank.d603.s5.e4_DDI-DrugBank.d603.s5.e5 false alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine .
DDI-DrugBank.d603.s5.e4_DDI-DrugBank.d603.s5.e1 false alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine .
DDI-DrugBank.d603.s5.e5_DDI-DrugBank.d603.s5.e1 false alpha-adrenergic blocking agents , such as prazosin , terazosin , and doxazosin , can antagonize the effects of proamatine .
DDI-DrugBank.d603.s5.e6_DDI-DrugBank.d603.s5.e7 false potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine
DDI-DrugBank.d603.s5.e6_DDI-DrugBank.d603.s5.e8 false potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine
DDI-DrugBank.d603.s5.e6_DDI-DrugBank.d603.s5.e9 false potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine
DDI-DrugBank.d603.s5.e7_DDI-DrugBank.d603.s5.e8 false potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine
DDI-DrugBank.d603.s5.e7_DDI-DrugBank.d603.s5.e9 false potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine
DDI-DrugBank.d603.s5.e8_DDI-DrugBank.d603.s5.e9 false potential for drug interactions : it appears possible , although there is no supporting experimental evidence , that the high renal clearance of desglymidodrine ( a base ) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin , cimetidine , ranitidine , procainamide , triamterene , flecainide , and quinidine
DDI-DrugBank.d716.s4
DDI-DrugBank.d578.s8
DDI-DrugBank.d578.s8.e2_DDI-DrugBank.d578.s8.e0 false this could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn .
DDI-DrugBank.d578.s8.e2_DDI-DrugBank.d578.s8.e1 false this could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn .
DDI-DrugBank.d578.s8.e0_DDI-DrugBank.d578.s8.e1 false this could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn .
DDI-DrugBank.d743.s12
DDI-DrugBank.d743.s12.e0_DDI-DrugBank.d743.s12.e1 true concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12.e0_DDI-DrugBank.d743.s12.e2 true concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12.e0_DDI-DrugBank.d743.s12.e3 true concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12.e0_DDI-DrugBank.d743.s12.e4 false concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12.e0_DDI-DrugBank.d743.s12.e6 false concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12.e0_DDI-DrugBank.d743.s12.e5 false concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12.e1_DDI-DrugBank.d743.s12.e2 false concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12.e1_DDI-DrugBank.d743.s12.e3 false concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12.e1_DDI-DrugBank.d743.s12.e4 false concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12.e1_DDI-DrugBank.d743.s12.e6 false concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12.e1_DDI-DrugBank.d743.s12.e5 false concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12.e2_DDI-DrugBank.d743.s12.e3 false concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12.e2_DDI-DrugBank.d743.s12.e4 false concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12.e2_DDI-DrugBank.d743.s12.e6 false concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12.e2_DDI-DrugBank.d743.s12.e5 false concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12.e3_DDI-DrugBank.d743.s12.e4 false concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12.e3_DDI-DrugBank.d743.s12.e6 false concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12.e3_DDI-DrugBank.d743.s12.e5 false concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12.e4_DDI-DrugBank.d743.s12.e6 false concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12.e4_DDI-DrugBank.d743.s12.e5 false concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d743.s12.e6_DDI-DrugBank.d743.s12.e5 false concomitant administration of terfenadine with clarithromycin , erythromycin , or troleandomycin is contraindicated : pending full characterization of potential interactions , concomitant administration of terfenadine with other macrolide antibiotics , including azithromycin , is not recommended .
DDI-DrugBank.d671.s2
DDI-DrugBank.d671.s2.e0_DDI-DrugBank.d671.s2.e1 true decreased seizure threshold has been reported in patients receiving cylert concomitantly with antiepileptic medications.
DDI-DrugBank.d779.s14
DDI-DrugBank.d604.s3
DDI-DrugBank.d639.s0
DDI-DrugBank.d639.s0.e1_DDI-DrugBank.d639.s0.e2 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e1_DDI-DrugBank.d639.s0.e3 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e1_DDI-DrugBank.d639.s0.e4 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e1_DDI-DrugBank.d639.s0.e5 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e1_DDI-DrugBank.d639.s0.e6 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e1_DDI-DrugBank.d639.s0.e7 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e1_DDI-DrugBank.d639.s0.e8 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e1_DDI-DrugBank.d639.s0.e9 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e1_DDI-DrugBank.d639.s0.e0 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e2_DDI-DrugBank.d639.s0.e3 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e2_DDI-DrugBank.d639.s0.e4 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e2_DDI-DrugBank.d639.s0.e5 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e2_DDI-DrugBank.d639.s0.e6 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e2_DDI-DrugBank.d639.s0.e7 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e2_DDI-DrugBank.d639.s0.e8 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e2_DDI-DrugBank.d639.s0.e9 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e2_DDI-DrugBank.d639.s0.e0 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e3_DDI-DrugBank.d639.s0.e4 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e3_DDI-DrugBank.d639.s0.e5 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e3_DDI-DrugBank.d639.s0.e6 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e3_DDI-DrugBank.d639.s0.e7 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e3_DDI-DrugBank.d639.s0.e8 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e3_DDI-DrugBank.d639.s0.e9 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e3_DDI-DrugBank.d639.s0.e0 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e4_DDI-DrugBank.d639.s0.e5 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e4_DDI-DrugBank.d639.s0.e6 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e4_DDI-DrugBank.d639.s0.e7 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e4_DDI-DrugBank.d639.s0.e8 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e4_DDI-DrugBank.d639.s0.e9 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e4_DDI-DrugBank.d639.s0.e0 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e5_DDI-DrugBank.d639.s0.e6 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e5_DDI-DrugBank.d639.s0.e7 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e5_DDI-DrugBank.d639.s0.e8 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e5_DDI-DrugBank.d639.s0.e9 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e5_DDI-DrugBank.d639.s0.e0 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e6_DDI-DrugBank.d639.s0.e7 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e6_DDI-DrugBank.d639.s0.e8 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e6_DDI-DrugBank.d639.s0.e9 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e6_DDI-DrugBank.d639.s0.e0 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e7_DDI-DrugBank.d639.s0.e8 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e7_DDI-DrugBank.d639.s0.e9 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e7_DDI-DrugBank.d639.s0.e0 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e8_DDI-DrugBank.d639.s0.e9 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e8_DDI-DrugBank.d639.s0.e0 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d639.s0.e9_DDI-DrugBank.d639.s0.e0 false co-administration of sutent with strong inhibitors of the cyp3a4 family ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconizole ) may increases sunitinib concentrations .
DDI-DrugBank.d759.s0
DDI-DrugBank.d759.s0.e0_DDI-DrugBank.d759.s0.e1 true limited evidence suggests that ascorbic acid may influence the intensity and duration of action of bishydroxycoumarin .
DDI-DrugBank.d700.s5
DDI-DrugBank.d700.s5.e0_DDI-DrugBank.d700.s5.e1 false both acyclovir/ganciclovir and mpag concentrations are increased in the presence of renal impairment , their coexistence may compete for tubular secretion and further increase in the concentrations of the two .
DDI-DrugBank.d700.s5.e0_DDI-DrugBank.d700.s5.e2 false both acyclovir/ganciclovir and mpag concentrations are increased in the presence of renal impairment , their coexistence may compete for tubular secretion and further increase in the concentrations of the two .
DDI-DrugBank.d700.s5.e1_DDI-DrugBank.d700.s5.e2 false both acyclovir/ganciclovir and mpag concentrations are increased in the presence of renal impairment , their coexistence may compete for tubular secretion and further increase in the concentrations of the two .
DDI-DrugBank.d627.s0
DDI-DrugBank.d627.s0.e0_DDI-DrugBank.d627.s0.e1 true pilocarpine should be administered with caution to patients taking beta adrenergic antagonists because of the possibility of conduction disturbances .
DDI-DrugBank.d693.s7
DDI-DrugBank.d665.s0
DDI-DrugBank.d665.s0.e1_DDI-DrugBank.d665.s0.e2 false concurrent administration of bacteriostatic antibiotics ( e.g. , erythromycin , tetracycline ) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth .
DDI-DrugBank.d665.s0.e1_DDI-DrugBank.d665.s0.e0 false concurrent administration of bacteriostatic antibiotics ( e.g. , erythromycin , tetracycline ) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth .
DDI-DrugBank.d665.s0.e1_DDI-DrugBank.d665.s0.e3 true concurrent administration of bacteriostatic antibiotics ( e.g. , erythromycin , tetracycline ) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth .
DDI-DrugBank.d665.s0.e2_DDI-DrugBank.d665.s0.e0 false concurrent administration of bacteriostatic antibiotics ( e.g. , erythromycin , tetracycline ) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth .
DDI-DrugBank.d665.s0.e2_DDI-DrugBank.d665.s0.e3 true concurrent administration of bacteriostatic antibiotics ( e.g. , erythromycin , tetracycline ) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth .
DDI-DrugBank.d665.s0.e0_DDI-DrugBank.d665.s0.e3 true concurrent administration of bacteriostatic antibiotics ( e.g. , erythromycin , tetracycline ) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth .
DDI-DrugBank.d756.s5
DDI-DrugBank.d658.s2
DDI-DrugBank.d634.s5
DDI-DrugBank.d634.s5.e0_DDI-DrugBank.d634.s5.e1 false theophylline : theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid ;
DDI-DrugBank.d634.s5.e0_DDI-DrugBank.d634.s5.e2 false theophylline : theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid ;
DDI-DrugBank.d634.s5.e1_DDI-DrugBank.d634.s5.e2 false theophylline : theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid ;
DDI-DrugBank.d739.s13
DDI-DrugBank.d739.s13.e0_DDI-DrugBank.d739.s13.e1 false phenobarbital , which induces hepatic metabolism , decreased the auc of montelukast approximately 40 % following a single 10-mg dose of montelukast .
DDI-DrugBank.d739.s13.e0_DDI-DrugBank.d739.s13.e2 false phenobarbital , which induces hepatic metabolism , decreased the auc of montelukast approximately 40 % following a single 10-mg dose of montelukast .
DDI-DrugBank.d739.s13.e1_DDI-DrugBank.d739.s13.e2 false phenobarbital , which induces hepatic metabolism , decreased the auc of montelukast approximately 40 % following a single 10-mg dose of montelukast .
DDI-DrugBank.d781.s2
DDI-DrugBank.d781.s2.e1_DDI-DrugBank.d781.s2.e0 false if diuretics can not be interrupted , close medical supervision should be provided with the first dose of aceon tablets , for at least two hours and until blood pressure has stabilized for another hour .
DDI-DrugBank.d572.s0
DDI-DrugBank.d572.s0.e0_DDI-DrugBank.d572.s0.e1 false cholestyramine : concomitant cholestyramine administration decreased the mean auc of total ezetimibe approximately 55 % .
DDI-DrugBank.d572.s0.e0_DDI-DrugBank.d572.s0.e2 false cholestyramine : concomitant cholestyramine administration decreased the mean auc of total ezetimibe approximately 55 % .
DDI-DrugBank.d572.s0.e1_DDI-DrugBank.d572.s0.e2 true cholestyramine : concomitant cholestyramine administration decreased the mean auc of total ezetimibe approximately 55 % .
DDI-DrugBank.d776.s26
DDI-DrugBank.d776.s26.e0_DDI-DrugBank.d776.s26.e1 true a controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of qtc interval .
DDI-DrugBank.d776.s26.e0_DDI-DrugBank.d776.s26.e2 false a controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of qtc interval .
DDI-DrugBank.d776.s26.e1_DDI-DrugBank.d776.s26.e2 false a controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of qtc interval .
DDI-DrugBank.d627.s2
DDI-DrugBank.d775.s8
DDI-DrugBank.d775.s8.e1_DDI-DrugBank.d775.s8.e2 false a greater potentiation of the neuromuscular blocking effects of mivacron may be expected with higher concentrations of enflurane or isoflurane .
DDI-DrugBank.d775.s8.e1_DDI-DrugBank.d775.s8.e0 false a greater potentiation of the neuromuscular blocking effects of mivacron may be expected with higher concentrations of enflurane or isoflurane .
DDI-DrugBank.d775.s8.e2_DDI-DrugBank.d775.s8.e0 false a greater potentiation of the neuromuscular blocking effects of mivacron may be expected with higher concentrations of enflurane or isoflurane .
DDI-DrugBank.d591.s5
DDI-DrugBank.d591.s5.e0_DDI-DrugBank.d591.s5.e1 false possible interactions with drugs known to be metabolized by cyp1a2 via competitive inhibition such as theophylline and imipramine may also occur .
DDI-DrugBank.d596.s7
DDI-DrugBank.d596.s7.e0_DDI-DrugBank.d596.s7.e1 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e0_DDI-DrugBank.d596.s7.e2 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e0_DDI-DrugBank.d596.s7.e3 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e0_DDI-DrugBank.d596.s7.e4 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e0_DDI-DrugBank.d596.s7.e5 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e0_DDI-DrugBank.d596.s7.e6 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e0_DDI-DrugBank.d596.s7.e7 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e0_DDI-DrugBank.d596.s7.e8 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e0_DDI-DrugBank.d596.s7.e9 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e1_DDI-DrugBank.d596.s7.e2 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e1_DDI-DrugBank.d596.s7.e3 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e1_DDI-DrugBank.d596.s7.e4 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e1_DDI-DrugBank.d596.s7.e5 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e1_DDI-DrugBank.d596.s7.e6 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e1_DDI-DrugBank.d596.s7.e7 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e1_DDI-DrugBank.d596.s7.e8 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e1_DDI-DrugBank.d596.s7.e9 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e2_DDI-DrugBank.d596.s7.e3 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e2_DDI-DrugBank.d596.s7.e4 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e2_DDI-DrugBank.d596.s7.e5 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e2_DDI-DrugBank.d596.s7.e6 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e2_DDI-DrugBank.d596.s7.e7 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e2_DDI-DrugBank.d596.s7.e8 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e2_DDI-DrugBank.d596.s7.e9 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e3_DDI-DrugBank.d596.s7.e4 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e3_DDI-DrugBank.d596.s7.e5 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e3_DDI-DrugBank.d596.s7.e6 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e3_DDI-DrugBank.d596.s7.e7 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e3_DDI-DrugBank.d596.s7.e8 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e3_DDI-DrugBank.d596.s7.e9 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e4_DDI-DrugBank.d596.s7.e5 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e4_DDI-DrugBank.d596.s7.e6 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e4_DDI-DrugBank.d596.s7.e7 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e4_DDI-DrugBank.d596.s7.e8 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e4_DDI-DrugBank.d596.s7.e9 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e5_DDI-DrugBank.d596.s7.e6 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e5_DDI-DrugBank.d596.s7.e7 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e5_DDI-DrugBank.d596.s7.e8 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e5_DDI-DrugBank.d596.s7.e9 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e6_DDI-DrugBank.d596.s7.e7 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e6_DDI-DrugBank.d596.s7.e8 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e6_DDI-DrugBank.d596.s7.e9 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e7_DDI-DrugBank.d596.s7.e8 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e7_DDI-DrugBank.d596.s7.e9 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d596.s7.e8_DDI-DrugBank.d596.s7.e9 false population pk analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids ( n=77 ) , antihypertensives ( n=72 ) , calcium channel blockers ( n=75 ) , antidiabetics ( n=21 ) , nonsteroidal anti-inflammatory drugs ( n=79 ) , estrogens ( n=70 ) , salicylate analgesics ( n=177 ) , antianginals ( n=35 ) , and antihistamines ( n=15 ) .
DDI-DrugBank.d588.s4
DDI-DrugBank.d588.s4.e0_DDI-DrugBank.d588.s4.e1 false digitalis glycosides : diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis .
DDI-DrugBank.d588.s4.e0_DDI-DrugBank.d588.s4.e2 false digitalis glycosides : diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis .
DDI-DrugBank.d588.s4.e1_DDI-DrugBank.d588.s4.e2 true digitalis glycosides : diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis .
DDI-DrugBank.d756.s0
DDI-DrugBank.d756.s0.e1_DDI-DrugBank.d756.s0.e0 false dosages of concomitantly administered opioids should be reduced by approximately half , because levomepromazine amplifies the therapeutic actions and side-effects of opioids .
DDI-DrugBank.d756.s0.e1_DDI-DrugBank.d756.s0.e2 true dosages of concomitantly administered opioids should be reduced by approximately half , because levomepromazine amplifies the therapeutic actions and side-effects of opioids .
DDI-DrugBank.d756.s0.e0_DDI-DrugBank.d756.s0.e2 false dosages of concomitantly administered opioids should be reduced by approximately half , because levomepromazine amplifies the therapeutic actions and side-effects of opioids .
DDI-DrugBank.d581.s1
DDI-DrugBank.d765.s0
DDI-DrugBank.d765.s0.e0_DDI-DrugBank.d765.s0.e1 true cyp3a4 inhibitors : ketoconazole , an inhibitor of the drug metabolizing enzyme cyp3a4 , significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers ( see clinical pharmacology , variability in metabolism and drug-drug interactions ) .
DDI-DrugBank.d756.s11
DDI-DrugBank.d775.s9
DDI-DrugBank.d678.s3
DDI-DrugBank.d572.s21
DDI-DrugBank.d728.s1
DDI-DrugBank.d728.s1.e1_DDI-DrugBank.d728.s1.e0 false no pharmacokinetic interaction between 85 mg/m2 eloxatin and infusional 5-fu has been observed in patients treated every 2 weeks .
DDI-DrugBank.d576.s4
DDI-DrugBank.d576.s4.e0_DDI-DrugBank.d576.s4.e1 true salicylates given concomitantly with anticoagulant drugs may predispose to systemic bleeding .
DDI-DrugBank.d735.s1
DDI-DrugBank.d726.s0
DDI-DrugBank.d776.s30
DDI-DrugBank.d736.s3
DDI-DrugBank.d736.s3.e1_DDI-DrugBank.d736.s3.e0 false thiazides may decrease arterial responsiveness to norepinephrine .
DDI-DrugBank.d575.s0
DDI-DrugBank.d575.s0.e0_DDI-DrugBank.d575.s0.e1 false in a study in which 34 different drugs were tested , therapeutically relevant concentrations of tolbutamide , sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent .
DDI-DrugBank.d575.s0.e0_DDI-DrugBank.d575.s0.e2 false in a study in which 34 different drugs were tested , therapeutically relevant concentrations of tolbutamide , sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent .
DDI-DrugBank.d575.s0.e0_DDI-DrugBank.d575.s0.e3 true in a study in which 34 different drugs were tested , therapeutically relevant concentrations of tolbutamide , sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent .
DDI-DrugBank.d575.s0.e1_DDI-DrugBank.d575.s0.e2 false in a study in which 34 different drugs were tested , therapeutically relevant concentrations of tolbutamide , sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent .
DDI-DrugBank.d575.s0.e1_DDI-DrugBank.d575.s0.e3 true in a study in which 34 different drugs were tested , therapeutically relevant concentrations of tolbutamide , sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent .
DDI-DrugBank.d575.s0.e2_DDI-DrugBank.d575.s0.e3 true in a study in which 34 different drugs were tested , therapeutically relevant concentrations of tolbutamide , sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent .
DDI-DrugBank.d666.s6
DDI-DrugBank.d675.s3
DDI-DrugBank.d742.s4
DDI-DrugBank.d696.s1
DDI-DrugBank.d696.s1.e2_DDI-DrugBank.d696.s1.e3 false concurrent use with vasoconstrictor agents including ergot alkaloids , sumatriptan , and nicotine ( e.g. smoking ) may result in enhanced vasoconstriction .
DDI-DrugBank.d696.s1.e2_DDI-DrugBank.d696.s1.e0 false concurrent use with vasoconstrictor agents including ergot alkaloids , sumatriptan , and nicotine ( e.g. smoking ) may result in enhanced vasoconstriction .
DDI-DrugBank.d696.s1.e2_DDI-DrugBank.d696.s1.e1 false concurrent use with vasoconstrictor agents including ergot alkaloids , sumatriptan , and nicotine ( e.g. smoking ) may result in enhanced vasoconstriction .
DDI-DrugBank.d696.s1.e3_DDI-DrugBank.d696.s1.e0 false concurrent use with vasoconstrictor agents including ergot alkaloids , sumatriptan , and nicotine ( e.g. smoking ) may result in enhanced vasoconstriction .
DDI-DrugBank.d696.s1.e3_DDI-DrugBank.d696.s1.e1 false concurrent use with vasoconstrictor agents including ergot alkaloids , sumatriptan , and nicotine ( e.g. smoking ) may result in enhanced vasoconstriction .
DDI-DrugBank.d696.s1.e0_DDI-DrugBank.d696.s1.e1 false concurrent use with vasoconstrictor agents including ergot alkaloids , sumatriptan , and nicotine ( e.g. smoking ) may result in enhanced vasoconstriction .
DDI-DrugBank.d775.s5
DDI-DrugBank.d775.s5.e0_DDI-DrugBank.d775.s5.e1 false isoflurane and enflurane ( administered with nitrous oxide/oxygen to achieve 1.25 m.c.
DDI-DrugBank.d775.s5.e0_DDI-DrugBank.d775.s5.e2 false isoflurane and enflurane ( administered with nitrous oxide/oxygen to achieve 1.25 m.c.
DDI-DrugBank.d775.s5.e0_DDI-DrugBank.d775.s5.e3 false isoflurane and enflurane ( administered with nitrous oxide/oxygen to achieve 1.25 m.c.
DDI-DrugBank.d775.s5.e1_DDI-DrugBank.d775.s5.e2 false isoflurane and enflurane ( administered with nitrous oxide/oxygen to achieve 1.25 m.c.
DDI-DrugBank.d775.s5.e1_DDI-DrugBank.d775.s5.e3 false isoflurane and enflurane ( administered with nitrous oxide/oxygen to achieve 1.25 m.c.
DDI-DrugBank.d775.s5.e2_DDI-DrugBank.d775.s5.e3 false isoflurane and enflurane ( administered with nitrous oxide/oxygen to achieve 1.25 m.c.
DDI-DrugBank.d763.s2
DDI-DrugBank.d636.s2
DDI-DrugBank.d636.s2.e1_DDI-DrugBank.d636.s2.e2 false those anticonvulsants include divalproex sodium , valproic acid , and phenobarbital .
DDI-DrugBank.d636.s2.e1_DDI-DrugBank.d636.s2.e3 false those anticonvulsants include divalproex sodium , valproic acid , and phenobarbital .
DDI-DrugBank.d636.s2.e1_DDI-DrugBank.d636.s2.e0 false those anticonvulsants include divalproex sodium , valproic acid , and phenobarbital .
DDI-DrugBank.d636.s2.e2_DDI-DrugBank.d636.s2.e3 false those anticonvulsants include divalproex sodium , valproic acid , and phenobarbital .
DDI-DrugBank.d636.s2.e2_DDI-DrugBank.d636.s2.e0 false those anticonvulsants include divalproex sodium , valproic acid , and phenobarbital .
DDI-DrugBank.d636.s2.e3_DDI-DrugBank.d636.s2.e0 false those anticonvulsants include divalproex sodium , valproic acid , and phenobarbital .
DDI-DrugBank.d588.s5
DDI-DrugBank.d622.s3
DDI-DrugBank.d622.s3.e0_DDI-DrugBank.d622.s3.e1 false morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3.e0_DDI-DrugBank.d622.s3.e2 false morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3.e0_DDI-DrugBank.d622.s3.e3 false morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3.e0_DDI-DrugBank.d622.s3.e4 false morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3.e0_DDI-DrugBank.d622.s3.e5 false morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3.e1_DDI-DrugBank.d622.s3.e2 false morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3.e1_DDI-DrugBank.d622.s3.e3 false morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3.e1_DDI-DrugBank.d622.s3.e4 false morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3.e1_DDI-DrugBank.d622.s3.e5 false morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3.e2_DDI-DrugBank.d622.s3.e3 false morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3.e2_DDI-DrugBank.d622.s3.e4 false morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3.e2_DDI-DrugBank.d622.s3.e5 false morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3.e3_DDI-DrugBank.d622.s3.e4 false morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3.e3_DDI-DrugBank.d622.s3.e5 false morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d622.s3.e4_DDI-DrugBank.d622.s3.e5 false morphine , theophylline , aminophylline , succinylcholine , reserpine , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning .
DDI-DrugBank.d739.s7
DDI-DrugBank.d622.s0
DDI-DrugBank.d622.s0.e0_DDI-DrugBank.d622.s0.e1 true when atropine and pralidoxime are used together , the signs of atropinization ( flushing , mydriasis , tachycardia , dryness of the mouth and nose ) may occur earlier than might be expected when atropine is used alone .
DDI-DrugBank.d622.s0.e0_DDI-DrugBank.d622.s0.e2 false when atropine and pralidoxime are used together , the signs of atropinization ( flushing , mydriasis , tachycardia , dryness of the mouth and nose ) may occur earlier than might be expected when atropine is used alone .
DDI-DrugBank.d622.s0.e1_DDI-DrugBank.d622.s0.e2 false when atropine and pralidoxime are used together , the signs of atropinization ( flushing , mydriasis , tachycardia , dryness of the mouth and nose ) may occur earlier than might be expected when atropine is used alone .
DDI-DrugBank.d736.s1
DDI-DrugBank.d736.s1.e1_DDI-DrugBank.d736.s1.e0 false hypokalemia may develop during concomitant use of steroids or acth .
DDI-DrugBank.d652.s0
DDI-DrugBank.d652.s0.e0_DDI-DrugBank.d652.s0.e1 true the effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics .
DDI-DrugBank.d652.s0.e0_DDI-DrugBank.d652.s0.e2 true the effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics .
DDI-DrugBank.d652.s0.e1_DDI-DrugBank.d652.s0.e2 false the effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics .
DDI-DrugBank.d712.s1
DDI-DrugBank.d712.s1.e0_DDI-DrugBank.d712.s1.e1 true administration of paclitaxel in combination with herceptin resulted in a two-fold decrease in herceptin clearance in a non-human primate study and in a 1.5-fold increase in herceptin serum levels in clinical studies .
DDI-DrugBank.d712.s1.e0_DDI-DrugBank.d712.s1.e2 false administration of paclitaxel in combination with herceptin resulted in a two-fold decrease in herceptin clearance in a non-human primate study and in a 1.5-fold increase in herceptin serum levels in clinical studies .
DDI-DrugBank.d712.s1.e0_DDI-DrugBank.d712.s1.e3 false administration of paclitaxel in combination with herceptin resulted in a two-fold decrease in herceptin clearance in a non-human primate study and in a 1.5-fold increase in herceptin serum levels in clinical studies .
DDI-DrugBank.d712.s1.e1_DDI-DrugBank.d712.s1.e2 false administration of paclitaxel in combination with herceptin resulted in a two-fold decrease in herceptin clearance in a non-human primate study and in a 1.5-fold increase in herceptin serum levels in clinical studies .
DDI-DrugBank.d712.s1.e1_DDI-DrugBank.d712.s1.e3 false administration of paclitaxel in combination with herceptin resulted in a two-fold decrease in herceptin clearance in a non-human primate study and in a 1.5-fold increase in herceptin serum levels in clinical studies .
DDI-DrugBank.d712.s1.e2_DDI-DrugBank.d712.s1.e3 false administration of paclitaxel in combination with herceptin resulted in a two-fold decrease in herceptin clearance in a non-human primate study and in a 1.5-fold increase in herceptin serum levels in clinical studies .
DDI-DrugBank.d632.s0
DDI-DrugBank.d632.s0.e2_DDI-DrugBank.d632.s0.e0 false due to its effects on gastric emptying , symlin therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , anticholinergic agents such as atropine ) and agents that slow the intestinal absorption of nutrients ( e.g. , alpha glucosidase inhibitors ) .
DDI-DrugBank.d632.s0.e2_DDI-DrugBank.d632.s0.e1 false due to its effects on gastric emptying , symlin therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , anticholinergic agents such as atropine ) and agents that slow the intestinal absorption of nutrients ( e.g. , alpha glucosidase inhibitors ) .
DDI-DrugBank.d632.s0.e2_DDI-DrugBank.d632.s0.e3 false due to its effects on gastric emptying , symlin therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , anticholinergic agents such as atropine ) and agents that slow the intestinal absorption of nutrients ( e.g. , alpha glucosidase inhibitors ) .
DDI-DrugBank.d632.s0.e0_DDI-DrugBank.d632.s0.e1 true due to its effects on gastric emptying , symlin therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , anticholinergic agents such as atropine ) and agents that slow the intestinal absorption of nutrients ( e.g. , alpha glucosidase inhibitors ) .
DDI-DrugBank.d632.s0.e0_DDI-DrugBank.d632.s0.e3 true due to its effects on gastric emptying , symlin therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , anticholinergic agents such as atropine ) and agents that slow the intestinal absorption of nutrients ( e.g. , alpha glucosidase inhibitors ) .
DDI-DrugBank.d632.s0.e1_DDI-DrugBank.d632.s0.e3 false due to its effects on gastric emptying , symlin therapy should not be considered for patients taking drugs that alter gastrointestinal motility ( e.g. , anticholinergic agents such as atropine ) and agents that slow the intestinal absorption of nutrients ( e.g. , alpha glucosidase inhibitors ) .
DDI-DrugBank.d588.s12
DDI-DrugBank.d588.s12.e0_DDI-DrugBank.d588.s12.e1 true methenamine : efficacy may be decreased due to urinary alkalizing effect of metolazone .
DDI-DrugBank.d639.s5
DDI-DrugBank.d623.s6
DDI-DrugBank.d661.s0
DDI-DrugBank.d661.s0.e1_DDI-DrugBank.d661.s0.e2 false : the use of zemuron ( rocuronium bromide ) injection before succinylcholine , for the purpose of attenuating some of the side effects of succinylcholine , has not been studied .
DDI-DrugBank.d661.s0.e1_DDI-DrugBank.d661.s0.e3 false : the use of zemuron ( rocuronium bromide ) injection before succinylcholine , for the purpose of attenuating some of the side effects of succinylcholine , has not been studied .
DDI-DrugBank.d661.s0.e1_DDI-DrugBank.d661.s0.e0 false : the use of zemuron ( rocuronium bromide ) injection before succinylcholine , for the purpose of attenuating some of the side effects of succinylcholine , has not been studied .
DDI-DrugBank.d661.s0.e2_DDI-DrugBank.d661.s0.e3 false : the use of zemuron ( rocuronium bromide ) injection before succinylcholine , for the purpose of attenuating some of the side effects of succinylcholine , has not been studied .
DDI-DrugBank.d661.s0.e2_DDI-DrugBank.d661.s0.e0 false : the use of zemuron ( rocuronium bromide ) injection before succinylcholine , for the purpose of attenuating some of the side effects of succinylcholine , has not been studied .
DDI-DrugBank.d661.s0.e3_DDI-DrugBank.d661.s0.e0 false : the use of zemuron ( rocuronium bromide ) injection before succinylcholine , for the purpose of attenuating some of the side effects of succinylcholine , has not been studied .
DDI-DrugBank.d770.s0
DDI-DrugBank.d588.s0
DDI-DrugBank.d588.s0.e1_DDI-DrugBank.d588.s0.e3 true diuretics : furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes .
DDI-DrugBank.d588.s0.e1_DDI-DrugBank.d588.s0.e0 false diuretics : furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes .
DDI-DrugBank.d588.s0.e1_DDI-DrugBank.d588.s0.e2 false diuretics : furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes .
DDI-DrugBank.d588.s0.e3_DDI-DrugBank.d588.s0.e0 false diuretics : furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes .
DDI-DrugBank.d588.s0.e3_DDI-DrugBank.d588.s0.e2 false diuretics : furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes .
DDI-DrugBank.d588.s0.e0_DDI-DrugBank.d588.s0.e2 false diuretics : furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes .
DDI-DrugBank.d588.s11
DDI-DrugBank.d588.s11.e1_DDI-DrugBank.d588.s11.e2 true sympathomimetics : metolazone may decrease arterial responsiveness to norepinephrine , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use .
DDI-DrugBank.d588.s11.e1_DDI-DrugBank.d588.s11.e0 false sympathomimetics : metolazone may decrease arterial responsiveness to norepinephrine , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use .
DDI-DrugBank.d588.s11.e2_DDI-DrugBank.d588.s11.e0 false sympathomimetics : metolazone may decrease arterial responsiveness to norepinephrine , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use .
DDI-DrugBank.d693.s1
DDI-DrugBank.d693.s1.e0_DDI-DrugBank.d693.s1.e1 false when daily doses of sulfasalazine 2 g and weekly doses of methotrexate 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study , the pharmacokinetic disposition of the drugs was not altered .
DDI-DrugBank.d689.s2
DDI-DrugBank.d698.s0
DDI-DrugBank.d698.s0.e0_DDI-DrugBank.d698.s0.e1 false interactions for vitamin b2 ( riboflavin ): alcohol - impairs the intestinal absorption of riboflavin
DDI-DrugBank.d698.s0.e0_DDI-DrugBank.d698.s0.e2 false interactions for vitamin b2 ( riboflavin ): alcohol - impairs the intestinal absorption of riboflavin
DDI-DrugBank.d698.s0.e0_DDI-DrugBank.d698.s0.e3 false interactions for vitamin b2 ( riboflavin ): alcohol - impairs the intestinal absorption of riboflavin
DDI-DrugBank.d698.s0.e1_DDI-DrugBank.d698.s0.e2 false interactions for vitamin b2 ( riboflavin ): alcohol - impairs the intestinal absorption of riboflavin
DDI-DrugBank.d698.s0.e1_DDI-DrugBank.d698.s0.e3 false interactions for vitamin b2 ( riboflavin ): alcohol - impairs the intestinal absorption of riboflavin
DDI-DrugBank.d698.s0.e2_DDI-DrugBank.d698.s0.e3 true interactions for vitamin b2 ( riboflavin ): alcohol - impairs the intestinal absorption of riboflavin
DDI-DrugBank.d652.s5
DDI-DrugBank.d645.s1
DDI-DrugBank.d661.s5
DDI-DrugBank.d743.s6
DDI-DrugBank.d653.s2
DDI-DrugBank.d653.s2.e0_DDI-DrugBank.d653.s2.e1 false drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance .
DDI-DrugBank.d653.s2.e0_DDI-DrugBank.d653.s2.e2 true drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance .
DDI-DrugBank.d653.s2.e1_DDI-DrugBank.d653.s2.e2 true drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance .
DDI-DrugBank.d572.s9
DDI-DrugBank.d572.s9.e0_DDI-DrugBank.d572.s9.e1 false cyclosporine : the total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications , including cyclosporine .
DDI-DrugBank.d572.s9.e0_DDI-DrugBank.d572.s9.e2 false cyclosporine : the total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications , including cyclosporine .
DDI-DrugBank.d572.s9.e1_DDI-DrugBank.d572.s9.e2 true cyclosporine : the total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications , including cyclosporine .
DDI-DrugBank.d584.s4
DDI-DrugBank.d666.s3
DDI-DrugBank.d666.s3.e0_DDI-DrugBank.d666.s3.e1 true pindolol has been shown to increase serum thioridazine levels when both drugs are co-administered .
DDI-DrugBank.d633.s15
DDI-DrugBank.d633.s15.e1_DDI-DrugBank.d633.s15.e2 false mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to mexitil , has been reported to lower serum digoxin levels .
DDI-DrugBank.d633.s15.e1_DDI-DrugBank.d633.s15.e4 false mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to mexitil , has been reported to lower serum digoxin levels .
DDI-DrugBank.d633.s15.e1_DDI-DrugBank.d633.s15.e0 false mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to mexitil , has been reported to lower serum digoxin levels .
DDI-DrugBank.d633.s15.e1_DDI-DrugBank.d633.s15.e3 false mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to mexitil , has been reported to lower serum digoxin levels .
DDI-DrugBank.d633.s15.e2_DDI-DrugBank.d633.s15.e4 true mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to mexitil , has been reported to lower serum digoxin levels .
DDI-DrugBank.d633.s15.e2_DDI-DrugBank.d633.s15.e0 false mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to mexitil , has been reported to lower serum digoxin levels .
DDI-DrugBank.d633.s15.e2_DDI-DrugBank.d633.s15.e3 false mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to mexitil , has been reported to lower serum digoxin levels .
DDI-DrugBank.d633.s15.e4_DDI-DrugBank.d633.s15.e0 false mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to mexitil , has been reported to lower serum digoxin levels .
DDI-DrugBank.d633.s15.e4_DDI-DrugBank.d633.s15.e3 false mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to mexitil , has been reported to lower serum digoxin levels .
DDI-DrugBank.d633.s15.e0_DDI-DrugBank.d633.s15.e3 false mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide , when used to treat gastrointestinal symptoms due to mexitil , has been reported to lower serum digoxin levels .
DDI-DrugBank.d776.s38
DDI-DrugBank.d776.s38.e0_DDI-DrugBank.d776.s38.e1 true fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ;
DDI-DrugBank.d776.s38.e0_DDI-DrugBank.d776.s38.e2 true fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ;
DDI-DrugBank.d776.s38.e0_DDI-DrugBank.d776.s38.e4 false fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ;
DDI-DrugBank.d776.s38.e0_DDI-DrugBank.d776.s38.e5 false fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ;
DDI-DrugBank.d776.s38.e0_DDI-DrugBank.d776.s38.e3 false fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ;
DDI-DrugBank.d776.s38.e1_DDI-DrugBank.d776.s38.e2 false fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ;
DDI-DrugBank.d776.s38.e1_DDI-DrugBank.d776.s38.e4 false fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ;
DDI-DrugBank.d776.s38.e1_DDI-DrugBank.d776.s38.e5 false fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ;
DDI-DrugBank.d776.s38.e1_DDI-DrugBank.d776.s38.e3 false fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ;
DDI-DrugBank.d776.s38.e2_DDI-DrugBank.d776.s38.e4 false fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ;
DDI-DrugBank.d776.s38.e2_DDI-DrugBank.d776.s38.e5 false fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ;
DDI-DrugBank.d776.s38.e2_DDI-DrugBank.d776.s38.e3 false fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ;
DDI-DrugBank.d776.s38.e4_DDI-DrugBank.d776.s38.e5 false fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ;
DDI-DrugBank.d776.s38.e4_DDI-DrugBank.d776.s38.e3 false fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ;
DDI-DrugBank.d776.s38.e5_DDI-DrugBank.d776.s38.e3 false fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels ;
DDI-DrugBank.d581.s0
DDI-DrugBank.d739.s9
DDI-DrugBank.d572.s36
DDI-DrugBank.d572.s25
DDI-DrugBank.d659.s0
DDI-DrugBank.d659.s0.e0_DDI-DrugBank.d659.s0.e1 true although a causal relationship has not been established , there have been reports of bleeding and/or prolonged prothrombin time in patients treated with trental with and without anticoagulants or platelet aggregation inhibitors .
DDI-DrugBank.d659.s0.e0_DDI-DrugBank.d659.s0.e2 true although a causal relationship has not been established , there have been reports of bleeding and/or prolonged prothrombin time in patients treated with trental with and without anticoagulants or platelet aggregation inhibitors .
DDI-DrugBank.d659.s0.e1_DDI-DrugBank.d659.s0.e2 false although a causal relationship has not been established , there have been reports of bleeding and/or prolonged prothrombin time in patients treated with trental with and without anticoagulants or platelet aggregation inhibitors .
DDI-DrugBank.d576.s0
DDI-DrugBank.d690.s1
DDI-DrugBank.d573.s1
DDI-DrugBank.d573.s1.e0_DDI-DrugBank.d573.s1.e1 true if at all possible guanethidine should be discontinued well before minoxidil is begun .
DDI-DrugBank.d637.s1
DDI-DrugBank.d637.s1.e1_DDI-DrugBank.d637.s1.e0 false use of neuroleptics in conjunction with oral morphine may increase the risk of respiratory depression , hypotension and profound sedation or coma .
DDI-DrugBank.d739.s10
DDI-DrugBank.d739.s10.e0_DDI-DrugBank.d739.s10.e1 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e0_DDI-DrugBank.d739.s10.e2 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e0_DDI-DrugBank.d739.s10.e3 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e0_DDI-DrugBank.d739.s10.e5 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e0_DDI-DrugBank.d739.s10.e6 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e0_DDI-DrugBank.d739.s10.e7 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e0_DDI-DrugBank.d739.s10.e8 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e0_DDI-DrugBank.d739.s10.e9 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e0_DDI-DrugBank.d739.s10.e4 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e1_DDI-DrugBank.d739.s10.e2 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e1_DDI-DrugBank.d739.s10.e3 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e1_DDI-DrugBank.d739.s10.e5 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e1_DDI-DrugBank.d739.s10.e6 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e1_DDI-DrugBank.d739.s10.e7 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e1_DDI-DrugBank.d739.s10.e8 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e1_DDI-DrugBank.d739.s10.e9 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e1_DDI-DrugBank.d739.s10.e4 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e2_DDI-DrugBank.d739.s10.e3 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e2_DDI-DrugBank.d739.s10.e5 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e2_DDI-DrugBank.d739.s10.e6 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e2_DDI-DrugBank.d739.s10.e7 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e2_DDI-DrugBank.d739.s10.e8 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e2_DDI-DrugBank.d739.s10.e9 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e2_DDI-DrugBank.d739.s10.e4 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e3_DDI-DrugBank.d739.s10.e5 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e3_DDI-DrugBank.d739.s10.e6 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e3_DDI-DrugBank.d739.s10.e7 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e3_DDI-DrugBank.d739.s10.e8 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e3_DDI-DrugBank.d739.s10.e9 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e3_DDI-DrugBank.d739.s10.e4 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e5_DDI-DrugBank.d739.s10.e6 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e5_DDI-DrugBank.d739.s10.e7 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e5_DDI-DrugBank.d739.s10.e8 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e5_DDI-DrugBank.d739.s10.e9 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e5_DDI-DrugBank.d739.s10.e4 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e6_DDI-DrugBank.d739.s10.e7 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e6_DDI-DrugBank.d739.s10.e8 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e6_DDI-DrugBank.d739.s10.e9 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e6_DDI-DrugBank.d739.s10.e4 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e7_DDI-DrugBank.d739.s10.e8 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e7_DDI-DrugBank.d739.s10.e9 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e7_DDI-DrugBank.d739.s10.e4 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e8_DDI-DrugBank.d739.s10.e9 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e8_DDI-DrugBank.d739.s10.e4 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d739.s10.e9_DDI-DrugBank.d739.s10.e4 false in drug-interaction studies , the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs : theophylline , prednisone , prednisolone , oral contraceptives ( norethindrone 1 mg/ethinyl estradiol 35 mcg ) , terfenadine , digoxin , and warfarin .
DDI-DrugBank.d784.s3
DDI-DrugBank.d784.s3.e0_DDI-DrugBank.d784.s3.e2 false mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when ditropan xl was administered with ketoconazole , a potent cyp3a4 inhibitor .
DDI-DrugBank.d784.s3.e0_DDI-DrugBank.d784.s3.e1 false mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when ditropan xl was administered with ketoconazole , a potent cyp3a4 inhibitor .
DDI-DrugBank.d784.s3.e2_DDI-DrugBank.d784.s3.e1 false mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when ditropan xl was administered with ketoconazole , a potent cyp3a4 inhibitor .
DDI-DrugBank.d578.s6
DDI-DrugBank.d680.s3
DDI-DrugBank.d680.s3.e0_DDI-DrugBank.d680.s3.e1 false therefore , when coadministered with pantoprazole , adjustment of the dosage of pantoprazole or of such drugs may not be necessary .
DDI-DrugBank.d776.s25
DDI-DrugBank.d776.s25.e0_DDI-DrugBank.d776.s25.e1 false cisapride : there have been reports of cardiac events , including torsade de pointes in patients to whom fluconazole and cisapride were coadministered .
DDI-DrugBank.d776.s25.e0_DDI-DrugBank.d776.s25.e2 false cisapride : there have been reports of cardiac events , including torsade de pointes in patients to whom fluconazole and cisapride were coadministered .
DDI-DrugBank.d776.s25.e1_DDI-DrugBank.d776.s25.e2 true cisapride : there have been reports of cardiac events , including torsade de pointes in patients to whom fluconazole and cisapride were coadministered .
DDI-DrugBank.d776.s31
DDI-DrugBank.d776.s31.e0_DDI-DrugBank.d776.s31.e1 false rifabutin : there have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered .
DDI-DrugBank.d776.s31.e0_DDI-DrugBank.d776.s31.e2 false rifabutin : there have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered .
DDI-DrugBank.d776.s31.e1_DDI-DrugBank.d776.s31.e2 true rifabutin : there have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered .
DDI-DrugBank.d743.s3
DDI-DrugBank.d597.s14
DDI-DrugBank.d597.s14.e2_DDI-DrugBank.d597.s14.e1 false : clinical studies , as well as post-marketing observations , have shown that nsaids can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients
DDI-DrugBank.d597.s14.e2_DDI-DrugBank.d597.s14.e3 false : clinical studies , as well as post-marketing observations , have shown that nsaids can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients
DDI-DrugBank.d597.s14.e1_DDI-DrugBank.d597.s14.e3 true : clinical studies , as well as post-marketing observations , have shown that nsaids can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients
DDI-DrugBank.d597.s24
DDI-DrugBank.d597.s24.e0_DDI-DrugBank.d597.s24.e1 false meloxicam did not have a significant effect on the pharmacokinetics of single doses of methotrexate .
DDI-DrugBank.d640.s0
DDI-DrugBank.d640.s0.e0_DDI-DrugBank.d640.s0.e1 false diuretics : excessive reductions in blood pressure may occur in patients on diuretic therapy when ace inhibitors are started .
DDI-DrugBank.d716.s1
DDI-DrugBank.d716.s1.e0_DDI-DrugBank.d716.s1.e1 true changes in insulin and other diabetes drug therapies may be necessary during treatment with mazindol .
DDI-DrugBank.d775.s10
DDI-DrugBank.d775.s10.e0_DDI-DrugBank.d775.s10.e5 true other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e0_DDI-DrugBank.d775.s10.e7 true other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e0_DDI-DrugBank.d775.s10.e8 true other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e0_DDI-DrugBank.d775.s10.e9 true other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e0_DDI-DrugBank.d775.s10.e1 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e0_DDI-DrugBank.d775.s10.e2 true other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e0_DDI-DrugBank.d775.s10.e3 true other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e0_DDI-DrugBank.d775.s10.e4 true other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e0_DDI-DrugBank.d775.s10.e6 true other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e5_DDI-DrugBank.d775.s10.e7 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e5_DDI-DrugBank.d775.s10.e8 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e5_DDI-DrugBank.d775.s10.e9 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e5_DDI-DrugBank.d775.s10.e1 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e5_DDI-DrugBank.d775.s10.e2 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e5_DDI-DrugBank.d775.s10.e3 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e5_DDI-DrugBank.d775.s10.e4 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e5_DDI-DrugBank.d775.s10.e6 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e7_DDI-DrugBank.d775.s10.e8 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e7_DDI-DrugBank.d775.s10.e9 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e7_DDI-DrugBank.d775.s10.e1 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e7_DDI-DrugBank.d775.s10.e2 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e7_DDI-DrugBank.d775.s10.e3 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e7_DDI-DrugBank.d775.s10.e4 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e7_DDI-DrugBank.d775.s10.e6 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e8_DDI-DrugBank.d775.s10.e9 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e8_DDI-DrugBank.d775.s10.e1 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e8_DDI-DrugBank.d775.s10.e2 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e8_DDI-DrugBank.d775.s10.e3 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e8_DDI-DrugBank.d775.s10.e4 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e8_DDI-DrugBank.d775.s10.e6 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e9_DDI-DrugBank.d775.s10.e1 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e9_DDI-DrugBank.d775.s10.e2 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e9_DDI-DrugBank.d775.s10.e3 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e9_DDI-DrugBank.d775.s10.e4 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e9_DDI-DrugBank.d775.s10.e6 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e1_DDI-DrugBank.d775.s10.e2 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e1_DDI-DrugBank.d775.s10.e3 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e1_DDI-DrugBank.d775.s10.e4 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e1_DDI-DrugBank.d775.s10.e6 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e2_DDI-DrugBank.d775.s10.e3 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e2_DDI-DrugBank.d775.s10.e4 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e2_DDI-DrugBank.d775.s10.e6 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e3_DDI-DrugBank.d775.s10.e4 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e3_DDI-DrugBank.d775.s10.e6 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d775.s10.e4_DDI-DrugBank.d775.s10.e6 false other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as mivacron include certain antibiotics ( e.g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .
DDI-DrugBank.d602.s1
DDI-DrugBank.d602.s1.e1_DDI-DrugBank.d602.s1.e0 false concomitant treatment with nexavar resulted in a 21 % increase in the auc of doxorubicin .
DDI-DrugBank.d736.s6
DDI-DrugBank.d736.s6.e0_DDI-DrugBank.d736.s6.e2 false lithium renal clearance is reduced by thiazides , increasing the risk of lithium toxicity .
DDI-DrugBank.d736.s6.e0_DDI-DrugBank.d736.s6.e1 true lithium renal clearance is reduced by thiazides , increasing the risk of lithium toxicity .
DDI-DrugBank.d736.s6.e2_DDI-DrugBank.d736.s6.e1 false lithium renal clearance is reduced by thiazides , increasing the risk of lithium toxicity .
DDI-DrugBank.d645.s4
DDI-DrugBank.d645.s4.e0_DDI-DrugBank.d645.s4.e1 true terbinafine decreases the clearance of caffeine by 19 % .
DDI-DrugBank.d653.s9
DDI-DrugBank.d585.s6
DDI-DrugBank.d585.s6.e0_DDI-DrugBank.d585.s6.e1 true because antacids may interfere with the absorption of anticholinergic agents , simultaneous use of these drugs should be avoided .
DDI-DrugBank.d641.s6
DDI-DrugBank.d779.s18
DDI-DrugBank.d634.s2
DDI-DrugBank.d608.s1
DDI-DrugBank.d608.s1.e1_DDI-DrugBank.d608.s1.e0 false however , increased prothrombin time and bleeding have been reported in patients on concomitant tolectin and warfarin therapy .
DDI-DrugBank.d678.s2
DDI-DrugBank.d700.s2
DDI-DrugBank.d700.s2.e0_DDI-DrugBank.d700.s2.e1 false cyclosporine : when studied in stable renal transplant patients , cyclosporine , usp ( modified ) pharmacokinetics were unaffected by steady state dosing of myfortic .
DDI-DrugBank.d700.s2.e0_DDI-DrugBank.d700.s2.e2 false cyclosporine : when studied in stable renal transplant patients , cyclosporine , usp ( modified ) pharmacokinetics were unaffected by steady state dosing of myfortic .
DDI-DrugBank.d700.s2.e1_DDI-DrugBank.d700.s2.e2 false cyclosporine : when studied in stable renal transplant patients , cyclosporine , usp ( modified ) pharmacokinetics were unaffected by steady state dosing of myfortic .
DDI-DrugBank.d703.s0
DDI-DrugBank.d703.s0.e1_DDI-DrugBank.d703.s0.e0 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e1_DDI-DrugBank.d703.s0.e2 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e1_DDI-DrugBank.d703.s0.e3 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e1_DDI-DrugBank.d703.s0.e4 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e1_DDI-DrugBank.d703.s0.e5 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e1_DDI-DrugBank.d703.s0.e6 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e1_DDI-DrugBank.d703.s0.e7 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e1_DDI-DrugBank.d703.s0.e8 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e1_DDI-DrugBank.d703.s0.e9 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e0_DDI-DrugBank.d703.s0.e2 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e0_DDI-DrugBank.d703.s0.e3 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e0_DDI-DrugBank.d703.s0.e4 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e0_DDI-DrugBank.d703.s0.e5 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e0_DDI-DrugBank.d703.s0.e6 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e0_DDI-DrugBank.d703.s0.e7 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e0_DDI-DrugBank.d703.s0.e8 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e0_DDI-DrugBank.d703.s0.e9 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e2_DDI-DrugBank.d703.s0.e3 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e2_DDI-DrugBank.d703.s0.e4 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e2_DDI-DrugBank.d703.s0.e5 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e2_DDI-DrugBank.d703.s0.e6 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e2_DDI-DrugBank.d703.s0.e7 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e2_DDI-DrugBank.d703.s0.e8 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e2_DDI-DrugBank.d703.s0.e9 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e3_DDI-DrugBank.d703.s0.e4 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e3_DDI-DrugBank.d703.s0.e5 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e3_DDI-DrugBank.d703.s0.e6 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e3_DDI-DrugBank.d703.s0.e7 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e3_DDI-DrugBank.d703.s0.e8 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e3_DDI-DrugBank.d703.s0.e9 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e4_DDI-DrugBank.d703.s0.e5 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e4_DDI-DrugBank.d703.s0.e6 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e4_DDI-DrugBank.d703.s0.e7 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e4_DDI-DrugBank.d703.s0.e8 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e4_DDI-DrugBank.d703.s0.e9 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e5_DDI-DrugBank.d703.s0.e6 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e5_DDI-DrugBank.d703.s0.e7 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e5_DDI-DrugBank.d703.s0.e8 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e5_DDI-DrugBank.d703.s0.e9 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e6_DDI-DrugBank.d703.s0.e7 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e6_DDI-DrugBank.d703.s0.e8 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e6_DDI-DrugBank.d703.s0.e9 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e7_DDI-DrugBank.d703.s0.e8 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e7_DDI-DrugBank.d703.s0.e9 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d703.s0.e8_DDI-DrugBank.d703.s0.e9 false interaction with other central nervous system depressants : meperidine should be used with great caution and in reduced dosage in patients who are concurrently receiving other narcotic analgesics , general anesthetics , phenothiazines , other tranquilizers , sedative-hypnotics ( including barbiturates ) , tricyclic antidepressants and other cns depressants ( including alcohol ) .
DDI-DrugBank.d783.s1
DDI-DrugBank.d709.s5
DDI-DrugBank.d709.s5.e0_DDI-DrugBank.d709.s5.e1 false although such a risk is not verified for roxithromycin , combination of roxithromycin with such drugs is not recommended .
DDI-DrugBank.d779.s13
DDI-DrugBank.d604.s4
DDI-DrugBank.d604.s4.e0_DDI-DrugBank.d604.s4.e3 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e0_DDI-DrugBank.d604.s4.e4 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e0_DDI-DrugBank.d604.s4.e6 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e0_DDI-DrugBank.d604.s4.e7 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e0_DDI-DrugBank.d604.s4.e8 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e0_DDI-DrugBank.d604.s4.e9 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e0_DDI-DrugBank.d604.s4.e1 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e0_DDI-DrugBank.d604.s4.e2 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e0_DDI-DrugBank.d604.s4.e5 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e3_DDI-DrugBank.d604.s4.e4 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e3_DDI-DrugBank.d604.s4.e6 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e3_DDI-DrugBank.d604.s4.e7 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e3_DDI-DrugBank.d604.s4.e8 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e3_DDI-DrugBank.d604.s4.e9 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e3_DDI-DrugBank.d604.s4.e1 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e3_DDI-DrugBank.d604.s4.e2 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e3_DDI-DrugBank.d604.s4.e5 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e4_DDI-DrugBank.d604.s4.e6 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e4_DDI-DrugBank.d604.s4.e7 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e4_DDI-DrugBank.d604.s4.e8 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e4_DDI-DrugBank.d604.s4.e9 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e4_DDI-DrugBank.d604.s4.e1 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e4_DDI-DrugBank.d604.s4.e2 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e4_DDI-DrugBank.d604.s4.e5 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e6_DDI-DrugBank.d604.s4.e7 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e6_DDI-DrugBank.d604.s4.e8 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e6_DDI-DrugBank.d604.s4.e9 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e6_DDI-DrugBank.d604.s4.e1 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e6_DDI-DrugBank.d604.s4.e2 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e6_DDI-DrugBank.d604.s4.e5 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e7_DDI-DrugBank.d604.s4.e8 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e7_DDI-DrugBank.d604.s4.e9 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e7_DDI-DrugBank.d604.s4.e1 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e7_DDI-DrugBank.d604.s4.e2 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e7_DDI-DrugBank.d604.s4.e5 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e8_DDI-DrugBank.d604.s4.e9 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e8_DDI-DrugBank.d604.s4.e1 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e8_DDI-DrugBank.d604.s4.e2 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e8_DDI-DrugBank.d604.s4.e5 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e9_DDI-DrugBank.d604.s4.e1 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e9_DDI-DrugBank.d604.s4.e2 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e9_DDI-DrugBank.d604.s4.e5 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e1_DDI-DrugBank.d604.s4.e2 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e1_DDI-DrugBank.d604.s4.e5 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d604.s4.e2_DDI-DrugBank.d604.s4.e5 false important non-thalidomide drug interactions drugs that interfere with hormonal contraceptives : concomitant use of hiv-protease inhibitors , griseofulvin , modafinil , penicillins , rifampin , rifabutin , phenytoin , carbamazepine , or certain herbal supplements such as st.
DDI-DrugBank.d655.s0
DDI-DrugBank.d655.s0.e0_DDI-DrugBank.d655.s0.e4 true methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e0_DDI-DrugBank.d655.s0.e5 true methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e0_DDI-DrugBank.d655.s0.e6 true methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e0_DDI-DrugBank.d655.s0.e7 true methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e0_DDI-DrugBank.d655.s0.e8 true methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e0_DDI-DrugBank.d655.s0.e9 true methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e0_DDI-DrugBank.d655.s0.e1 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e0_DDI-DrugBank.d655.s0.e2 true methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e0_DDI-DrugBank.d655.s0.e3 true methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e4_DDI-DrugBank.d655.s0.e5 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e4_DDI-DrugBank.d655.s0.e6 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e4_DDI-DrugBank.d655.s0.e7 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e4_DDI-DrugBank.d655.s0.e8 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e4_DDI-DrugBank.d655.s0.e9 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e4_DDI-DrugBank.d655.s0.e1 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e4_DDI-DrugBank.d655.s0.e2 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e4_DDI-DrugBank.d655.s0.e3 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e5_DDI-DrugBank.d655.s0.e6 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e5_DDI-DrugBank.d655.s0.e7 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e5_DDI-DrugBank.d655.s0.e8 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e5_DDI-DrugBank.d655.s0.e9 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e5_DDI-DrugBank.d655.s0.e1 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e5_DDI-DrugBank.d655.s0.e2 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e5_DDI-DrugBank.d655.s0.e3 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e6_DDI-DrugBank.d655.s0.e7 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e6_DDI-DrugBank.d655.s0.e8 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e6_DDI-DrugBank.d655.s0.e9 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e6_DDI-DrugBank.d655.s0.e1 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e6_DDI-DrugBank.d655.s0.e2 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e6_DDI-DrugBank.d655.s0.e3 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e7_DDI-DrugBank.d655.s0.e8 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e7_DDI-DrugBank.d655.s0.e9 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e7_DDI-DrugBank.d655.s0.e1 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e7_DDI-DrugBank.d655.s0.e2 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e7_DDI-DrugBank.d655.s0.e3 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e8_DDI-DrugBank.d655.s0.e9 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e8_DDI-DrugBank.d655.s0.e1 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e8_DDI-DrugBank.d655.s0.e2 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e8_DDI-DrugBank.d655.s0.e3 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e9_DDI-DrugBank.d655.s0.e1 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e9_DDI-DrugBank.d655.s0.e2 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e9_DDI-DrugBank.d655.s0.e3 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e1_DDI-DrugBank.d655.s0.e2 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e1_DDI-DrugBank.d655.s0.e3 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d655.s0.e2_DDI-DrugBank.d655.s0.e3 false methscopolamine may interact with antidepressants ( tricyclic type ) , mao inhibitors ( e.g. , phenelzine , linezolid , tranylcypromine , isocarboxazid , selegiline , furazolidone ) , quinidine , amantadine , antihistamines ( e.g. , diphenhydramine ) , other anticholinergics , potassium chloride supplements , antacids , absorbent-type anti-diarrhea medicines ( e.g. , kaolin-pectin ) , phenothiazines ( e.g. , chlorpromazine , promethazine ) .
DDI-DrugBank.d699.s0
DDI-DrugBank.d699.s0.e0_DDI-DrugBank.d699.s0.e5 true mequitazine can interact with cns depressant , antichlolinergic , tca , maois , and alcohol .
DDI-DrugBank.d699.s0.e0_DDI-DrugBank.d699.s0.e1 true mequitazine can interact with cns depressant , antichlolinergic , tca , maois , and alcohol .
DDI-DrugBank.d699.s0.e0_DDI-DrugBank.d699.s0.e2 true mequitazine can interact with cns depressant , antichlolinergic , tca , maois , and alcohol .
DDI-DrugBank.d699.s0.e0_DDI-DrugBank.d699.s0.e3 true mequitazine can interact with cns depressant , antichlolinergic , tca , maois , and alcohol .
DDI-DrugBank.d699.s0.e0_DDI-DrugBank.d699.s0.e4 true mequitazine can interact with cns depressant , antichlolinergic , tca , maois , and alcohol .
DDI-DrugBank.d699.s0.e5_DDI-DrugBank.d699.s0.e1 false mequitazine can interact with cns depressant , antichlolinergic , tca , maois , and alcohol .
DDI-DrugBank.d699.s0.e5_DDI-DrugBank.d699.s0.e2 false mequitazine can interact with cns depressant , antichlolinergic , tca , maois , and alcohol .
DDI-DrugBank.d699.s0.e5_DDI-DrugBank.d699.s0.e3 false mequitazine can interact with cns depressant , antichlolinergic , tca , maois , and alcohol .
DDI-DrugBank.d699.s0.e5_DDI-DrugBank.d699.s0.e4 false mequitazine can interact with cns depressant , antichlolinergic , tca , maois , and alcohol .
DDI-DrugBank.d699.s0.e1_DDI-DrugBank.d699.s0.e2 false mequitazine can interact with cns depressant , antichlolinergic , tca , maois , and alcohol .
DDI-DrugBank.d699.s0.e1_DDI-DrugBank.d699.s0.e3 false mequitazine can interact with cns depressant , antichlolinergic , tca , maois , and alcohol .
DDI-DrugBank.d699.s0.e1_DDI-DrugBank.d699.s0.e4 false mequitazine can interact with cns depressant , antichlolinergic , tca , maois , and alcohol .
DDI-DrugBank.d699.s0.e2_DDI-DrugBank.d699.s0.e3 false mequitazine can interact with cns depressant , antichlolinergic , tca , maois , and alcohol .
DDI-DrugBank.d699.s0.e2_DDI-DrugBank.d699.s0.e4 false mequitazine can interact with cns depressant , antichlolinergic , tca , maois , and alcohol .
DDI-DrugBank.d699.s0.e3_DDI-DrugBank.d699.s0.e4 false mequitazine can interact with cns depressant , antichlolinergic , tca , maois , and alcohol .
DDI-DrugBank.d756.s9
DDI-DrugBank.d575.s4
DDI-DrugBank.d602.s0
DDI-DrugBank.d602.s0.e1_DDI-DrugBank.d602.s0.e0 false caution is recommended when administering nexavar with compounds that are metabolized/eliminated predominantly by the ugt1a1 pathway ( e.g. irinotecan ) .
DDI-DrugBank.d633.s4
DDI-DrugBank.d633.s4.e0_DDI-DrugBank.d633.s4.e1 false in this crossover steady state study , the pharmacokinetics of propafenone were unaffected in either phenotype by the coadministration of mexiletine .
DDI-DrugBank.d610.s3
DDI-DrugBank.d610.s3.e0_DDI-DrugBank.d610.s3.e1 true ethanol decreases the elimination of abacavir causing an increase in overall exposure .
DDI-DrugBank.d610.s3.e2_DDI-DrugBank.d610.s3.e3 false the addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir .
DDI-DrugBank.d675.s1
DDI-DrugBank.d659.s3
DDI-DrugBank.d700.s12
DDI-DrugBank.d700.s12.e1_DDI-DrugBank.d700.s12.e0 false live vaccines : during treatment with myfortic , the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective .
DDI-DrugBank.d700.s12.e1_DDI-DrugBank.d700.s12.e2 true live vaccines : during treatment with myfortic , the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective .
DDI-DrugBank.d700.s12.e0_DDI-DrugBank.d700.s12.e2 false live vaccines : during treatment with myfortic , the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective .
DDI-DrugBank.d784.s5
DDI-DrugBank.d572.s18
DDI-DrugBank.d779.s4
DDI-DrugBank.d751.s0
DDI-DrugBank.d751.s0.e2_DDI-DrugBank.d751.s0.e0 false aggrastat has been studied on a background of aspirin and heparin .
DDI-DrugBank.d751.s0.e2_DDI-DrugBank.d751.s0.e1 false aggrastat has been studied on a background of aspirin and heparin .
DDI-DrugBank.d751.s0.e0_DDI-DrugBank.d751.s0.e1 false aggrastat has been studied on a background of aspirin and heparin .
DDI-DrugBank.d711.s1
DDI-DrugBank.d711.s1.e0_DDI-DrugBank.d711.s1.e2 false since bacteriostatic drugs may interfere with the bactericidal action of penicillin , it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin .
DDI-DrugBank.d711.s1.e0_DDI-DrugBank.d711.s1.e1 false since bacteriostatic drugs may interfere with the bactericidal action of penicillin , it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin .
DDI-DrugBank.d711.s1.e2_DDI-DrugBank.d711.s1.e1 false since bacteriostatic drugs may interfere with the bactericidal action of penicillin , it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin .
DDI-DrugBank.d584.s8
DDI-DrugBank.d713.s1
DDI-DrugBank.d726.s2
DDI-DrugBank.d726.s2.e1_DDI-DrugBank.d726.s2.e0 false dose adjustment of zemplar capsules may be required , and ipth and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong cyp3a4 inhibitor such as ketoconazole .
DDI-DrugBank.d761.s9
DDI-DrugBank.d761.s9.e0_DDI-DrugBank.d761.s9.e3 false phenytoin : in 12 normal-weight subjects receiving xenical 120 mg three times a day for 7 days , xenical did not alter the pharmacokinetics of a single 300-mg dose of phenytoin .
DDI-DrugBank.d761.s9.e0_DDI-DrugBank.d761.s9.e1 false phenytoin : in 12 normal-weight subjects receiving xenical 120 mg three times a day for 7 days , xenical did not alter the pharmacokinetics of a single 300-mg dose of phenytoin .
DDI-DrugBank.d761.s9.e0_DDI-DrugBank.d761.s9.e2 false phenytoin : in 12 normal-weight subjects receiving xenical 120 mg three times a day for 7 days , xenical did not alter the pharmacokinetics of a single 300-mg dose of phenytoin .
DDI-DrugBank.d761.s9.e3_DDI-DrugBank.d761.s9.e1 false phenytoin : in 12 normal-weight subjects receiving xenical 120 mg three times a day for 7 days , xenical did not alter the pharmacokinetics of a single 300-mg dose of phenytoin .
DDI-DrugBank.d761.s9.e3_DDI-DrugBank.d761.s9.e2 false phenytoin : in 12 normal-weight subjects receiving xenical 120 mg three times a day for 7 days , xenical did not alter the pharmacokinetics of a single 300-mg dose of phenytoin .
DDI-DrugBank.d761.s9.e1_DDI-DrugBank.d761.s9.e2 false phenytoin : in 12 normal-weight subjects receiving xenical 120 mg three times a day for 7 days , xenical did not alter the pharmacokinetics of a single 300-mg dose of phenytoin .
DDI-DrugBank.d666.s0
DDI-DrugBank.d666.s0.e0_DDI-DrugBank.d666.s0.e1 true catecholamine-depleting drugs ( e.g. , reserpine ) may have an additive effect when given with beta-blocking agents .
DDI-DrugBank.d741.s1
DDI-DrugBank.d704.s3
DDI-DrugBank.d658.s1
DDI-DrugBank.d628.s2
DDI-DrugBank.d776.s19
DDI-DrugBank.d776.s19.e0_DDI-DrugBank.d776.s19.e2 false careful monitoring of serum theophylline concentrations in patients receiving diflucan and theophylline is recommended .
DDI-DrugBank.d776.s19.e0_DDI-DrugBank.d776.s19.e1 false careful monitoring of serum theophylline concentrations in patients receiving diflucan and theophylline is recommended .
DDI-DrugBank.d776.s19.e2_DDI-DrugBank.d776.s19.e1 false careful monitoring of serum theophylline concentrations in patients receiving diflucan and theophylline is recommended .
DDI-DrugBank.d572.s37
DDI-DrugBank.d780.s6
DDI-DrugBank.d780.s6.e1_DDI-DrugBank.d780.s6.e2 false neuromuscular blocking agents ( such as suxamethonium chloride ): concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade .
DDI-DrugBank.d780.s6.e1_DDI-DrugBank.d780.s6.e0 false neuromuscular blocking agents ( such as suxamethonium chloride ): concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade .
DDI-DrugBank.d780.s6.e1_DDI-DrugBank.d780.s6.e3 false neuromuscular blocking agents ( such as suxamethonium chloride ): concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade .
DDI-DrugBank.d780.s6.e2_DDI-DrugBank.d780.s6.e0 false neuromuscular blocking agents ( such as suxamethonium chloride ): concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade .
DDI-DrugBank.d780.s6.e2_DDI-DrugBank.d780.s6.e3 true neuromuscular blocking agents ( such as suxamethonium chloride ): concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade .
DDI-DrugBank.d780.s6.e0_DDI-DrugBank.d780.s6.e3 false neuromuscular blocking agents ( such as suxamethonium chloride ): concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade .
DDI-DrugBank.d693.s0
DDI-DrugBank.d693.s0.e0_DDI-DrugBank.d693.s0.e1 false reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine .
DDI-DrugBank.d693.s0.e0_DDI-DrugBank.d693.s0.e2 true reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine .
DDI-DrugBank.d693.s0.e1_DDI-DrugBank.d693.s0.e2 true reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine .
DDI-DrugBank.d777.s0
DDI-DrugBank.d777.s0.e1_DDI-DrugBank.d777.s0.e0 false the interaction of streptase , streptokinase , with other drugs has not been well studied .
DDI-DrugBank.d591.s4
DDI-DrugBank.d739.s5
DDI-DrugBank.d739.s5.e0_DDI-DrugBank.d739.s5.e1 false - did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone .
DDI-DrugBank.d739.s5.e0_DDI-DrugBank.d739.s5.e2 false - did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone .
DDI-DrugBank.d739.s5.e0_DDI-DrugBank.d739.s5.e3 false - did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone .
DDI-DrugBank.d739.s5.e1_DDI-DrugBank.d739.s5.e2 false - did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone .
DDI-DrugBank.d739.s5.e1_DDI-DrugBank.d739.s5.e3 false - did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone .
DDI-DrugBank.d739.s5.e2_DDI-DrugBank.d739.s5.e3 false - did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone .
DDI-DrugBank.d769.s0
DDI-DrugBank.d769.s0.e1_DDI-DrugBank.d769.s0.e0 false coumarin-derivative anticoagulants : prolongation of prothrombin time ( pt ) and international normalized ratio ( inr ) were observed in patients receiving zolinza concomitantly with coumarin-derivative anticoagulants .
DDI-DrugBank.d769.s0.e1_DDI-DrugBank.d769.s0.e2 true coumarin-derivative anticoagulants : prolongation of prothrombin time ( pt ) and international normalized ratio ( inr ) were observed in patients receiving zolinza concomitantly with coumarin-derivative anticoagulants .
DDI-DrugBank.d769.s0.e0_DDI-DrugBank.d769.s0.e2 false coumarin-derivative anticoagulants : prolongation of prothrombin time ( pt ) and international normalized ratio ( inr ) were observed in patients receiving zolinza concomitantly with coumarin-derivative anticoagulants .
DDI-DrugBank.d776.s21
DDI-DrugBank.d752.s10
DDI-DrugBank.d752.s10.e2_DDI-DrugBank.d752.s10.e3 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e2_DDI-DrugBank.d752.s10.e4 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e2_DDI-DrugBank.d752.s10.e5 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e2_DDI-DrugBank.d752.s10.e6 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e2_DDI-DrugBank.d752.s10.e7 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e2_DDI-DrugBank.d752.s10.e8 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e2_DDI-DrugBank.d752.s10.e9 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e2_DDI-DrugBank.d752.s10.e0 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e2_DDI-DrugBank.d752.s10.e1 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e3_DDI-DrugBank.d752.s10.e4 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e3_DDI-DrugBank.d752.s10.e5 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e3_DDI-DrugBank.d752.s10.e6 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e3_DDI-DrugBank.d752.s10.e7 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e3_DDI-DrugBank.d752.s10.e8 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e3_DDI-DrugBank.d752.s10.e9 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e3_DDI-DrugBank.d752.s10.e0 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e3_DDI-DrugBank.d752.s10.e1 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e4_DDI-DrugBank.d752.s10.e5 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e4_DDI-DrugBank.d752.s10.e6 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e4_DDI-DrugBank.d752.s10.e7 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e4_DDI-DrugBank.d752.s10.e8 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e4_DDI-DrugBank.d752.s10.e9 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e4_DDI-DrugBank.d752.s10.e0 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e4_DDI-DrugBank.d752.s10.e1 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e5_DDI-DrugBank.d752.s10.e6 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e5_DDI-DrugBank.d752.s10.e7 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e5_DDI-DrugBank.d752.s10.e8 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e5_DDI-DrugBank.d752.s10.e9 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e5_DDI-DrugBank.d752.s10.e0 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e5_DDI-DrugBank.d752.s10.e1 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e6_DDI-DrugBank.d752.s10.e7 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e6_DDI-DrugBank.d752.s10.e8 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e6_DDI-DrugBank.d752.s10.e9 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e6_DDI-DrugBank.d752.s10.e0 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e6_DDI-DrugBank.d752.s10.e1 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e7_DDI-DrugBank.d752.s10.e8 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e7_DDI-DrugBank.d752.s10.e9 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e7_DDI-DrugBank.d752.s10.e0 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e7_DDI-DrugBank.d752.s10.e1 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e8_DDI-DrugBank.d752.s10.e9 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e8_DDI-DrugBank.d752.s10.e0 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e8_DDI-DrugBank.d752.s10.e1 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e9_DDI-DrugBank.d752.s10.e0 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e9_DDI-DrugBank.d752.s10.e1 false the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d752.s10.e0_DDI-DrugBank.d752.s10.e1 true the sedative effect of versed syrup is accentuated by any concomitantly administered medication which depresses the central nervous system , particularly narcotics ( eg , morphine , meperidine and fentanyl ) , propofol , ketamine , nitrous oxide , secobarbital and droperidol .
DDI-DrugBank.d784.s2
DDI-DrugBank.d776.s16
DDI-DrugBank.d776.s16.e0_DDI-DrugBank.d776.s16.e1 false rifampin : rifampin enhances the metabolism of concurrently administered diflucan .
DDI-DrugBank.d776.s16.e0_DDI-DrugBank.d776.s16.e2 false rifampin : rifampin enhances the metabolism of concurrently administered diflucan .
DDI-DrugBank.d776.s16.e1_DDI-DrugBank.d776.s16.e2 true rifampin : rifampin enhances the metabolism of concurrently administered diflucan .
DDI-DrugBank.d781.s11
DDI-DrugBank.d781.s11.e0_DDI-DrugBank.d781.s11.e1 false digoxin : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded .
DDI-DrugBank.d781.s11.e0_DDI-DrugBank.d781.s11.e3 false digoxin : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded .
DDI-DrugBank.d781.s11.e0_DDI-DrugBank.d781.s11.e4 false digoxin : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded .
DDI-DrugBank.d781.s11.e0_DDI-DrugBank.d781.s11.e5 false digoxin : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded .
DDI-DrugBank.d781.s11.e0_DDI-DrugBank.d781.s11.e2 false digoxin : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded .
DDI-DrugBank.d781.s11.e1_DDI-DrugBank.d781.s11.e3 false digoxin : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded .
DDI-DrugBank.d781.s11.e1_DDI-DrugBank.d781.s11.e4 false digoxin : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded .
DDI-DrugBank.d781.s11.e1_DDI-DrugBank.d781.s11.e5 false digoxin : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded .
DDI-DrugBank.d781.s11.e1_DDI-DrugBank.d781.s11.e2 false digoxin : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded .
DDI-DrugBank.d781.s11.e3_DDI-DrugBank.d781.s11.e4 false digoxin : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded .
DDI-DrugBank.d781.s11.e3_DDI-DrugBank.d781.s11.e5 false digoxin : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded .
DDI-DrugBank.d781.s11.e3_DDI-DrugBank.d781.s11.e2 false digoxin : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded .
DDI-DrugBank.d781.s11.e4_DDI-DrugBank.d781.s11.e5 false digoxin : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded .
DDI-DrugBank.d781.s11.e4_DDI-DrugBank.d781.s11.e2 false digoxin : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded .
DDI-DrugBank.d781.s11.e5_DDI-DrugBank.d781.s11.e2 false digoxin : a controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with aceon tablets , but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded .
DDI-DrugBank.d680.s10
DDI-DrugBank.d741.s2
DDI-DrugBank.d736.s0
DDI-DrugBank.d652.s3
DDI-DrugBank.d652.s3.e0_DDI-DrugBank.d652.s3.e1 true absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3.e0_DDI-DrugBank.d652.s3.e2 false absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3.e0_DDI-DrugBank.d652.s3.e3 false absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3.e0_DDI-DrugBank.d652.s3.e4 false absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3.e0_DDI-DrugBank.d652.s3.e5 false absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3.e0_DDI-DrugBank.d652.s3.e6 false absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3.e1_DDI-DrugBank.d652.s3.e2 true absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3.e1_DDI-DrugBank.d652.s3.e3 false absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3.e1_DDI-DrugBank.d652.s3.e4 false absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3.e1_DDI-DrugBank.d652.s3.e5 false absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3.e1_DDI-DrugBank.d652.s3.e6 false absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3.e2_DDI-DrugBank.d652.s3.e3 false absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3.e2_DDI-DrugBank.d652.s3.e4 false absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3.e2_DDI-DrugBank.d652.s3.e5 false absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3.e2_DDI-DrugBank.d652.s3.e6 false absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3.e3_DDI-DrugBank.d652.s3.e4 false absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3.e3_DDI-DrugBank.d652.s3.e5 false absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3.e3_DDI-DrugBank.d652.s3.e6 false absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3.e4_DDI-DrugBank.d652.s3.e5 false absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3.e4_DDI-DrugBank.d652.s3.e6 false absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d652.s3.e5_DDI-DrugBank.d652.s3.e6 false absorption of drugs from the stomach may be diminished ( e.g. , digoxin ) by metoclopramide , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased ( e.g. , acetaminophen , tetracycline , levodopa , ethanol , cyclosporine ) .
DDI-DrugBank.d619.s3
DDI-DrugBank.d720.s2
DDI-DrugBank.d720.s2.e1_DDI-DrugBank.d720.s2.e0 false mao-a inhibitors reduce sumatriptan clearance , significantly increasing systemic exposure .
DDI-DrugBank.d776.s9
DDI-DrugBank.d641.s4
DDI-DrugBank.d641.s4.e1_DDI-DrugBank.d641.s4.e0 false patients with mild to moderate renal insufficiency should avoid taking nsaids with short elimination half-lives for a period of 2 days before , the day of , and 2 days following administration of alimta .
DDI-DrugBank.d781.s8
DDI-DrugBank.d781.s8.e0_DDI-DrugBank.d781.s8.e1 false lithium : increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ace inhibitor therapy .
DDI-DrugBank.d781.s8.e0_DDI-DrugBank.d781.s8.e2 false lithium : increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ace inhibitor therapy .
DDI-DrugBank.d781.s8.e0_DDI-DrugBank.d781.s8.e3 false lithium : increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ace inhibitor therapy .
DDI-DrugBank.d781.s8.e1_DDI-DrugBank.d781.s8.e2 false lithium : increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ace inhibitor therapy .
DDI-DrugBank.d781.s8.e1_DDI-DrugBank.d781.s8.e3 false lithium : increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ace inhibitor therapy .
DDI-DrugBank.d781.s8.e2_DDI-DrugBank.d781.s8.e3 false lithium : increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ace inhibitor therapy .
DDI-DrugBank.d572.s12
DDI-DrugBank.d572.s12.e0_DDI-DrugBank.d572.s12.e1 false a 104-week dietary carcinogenicity study with ezetimibe was also conducted in mice at doses up to 500 mg/kg/day ( > 150 times the human exposure at 10 mg daily based on auc0 - 24hr for total ezetimibe ) .
DDI-DrugBank.d721.s4
DDI-DrugBank.d721.s4.e0_DDI-DrugBank.d721.s4.e1 false in vitro studies show that tiludronate does not displace warfarin from its binding site on protein .
DDI-DrugBank.d615.s2
DDI-DrugBank.d722.s1
DDI-DrugBank.d722.s1.e1_DDI-DrugBank.d722.s1.e2 false as there is in vitro evidence that aminosalicylate derivatives ( e.g. , olsalazine , mesalazine , or sulphasalazine ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy .
DDI-DrugBank.d722.s1.e1_DDI-DrugBank.d722.s1.e3 false as there is in vitro evidence that aminosalicylate derivatives ( e.g. , olsalazine , mesalazine , or sulphasalazine ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy .
DDI-DrugBank.d722.s1.e1_DDI-DrugBank.d722.s1.e4 true as there is in vitro evidence that aminosalicylate derivatives ( e.g. , olsalazine , mesalazine , or sulphasalazine ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy .
DDI-DrugBank.d722.s1.e1_DDI-DrugBank.d722.s1.e0 false as there is in vitro evidence that aminosalicylate derivatives ( e.g. , olsalazine , mesalazine , or sulphasalazine ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy .
DDI-DrugBank.d722.s1.e2_DDI-DrugBank.d722.s1.e3 false as there is in vitro evidence that aminosalicylate derivatives ( e.g. , olsalazine , mesalazine , or sulphasalazine ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy .
DDI-DrugBank.d722.s1.e2_DDI-DrugBank.d722.s1.e4 true as there is in vitro evidence that aminosalicylate derivatives ( e.g. , olsalazine , mesalazine , or sulphasalazine ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy .
DDI-DrugBank.d722.s1.e2_DDI-DrugBank.d722.s1.e0 false as there is in vitro evidence that aminosalicylate derivatives ( e.g. , olsalazine , mesalazine , or sulphasalazine ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy .
DDI-DrugBank.d722.s1.e3_DDI-DrugBank.d722.s1.e4 true as there is in vitro evidence that aminosalicylate derivatives ( e.g. , olsalazine , mesalazine , or sulphasalazine ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy .
DDI-DrugBank.d722.s1.e3_DDI-DrugBank.d722.s1.e0 false as there is in vitro evidence that aminosalicylate derivatives ( e.g. , olsalazine , mesalazine , or sulphasalazine ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy .
DDI-DrugBank.d722.s1.e4_DDI-DrugBank.d722.s1.e0 false as there is in vitro evidence that aminosalicylate derivatives ( e.g. , olsalazine , mesalazine , or sulphasalazine ) inhibit the tpmt enzyme , they should be administered with caution to patients receiving concurrent thioguanine therapy .
DDI-DrugBank.d776.s3
DDI-DrugBank.d776.s3.e1_DDI-DrugBank.d776.s3.e0 false one fatality has been reported from hypoglycemia in association with combined diflucan and glyburide use .
DDI-DrugBank.d742.s3
DDI-DrugBank.d645.s0
DDI-DrugBank.d645.s0.e0_DDI-DrugBank.d645.s0.e1 false in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine .
DDI-DrugBank.d645.s0.e0_DDI-DrugBank.d645.s0.e2 false in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine .
DDI-DrugBank.d645.s0.e0_DDI-DrugBank.d645.s0.e3 false in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine .
DDI-DrugBank.d645.s0.e0_DDI-DrugBank.d645.s0.e4 false in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine .
DDI-DrugBank.d645.s0.e1_DDI-DrugBank.d645.s0.e2 false in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine .
DDI-DrugBank.d645.s0.e1_DDI-DrugBank.d645.s0.e3 false in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine .
DDI-DrugBank.d645.s0.e1_DDI-DrugBank.d645.s0.e4 false in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine .
DDI-DrugBank.d645.s0.e2_DDI-DrugBank.d645.s0.e3 false in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine .
DDI-DrugBank.d645.s0.e2_DDI-DrugBank.d645.s0.e4 false in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine .
DDI-DrugBank.d645.s0.e3_DDI-DrugBank.d645.s0.e4 false in vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide , ethinylestradiol , ethoxycoumarin , and cyclosporine .
DDI-DrugBank.d639.s3
DDI-DrugBank.d578.s11
DDI-DrugBank.d578.s11.e0_DDI-DrugBank.d578.s11.e1 true there are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids .
DDI-DrugBank.d597.s20
DDI-DrugBank.d597.s20.e0_DDI-DrugBank.d597.s20.e1 false in a study conducted in healthy subjects , mean pre-dose lithium concentration and auc were increased by 21 % in subjects receiving lithium doses ranging from 804 to 1072 mg bid with meloxicam 15 mg qd as compared to subjects receiving lithium alone .
DDI-DrugBank.d597.s20.e0_DDI-DrugBank.d597.s20.e2 false in a study conducted in healthy subjects , mean pre-dose lithium concentration and auc were increased by 21 % in subjects receiving lithium doses ranging from 804 to 1072 mg bid with meloxicam 15 mg qd as compared to subjects receiving lithium alone .
DDI-DrugBank.d597.s20.e0_DDI-DrugBank.d597.s20.e3 false in a study conducted in healthy subjects , mean pre-dose lithium concentration and auc were increased by 21 % in subjects receiving lithium doses ranging from 804 to 1072 mg bid with meloxicam 15 mg qd as compared to subjects receiving lithium alone .
DDI-DrugBank.d597.s20.e1_DDI-DrugBank.d597.s20.e2 true in a study conducted in healthy subjects , mean pre-dose lithium concentration and auc were increased by 21 % in subjects receiving lithium doses ranging from 804 to 1072 mg bid with meloxicam 15 mg qd as compared to subjects receiving lithium alone .
DDI-DrugBank.d597.s20.e1_DDI-DrugBank.d597.s20.e3 false in a study conducted in healthy subjects , mean pre-dose lithium concentration and auc were increased by 21 % in subjects receiving lithium doses ranging from 804 to 1072 mg bid with meloxicam 15 mg qd as compared to subjects receiving lithium alone .
DDI-DrugBank.d597.s20.e2_DDI-DrugBank.d597.s20.e3 false in a study conducted in healthy subjects , mean pre-dose lithium concentration and auc were increased by 21 % in subjects receiving lithium doses ranging from 804 to 1072 mg bid with meloxicam 15 mg qd as compared to subjects receiving lithium alone .
DDI-DrugBank.d770.s4
DDI-DrugBank.d770.s4.e1_DDI-DrugBank.d770.s4.e0 false however , in patients with paget 's disease prior diphosphonate use appears to reduce the anti-resorptive response to calcitonin ( salmon ) nasal spray .
DDI-DrugBank.d756.s2
DDI-DrugBank.d756.s2.e0_DDI-DrugBank.d756.s2.e1 true additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates .
DDI-DrugBank.d756.s2.e0_DDI-DrugBank.d756.s2.e2 true additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates .
DDI-DrugBank.d756.s2.e1_DDI-DrugBank.d756.s2.e2 false additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates .
DDI-DrugBank.d725.s1
DDI-DrugBank.d725.s1.e0_DDI-DrugBank.d725.s1.e1 false mao inhibitors : the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( maoi ) .
DDI-DrugBank.d725.s1.e0_DDI-DrugBank.d725.s1.e2 false mao inhibitors : the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( maoi ) .
DDI-DrugBank.d725.s1.e0_DDI-DrugBank.d725.s1.e3 false mao inhibitors : the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( maoi ) .
DDI-DrugBank.d725.s1.e1_DDI-DrugBank.d725.s1.e2 true mao inhibitors : the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( maoi ) .
DDI-DrugBank.d725.s1.e1_DDI-DrugBank.d725.s1.e3 true mao inhibitors : the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( maoi ) .
DDI-DrugBank.d725.s1.e2_DDI-DrugBank.d725.s1.e3 false mao inhibitors : the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( maoi ) .
DDI-DrugBank.d641.s0
DDI-DrugBank.d576.s6
DDI-DrugBank.d576.s6.e1_DDI-DrugBank.d576.s6.e2 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e1_DDI-DrugBank.d576.s6.e3 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e1_DDI-DrugBank.d576.s6.e4 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e1_DDI-DrugBank.d576.s6.e5 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e1_DDI-DrugBank.d576.s6.e6 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e1_DDI-DrugBank.d576.s6.e7 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e1_DDI-DrugBank.d576.s6.e8 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e1_DDI-DrugBank.d576.s6.e9 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e1_DDI-DrugBank.d576.s6.e0 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e2_DDI-DrugBank.d576.s6.e3 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e2_DDI-DrugBank.d576.s6.e4 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e2_DDI-DrugBank.d576.s6.e5 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e2_DDI-DrugBank.d576.s6.e6 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e2_DDI-DrugBank.d576.s6.e7 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e2_DDI-DrugBank.d576.s6.e8 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e2_DDI-DrugBank.d576.s6.e9 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e2_DDI-DrugBank.d576.s6.e0 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e3_DDI-DrugBank.d576.s6.e4 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e3_DDI-DrugBank.d576.s6.e5 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e3_DDI-DrugBank.d576.s6.e6 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e3_DDI-DrugBank.d576.s6.e7 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e3_DDI-DrugBank.d576.s6.e8 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e3_DDI-DrugBank.d576.s6.e9 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e3_DDI-DrugBank.d576.s6.e0 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e4_DDI-DrugBank.d576.s6.e5 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e4_DDI-DrugBank.d576.s6.e6 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e4_DDI-DrugBank.d576.s6.e7 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e4_DDI-DrugBank.d576.s6.e8 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e4_DDI-DrugBank.d576.s6.e9 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e4_DDI-DrugBank.d576.s6.e0 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e5_DDI-DrugBank.d576.s6.e6 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e5_DDI-DrugBank.d576.s6.e7 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e5_DDI-DrugBank.d576.s6.e8 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e5_DDI-DrugBank.d576.s6.e9 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e5_DDI-DrugBank.d576.s6.e0 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e6_DDI-DrugBank.d576.s6.e7 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e6_DDI-DrugBank.d576.s6.e8 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e6_DDI-DrugBank.d576.s6.e9 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e6_DDI-DrugBank.d576.s6.e0 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e7_DDI-DrugBank.d576.s6.e8 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e7_DDI-DrugBank.d576.s6.e9 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e7_DDI-DrugBank.d576.s6.e0 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e8_DDI-DrugBank.d576.s6.e9 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e8_DDI-DrugBank.d576.s6.e0 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d576.s6.e9_DDI-DrugBank.d576.s6.e0 false salicylate competes with a number of drugs for protein binding sites , notably penicillin , thiopental , thyroxine , triiodothyronine , phenytoin , sulfinpyrazone , naproxen , warfarin , methotrexate , and possibly corticosteroids .
DDI-DrugBank.d758.s0
DDI-DrugBank.d758.s0.e0_DDI-DrugBank.d758.s0.e1 true the cns depressant effects of oxycodone hydrochloride may be additive with that of other cns depressants ..
DDI-DrugBank.d606.s0
DDI-DrugBank.d606.s0.e2_DDI-DrugBank.d606.s0.e0 false mao inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine .
DDI-DrugBank.d606.s0.e2_DDI-DrugBank.d606.s0.e1 false mao inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine .
DDI-DrugBank.d606.s0.e0_DDI-DrugBank.d606.s0.e1 false mao inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine .
DDI-DrugBank.d761.s1
DDI-DrugBank.d761.s1.e0_DDI-DrugBank.d761.s1.e2 false cyclosporine : preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine .
DDI-DrugBank.d761.s1.e0_DDI-DrugBank.d761.s1.e3 false cyclosporine : preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine .
DDI-DrugBank.d761.s1.e0_DDI-DrugBank.d761.s1.e5 false cyclosporine : preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine .
DDI-DrugBank.d761.s1.e0_DDI-DrugBank.d761.s1.e1 false cyclosporine : preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine .
DDI-DrugBank.d761.s1.e0_DDI-DrugBank.d761.s1.e4 false cyclosporine : preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine .
DDI-DrugBank.d761.s1.e2_DDI-DrugBank.d761.s1.e3 false cyclosporine : preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine .
DDI-DrugBank.d761.s1.e2_DDI-DrugBank.d761.s1.e5 false cyclosporine : preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine .
DDI-DrugBank.d761.s1.e2_DDI-DrugBank.d761.s1.e1 false cyclosporine : preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine .
DDI-DrugBank.d761.s1.e2_DDI-DrugBank.d761.s1.e4 false cyclosporine : preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine .
DDI-DrugBank.d761.s1.e3_DDI-DrugBank.d761.s1.e5 false cyclosporine : preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine .
DDI-DrugBank.d761.s1.e3_DDI-DrugBank.d761.s1.e1 false cyclosporine : preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine .
DDI-DrugBank.d761.s1.e3_DDI-DrugBank.d761.s1.e4 false cyclosporine : preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine .
DDI-DrugBank.d761.s1.e5_DDI-DrugBank.d761.s1.e1 false cyclosporine : preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine .
DDI-DrugBank.d761.s1.e5_DDI-DrugBank.d761.s1.e4 false cyclosporine : preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine .
DDI-DrugBank.d761.s1.e1_DDI-DrugBank.d761.s1.e4 false cyclosporine : preliminary data from a xenical and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when xenical was coadministered with cyclosporine .
DDI-DrugBank.d742.s9
DDI-DrugBank.d742.s9.e0_DDI-DrugBank.d742.s9.e1 true accordingly , patients should be advised to avoid alcohol while taking remeron soltab .
DDI-DrugBank.d742.s9.e2_DDI-DrugBank.d742.s9.e3 false diazepam : concomitant administration of diazepam ( 15 mg ) had a minimal effect on plasma levels of mirtazapine ( 15 mg ) in 12 healthy subjects .
DDI-DrugBank.d742.s9.e2_DDI-DrugBank.d742.s9.e4 false diazepam : concomitant administration of diazepam ( 15 mg ) had a minimal effect on plasma levels of mirtazapine ( 15 mg ) in 12 healthy subjects .
DDI-DrugBank.d742.s9.e3_DDI-DrugBank.d742.s9.e4 true diazepam : concomitant administration of diazepam ( 15 mg ) had a minimal effect on plasma levels of mirtazapine ( 15 mg ) in 12 healthy subjects .
DDI-DrugBank.d769.s1
DDI-DrugBank.d769.s1.e0_DDI-DrugBank.d769.s1.e1 true physicians should carefully monitor pt and inr in patients concurrently administered zolinza and coumarin derivatives .
DDI-DrugBank.d732.s3
DDI-DrugBank.d572.s6
DDI-DrugBank.d572.s6.e0_DDI-DrugBank.d572.s6.e1 false fenofibrate : in a pharmacokinetic study , concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold .
DDI-DrugBank.d572.s6.e0_DDI-DrugBank.d572.s6.e2 false fenofibrate : in a pharmacokinetic study , concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold .
DDI-DrugBank.d572.s6.e1_DDI-DrugBank.d572.s6.e2 true fenofibrate : in a pharmacokinetic study , concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold .
DDI-DrugBank.d576.s2
DDI-DrugBank.d742.s8
DDI-DrugBank.d742.s8.e1_DDI-DrugBank.d742.s8.e0 false however , the impairment of cognitive and motor skills produced by remeron were shown to be additive with those produced by alcohol .
DDI-DrugBank.d753.s1
DDI-DrugBank.d632.s3
DDI-DrugBank.d632.s3.e1_DDI-DrugBank.d632.s3.e0 false when the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness ( such as analgesics ) , the agent should be administered at least 1 hour prior to or 2 hours after symlin injection .
DDI-DrugBank.d616.s1
DDI-DrugBank.d616.s1.e0_DDI-DrugBank.d616.s1.e1 true caution should be exercised when administering zadaxin therapy in combination with other immunomodulating drugs .
DDI-DrugBank.d628.s3
DDI-DrugBank.d628.s3.e2_DDI-DrugBank.d628.s3.e0 false during maintenance of anesthesia or sedation , the rate of diprivan injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents ( eg , nitrous oxide or opioids ) .
DDI-DrugBank.d628.s3.e2_DDI-DrugBank.d628.s3.e1 false during maintenance of anesthesia or sedation , the rate of diprivan injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents ( eg , nitrous oxide or opioids ) .
DDI-DrugBank.d628.s3.e2_DDI-DrugBank.d628.s3.e3 false during maintenance of anesthesia or sedation , the rate of diprivan injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents ( eg , nitrous oxide or opioids ) .
DDI-DrugBank.d628.s3.e0_DDI-DrugBank.d628.s3.e1 true during maintenance of anesthesia or sedation , the rate of diprivan injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents ( eg , nitrous oxide or opioids ) .
DDI-DrugBank.d628.s3.e0_DDI-DrugBank.d628.s3.e3 true during maintenance of anesthesia or sedation , the rate of diprivan injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents ( eg , nitrous oxide or opioids ) .
DDI-DrugBank.d628.s3.e1_DDI-DrugBank.d628.s3.e3 false during maintenance of anesthesia or sedation , the rate of diprivan injectable emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents ( eg , nitrous oxide or opioids ) .
DDI-DrugBank.d599.s0
DDI-DrugBank.d776.s29
DDI-DrugBank.d711.s3
DDI-DrugBank.d711.s3.e1_DDI-DrugBank.d711.s3.e0 false the concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity .
DDI-DrugBank.d695.s1
DDI-DrugBank.d695.s1.e1_DDI-DrugBank.d695.s1.e0 false combination therapy with cerezyme ( imiglucerase ) and zavesca is not indicated .
DDI-DrugBank.d695.s1.e1_DDI-DrugBank.d695.s1.e2 true combination therapy with cerezyme ( imiglucerase ) and zavesca is not indicated .
DDI-DrugBank.d695.s1.e0_DDI-DrugBank.d695.s1.e2 true combination therapy with cerezyme ( imiglucerase ) and zavesca is not indicated .
DDI-DrugBank.d752.s4
DDI-DrugBank.d628.s4
DDI-DrugBank.d628.s4.e0_DDI-DrugBank.d628.s4.e1 false the concurrent administration of potent inhalational agents ( eg , isoflurane , enflurane , and halothane ) during maintenance with diprivan injectable emulsion has not been extensively evaluated .
DDI-DrugBank.d628.s4.e0_DDI-DrugBank.d628.s4.e2 false the concurrent administration of potent inhalational agents ( eg , isoflurane , enflurane , and halothane ) during maintenance with diprivan injectable emulsion has not been extensively evaluated .
DDI-DrugBank.d628.s4.e0_DDI-DrugBank.d628.s4.e3 false the concurrent administration of potent inhalational agents ( eg , isoflurane , enflurane , and halothane ) during maintenance with diprivan injectable emulsion has not been extensively evaluated .
DDI-DrugBank.d628.s4.e1_DDI-DrugBank.d628.s4.e2 false the concurrent administration of potent inhalational agents ( eg , isoflurane , enflurane , and halothane ) during maintenance with diprivan injectable emulsion has not been extensively evaluated .
DDI-DrugBank.d628.s4.e1_DDI-DrugBank.d628.s4.e3 false the concurrent administration of potent inhalational agents ( eg , isoflurane , enflurane , and halothane ) during maintenance with diprivan injectable emulsion has not been extensively evaluated .
DDI-DrugBank.d628.s4.e2_DDI-DrugBank.d628.s4.e3 false the concurrent administration of potent inhalational agents ( eg , isoflurane , enflurane , and halothane ) during maintenance with diprivan injectable emulsion has not been extensively evaluated .
DDI-DrugBank.d598.s0
DDI-DrugBank.d598.s0.e0_DDI-DrugBank.d598.s0.e1 true trimethoprim may inhibit the hepatic metabolism of phenytoin .
DDI-DrugBank.d652.s1
DDI-DrugBank.d652.s1.e0_DDI-DrugBank.d652.s1.e1 true additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers .
DDI-DrugBank.d652.s1.e0_DDI-DrugBank.d652.s1.e2 true additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers .
DDI-DrugBank.d652.s1.e0_DDI-DrugBank.d652.s1.e3 true additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers .
DDI-DrugBank.d652.s1.e0_DDI-DrugBank.d652.s1.e4 true additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers .
DDI-DrugBank.d652.s1.e0_DDI-DrugBank.d652.s1.e5 true additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers .
DDI-DrugBank.d652.s1.e1_DDI-DrugBank.d652.s1.e2 false additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers .
DDI-DrugBank.d652.s1.e1_DDI-DrugBank.d652.s1.e3 false additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers .
DDI-DrugBank.d652.s1.e1_DDI-DrugBank.d652.s1.e4 false additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers .
DDI-DrugBank.d652.s1.e1_DDI-DrugBank.d652.s1.e5 false additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers .
DDI-DrugBank.d652.s1.e2_DDI-DrugBank.d652.s1.e3 false additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers .
DDI-DrugBank.d652.s1.e2_DDI-DrugBank.d652.s1.e4 false additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers .
DDI-DrugBank.d652.s1.e2_DDI-DrugBank.d652.s1.e5 false additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers .
DDI-DrugBank.d652.s1.e3_DDI-DrugBank.d652.s1.e4 false additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers .
DDI-DrugBank.d652.s1.e3_DDI-DrugBank.d652.s1.e5 false additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers .
DDI-DrugBank.d652.s1.e4_DDI-DrugBank.d652.s1.e5 false additive sedative effects can occur when metoclopramide is given with alcohol , sedatives , hypnotics , narcotics , or tranquilizers .
DDI-DrugBank.d687.s2
DDI-DrugBank.d633.s20
DDI-DrugBank.d633.s20.e0_DDI-DrugBank.d633.s20.e1 true additionally , in one controlled study in five normal subjects and seven patients , the clearance of caffeine was decreased 50 % following the administration of mexitil
DDI-DrugBank.d736.s4
DDI-DrugBank.d572.s34
DDI-DrugBank.d715.s0
DDI-DrugBank.d715.s0.e2_DDI-DrugBank.d715.s0.e0 false caution should be observed in administering demser to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis .
DDI-DrugBank.d715.s0.e2_DDI-DrugBank.d715.s0.e1 false caution should be observed in administering demser to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis .
DDI-DrugBank.d715.s0.e0_DDI-DrugBank.d715.s0.e1 true caution should be observed in administering demser to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis .
DDI-DrugBank.d642.s1
DDI-DrugBank.d642.s1.e0_DDI-DrugBank.d642.s1.e1 true concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective .
DDI-DrugBank.d642.s1.e0_DDI-DrugBank.d642.s1.e2 false concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective .
DDI-DrugBank.d642.s1.e1_DDI-DrugBank.d642.s1.e2 false concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective .
DDI-DrugBank.d595.s2
DDI-DrugBank.d595.s2.e0_DDI-DrugBank.d595.s2.e1 false the addition of sodium bicarbonate to parenteral solutions containing calcium should be avoided , except where compatibility has been previously established .
DDI-DrugBank.d739.s14
DDI-DrugBank.d776.s34
DDI-DrugBank.d776.s34.e0_DDI-DrugBank.d776.s34.e1 true patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored .
DDI-DrugBank.d743.s9
DDI-DrugBank.d743.s9.e1_DDI-DrugBank.d743.s9.e2 false macrolides : clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent .
DDI-DrugBank.d743.s9.e1_DDI-DrugBank.d743.s9.e3 true macrolides : clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent .
DDI-DrugBank.d743.s9.e1_DDI-DrugBank.d743.s9.e4 false macrolides : clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent .
DDI-DrugBank.d743.s9.e1_DDI-DrugBank.d743.s9.e0 false macrolides : clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent .
DDI-DrugBank.d743.s9.e2_DDI-DrugBank.d743.s9.e3 true macrolides : clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent .
DDI-DrugBank.d743.s9.e2_DDI-DrugBank.d743.s9.e4 false macrolides : clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent .
DDI-DrugBank.d743.s9.e2_DDI-DrugBank.d743.s9.e0 false macrolides : clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent .
DDI-DrugBank.d743.s9.e3_DDI-DrugBank.d743.s9.e4 false macrolides : clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent .
DDI-DrugBank.d743.s9.e3_DDI-DrugBank.d743.s9.e0 false macrolides : clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent .
DDI-DrugBank.d743.s9.e4_DDI-DrugBank.d743.s9.e0 false macrolides : clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole , but to a lesser extent .
DDI-DrugBank.d700.s7
DDI-DrugBank.d700.s7.e0_DDI-DrugBank.d700.s7.e1 false cholestyramine and drugs that bind bile acids : these drugs interrupt enterohepatic recirculation and reduce mpa exposure when coadministered with mycophenolate mofetil .
DDI-DrugBank.d700.s7.e0_DDI-DrugBank.d700.s7.e2 false cholestyramine and drugs that bind bile acids : these drugs interrupt enterohepatic recirculation and reduce mpa exposure when coadministered with mycophenolate mofetil .
DDI-DrugBank.d700.s7.e1_DDI-DrugBank.d700.s7.e2 false cholestyramine and drugs that bind bile acids : these drugs interrupt enterohepatic recirculation and reduce mpa exposure when coadministered with mycophenolate mofetil .
DDI-DrugBank.d597.s18
DDI-DrugBank.d597.s18.e0_DDI-DrugBank.d597.s18.e1 true nevertheless , during concomitant therapy with furosemide and mobic , patients should be observed closely for signs of declining renal function , as well as to assure diuretic efficacy .
DDI-DrugBank.d653.s8
DDI-DrugBank.d653.s8.e0_DDI-DrugBank.d653.s8.e1 true there are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids .
DDI-DrugBank.d632.s4
DDI-DrugBank.d632.s4.e2_DDI-DrugBank.d632.s4.e0 false in clinical trials , the concomitant use of sulfonylureas or biguanides did not alter the adverse event profile of symlin .
DDI-DrugBank.d632.s4.e2_DDI-DrugBank.d632.s4.e1 false in clinical trials , the concomitant use of sulfonylureas or biguanides did not alter the adverse event profile of symlin .
DDI-DrugBank.d632.s4.e0_DDI-DrugBank.d632.s4.e1 false in clinical trials , the concomitant use of sulfonylureas or biguanides did not alter the adverse event profile of symlin .
DDI-DrugBank.d577.s2
DDI-DrugBank.d633.s12
DDI-DrugBank.d633.s12.e1_DDI-DrugBank.d633.s12.e3 false ecg intervals ( pr , qrs , and qt ) were not affected by concurrent mexitil and digoxin , diuretics , or propranolol .
DDI-DrugBank.d633.s12.e1_DDI-DrugBank.d633.s12.e0 false ecg intervals ( pr , qrs , and qt ) were not affected by concurrent mexitil and digoxin , diuretics , or propranolol .
DDI-DrugBank.d633.s12.e1_DDI-DrugBank.d633.s12.e2 false ecg intervals ( pr , qrs , and qt ) were not affected by concurrent mexitil and digoxin , diuretics , or propranolol .
DDI-DrugBank.d633.s12.e3_DDI-DrugBank.d633.s12.e0 false ecg intervals ( pr , qrs , and qt ) were not affected by concurrent mexitil and digoxin , diuretics , or propranolol .
DDI-DrugBank.d633.s12.e3_DDI-DrugBank.d633.s12.e2 false ecg intervals ( pr , qrs , and qt ) were not affected by concurrent mexitil and digoxin , diuretics , or propranolol .
DDI-DrugBank.d633.s12.e0_DDI-DrugBank.d633.s12.e2 false ecg intervals ( pr , qrs , and qt ) were not affected by concurrent mexitil and digoxin , diuretics , or propranolol .
DDI-DrugBank.d722.s0
DDI-DrugBank.d722.s0.e1_DDI-DrugBank.d722.s0.e3 true there is usually complete cross-resistance between purinethol ( mercaptopurine ) and tabloid brand thioguanine .
DDI-DrugBank.d722.s0.e1_DDI-DrugBank.d722.s0.e0 false there is usually complete cross-resistance between purinethol ( mercaptopurine ) and tabloid brand thioguanine .
DDI-DrugBank.d722.s0.e1_DDI-DrugBank.d722.s0.e2 true there is usually complete cross-resistance between purinethol ( mercaptopurine ) and tabloid brand thioguanine .
DDI-DrugBank.d722.s0.e3_DDI-DrugBank.d722.s0.e0 false there is usually complete cross-resistance between purinethol ( mercaptopurine ) and tabloid brand thioguanine .
DDI-DrugBank.d722.s0.e3_DDI-DrugBank.d722.s0.e2 false there is usually complete cross-resistance between purinethol ( mercaptopurine ) and tabloid brand thioguanine .
DDI-DrugBank.d722.s0.e0_DDI-DrugBank.d722.s0.e2 true there is usually complete cross-resistance between purinethol ( mercaptopurine ) and tabloid brand thioguanine .
DDI-DrugBank.d661.s4
DDI-DrugBank.d661.s4.e0_DDI-DrugBank.d661.s4.e1 false there are no controlled studies documenting the use of zemuron before or after other nondepolarizing muscle relaxants .
DDI-DrugBank.d638.s3
DDI-DrugBank.d625.s1
DDI-DrugBank.d625.s1.e0_DDI-DrugBank.d625.s1.e1 true impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous melphalan and who subsequently received cyclosporin to prevent graft-versus-host disease
DDI-DrugBank.d632.s6
DDI-DrugBank.d632.s6.e1_DDI-DrugBank.d632.s6.e3 false mixing symlin and insulin the pharmacokinetic parameters of symlin were altered when mixed with regular , nph , and 70/30 premixed formulations of recombinant human insulin immediately prior to injection .
DDI-DrugBank.d632.s6.e1_DDI-DrugBank.d632.s6.e0 false mixing symlin and insulin the pharmacokinetic parameters of symlin were altered when mixed with regular , nph , and 70/30 premixed formulations of recombinant human insulin immediately prior to injection .
DDI-DrugBank.d632.s6.e1_DDI-DrugBank.d632.s6.e2 false mixing symlin and insulin the pharmacokinetic parameters of symlin were altered when mixed with regular , nph , and 70/30 premixed formulations of recombinant human insulin immediately prior to injection .
DDI-DrugBank.d632.s6.e3_DDI-DrugBank.d632.s6.e0 false mixing symlin and insulin the pharmacokinetic parameters of symlin were altered when mixed with regular , nph , and 70/30 premixed formulations of recombinant human insulin immediately prior to injection .
DDI-DrugBank.d632.s6.e3_DDI-DrugBank.d632.s6.e2 false mixing symlin and insulin the pharmacokinetic parameters of symlin were altered when mixed with regular , nph , and 70/30 premixed formulations of recombinant human insulin immediately prior to injection .
DDI-DrugBank.d632.s6.e0_DDI-DrugBank.d632.s6.e2 false mixing symlin and insulin the pharmacokinetic parameters of symlin were altered when mixed with regular , nph , and 70/30 premixed formulations of recombinant human insulin immediately prior to injection .
DDI-DrugBank.d700.s13
DDI-DrugBank.d641.s2
DDI-DrugBank.d641.s2.e0_DDI-DrugBank.d641.s2.e1 true concomitant administration of substances that are also tubularly secreted ( e.g. , probenecid ) could potentially result in delayed clearance of alimta .
DDI-DrugBank.d631.s1
DDI-DrugBank.d608.s6
DDI-DrugBank.d572.s16
DDI-DrugBank.d578.s0
DDI-DrugBank.d648.s1
DDI-DrugBank.d648.s1.e0_DDI-DrugBank.d648.s1.e2 false warfarin : the coadministration of evista and warfarin has not been assessed under chronic conditions .
DDI-DrugBank.d648.s1.e0_DDI-DrugBank.d648.s1.e1 false warfarin : the coadministration of evista and warfarin has not been assessed under chronic conditions .
DDI-DrugBank.d648.s1.e2_DDI-DrugBank.d648.s1.e1 false warfarin : the coadministration of evista and warfarin has not been assessed under chronic conditions .
DDI-DrugBank.d771.s4
DDI-DrugBank.d670.s8
DDI-DrugBank.d753.s4
DDI-DrugBank.d753.s4.e0_DDI-DrugBank.d753.s4.e1 true in addition , cns toxicity has been reported ( confusion , disorientation , respiratory depression , apnea , seizures ) following coadministration of cimetidine with opioid analgesics ;
DDI-DrugBank.d763.s4
DDI-DrugBank.d763.s4.e0_DDI-DrugBank.d763.s4.e1 false however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4.e0_DDI-DrugBank.d763.s4.e2 false however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4.e0_DDI-DrugBank.d763.s4.e3 false however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4.e0_DDI-DrugBank.d763.s4.e4 false however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4.e0_DDI-DrugBank.d763.s4.e5 false however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4.e0_DDI-DrugBank.d763.s4.e6 false however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4.e1_DDI-DrugBank.d763.s4.e2 false however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4.e1_DDI-DrugBank.d763.s4.e3 false however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4.e1_DDI-DrugBank.d763.s4.e4 false however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4.e1_DDI-DrugBank.d763.s4.e5 false however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4.e1_DDI-DrugBank.d763.s4.e6 false however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4.e2_DDI-DrugBank.d763.s4.e3 false however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4.e2_DDI-DrugBank.d763.s4.e4 false however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4.e2_DDI-DrugBank.d763.s4.e5 false however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4.e2_DDI-DrugBank.d763.s4.e6 false however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4.e3_DDI-DrugBank.d763.s4.e4 false however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4.e3_DDI-DrugBank.d763.s4.e5 false however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4.e3_DDI-DrugBank.d763.s4.e6 false however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4.e4_DDI-DrugBank.d763.s4.e5 false however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4.e4_DDI-DrugBank.d763.s4.e6 false however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d763.s4.e5_DDI-DrugBank.d763.s4.e6 false however , on the basis of available data , no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 tramadol : although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed , data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 chemotherapy : tumor response to chemotherapy in the p 388 mouse leukemia model is not affected by ondansetron .
DDI-DrugBank.d595.s1
DDI-DrugBank.d595.s1.e0_DDI-DrugBank.d595.s1.e1 false norepinephrine and dobutamine are incompatible with sodium bicarbonate solution .
DDI-DrugBank.d595.s1.e0_DDI-DrugBank.d595.s1.e2 true norepinephrine and dobutamine are incompatible with sodium bicarbonate solution .
DDI-DrugBank.d595.s1.e1_DDI-DrugBank.d595.s1.e2 true norepinephrine and dobutamine are incompatible with sodium bicarbonate solution .
DDI-DrugBank.d765.s1
DDI-DrugBank.d765.s1.e0_DDI-DrugBank.d765.s1.e2 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e0_DDI-DrugBank.d765.s1.e3 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e0_DDI-DrugBank.d765.s1.e5 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e0_DDI-DrugBank.d765.s1.e6 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e0_DDI-DrugBank.d765.s1.e7 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e0_DDI-DrugBank.d765.s1.e8 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e0_DDI-DrugBank.d765.s1.e9 true for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e0_DDI-DrugBank.d765.s1.e1 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e0_DDI-DrugBank.d765.s1.e4 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e2_DDI-DrugBank.d765.s1.e3 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e2_DDI-DrugBank.d765.s1.e5 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e2_DDI-DrugBank.d765.s1.e6 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e2_DDI-DrugBank.d765.s1.e7 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e2_DDI-DrugBank.d765.s1.e8 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e2_DDI-DrugBank.d765.s1.e9 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e2_DDI-DrugBank.d765.s1.e1 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e2_DDI-DrugBank.d765.s1.e4 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e3_DDI-DrugBank.d765.s1.e5 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e3_DDI-DrugBank.d765.s1.e6 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e3_DDI-DrugBank.d765.s1.e7 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e3_DDI-DrugBank.d765.s1.e8 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e3_DDI-DrugBank.d765.s1.e9 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e3_DDI-DrugBank.d765.s1.e1 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e3_DDI-DrugBank.d765.s1.e4 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e5_DDI-DrugBank.d765.s1.e6 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e5_DDI-DrugBank.d765.s1.e7 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e5_DDI-DrugBank.d765.s1.e8 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e5_DDI-DrugBank.d765.s1.e9 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e5_DDI-DrugBank.d765.s1.e1 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e5_DDI-DrugBank.d765.s1.e4 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e6_DDI-DrugBank.d765.s1.e7 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e6_DDI-DrugBank.d765.s1.e8 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e6_DDI-DrugBank.d765.s1.e9 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e6_DDI-DrugBank.d765.s1.e1 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e6_DDI-DrugBank.d765.s1.e4 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e7_DDI-DrugBank.d765.s1.e8 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e7_DDI-DrugBank.d765.s1.e9 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e7_DDI-DrugBank.d765.s1.e1 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e7_DDI-DrugBank.d765.s1.e4 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e8_DDI-DrugBank.d765.s1.e9 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e8_DDI-DrugBank.d765.s1.e1 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e8_DDI-DrugBank.d765.s1.e4 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e9_DDI-DrugBank.d765.s1.e1 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e9_DDI-DrugBank.d765.s1.e4 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d765.s1.e1_DDI-DrugBank.d765.s1.e4 false for patients receiving ketoconazole or other potent cyp3a4 inhibitors such as other azole antifungals ( eg , itraconazole , miconazole ) or macrolide antibiotics ( eg , erythromycin , clarithromycin ) or cyclosporine or vinblastine , the recommended dose of detrol la is 2 mg daily .
DDI-DrugBank.d610.s4
DDI-DrugBank.d610.s4.e0_DDI-DrugBank.d610.s4.e2 false in a study of 11 hiv-infected patients receiving methadone-maintenance therapy ( 40 mg and 90 mg daily ) with 600 mg of ziagen twice daily ( twice the currently recommended dose ) , oral methadone clearance increased 22 % ( 90 % ci 6 % to 42 % ) .
DDI-DrugBank.d610.s4.e0_DDI-DrugBank.d610.s4.e1 true in a study of 11 hiv-infected patients receiving methadone-maintenance therapy ( 40 mg and 90 mg daily ) with 600 mg of ziagen twice daily ( twice the currently recommended dose ) , oral methadone clearance increased 22 % ( 90 % ci 6 % to 42 % ) .
DDI-DrugBank.d610.s4.e2_DDI-DrugBank.d610.s4.e1 false in a study of 11 hiv-infected patients receiving methadone-maintenance therapy ( 40 mg and 90 mg daily ) with 600 mg of ziagen twice daily ( twice the currently recommended dose ) , oral methadone clearance increased 22 % ( 90 % ci 6 % to 42 % ) .
DDI-DrugBank.d670.s3
DDI-DrugBank.d585.s7
DDI-DrugBank.d579.s1
DDI-DrugBank.d579.s1.e0_DDI-DrugBank.d579.s1.e2 true the action of mecamylamine may be potentiated by anesthesia , other antihypertensive drugs and alcohol .
DDI-DrugBank.d579.s1.e0_DDI-DrugBank.d579.s1.e1 true the action of mecamylamine may be potentiated by anesthesia , other antihypertensive drugs and alcohol .
DDI-DrugBank.d579.s1.e2_DDI-DrugBank.d579.s1.e1 false the action of mecamylamine may be potentiated by anesthesia , other antihypertensive drugs and alcohol .
DDI-DrugBank.d737.s1
DDI-DrugBank.d665.s6
DDI-DrugBank.d665.s6.e1_DDI-DrugBank.d665.s6.e0 false penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins .
DDI-DrugBank.d665.s6.e1_DDI-DrugBank.d665.s6.e2 false penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins .
DDI-DrugBank.d665.s6.e0_DDI-DrugBank.d665.s6.e2 false penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins .
DDI-DrugBank.d763.s5
DDI-DrugBank.d763.s5.e0_DDI-DrugBank.d763.s5.e1 false in humans , carmustine , etoposide , and cisplatin do not affect the pharmacokinetics of ondansetron .
DDI-DrugBank.d763.s5.e0_DDI-DrugBank.d763.s5.e2 false in humans , carmustine , etoposide , and cisplatin do not affect the pharmacokinetics of ondansetron .
DDI-DrugBank.d763.s5.e0_DDI-DrugBank.d763.s5.e3 false in humans , carmustine , etoposide , and cisplatin do not affect the pharmacokinetics of ondansetron .
DDI-DrugBank.d763.s5.e1_DDI-DrugBank.d763.s5.e2 false in humans , carmustine , etoposide , and cisplatin do not affect the pharmacokinetics of ondansetron .
DDI-DrugBank.d763.s5.e1_DDI-DrugBank.d763.s5.e3 false in humans , carmustine , etoposide , and cisplatin do not affect the pharmacokinetics of ondansetron .
DDI-DrugBank.d763.s5.e2_DDI-DrugBank.d763.s5.e3 false in humans , carmustine , etoposide , and cisplatin do not affect the pharmacokinetics of ondansetron .
DDI-DrugBank.d584.s0
DDI-DrugBank.d584.s0.e0_DDI-DrugBank.d584.s0.e1 false anticoagulants anabolic steroids may increase sensitivity to oral anticoagulants .
DDI-DrugBank.d584.s0.e0_DDI-DrugBank.d584.s0.e2 false anticoagulants anabolic steroids may increase sensitivity to oral anticoagulants .
DDI-DrugBank.d584.s0.e1_DDI-DrugBank.d584.s0.e2 true anticoagulants anabolic steroids may increase sensitivity to oral anticoagulants .
DDI-DrugBank.d641.s7
DDI-DrugBank.d752.s2
DDI-DrugBank.d678.s0
DDI-DrugBank.d761.s8
DDI-DrugBank.d761.s8.e1_DDI-DrugBank.d761.s8.e0 false oral contraceptives : in 20 normal-weight female subjects , the treatment of xenical 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives .
DDI-DrugBank.d761.s8.e1_DDI-DrugBank.d761.s8.e2 false oral contraceptives : in 20 normal-weight female subjects , the treatment of xenical 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives .
DDI-DrugBank.d761.s8.e0_DDI-DrugBank.d761.s8.e2 false oral contraceptives : in 20 normal-weight female subjects , the treatment of xenical 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives .
DDI-DrugBank.d576.s5
DDI-DrugBank.d576.s5.e0_DDI-DrugBank.d576.s5.e1 true salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class .
DDI-DrugBank.d661.s6
DDI-DrugBank.d573.s0
DDI-DrugBank.d573.s0.e0_DDI-DrugBank.d573.s0.e1 false interaction with guanethidine : although minoxidil does not itself cause orthostatic hypotension , its administration to patients already receiving guanethidine can result in profound orthostatic effects .
DDI-DrugBank.d573.s0.e0_DDI-DrugBank.d573.s0.e2 false interaction with guanethidine : although minoxidil does not itself cause orthostatic hypotension , its administration to patients already receiving guanethidine can result in profound orthostatic effects .
DDI-DrugBank.d573.s0.e1_DDI-DrugBank.d573.s0.e2 true interaction with guanethidine : although minoxidil does not itself cause orthostatic hypotension , its administration to patients already receiving guanethidine can result in profound orthostatic effects .
DDI-DrugBank.d775.s4
DDI-DrugBank.d775.s4.e0_DDI-DrugBank.d775.s4.e1 false there are no clinical data on the use of mivacron with other nondepolarizing neuromuscular blocking agents .
DDI-DrugBank.d743.s13
DDI-DrugBank.d743.s13.e0_DDI-DrugBank.d743.s13.e1 false studies to evaluate potential interactions of terfenadine with azithromycin are in progress .
DDI-DrugBank.d766.s2
DDI-DrugBank.d766.s2.e0_DDI-DrugBank.d766.s2.e1 true in vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites .
DDI-DrugBank.d766.s2.e0_DDI-DrugBank.d766.s2.e2 false in vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites .
DDI-DrugBank.d766.s2.e1_DDI-DrugBank.d766.s2.e2 false in vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites .
DDI-DrugBank.d588.s9
DDI-DrugBank.d744.s0
DDI-DrugBank.d744.s0.e0_DDI-DrugBank.d744.s0.e2 true acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with somavert .
DDI-DrugBank.d744.s0.e0_DDI-DrugBank.d744.s0.e1 false acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with somavert .
DDI-DrugBank.d744.s0.e2_DDI-DrugBank.d744.s0.e1 false acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with somavert .
DDI-DrugBank.d700.s8
DDI-DrugBank.d700.s8.e0_DDI-DrugBank.d700.s8.e1 true therefore , do not administer myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of myfortic .
DDI-DrugBank.d700.s8.e0_DDI-DrugBank.d700.s8.e2 true therefore , do not administer myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of myfortic .
DDI-DrugBank.d700.s8.e0_DDI-DrugBank.d700.s8.e3 false therefore , do not administer myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of myfortic .
DDI-DrugBank.d700.s8.e1_DDI-DrugBank.d700.s8.e2 false therefore , do not administer myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of myfortic .
DDI-DrugBank.d700.s8.e1_DDI-DrugBank.d700.s8.e3 false therefore , do not administer myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of myfortic .
DDI-DrugBank.d700.s8.e2_DDI-DrugBank.d700.s8.e3 false therefore , do not administer myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids , for example bile acid sequestrates or oral activated charcoal , because of the potential to reduce the efficacy of myfortic .
DDI-DrugBank.d737.s11
DDI-DrugBank.d661.s2
DDI-DrugBank.d661.s2.e1_DDI-DrugBank.d661.s2.e0 false the median duration of action of zemuron 0.6 mg/kg administered after a 1 mg/kg dose of succinylcholine when t 1 returned to 75 % of control was 36 minutes ( range 14 - 57 , n=12 ) vs.
DDI-DrugBank.d743.s7
DDI-DrugBank.d743.s7.e0_DDI-DrugBank.d743.s7.e1 true concomitant administration of itraconazole and terfenadine is contraindicated .
DDI-DrugBank.d776.s6
DDI-DrugBank.d776.s6.e1_DDI-DrugBank.d776.s6.e0 false coumarin-type anticoagulants : prothrombin time may be increased in patients receiving concomitant diflucan and coumarin-type anticoagulants .
DDI-DrugBank.d776.s6.e1_DDI-DrugBank.d776.s6.e2 true coumarin-type anticoagulants : prothrombin time may be increased in patients receiving concomitant diflucan and coumarin-type anticoagulants .
DDI-DrugBank.d776.s6.e0_DDI-DrugBank.d776.s6.e2 false coumarin-type anticoagulants : prothrombin time may be increased in patients receiving concomitant diflucan and coumarin-type anticoagulants .
DDI-DrugBank.d779.s0
DDI-DrugBank.d779.s0.e0_DDI-DrugBank.d779.s0.e1 true when methyldopa is used with other antihypertensive drugs , potentiation of antihypertensive effect may occur .
DDI-DrugBank.d633.s14
DDI-DrugBank.d584.s10
DDI-DrugBank.d584.s10.e1_DDI-DrugBank.d584.s10.e3 false adrenal steroids or acth in patients with edema , concomitant administration with adrenal cortical steroids or acth may increase the edema .
DDI-DrugBank.d584.s10.e1_DDI-DrugBank.d584.s10.e0 false adrenal steroids or acth in patients with edema , concomitant administration with adrenal cortical steroids or acth may increase the edema .
DDI-DrugBank.d584.s10.e1_DDI-DrugBank.d584.s10.e2 false adrenal steroids or acth in patients with edema , concomitant administration with adrenal cortical steroids or acth may increase the edema .
DDI-DrugBank.d584.s10.e3_DDI-DrugBank.d584.s10.e0 false adrenal steroids or acth in patients with edema , concomitant administration with adrenal cortical steroids or acth may increase the edema .
DDI-DrugBank.d584.s10.e3_DDI-DrugBank.d584.s10.e2 false adrenal steroids or acth in patients with edema , concomitant administration with adrenal cortical steroids or acth may increase the edema .
DDI-DrugBank.d584.s10.e0_DDI-DrugBank.d584.s10.e2 false adrenal steroids or acth in patients with edema , concomitant administration with adrenal cortical steroids or acth may increase the edema .
DDI-DrugBank.d584.s11
DDI-DrugBank.d598.s1
DDI-DrugBank.d598.s1.e0_DDI-DrugBank.d598.s1.e1 true trimethoprim , given at a common clinical dosage , increased the phenytoin half-life by 51 % and decreased the phenytoin metabolic clearance rate by 30 % .
DDI-DrugBank.d598.s1.e0_DDI-DrugBank.d598.s1.e2 true trimethoprim , given at a common clinical dosage , increased the phenytoin half-life by 51 % and decreased the phenytoin metabolic clearance rate by 30 % .
DDI-DrugBank.d598.s1.e1_DDI-DrugBank.d598.s1.e2 false trimethoprim , given at a common clinical dosage , increased the phenytoin half-life by 51 % and decreased the phenytoin metabolic clearance rate by 30 % .
DDI-DrugBank.d602.s3
DDI-DrugBank.d659.s7
DDI-DrugBank.d776.s14
DDI-DrugBank.d776.s14.e0_DDI-DrugBank.d776.s14.e2 false careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving diflucan and cyclosporine .
DDI-DrugBank.d776.s14.e0_DDI-DrugBank.d776.s14.e1 false careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving diflucan and cyclosporine .
DDI-DrugBank.d776.s14.e2_DDI-DrugBank.d776.s14.e1 false careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving diflucan and cyclosporine .
DDI-DrugBank.d693.s3
DDI-DrugBank.d781.s5
DDI-DrugBank.d781.s5.e0_DDI-DrugBank.d781.s5.e2 false potassium supplements and potassium-sparing diuretics : aceon tablets may increase serum potassium because of its potential to decrease aldosterone production .
DDI-DrugBank.d781.s5.e0_DDI-DrugBank.d781.s5.e1 false potassium supplements and potassium-sparing diuretics : aceon tablets may increase serum potassium because of its potential to decrease aldosterone production .
DDI-DrugBank.d781.s5.e2_DDI-DrugBank.d781.s5.e1 false potassium supplements and potassium-sparing diuretics : aceon tablets may increase serum potassium because of its potential to decrease aldosterone production .
DDI-DrugBank.d628.s7
DDI-DrugBank.d628.s7.e0_DDI-DrugBank.d628.s7.e1 false no significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation ( including a range of muscle relaxants , inhalational agents , analgesic agents , and local anesthetic agents ) have been observed .
DDI-DrugBank.d628.s7.e0_DDI-DrugBank.d628.s7.e2 false no significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation ( including a range of muscle relaxants , inhalational agents , analgesic agents , and local anesthetic agents ) have been observed .
DDI-DrugBank.d628.s7.e1_DDI-DrugBank.d628.s7.e2 false no significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation ( including a range of muscle relaxants , inhalational agents , analgesic agents , and local anesthetic agents ) have been observed .
DDI-DrugBank.d584.s5
DDI-DrugBank.d584.s5.e0_DDI-DrugBank.d584.s5.e1 false a 5.5-fold decrease in the mean warfarin dose from 6.13 mg/day to 1.13 mg/day ( approximately 80 - 85 % reduction of warfarin dose ) , was necessary to maintain a target inr of 1.5 .
DDI-DrugBank.d581.s2
DDI-DrugBank.d581.s2.e0_DDI-DrugBank.d581.s2.e1 true patients receiving lithium and neulasta should have more frequent monitoring of neutrophil counts .
DDI-DrugBank.d680.s7
DDI-DrugBank.d680.s7.e1_DDI-DrugBank.d680.s7.e0 false patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in inr and prothrombin time .
DDI-DrugBank.d643.s0
DDI-DrugBank.d643.s0.e0_DDI-DrugBank.d643.s0.e3 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e0_DDI-DrugBank.d643.s0.e4 true melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e0_DDI-DrugBank.d643.s0.e5 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e0_DDI-DrugBank.d643.s0.e7 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e0_DDI-DrugBank.d643.s0.e8 true melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e0_DDI-DrugBank.d643.s0.e1 true melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e0_DDI-DrugBank.d643.s0.e2 true melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e0_DDI-DrugBank.d643.s0.e6 true melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e0_DDI-DrugBank.d643.s0.e9 true melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e3_DDI-DrugBank.d643.s0.e4 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e3_DDI-DrugBank.d643.s0.e5 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e3_DDI-DrugBank.d643.s0.e7 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e3_DDI-DrugBank.d643.s0.e8 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e3_DDI-DrugBank.d643.s0.e1 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e3_DDI-DrugBank.d643.s0.e2 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e3_DDI-DrugBank.d643.s0.e6 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e3_DDI-DrugBank.d643.s0.e9 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e4_DDI-DrugBank.d643.s0.e5 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e4_DDI-DrugBank.d643.s0.e7 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e4_DDI-DrugBank.d643.s0.e8 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e4_DDI-DrugBank.d643.s0.e1 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e4_DDI-DrugBank.d643.s0.e2 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e4_DDI-DrugBank.d643.s0.e6 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e4_DDI-DrugBank.d643.s0.e9 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e5_DDI-DrugBank.d643.s0.e7 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e5_DDI-DrugBank.d643.s0.e8 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e5_DDI-DrugBank.d643.s0.e1 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e5_DDI-DrugBank.d643.s0.e2 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e5_DDI-DrugBank.d643.s0.e6 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e5_DDI-DrugBank.d643.s0.e9 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e7_DDI-DrugBank.d643.s0.e8 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e7_DDI-DrugBank.d643.s0.e1 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e7_DDI-DrugBank.d643.s0.e2 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e7_DDI-DrugBank.d643.s0.e6 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e7_DDI-DrugBank.d643.s0.e9 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e8_DDI-DrugBank.d643.s0.e1 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e8_DDI-DrugBank.d643.s0.e2 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e8_DDI-DrugBank.d643.s0.e6 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e8_DDI-DrugBank.d643.s0.e9 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e1_DDI-DrugBank.d643.s0.e2 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e1_DDI-DrugBank.d643.s0.e6 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e1_DDI-DrugBank.d643.s0.e9 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e2_DDI-DrugBank.d643.s0.e6 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e2_DDI-DrugBank.d643.s0.e9 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d643.s0.e6_DDI-DrugBank.d643.s0.e9 false melatonin may interact with the following drugs : aspirin and other nsaids ( may lower melatonin levels ) , fluvoxamine ( bioavailability of oral melatonin is increased with coadministration ) , beta blockers ( may decrease melatonin levels ) , fluoxetine ( reports of psychotic episodes when coadministered ) , progestin ( coadministration of melatonin with progestin can inhibit ovarian function in women ) , benzodiazepenes and other sedating drugs ( may result in additive sedation and an increased incidence of adverse effects ) , and corticosteroids ( coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids ) .
DDI-DrugBank.d725.s2
DDI-DrugBank.d752.s9
DDI-DrugBank.d752.s9.e1_DDI-DrugBank.d752.s9.e0 false the difficulty in achieving adequate sedation may have been the result of decreased absorption of the sedatives due to both the gastrointestinal effects and stimulant effects of methylphenidate .
DDI-DrugBank.d597.s23
DDI-DrugBank.d597.s23.e0_DDI-DrugBank.d597.s23.e1 false methotrexate : a study in 13 rheumatoid arthritis ( ra ) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly .
DDI-DrugBank.d597.s23.e0_DDI-DrugBank.d597.s23.e2 false methotrexate : a study in 13 rheumatoid arthritis ( ra ) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly .
DDI-DrugBank.d597.s23.e1_DDI-DrugBank.d597.s23.e2 false methotrexate : a study in 13 rheumatoid arthritis ( ra ) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly .
DDI-DrugBank.d572.s1
DDI-DrugBank.d572.s1.e0_DDI-DrugBank.d572.s1.e1 true the incremental ldl-c reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction .
DDI-DrugBank.d763.s1
DDI-DrugBank.d763.s1.e0_DDI-DrugBank.d763.s1.e1 false because ondansetron is metabolized by hepatic cytochrome p-450 drug-metabolizing enzymes ( cyp3a4 , cyp2d6 , cyp1a2 ) , inducers or inhibitors of these enzymes may change the clearance and , hence , the half-life of ondansetron .
DDI-DrugBank.d645.s3
DDI-DrugBank.d645.s3.e0_DDI-DrugBank.d645.s3.e1 false in vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin .
DDI-DrugBank.d645.s3.e0_DDI-DrugBank.d645.s3.e2 false in vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin .
DDI-DrugBank.d645.s3.e1_DDI-DrugBank.d645.s3.e2 false in vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin .
DDI-DrugBank.d633.s7
DDI-DrugBank.d633.s7.e0_DDI-DrugBank.d633.s7.e1 false in a large compassionate use program mexitil has been used concurrently with commonly employed antianginal , antihypertensive , and anticoagulant drugs without observed interactions .
DDI-DrugBank.d633.s7.e0_DDI-DrugBank.d633.s7.e2 false in a large compassionate use program mexitil has been used concurrently with commonly employed antianginal , antihypertensive , and anticoagulant drugs without observed interactions .
DDI-DrugBank.d633.s7.e1_DDI-DrugBank.d633.s7.e2 false in a large compassionate use program mexitil has been used concurrently with commonly employed antianginal , antihypertensive , and anticoagulant drugs without observed interactions .
DDI-DrugBank.d645.s5
DDI-DrugBank.d645.s5.e0_DDI-DrugBank.d645.s5.e1 true terbinafine increases the clearance of cyclosporine by 15 % .
DDI-DrugBank.d753.s2
DDI-DrugBank.d753.s2.e0_DDI-DrugBank.d753.s2.e1 true anticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation , which may lead to paralytic ileus .
DDI-DrugBank.d595.s6
DDI-DrugBank.d611.s1
DDI-DrugBank.d611.s1.e0_DDI-DrugBank.d611.s1.e1 true beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants , since the action of beta adrenergic agonists on the vascular system may be potentiated .
DDI-DrugBank.d611.s1.e0_DDI-DrugBank.d611.s1.e2 true beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants , since the action of beta adrenergic agonists on the vascular system may be potentiated .
DDI-DrugBank.d611.s1.e0_DDI-DrugBank.d611.s1.e3 false beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants , since the action of beta adrenergic agonists on the vascular system may be potentiated .
DDI-DrugBank.d611.s1.e1_DDI-DrugBank.d611.s1.e2 false beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants , since the action of beta adrenergic agonists on the vascular system may be potentiated .
DDI-DrugBank.d611.s1.e1_DDI-DrugBank.d611.s1.e3 false beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants , since the action of beta adrenergic agonists on the vascular system may be potentiated .
DDI-DrugBank.d611.s1.e2_DDI-DrugBank.d611.s1.e3 false beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants , since the action of beta adrenergic agonists on the vascular system may be potentiated .
DDI-DrugBank.d711.s4
DDI-DrugBank.d711.s4.e0_DDI-DrugBank.d711.s4.e1 true concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective .
DDI-DrugBank.d711.s4.e0_DDI-DrugBank.d711.s4.e2 false concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective .
DDI-DrugBank.d711.s4.e1_DDI-DrugBank.d711.s4.e2 false concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective .
DDI-DrugBank.d628.s5
DDI-DrugBank.d590.s4
DDI-DrugBank.d590.s4.e0_DDI-DrugBank.d590.s4.e1 false for information on drug interactions associated with ranitidine , refer to the zantac package insert .
DDI-DrugBank.d689.s1
DDI-DrugBank.d689.s1.e0_DDI-DrugBank.d689.s1.e1 false mao inhibitors - the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( maoi ) .
DDI-DrugBank.d689.s1.e0_DDI-DrugBank.d689.s1.e2 false mao inhibitors - the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( maoi ) .
DDI-DrugBank.d689.s1.e0_DDI-DrugBank.d689.s1.e3 false mao inhibitors - the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( maoi ) .
DDI-DrugBank.d689.s1.e1_DDI-DrugBank.d689.s1.e2 true mao inhibitors - the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( maoi ) .
DDI-DrugBank.d689.s1.e1_DDI-DrugBank.d689.s1.e3 true mao inhibitors - the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( maoi ) .
DDI-DrugBank.d689.s1.e2_DDI-DrugBank.d689.s1.e3 false mao inhibitors - the pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( maoi ) .
DDI-DrugBank.d704.s1
DDI-DrugBank.d704.s1.e0_DDI-DrugBank.d704.s1.e1 true however , interactions may be expected and flomax capsules should not be used in combination with other alpha-adrenergic blocking agents .
DDI-DrugBank.d653.s7
DDI-DrugBank.d653.s7.e0_DDI-DrugBank.d653.s7.e1 true the effect of corticosteroids on oral anticoagulants is variable .
DDI-DrugBank.d578.s4
DDI-DrugBank.d578.s4.e0_DDI-DrugBank.d578.s4.e1 false drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response .
DDI-DrugBank.d578.s4.e0_DDI-DrugBank.d578.s4.e2 false drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response .
DDI-DrugBank.d578.s4.e0_DDI-DrugBank.d578.s4.e3 true drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response .
DDI-DrugBank.d578.s4.e0_DDI-DrugBank.d578.s4.e4 true drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response .
DDI-DrugBank.d578.s4.e1_DDI-DrugBank.d578.s4.e2 false drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response .
DDI-DrugBank.d578.s4.e1_DDI-DrugBank.d578.s4.e3 true drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response .
DDI-DrugBank.d578.s4.e1_DDI-DrugBank.d578.s4.e4 true drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response .
DDI-DrugBank.d578.s4.e2_DDI-DrugBank.d578.s4.e3 true drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response .
DDI-DrugBank.d578.s4.e2_DDI-DrugBank.d578.s4.e4 true drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response .
DDI-DrugBank.d578.s4.e3_DDI-DrugBank.d578.s4.e4 false drugs that induce hepatic enzymes such as phenobarbital , phenytoin , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response .
DDI-DrugBank.d734.s2
DDI-DrugBank.d734.s2.e0_DDI-DrugBank.d734.s2.e1 true concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs .
DDI-DrugBank.d784.s1
DDI-DrugBank.d743.s5
DDI-DrugBank.d743.s5.e0_DDI-DrugBank.d743.s5.e1 false itraconazole : torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources .
DDI-DrugBank.d743.s5.e0_DDI-DrugBank.d743.s5.e2 false itraconazole : torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources .
DDI-DrugBank.d743.s5.e0_DDI-DrugBank.d743.s5.e3 false itraconazole : torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources .
DDI-DrugBank.d743.s5.e0_DDI-DrugBank.d743.s5.e4 false itraconazole : torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources .
DDI-DrugBank.d743.s5.e1_DDI-DrugBank.d743.s5.e2 false itraconazole : torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources .
DDI-DrugBank.d743.s5.e1_DDI-DrugBank.d743.s5.e3 false itraconazole : torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources .
DDI-DrugBank.d743.s5.e1_DDI-DrugBank.d743.s5.e4 false itraconazole : torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources .
DDI-DrugBank.d743.s5.e2_DDI-DrugBank.d743.s5.e3 true itraconazole : torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources .
DDI-DrugBank.d743.s5.e2_DDI-DrugBank.d743.s5.e4 false itraconazole : torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources .
DDI-DrugBank.d743.s5.e3_DDI-DrugBank.d743.s5.e4 false itraconazole : torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources .
DDI-DrugBank.d739.s12
DDI-DrugBank.d739.s12.e0_DDI-DrugBank.d739.s12.e1 false these medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants .
DDI-DrugBank.d739.s12.e0_DDI-DrugBank.d739.s12.e2 false these medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants .
DDI-DrugBank.d739.s12.e0_DDI-DrugBank.d739.s12.e3 false these medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants .
DDI-DrugBank.d739.s12.e0_DDI-DrugBank.d739.s12.e4 false these medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants .
DDI-DrugBank.d739.s12.e1_DDI-DrugBank.d739.s12.e2 false these medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants .
DDI-DrugBank.d739.s12.e1_DDI-DrugBank.d739.s12.e3 false these medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants .
DDI-DrugBank.d739.s12.e1_DDI-DrugBank.d739.s12.e4 false these medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants .
DDI-DrugBank.d739.s12.e2_DDI-DrugBank.d739.s12.e3 false these medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants .
DDI-DrugBank.d739.s12.e2_DDI-DrugBank.d739.s12.e4 false these medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants .
DDI-DrugBank.d739.s12.e3_DDI-DrugBank.d739.s12.e4 false these medications included thyroid hormones , sedative hypnotics , non-steroidal anti-inflammatory agents , benzodiazepines , and decongestants .
DDI-DrugBank.d640.s11
DDI-DrugBank.d776.s39
DDI-DrugBank.d776.s39.e0_DDI-DrugBank.d776.s39.e1 false however , in some patients there were decreases up to 47 % and 33 % of ethinyl estradiol and levonorgestrel levels .
DDI-DrugBank.d700.s6
DDI-DrugBank.d700.s6.e0_DDI-DrugBank.d700.s6.e1 false azathioprine/mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6.e0_DDI-DrugBank.d700.s6.e2 false azathioprine/mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6.e0_DDI-DrugBank.d700.s6.e3 false azathioprine/mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6.e0_DDI-DrugBank.d700.s6.e5 false azathioprine/mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6.e0_DDI-DrugBank.d700.s6.e6 false azathioprine/mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6.e0_DDI-DrugBank.d700.s6.e4 false azathioprine/mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6.e1_DDI-DrugBank.d700.s6.e2 false azathioprine/mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6.e1_DDI-DrugBank.d700.s6.e3 false azathioprine/mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6.e1_DDI-DrugBank.d700.s6.e5 false azathioprine/mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6.e1_DDI-DrugBank.d700.s6.e6 false azathioprine/mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6.e1_DDI-DrugBank.d700.s6.e4 false azathioprine/mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6.e2_DDI-DrugBank.d700.s6.e3 false azathioprine/mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6.e2_DDI-DrugBank.d700.s6.e5 false azathioprine/mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6.e2_DDI-DrugBank.d700.s6.e6 false azathioprine/mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6.e2_DDI-DrugBank.d700.s6.e4 false azathioprine/mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6.e3_DDI-DrugBank.d700.s6.e5 false azathioprine/mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6.e3_DDI-DrugBank.d700.s6.e6 false azathioprine/mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6.e3_DDI-DrugBank.d700.s6.e4 false azathioprine/mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6.e5_DDI-DrugBank.d700.s6.e6 false azathioprine/mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6.e5_DDI-DrugBank.d700.s6.e4 false azathioprine/mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d700.s6.e6_DDI-DrugBank.d700.s6.e4 false azathioprine/mycophenolate mofetil : given that azathioprine and mycophenolate mofetil inhibit purine metabolism , it is recommended that myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil .
DDI-DrugBank.d576.s8
DDI-DrugBank.d631.s2
DDI-DrugBank.d631.s2.e0_DDI-DrugBank.d631.s2.e1 false folinic acid ( leucovorin ) should be administered until normal hematopoiesis is restored .
DDI-DrugBank.d572.s20
DDI-DrugBank.d750.s0
DDI-DrugBank.d750.s0.e0_DDI-DrugBank.d750.s0.e1 true concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug interaction .
DDI-DrugBank.d597.s16
DDI-DrugBank.d597.s16.e0_DDI-DrugBank.d597.s16.e1 false studies with furosemide agents and meloxicam have not demonstrated a reduction in natriuretic effect .
DDI-DrugBank.d584.s3
DDI-DrugBank.d584.s3.e0_DDI-DrugBank.d584.s3.e1 false warfarin : a multidose study of oxandrolone , given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in s-warfarin half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml : similar increases in r-warfarin half-life and auc were also detected .
DDI-DrugBank.d584.s3.e0_DDI-DrugBank.d584.s3.e2 false warfarin : a multidose study of oxandrolone , given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in s-warfarin half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml : similar increases in r-warfarin half-life and auc were also detected .
DDI-DrugBank.d584.s3.e0_DDI-DrugBank.d584.s3.e3 false warfarin : a multidose study of oxandrolone , given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in s-warfarin half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml : similar increases in r-warfarin half-life and auc were also detected .
DDI-DrugBank.d584.s3.e0_DDI-DrugBank.d584.s3.e4 false warfarin : a multidose study of oxandrolone , given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in s-warfarin half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml : similar increases in r-warfarin half-life and auc were also detected .
DDI-DrugBank.d584.s3.e1_DDI-DrugBank.d584.s3.e2 true warfarin : a multidose study of oxandrolone , given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in s-warfarin half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml : similar increases in r-warfarin half-life and auc were also detected .
DDI-DrugBank.d584.s3.e1_DDI-DrugBank.d584.s3.e3 false warfarin : a multidose study of oxandrolone , given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in s-warfarin half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml : similar increases in r-warfarin half-life and auc were also detected .
DDI-DrugBank.d584.s3.e1_DDI-DrugBank.d584.s3.e4 false warfarin : a multidose study of oxandrolone , given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in s-warfarin half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml : similar increases in r-warfarin half-life and auc were also detected .
DDI-DrugBank.d584.s3.e2_DDI-DrugBank.d584.s3.e3 false warfarin : a multidose study of oxandrolone , given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in s-warfarin half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml : similar increases in r-warfarin half-life and auc were also detected .
DDI-DrugBank.d584.s3.e2_DDI-DrugBank.d584.s3.e4 false warfarin : a multidose study of oxandrolone , given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in s-warfarin half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml : similar increases in r-warfarin half-life and auc were also detected .
DDI-DrugBank.d584.s3.e3_DDI-DrugBank.d584.s3.e4 false warfarin : a multidose study of oxandrolone , given as 5 or 10 mg bid in 15 healthy subjects concurrently treated with warfarin , resulted in a mean increase in s-warfarin half-life from 26 to 48 hours and auc from 4.55 to 12.08 ng*hr/ml : similar increases in r-warfarin half-life and auc were also detected .
DDI-DrugBank.d771.s0
DDI-DrugBank.d595.s5
DDI-DrugBank.d619.s1
DDI-DrugBank.d737.s4
DDI-DrugBank.d737.s4.e0_DDI-DrugBank.d737.s4.e1 false cimetidine : cimetidine , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system , caused a 50 % increase in pramipexole auc and a 40 % increase in half-life ( n= 12 ) .
DDI-DrugBank.d737.s4.e0_DDI-DrugBank.d737.s4.e2 false cimetidine : cimetidine , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system , caused a 50 % increase in pramipexole auc and a 40 % increase in half-life ( n= 12 ) .
DDI-DrugBank.d737.s4.e1_DDI-DrugBank.d737.s4.e2 true cimetidine : cimetidine , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system , caused a 50 % increase in pramipexole auc and a 40 % increase in half-life ( n= 12 ) .
DDI-DrugBank.d588.s1
DDI-DrugBank.d588.s1.e1_DDI-DrugBank.d588.s1.e0 false other antihypertensives : when mykrox tablets are used with other antihypertensive drugs , care must be taken , especially during initial therapy .
DDI-DrugBank.d588.s1.e1_DDI-DrugBank.d588.s1.e2 true other antihypertensives : when mykrox tablets are used with other antihypertensive drugs , care must be taken , especially during initial therapy .
DDI-DrugBank.d588.s1.e0_DDI-DrugBank.d588.s1.e2 false other antihypertensives : when mykrox tablets are used with other antihypertensive drugs , care must be taken , especially during initial therapy .
DDI-DrugBank.d776.s4
DDI-DrugBank.d776.s4.e1_DDI-DrugBank.d776.s4.e2 false diflucan reduces the metabolism of tolbutamide , glyburide , and glipizide and increases the plasma concentration of these agents .
DDI-DrugBank.d776.s4.e1_DDI-DrugBank.d776.s4.e3 false diflucan reduces the metabolism of tolbutamide , glyburide , and glipizide and increases the plasma concentration of these agents .
DDI-DrugBank.d776.s4.e1_DDI-DrugBank.d776.s4.e0 false diflucan reduces the metabolism of tolbutamide , glyburide , and glipizide and increases the plasma concentration of these agents .
DDI-DrugBank.d776.s4.e2_DDI-DrugBank.d776.s4.e3 false diflucan reduces the metabolism of tolbutamide , glyburide , and glipizide and increases the plasma concentration of these agents .
DDI-DrugBank.d776.s4.e2_DDI-DrugBank.d776.s4.e0 false diflucan reduces the metabolism of tolbutamide , glyburide , and glipizide and increases the plasma concentration of these agents .
DDI-DrugBank.d776.s4.e3_DDI-DrugBank.d776.s4.e0 false diflucan reduces the metabolism of tolbutamide , glyburide , and glipizide and increases the plasma concentration of these agents .
DDI-DrugBank.d766.s3
DDI-DrugBank.d766.s3.e1_DDI-DrugBank.d766.s3.e2 false based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( clotrimazole , ketoconazole , miconazole ) were potent , non-competitive inhibitors of trimetrexate metabolism .
DDI-DrugBank.d766.s3.e1_DDI-DrugBank.d766.s3.e3 false based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( clotrimazole , ketoconazole , miconazole ) were potent , non-competitive inhibitors of trimetrexate metabolism .
DDI-DrugBank.d766.s3.e1_DDI-DrugBank.d766.s3.e4 true based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( clotrimazole , ketoconazole , miconazole ) were potent , non-competitive inhibitors of trimetrexate metabolism .
DDI-DrugBank.d766.s3.e1_DDI-DrugBank.d766.s3.e0 false based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( clotrimazole , ketoconazole , miconazole ) were potent , non-competitive inhibitors of trimetrexate metabolism .
DDI-DrugBank.d766.s3.e2_DDI-DrugBank.d766.s3.e3 false based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( clotrimazole , ketoconazole , miconazole ) were potent , non-competitive inhibitors of trimetrexate metabolism .
DDI-DrugBank.d766.s3.e2_DDI-DrugBank.d766.s3.e4 true based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( clotrimazole , ketoconazole , miconazole ) were potent , non-competitive inhibitors of trimetrexate metabolism .
DDI-DrugBank.d766.s3.e2_DDI-DrugBank.d766.s3.e0 false based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( clotrimazole , ketoconazole , miconazole ) were potent , non-competitive inhibitors of trimetrexate metabolism .
DDI-DrugBank.d766.s3.e3_DDI-DrugBank.d766.s3.e4 true based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( clotrimazole , ketoconazole , miconazole ) were potent , non-competitive inhibitors of trimetrexate metabolism .
DDI-DrugBank.d766.s3.e3_DDI-DrugBank.d766.s3.e0 false based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( clotrimazole , ketoconazole , miconazole ) were potent , non-competitive inhibitors of trimetrexate metabolism .
DDI-DrugBank.d766.s3.e4_DDI-DrugBank.d766.s3.e0 false based on an in vitro rat liver model , nitrogen substituted imidazole drugs ( clotrimazole , ketoconazole , miconazole ) were potent , non-competitive inhibitors of trimetrexate metabolism .
DDI-DrugBank.d596.s2
DDI-DrugBank.d783.s0
DDI-DrugBank.d783.s0.e1_DDI-DrugBank.d783.s0.e2 false posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants .
DDI-DrugBank.d783.s0.e1_DDI-DrugBank.d783.s0.e3 false posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants .
DDI-DrugBank.d783.s0.e1_DDI-DrugBank.d783.s0.e4 false posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants .
DDI-DrugBank.d783.s0.e1_DDI-DrugBank.d783.s0.e0 false posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants .
DDI-DrugBank.d783.s0.e1_DDI-DrugBank.d783.s0.e5 false posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants .
DDI-DrugBank.d783.s0.e2_DDI-DrugBank.d783.s0.e3 false posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants .
DDI-DrugBank.d783.s0.e2_DDI-DrugBank.d783.s0.e4 false posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants .
DDI-DrugBank.d783.s0.e2_DDI-DrugBank.d783.s0.e0 false posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants .
DDI-DrugBank.d783.s0.e2_DDI-DrugBank.d783.s0.e5 false posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants .
DDI-DrugBank.d783.s0.e3_DDI-DrugBank.d783.s0.e4 false posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants .
DDI-DrugBank.d783.s0.e3_DDI-DrugBank.d783.s0.e0 false posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants .
DDI-DrugBank.d783.s0.e3_DDI-DrugBank.d783.s0.e5 false posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants .
DDI-DrugBank.d783.s0.e4_DDI-DrugBank.d783.s0.e0 false posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants .
DDI-DrugBank.d783.s0.e4_DDI-DrugBank.d783.s0.e5 false posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants .
DDI-DrugBank.d783.s0.e0_DDI-DrugBank.d783.s0.e5 true posicor inhibits some of the liver 's ability to metabolize some other drugs - terfenadine , astemizole , cisapride , cyclosporine , and tricyclic antidepressants .
DDI-DrugBank.d728.s3
DDI-DrugBank.d713.s3
DDI-DrugBank.d713.s3.e0_DDI-DrugBank.d713.s3.e1 false coadministration of sanctura with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of sanctura and/or the coadministered drug due to competition for this elimination pathway .
DDI-DrugBank.d631.s3
DDI-DrugBank.d631.s3.e0_DDI-DrugBank.d631.s3.e1 true mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly .
DDI-DrugBank.d704.s5
DDI-DrugBank.d704.s5.e0_DDI-DrugBank.d704.s5.e1 false results from limited in vitro and in vivo drug-drug interaction studies between tamsulosin hci and warfarin are inconclusive .
DDI-DrugBank.d720.s4
DDI-DrugBank.d720.s4.e0_DDI-DrugBank.d720.s4.e1 true if concomitant treatment with sumatriptan and an ssri is clinically warranted , appropriate observation of the patient is advised .
DDI-DrugBank.d784.s4
DDI-DrugBank.d784.s4.e1_DDI-DrugBank.d784.s4.e2 false other inhibitors of the cytochrome p450 3a4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4.e1_DDI-DrugBank.d784.s4.e4 false other inhibitors of the cytochrome p450 3a4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4.e1_DDI-DrugBank.d784.s4.e5 false other inhibitors of the cytochrome p450 3a4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4.e1_DDI-DrugBank.d784.s4.e6 false other inhibitors of the cytochrome p450 3a4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4.e1_DDI-DrugBank.d784.s4.e0 false other inhibitors of the cytochrome p450 3a4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4.e1_DDI-DrugBank.d784.s4.e3 false other inhibitors of the cytochrome p450 3a4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4.e2_DDI-DrugBank.d784.s4.e4 false other inhibitors of the cytochrome p450 3a4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4.e2_DDI-DrugBank.d784.s4.e5 false other inhibitors of the cytochrome p450 3a4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4.e2_DDI-DrugBank.d784.s4.e6 false other inhibitors of the cytochrome p450 3a4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4.e2_DDI-DrugBank.d784.s4.e0 false other inhibitors of the cytochrome p450 3a4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4.e2_DDI-DrugBank.d784.s4.e3 false other inhibitors of the cytochrome p450 3a4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4.e4_DDI-DrugBank.d784.s4.e5 false other inhibitors of the cytochrome p450 3a4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4.e4_DDI-DrugBank.d784.s4.e6 false other inhibitors of the cytochrome p450 3a4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4.e4_DDI-DrugBank.d784.s4.e0 false other inhibitors of the cytochrome p450 3a4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4.e4_DDI-DrugBank.d784.s4.e3 false other inhibitors of the cytochrome p450 3a4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4.e5_DDI-DrugBank.d784.s4.e6 false other inhibitors of the cytochrome p450 3a4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4.e5_DDI-DrugBank.d784.s4.e0 false other inhibitors of the cytochrome p450 3a4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4.e5_DDI-DrugBank.d784.s4.e3 false other inhibitors of the cytochrome p450 3a4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4.e6_DDI-DrugBank.d784.s4.e0 false other inhibitors of the cytochrome p450 3a4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4.e6_DDI-DrugBank.d784.s4.e3 false other inhibitors of the cytochrome p450 3a4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d784.s4.e0_DDI-DrugBank.d784.s4.e3 false other inhibitors of the cytochrome p450 3a4 enzyme system , such as antimycotic agents ( e.g. , itraconazole and miconazole ) or macrolide antibiotics ( e.g. , erythromycin and clarithromycin ) , may alter oxybutynin mean pharmacokinetic parameters ( i.e. , cmax and auc ) .
DDI-DrugBank.d776.s0
DDI-DrugBank.d680.s0
DDI-DrugBank.d732.s0
DDI-DrugBank.d732.s0.e1_DDI-DrugBank.d732.s0.e0 false chemet is not known to interact with other drugs including iron supplements ;
DDI-DrugBank.d572.s28
DDI-DrugBank.d638.s4
DDI-DrugBank.d578.s7
DDI-DrugBank.d578.s7.e0_DDI-DrugBank.d578.s7.e1 true methylprednisolone may increase the clearance of chronic high dose aspirin .
DDI-DrugBank.d659.s1
DDI-DrugBank.d743.s1
DDI-DrugBank.d619.s5
DDI-DrugBank.d619.s5.e0_DDI-DrugBank.d619.s5.e2 true one case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication ( ephedrine ) .
DDI-DrugBank.d619.s5.e0_DDI-DrugBank.d619.s5.e1 true one case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication ( ephedrine ) .
DDI-DrugBank.d619.s5.e2_DDI-DrugBank.d619.s5.e1 false one case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication ( ephedrine ) .
DDI-DrugBank.d576.s1
DDI-DrugBank.d576.s1.e3_DDI-DrugBank.d576.s1.e0 false aspirin and other salicylate drugs will be additive to disalcid and may increase plasma concentrations of salicylic acid to toxic levels .
DDI-DrugBank.d576.s1.e3_DDI-DrugBank.d576.s1.e2 false aspirin and other salicylate drugs will be additive to disalcid and may increase plasma concentrations of salicylic acid to toxic levels .
DDI-DrugBank.d576.s1.e3_DDI-DrugBank.d576.s1.e1 false aspirin and other salicylate drugs will be additive to disalcid and may increase plasma concentrations of salicylic acid to toxic levels .
DDI-DrugBank.d576.s1.e0_DDI-DrugBank.d576.s1.e2 true aspirin and other salicylate drugs will be additive to disalcid and may increase plasma concentrations of salicylic acid to toxic levels .
DDI-DrugBank.d576.s1.e0_DDI-DrugBank.d576.s1.e1 false aspirin and other salicylate drugs will be additive to disalcid and may increase plasma concentrations of salicylic acid to toxic levels .
DDI-DrugBank.d576.s1.e2_DDI-DrugBank.d576.s1.e1 false aspirin and other salicylate drugs will be additive to disalcid and may increase plasma concentrations of salicylic acid to toxic levels .
DDI-DrugBank.d597.s1
DDI-DrugBank.d597.s1.e0_DDI-DrugBank.d597.s1.e1 true this interaction should be given consideration in patients taking nsaids concomitantly with ace inhibitors .
DDI-DrugBank.d774.s0
DDI-DrugBank.d774.s0.e0_DDI-DrugBank.d774.s0.e1 true trilostane may interact with aminoglutethimide or mitotane ( causing too great a decrease in adrenal function ) .
DDI-DrugBank.d774.s0.e0_DDI-DrugBank.d774.s0.e2 true trilostane may interact with aminoglutethimide or mitotane ( causing too great a decrease in adrenal function ) .
DDI-DrugBank.d774.s0.e1_DDI-DrugBank.d774.s0.e2 false trilostane may interact with aminoglutethimide or mitotane ( causing too great a decrease in adrenal function ) .
DDI-DrugBank.d727.s4
DDI-DrugBank.d640.s8
DDI-DrugBank.d640.s8.e1_DDI-DrugBank.d640.s8.e0 false if a diuretic is also used , the risk of lithium toxicity may be increased .
DDI-DrugBank.d607.s0
DDI-DrugBank.d776.s17
DDI-DrugBank.d776.s17.e1_DDI-DrugBank.d776.s17.e0 false depending on clinical circumstances , consideration should be given to increasing the dose of diflucan when it is administered with rifampin .
DDI-DrugBank.d665.s4
DDI-DrugBank.d739.s2
DDI-DrugBank.d578.s2
DDI-DrugBank.d645.s7
DDI-DrugBank.d645.s7.e0_DDI-DrugBank.d645.s7.e1 true terbinafine clearance is increased 100 % by rifampin , a cyp450 enzyme inducer , and decreased 33 % by cimetidine , a cyp450 enzyme inhibitor .
DDI-DrugBank.d645.s7.e0_DDI-DrugBank.d645.s7.e2 true terbinafine clearance is increased 100 % by rifampin , a cyp450 enzyme inducer , and decreased 33 % by cimetidine , a cyp450 enzyme inhibitor .
DDI-DrugBank.d645.s7.e1_DDI-DrugBank.d645.s7.e2 false terbinafine clearance is increased 100 % by rifampin , a cyp450 enzyme inducer , and decreased 33 % by cimetidine , a cyp450 enzyme inhibitor .
DDI-DrugBank.d595.s0
DDI-DrugBank.d604.s0
DDI-DrugBank.d604.s0.e0_DDI-DrugBank.d604.s0.e2 false thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine .
DDI-DrugBank.d604.s0.e0_DDI-DrugBank.d604.s0.e3 false thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine .
DDI-DrugBank.d604.s0.e0_DDI-DrugBank.d604.s0.e4 false thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine .
DDI-DrugBank.d604.s0.e0_DDI-DrugBank.d604.s0.e1 true thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine .
DDI-DrugBank.d604.s0.e2_DDI-DrugBank.d604.s0.e3 false thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine .
DDI-DrugBank.d604.s0.e2_DDI-DrugBank.d604.s0.e4 false thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine .
DDI-DrugBank.d604.s0.e2_DDI-DrugBank.d604.s0.e1 false thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine .
DDI-DrugBank.d604.s0.e3_DDI-DrugBank.d604.s0.e4 false thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine .
DDI-DrugBank.d604.s0.e3_DDI-DrugBank.d604.s0.e1 false thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine .
DDI-DrugBank.d604.s0.e4_DDI-DrugBank.d604.s0.e1 false thalidomide has been reported to enhance the sedative activity of barbiturates , alcohol , chlorpromazine , and reserpine .
DDI-DrugBank.d770.s3
DDI-DrugBank.d784.s6
DDI-DrugBank.d648.s2
DDI-DrugBank.d632.s2
DDI-DrugBank.d597.s19
DDI-DrugBank.d597.s19.e0_DDI-DrugBank.d597.s19.e2 false lithium : in clinical trials , nsaids have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance .
DDI-DrugBank.d597.s19.e0_DDI-DrugBank.d597.s19.e3 false lithium : in clinical trials , nsaids have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance .
DDI-DrugBank.d597.s19.e0_DDI-DrugBank.d597.s19.e1 false lithium : in clinical trials , nsaids have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance .
DDI-DrugBank.d597.s19.e2_DDI-DrugBank.d597.s19.e3 false lithium : in clinical trials , nsaids have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance .
DDI-DrugBank.d597.s19.e2_DDI-DrugBank.d597.s19.e1 false lithium : in clinical trials , nsaids have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance .
DDI-DrugBank.d597.s19.e3_DDI-DrugBank.d597.s19.e1 false lithium : in clinical trials , nsaids have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance .
DDI-DrugBank.d633.s19
DDI-DrugBank.d665.s1
DDI-DrugBank.d647.s0
DDI-DrugBank.d604.s2
DDI-DrugBank.d604.s2.e1_DDI-DrugBank.d604.s2.e2 false oral contraceptives : in 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied .
DDI-DrugBank.d604.s2.e1_DDI-DrugBank.d604.s2.e3 false oral contraceptives : in 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied .
DDI-DrugBank.d604.s2.e1_DDI-DrugBank.d604.s2.e4 false oral contraceptives : in 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied .
DDI-DrugBank.d604.s2.e1_DDI-DrugBank.d604.s2.e0 false oral contraceptives : in 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied .
DDI-DrugBank.d604.s2.e2_DDI-DrugBank.d604.s2.e3 false oral contraceptives : in 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied .
DDI-DrugBank.d604.s2.e2_DDI-DrugBank.d604.s2.e4 false oral contraceptives : in 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied .
DDI-DrugBank.d604.s2.e2_DDI-DrugBank.d604.s2.e0 false oral contraceptives : in 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied .
DDI-DrugBank.d604.s2.e3_DDI-DrugBank.d604.s2.e4 false oral contraceptives : in 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied .
DDI-DrugBank.d604.s2.e3_DDI-DrugBank.d604.s2.e0 false oral contraceptives : in 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied .
DDI-DrugBank.d604.s2.e4_DDI-DrugBank.d604.s2.e0 false oral contraceptives : in 10 healthy women , the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied .
DDI-DrugBank.d596.s0
DDI-DrugBank.d596.s0.e1_DDI-DrugBank.d596.s0.e2 false drug-drug interactions effect of exelon ( rivastigmine tartrate ) on the metabolism of other drugs : rivastigmine is primarily metabolized through hydrolysis by esterases .
DDI-DrugBank.d596.s0.e1_DDI-DrugBank.d596.s0.e0 false drug-drug interactions effect of exelon ( rivastigmine tartrate ) on the metabolism of other drugs : rivastigmine is primarily metabolized through hydrolysis by esterases .
DDI-DrugBank.d596.s0.e2_DDI-DrugBank.d596.s0.e0 false drug-drug interactions effect of exelon ( rivastigmine tartrate ) on the metabolism of other drugs : rivastigmine is primarily metabolized through hydrolysis by esterases .
DDI-DrugBank.d608.s5
DDI-DrugBank.d608.s5.e2_DDI-DrugBank.d608.s5.e3 false tolectin and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model , possibly enhancing the toxicity of methotrexate .
DDI-DrugBank.d608.s5.e2_DDI-DrugBank.d608.s5.e0 false tolectin and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model , possibly enhancing the toxicity of methotrexate .
DDI-DrugBank.d608.s5.e2_DDI-DrugBank.d608.s5.e1 false tolectin and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model , possibly enhancing the toxicity of methotrexate .
DDI-DrugBank.d608.s5.e3_DDI-DrugBank.d608.s5.e0 false tolectin and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model , possibly enhancing the toxicity of methotrexate .
DDI-DrugBank.d608.s5.e3_DDI-DrugBank.d608.s5.e1 false tolectin and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model , possibly enhancing the toxicity of methotrexate .
DDI-DrugBank.d608.s5.e0_DDI-DrugBank.d608.s5.e1 false tolectin and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model , possibly enhancing the toxicity of methotrexate .
DDI-DrugBank.d634.s4
DDI-DrugBank.d716.s6
DDI-DrugBank.d638.s0
DDI-DrugBank.d638.s0.e1_DDI-DrugBank.d638.s0.e0 false ritalin may decrease the hypotensive effect of guanethidine .
DDI-DrugBank.d572.s35
DDI-DrugBank.d776.s7
DDI-DrugBank.d776.s7.e1_DDI-DrugBank.d776.s7.e2 true in post-marketing experience , as with other azole antifungals , bleeding events ( bruising , epistaxis , gastrointestinal bleeding , hematuria , and melena ) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin .
DDI-DrugBank.d776.s7.e1_DDI-DrugBank.d776.s7.e0 false in post-marketing experience , as with other azole antifungals , bleeding events ( bruising , epistaxis , gastrointestinal bleeding , hematuria , and melena ) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin .
DDI-DrugBank.d776.s7.e2_DDI-DrugBank.d776.s7.e0 false in post-marketing experience , as with other azole antifungals , bleeding events ( bruising , epistaxis , gastrointestinal bleeding , hematuria , and melena ) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin .
DDI-DrugBank.d575.s2
DDI-DrugBank.d575.s2.e1_DDI-DrugBank.d575.s2.e0 false therefore , caution should be used in administering vumon ( teniposide injection ) to patients receiving these other agents .
DDI-DrugBank.d670.s7
DDI-DrugBank.d670.s7.e0_DDI-DrugBank.d670.s7.e1 true paliperidone may antagonize the effect of levodopa and other dopamine agonists .
DDI-DrugBank.d670.s7.e0_DDI-DrugBank.d670.s7.e2 true paliperidone may antagonize the effect of levodopa and other dopamine agonists .
DDI-DrugBank.d670.s7.e1_DDI-DrugBank.d670.s7.e2 false paliperidone may antagonize the effect of levodopa and other dopamine agonists .
DDI-DrugBank.d597.s9
DDI-DrugBank.d610.s2
DDI-DrugBank.d610.s2.e0_DDI-DrugBank.d610.s2.e1 false abacavir has no effect on the pharmacokinetic properties of ethanol .
DDI-DrugBank.d695.s0
DDI-DrugBank.d695.s0.e0_DDI-DrugBank.d695.s0.e1 true while co-administration of zavesca appeared to increase the clearance of cerezyme by 70 % , these results are not conclusive because of the small number of subjects studied and because patients took variable doses of cerezyme .
DDI-DrugBank.d695.s0.e0_DDI-DrugBank.d695.s0.e2 false while co-administration of zavesca appeared to increase the clearance of cerezyme by 70 % , these results are not conclusive because of the small number of subjects studied and because patients took variable doses of cerezyme .
DDI-DrugBank.d695.s0.e1_DDI-DrugBank.d695.s0.e2 false while co-administration of zavesca appeared to increase the clearance of cerezyme by 70 % , these results are not conclusive because of the small number of subjects studied and because patients took variable doses of cerezyme .
DDI-DrugBank.d777.s4
DDI-DrugBank.d777.s4.e1_DDI-DrugBank.d777.s4.e0 false anticoagulation and antiplatelets after treatment for myocardial infarction -- in the treatment of acute myocardial infarction , the use of aspirin has been shown to reduce the incidence of reinfarction and stroke .
DDI-DrugBank.d738.s0
DDI-DrugBank.d738.s0.e1_DDI-DrugBank.d738.s0.e0 false do not exceed a 5 mg daily dose of vesicare when administered with therapeutic doses of ketoconazole or other potent cyp3a4 inhibitors .
DDI-DrugBank.d688.s2
DDI-DrugBank.d688.s2.e0_DDI-DrugBank.d688.s2.e1 true administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate .
DDI-DrugBank.d776.s15
DDI-DrugBank.d712.s0
DDI-DrugBank.d599.s4
DDI-DrugBank.d599.s4.e0_DDI-DrugBank.d599.s4.e1 false if glucocorticoid replacement is required , the glucocorticoid dose should be carefully adjusted .
DDI-DrugBank.d779.s2
DDI-DrugBank.d779.s2.e1_DDI-DrugBank.d779.s2.e0 false patients may require reduced doses of anesthetics when on methyldopa .
DDI-DrugBank.d779.s8
DDI-DrugBank.d737.s10
DDI-DrugBank.d737.s10.e1_DDI-DrugBank.d737.s10.e9 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e1_DDI-DrugBank.d737.s10.e0 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e1_DDI-DrugBank.d737.s10.e2 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e1_DDI-DrugBank.d737.s10.e3 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e1_DDI-DrugBank.d737.s10.e4 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e1_DDI-DrugBank.d737.s10.e5 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e1_DDI-DrugBank.d737.s10.e6 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e1_DDI-DrugBank.d737.s10.e7 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e1_DDI-DrugBank.d737.s10.e8 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e9_DDI-DrugBank.d737.s10.e0 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e9_DDI-DrugBank.d737.s10.e2 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e9_DDI-DrugBank.d737.s10.e3 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e9_DDI-DrugBank.d737.s10.e4 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e9_DDI-DrugBank.d737.s10.e5 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e9_DDI-DrugBank.d737.s10.e6 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e9_DDI-DrugBank.d737.s10.e7 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e9_DDI-DrugBank.d737.s10.e8 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e0_DDI-DrugBank.d737.s10.e2 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e0_DDI-DrugBank.d737.s10.e3 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e0_DDI-DrugBank.d737.s10.e4 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e0_DDI-DrugBank.d737.s10.e5 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e0_DDI-DrugBank.d737.s10.e6 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e0_DDI-DrugBank.d737.s10.e7 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e0_DDI-DrugBank.d737.s10.e8 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e2_DDI-DrugBank.d737.s10.e3 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e2_DDI-DrugBank.d737.s10.e4 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e2_DDI-DrugBank.d737.s10.e5 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e2_DDI-DrugBank.d737.s10.e6 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e2_DDI-DrugBank.d737.s10.e7 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e2_DDI-DrugBank.d737.s10.e8 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e3_DDI-DrugBank.d737.s10.e4 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e3_DDI-DrugBank.d737.s10.e5 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e3_DDI-DrugBank.d737.s10.e6 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e3_DDI-DrugBank.d737.s10.e7 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e3_DDI-DrugBank.d737.s10.e8 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e4_DDI-DrugBank.d737.s10.e5 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e4_DDI-DrugBank.d737.s10.e6 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e4_DDI-DrugBank.d737.s10.e7 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e4_DDI-DrugBank.d737.s10.e8 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e5_DDI-DrugBank.d737.s10.e6 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e5_DDI-DrugBank.d737.s10.e7 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e5_DDI-DrugBank.d737.s10.e8 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e6_DDI-DrugBank.d737.s10.e7 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e6_DDI-DrugBank.d737.s10.e8 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d737.s10.e7_DDI-DrugBank.d737.s10.e8 false dopamine antagonists : since pramipexole is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of mirapex .
DDI-DrugBank.d597.s3
DDI-DrugBank.d633.s3
DDI-DrugBank.d780.s2
DDI-DrugBank.d608.s2
DDI-DrugBank.d608.s2.e0_DDI-DrugBank.d608.s2.e1 true therefore , caution should be exercised when administering tolectin to patients on anticoagulants .
DDI-DrugBank.d776.s22
DDI-DrugBank.d776.s22.e0_DDI-DrugBank.d776.s22.e2 false another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that diflucan taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly .
DDI-DrugBank.d776.s22.e0_DDI-DrugBank.d776.s22.e1 false another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that diflucan taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly .
DDI-DrugBank.d776.s22.e2_DDI-DrugBank.d776.s22.e1 false another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that diflucan taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly .
DDI-DrugBank.d700.s3
DDI-DrugBank.d700.s3.e0_DDI-DrugBank.d700.s3.e1 false acyclovir/ganciclovir : may be taken with myfortic ;
DDI-DrugBank.d700.s3.e0_DDI-DrugBank.d700.s3.e2 false acyclovir/ganciclovir : may be taken with myfortic ;
DDI-DrugBank.d700.s3.e1_DDI-DrugBank.d700.s3.e2 false acyclovir/ganciclovir : may be taken with myfortic ;
DDI-DrugBank.d781.s12
DDI-DrugBank.d781.s12.e0_DDI-DrugBank.d781.s12.e1 false gentamicin : animal data have suggested the possibility of interaction between perindopril and gentamicin .
DDI-DrugBank.d781.s12.e0_DDI-DrugBank.d781.s12.e2 false gentamicin : animal data have suggested the possibility of interaction between perindopril and gentamicin .
DDI-DrugBank.d781.s12.e1_DDI-DrugBank.d781.s12.e2 true gentamicin : animal data have suggested the possibility of interaction between perindopril and gentamicin .
DDI-DrugBank.d591.s3
DDI-DrugBank.d591.s3.e0_DDI-DrugBank.d591.s3.e1 true thus strong inhibitors of cytochrome p4501a2 , such as fluvoxamine , given concomitantly during administration of ropivacaine , can interact with ropivacaine leading to increased ropivacaine plasma levels .
DDI-DrugBank.d591.s3.e0_DDI-DrugBank.d591.s3.e2 false thus strong inhibitors of cytochrome p4501a2 , such as fluvoxamine , given concomitantly during administration of ropivacaine , can interact with ropivacaine leading to increased ropivacaine plasma levels .
DDI-DrugBank.d591.s3.e0_DDI-DrugBank.d591.s3.e3 false thus strong inhibitors of cytochrome p4501a2 , such as fluvoxamine , given concomitantly during administration of ropivacaine , can interact with ropivacaine leading to increased ropivacaine plasma levels .
DDI-DrugBank.d591.s3.e1_DDI-DrugBank.d591.s3.e2 false thus strong inhibitors of cytochrome p4501a2 , such as fluvoxamine , given concomitantly during administration of ropivacaine , can interact with ropivacaine leading to increased ropivacaine plasma levels .
DDI-DrugBank.d591.s3.e1_DDI-DrugBank.d591.s3.e3 false thus strong inhibitors of cytochrome p4501a2 , such as fluvoxamine , given concomitantly during administration of ropivacaine , can interact with ropivacaine leading to increased ropivacaine plasma levels .
DDI-DrugBank.d591.s3.e2_DDI-DrugBank.d591.s3.e3 false thus strong inhibitors of cytochrome p4501a2 , such as fluvoxamine , given concomitantly during administration of ropivacaine , can interact with ropivacaine leading to increased ropivacaine plasma levels .
DDI-DrugBank.d776.s27
DDI-DrugBank.d776.s27.e0_DDI-DrugBank.d776.s27.e1 true the combined use of fluconazole with cisapride is contraindicated .
DDI-DrugBank.d771.s3
DDI-DrugBank.d771.s3.e2_DDI-DrugBank.d771.s3.e0 false e.g. , other belladonna alkaloids , antihistamines ( including meclizine ) , tricyclic antidepressants , and muscle relaxants .
DDI-DrugBank.d771.s3.e2_DDI-DrugBank.d771.s3.e1 false e.g. , other belladonna alkaloids , antihistamines ( including meclizine ) , tricyclic antidepressants , and muscle relaxants .
DDI-DrugBank.d771.s3.e2_DDI-DrugBank.d771.s3.e3 false e.g. , other belladonna alkaloids , antihistamines ( including meclizine ) , tricyclic antidepressants , and muscle relaxants .
DDI-DrugBank.d771.s3.e2_DDI-DrugBank.d771.s3.e4 false e.g. , other belladonna alkaloids , antihistamines ( including meclizine ) , tricyclic antidepressants , and muscle relaxants .
DDI-DrugBank.d771.s3.e0_DDI-DrugBank.d771.s3.e1 false e.g. , other belladonna alkaloids , antihistamines ( including meclizine ) , tricyclic antidepressants , and muscle relaxants .
DDI-DrugBank.d771.s3.e0_DDI-DrugBank.d771.s3.e3 false e.g. , other belladonna alkaloids , antihistamines ( including meclizine ) , tricyclic antidepressants , and muscle relaxants .
DDI-DrugBank.d771.s3.e0_DDI-DrugBank.d771.s3.e4 false e.g. , other belladonna alkaloids , antihistamines ( including meclizine ) , tricyclic antidepressants , and muscle relaxants .
DDI-DrugBank.d771.s3.e1_DDI-DrugBank.d771.s3.e3 false e.g. , other belladonna alkaloids , antihistamines ( including meclizine ) , tricyclic antidepressants , and muscle relaxants .
DDI-DrugBank.d771.s3.e1_DDI-DrugBank.d771.s3.e4 false e.g. , other belladonna alkaloids , antihistamines ( including meclizine ) , tricyclic antidepressants , and muscle relaxants .
DDI-DrugBank.d771.s3.e3_DDI-DrugBank.d771.s3.e4 false e.g. , other belladonna alkaloids , antihistamines ( including meclizine ) , tricyclic antidepressants , and muscle relaxants .
DDI-DrugBank.d622.s2
DDI-DrugBank.d622.s2.e0_DDI-DrugBank.d622.s2.e1 false 2 - 4 the following precautions should be kept in mind in the treatment of anticholinesterase poisoning , although they do not bear directly on the use of pralidoxime : since barbiturates are potentiated by the anticholinesterases , they should be used cautiously in the treatment of convulsions ;
DDI-DrugBank.d622.s2.e0_DDI-DrugBank.d622.s2.e2 false 2 - 4 the following precautions should be kept in mind in the treatment of anticholinesterase poisoning , although they do not bear directly on the use of pralidoxime : since barbiturates are potentiated by the anticholinesterases , they should be used cautiously in the treatment of convulsions ;
DDI-DrugBank.d622.s2.e1_DDI-DrugBank.d622.s2.e2 true 2 - 4 the following precautions should be kept in mind in the treatment of anticholinesterase poisoning , although they do not bear directly on the use of pralidoxime : since barbiturates are potentiated by the anticholinesterases , they should be used cautiously in the treatment of convulsions ;
DDI-DrugBank.d680.s6
DDI-DrugBank.d588.s7
DDI-DrugBank.d588.s7.e0_DDI-DrugBank.d588.s7.e1 false lithium : serum lithium levels may increase .
DDI-DrugBank.d666.s5
DDI-DrugBank.d616.s0
DDI-DrugBank.d743.s0
DDI-DrugBank.d743.s0.e0_DDI-DrugBank.d743.s0.e1 false ketoconazole : spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate qt interval prolongation and rare serious cardiac events , e.g.
DDI-DrugBank.d743.s0.e0_DDI-DrugBank.d743.s0.e2 false ketoconazole : spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate qt interval prolongation and rare serious cardiac events , e.g.
DDI-DrugBank.d743.s0.e1_DDI-DrugBank.d743.s0.e2 true ketoconazole : spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate qt interval prolongation and rare serious cardiac events , e.g.
DDI-DrugBank.d704.s6
DDI-DrugBank.d704.s6.e0_DDI-DrugBank.d704.s6.e1 true therefore , caution should be exercised with concomitant administration of warfarin and flomax capsules .
DDI-DrugBank.d710.s9
DDI-DrugBank.d710.s9.e0_DDI-DrugBank.d710.s9.e1 true peak plasma concentrations and auc of rimantadine were reduced approximately 10 % in the presence of aspirin .
DDI-DrugBank.d648.s7
DDI-DrugBank.d777.s1
DDI-DrugBank.d777.s1.e3_DDI-DrugBank.d777.s1.e2 false use of anticoagulants and antiplatelet agents -- streptase , streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1.e3_DDI-DrugBank.d777.s1.e0 false use of anticoagulants and antiplatelet agents -- streptase , streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1.e3_DDI-DrugBank.d777.s1.e1 false use of anticoagulants and antiplatelet agents -- streptase , streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1.e3_DDI-DrugBank.d777.s1.e4 false use of anticoagulants and antiplatelet agents -- streptase , streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1.e3_DDI-DrugBank.d777.s1.e5 false use of anticoagulants and antiplatelet agents -- streptase , streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1.e2_DDI-DrugBank.d777.s1.e0 false use of anticoagulants and antiplatelet agents -- streptase , streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1.e2_DDI-DrugBank.d777.s1.e1 false use of anticoagulants and antiplatelet agents -- streptase , streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1.e2_DDI-DrugBank.d777.s1.e4 false use of anticoagulants and antiplatelet agents -- streptase , streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1.e2_DDI-DrugBank.d777.s1.e5 false use of anticoagulants and antiplatelet agents -- streptase , streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1.e0_DDI-DrugBank.d777.s1.e1 false use of anticoagulants and antiplatelet agents -- streptase , streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1.e0_DDI-DrugBank.d777.s1.e4 false use of anticoagulants and antiplatelet agents -- streptase , streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1.e0_DDI-DrugBank.d777.s1.e5 false use of anticoagulants and antiplatelet agents -- streptase , streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1.e1_DDI-DrugBank.d777.s1.e4 false use of anticoagulants and antiplatelet agents -- streptase , streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1.e1_DDI-DrugBank.d777.s1.e5 false use of anticoagulants and antiplatelet agents -- streptase , streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d777.s1.e4_DDI-DrugBank.d777.s1.e5 false use of anticoagulants and antiplatelet agents -- streptase , streptokinase , alone or in combination with antiplatelet agents and anticoagulants , may cause bleeding complications .
DDI-DrugBank.d776.s24
DDI-DrugBank.d776.s24.e0_DDI-DrugBank.d776.s24.e1 true the coadministration of fluconazole at doses lower than 400 mg/day with terfenadine should be carefully monitored .
DDI-DrugBank.d675.s6
DDI-DrugBank.d633.s2
DDI-DrugBank.d633.s2.e0_DDI-DrugBank.d633.s2.e1 false in another formal study ( n = 8 extensive and n = 7 poor metabolizers of cyp2d6 ) , coadministration of propafenone did not alter the kinetics of mexiletine in the poor cyp2d6 metabolizer group .
DDI-DrugBank.d591.s6
DDI-DrugBank.d591.s6.e0_DDI-DrugBank.d591.s6.e1 false coadministration of a selective and potent inhibitor of cyp3a4 , ketoconazole ( 100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole ) caused a 15 % reduction in in-vivo plasma clearance of ropivacaine .
DDI-DrugBank.d591.s6.e0_DDI-DrugBank.d591.s6.e2 false coadministration of a selective and potent inhibitor of cyp3a4 , ketoconazole ( 100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole ) caused a 15 % reduction in in-vivo plasma clearance of ropivacaine .
DDI-DrugBank.d591.s6.e0_DDI-DrugBank.d591.s6.e3 true coadministration of a selective and potent inhibitor of cyp3a4 , ketoconazole ( 100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole ) caused a 15 % reduction in in-vivo plasma clearance of ropivacaine .
DDI-DrugBank.d591.s6.e1_DDI-DrugBank.d591.s6.e2 false coadministration of a selective and potent inhibitor of cyp3a4 , ketoconazole ( 100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole ) caused a 15 % reduction in in-vivo plasma clearance of ropivacaine .
DDI-DrugBank.d591.s6.e1_DDI-DrugBank.d591.s6.e3 false coadministration of a selective and potent inhibitor of cyp3a4 , ketoconazole ( 100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole ) caused a 15 % reduction in in-vivo plasma clearance of ropivacaine .
DDI-DrugBank.d591.s6.e2_DDI-DrugBank.d591.s6.e3 false coadministration of a selective and potent inhibitor of cyp3a4 , ketoconazole ( 100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole ) caused a 15 % reduction in in-vivo plasma clearance of ropivacaine .
DDI-DrugBank.d609.s1
DDI-DrugBank.d694.s2
DDI-DrugBank.d694.s2.e0_DDI-DrugBank.d694.s2.e1 false no dosage adjustment of digoxin or januvia is recommended .
DDI-DrugBank.d597.s29
DDI-DrugBank.d659.s4
DDI-DrugBank.d659.s4.e0_DDI-DrugBank.d659.s4.e1 false trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4.e0_DDI-DrugBank.d659.s4.e2 false trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4.e0_DDI-DrugBank.d659.s4.e3 false trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4.e0_DDI-DrugBank.d659.s4.e4 false trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4.e0_DDI-DrugBank.d659.s4.e5 false trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4.e0_DDI-DrugBank.d659.s4.e6 false trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4.e1_DDI-DrugBank.d659.s4.e2 false trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4.e1_DDI-DrugBank.d659.s4.e3 false trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4.e1_DDI-DrugBank.d659.s4.e4 false trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4.e1_DDI-DrugBank.d659.s4.e5 false trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4.e1_DDI-DrugBank.d659.s4.e6 false trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4.e2_DDI-DrugBank.d659.s4.e3 false trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4.e2_DDI-DrugBank.d659.s4.e4 false trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4.e2_DDI-DrugBank.d659.s4.e5 false trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4.e2_DDI-DrugBank.d659.s4.e6 false trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4.e3_DDI-DrugBank.d659.s4.e4 false trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4.e3_DDI-DrugBank.d659.s4.e5 false trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4.e3_DDI-DrugBank.d659.s4.e6 false trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4.e4_DDI-DrugBank.d659.s4.e5 false trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4.e4_DDI-DrugBank.d659.s4.e6 false trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d659.s4.e5_DDI-DrugBank.d659.s4.e6 false trental has been used concurrently with antihypertensive drugs , beta blockers , digitalis , diuretics , antidiabetic agents , and antiarrhythmics , without observed problems .
DDI-DrugBank.d597.s13
DDI-DrugBank.d597.s13.e0_DDI-DrugBank.d597.s13.e1 false in vitro testing found no protein binding drug interaction between digoxin and meloxicam .
DDI-DrugBank.d717.s1
DDI-DrugBank.d717.s1.e1_DDI-DrugBank.d717.s1.e0 false therefore , physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering mitotane to patients on coumarin-type anticoagulants .
DDI-DrugBank.d717.s1.e1_DDI-DrugBank.d717.s1.e2 true therefore , physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering mitotane to patients on coumarin-type anticoagulants .
DDI-DrugBank.d717.s1.e0_DDI-DrugBank.d717.s1.e2 false therefore , physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering mitotane to patients on coumarin-type anticoagulants .
DDI-DrugBank.d608.s3
DDI-DrugBank.d608.s3.e1_DDI-DrugBank.d608.s3.e2 false in adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either tolectin or the hypoglycemic agents .
DDI-DrugBank.d608.s3.e1_DDI-DrugBank.d608.s3.e0 false in adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either tolectin or the hypoglycemic agents .
DDI-DrugBank.d608.s3.e1_DDI-DrugBank.d608.s3.e3 false in adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either tolectin or the hypoglycemic agents .
DDI-DrugBank.d608.s3.e2_DDI-DrugBank.d608.s3.e0 false in adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either tolectin or the hypoglycemic agents .
DDI-DrugBank.d608.s3.e2_DDI-DrugBank.d608.s3.e3 false in adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either tolectin or the hypoglycemic agents .
DDI-DrugBank.d608.s3.e0_DDI-DrugBank.d608.s3.e3 false in adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either tolectin or the hypoglycemic agents .
DDI-DrugBank.d693.s5
DDI-DrugBank.d739.s0
DDI-DrugBank.d739.s0.e0_DDI-DrugBank.d739.s0.e1 false montelukast at a dose of 10 mg once daily dosed to pharmacokinetic steady state - did not cause clinically significant changes in the kinetics of a single intravenous dose of theophylline ( predominantly a cytochrome p450 1a2 substrate ) .
DDI-DrugBank.d665.s5
DDI-DrugBank.d631.s0
DDI-DrugBank.d631.s0.e0_DDI-DrugBank.d631.s0.e2 false pyrimethamine may be used with sulfonamides , quinine and other antimalarials , and with other antibiotics .
DDI-DrugBank.d631.s0.e0_DDI-DrugBank.d631.s0.e1 false pyrimethamine may be used with sulfonamides , quinine and other antimalarials , and with other antibiotics .
DDI-DrugBank.d631.s0.e0_DDI-DrugBank.d631.s0.e3 false pyrimethamine may be used with sulfonamides , quinine and other antimalarials , and with other antibiotics .
DDI-DrugBank.d631.s0.e0_DDI-DrugBank.d631.s0.e4 false pyrimethamine may be used with sulfonamides , quinine and other antimalarials , and with other antibiotics .
DDI-DrugBank.d631.s0.e2_DDI-DrugBank.d631.s0.e1 false pyrimethamine may be used with sulfonamides , quinine and other antimalarials , and with other antibiotics .
DDI-DrugBank.d631.s0.e2_DDI-DrugBank.d631.s0.e3 false pyrimethamine may be used with sulfonamides , quinine and other antimalarials , and with other antibiotics .
DDI-DrugBank.d631.s0.e2_DDI-DrugBank.d631.s0.e4 false pyrimethamine may be used with sulfonamides , quinine and other antimalarials , and with other antibiotics .
DDI-DrugBank.d631.s0.e1_DDI-DrugBank.d631.s0.e3 false pyrimethamine may be used with sulfonamides , quinine and other antimalarials , and with other antibiotics .
DDI-DrugBank.d631.s0.e1_DDI-DrugBank.d631.s0.e4 false pyrimethamine may be used with sulfonamides , quinine and other antimalarials , and with other antibiotics .
DDI-DrugBank.d631.s0.e3_DDI-DrugBank.d631.s0.e4 false pyrimethamine may be used with sulfonamides , quinine and other antimalarials , and with other antibiotics .
DDI-DrugBank.d619.s2
DDI-DrugBank.d619.s2.e0_DDI-DrugBank.d619.s2.e1 true this is typical of the interaction of meperidine and maois .
DDI-DrugBank.d734.s0
DDI-DrugBank.d734.s0.e0_DDI-DrugBank.d734.s0.e1 true thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines .
DDI-DrugBank.d649.s0
DDI-DrugBank.d649.s0.e0_DDI-DrugBank.d649.s0.e2 true sulfamethizole may increase the effects of barbiturates , tolbutamide , and uricosurics .
DDI-DrugBank.d649.s0.e0_DDI-DrugBank.d649.s0.e1 true sulfamethizole may increase the effects of barbiturates , tolbutamide , and uricosurics .
DDI-DrugBank.d649.s0.e0_DDI-DrugBank.d649.s0.e3 true sulfamethizole may increase the effects of barbiturates , tolbutamide , and uricosurics .
DDI-DrugBank.d649.s0.e2_DDI-DrugBank.d649.s0.e1 false sulfamethizole may increase the effects of barbiturates , tolbutamide , and uricosurics .
DDI-DrugBank.d649.s0.e2_DDI-DrugBank.d649.s0.e3 false sulfamethizole may increase the effects of barbiturates , tolbutamide , and uricosurics .
DDI-DrugBank.d649.s0.e1_DDI-DrugBank.d649.s0.e3 false sulfamethizole may increase the effects of barbiturates , tolbutamide , and uricosurics .
DDI-DrugBank.d739.s3
DDI-DrugBank.d739.s3.e0_DDI-DrugBank.d739.s3.e1 false - did not change the plasma concentration profile of terfenadine ( a substrate of cytochrome p450 3a4 ) or fexofenadine , its carboxylated metabolite , and did not prolong the qtc interval following co-administration with terfenadine 60 mg twice daily .
DDI-DrugBank.d739.s3.e0_DDI-DrugBank.d739.s3.e2 false - did not change the plasma concentration profile of terfenadine ( a substrate of cytochrome p450 3a4 ) or fexofenadine , its carboxylated metabolite , and did not prolong the qtc interval following co-administration with terfenadine 60 mg twice daily .
DDI-DrugBank.d739.s3.e1_DDI-DrugBank.d739.s3.e2 false - did not change the plasma concentration profile of terfenadine ( a substrate of cytochrome p450 3a4 ) or fexofenadine , its carboxylated metabolite , and did not prolong the qtc interval following co-administration with terfenadine 60 mg twice daily .
DDI-DrugBank.d572.s8
DDI-DrugBank.d572.s8.e1_DDI-DrugBank.d572.s8.e2 false hmg-coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8.e1_DDI-DrugBank.d572.s8.e3 false hmg-coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8.e1_DDI-DrugBank.d572.s8.e4 false hmg-coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8.e1_DDI-DrugBank.d572.s8.e5 false hmg-coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8.e1_DDI-DrugBank.d572.s8.e6 false hmg-coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8.e1_DDI-DrugBank.d572.s8.e0 false hmg-coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8.e2_DDI-DrugBank.d572.s8.e3 false hmg-coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8.e2_DDI-DrugBank.d572.s8.e4 false hmg-coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8.e2_DDI-DrugBank.d572.s8.e5 false hmg-coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8.e2_DDI-DrugBank.d572.s8.e6 false hmg-coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8.e2_DDI-DrugBank.d572.s8.e0 false hmg-coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8.e3_DDI-DrugBank.d572.s8.e4 false hmg-coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8.e3_DDI-DrugBank.d572.s8.e5 false hmg-coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8.e3_DDI-DrugBank.d572.s8.e6 false hmg-coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8.e3_DDI-DrugBank.d572.s8.e0 false hmg-coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8.e4_DDI-DrugBank.d572.s8.e5 false hmg-coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8.e4_DDI-DrugBank.d572.s8.e6 false hmg-coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8.e4_DDI-DrugBank.d572.s8.e0 false hmg-coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8.e5_DDI-DrugBank.d572.s8.e6 false hmg-coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8.e5_DDI-DrugBank.d572.s8.e0 false hmg-coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d572.s8.e6_DDI-DrugBank.d572.s8.e0 false hmg-coa reductase inhibitors : no clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin , simvastatin , pravastatin , lovastatin , or fluvastatin .
DDI-DrugBank.d781.s14
DDI-DrugBank.d641.s3
DDI-DrugBank.d641.s3.e0_DDI-DrugBank.d641.s3.e2 false although ibuprofen ( 400 mg qid ) can be administered with alimta in patients with normal renal function ( creatinine clearance 80 ml/min ) , caution should be used when administering ibuprofen concurrently with alimta to patients with mild to moderate renal insufficiency ( creatinine clearance from 45 to 79 ml/min ) .
DDI-DrugBank.d641.s3.e0_DDI-DrugBank.d641.s3.e1 false although ibuprofen ( 400 mg qid ) can be administered with alimta in patients with normal renal function ( creatinine clearance 80 ml/min ) , caution should be used when administering ibuprofen concurrently with alimta to patients with mild to moderate renal insufficiency ( creatinine clearance from 45 to 79 ml/min ) .
DDI-DrugBank.d641.s3.e0_DDI-DrugBank.d641.s3.e3 false although ibuprofen ( 400 mg qid ) can be administered with alimta in patients with normal renal function ( creatinine clearance 80 ml/min ) , caution should be used when administering ibuprofen concurrently with alimta to patients with mild to moderate renal insufficiency ( creatinine clearance from 45 to 79 ml/min ) .
DDI-DrugBank.d641.s3.e2_DDI-DrugBank.d641.s3.e1 false although ibuprofen ( 400 mg qid ) can be administered with alimta in patients with normal renal function ( creatinine clearance 80 ml/min ) , caution should be used when administering ibuprofen concurrently with alimta to patients with mild to moderate renal insufficiency ( creatinine clearance from 45 to 79 ml/min ) .
DDI-DrugBank.d641.s3.e2_DDI-DrugBank.d641.s3.e3 true although ibuprofen ( 400 mg qid ) can be administered with alimta in patients with normal renal function ( creatinine clearance 80 ml/min ) , caution should be used when administering ibuprofen concurrently with alimta to patients with mild to moderate renal insufficiency ( creatinine clearance from 45 to 79 ml/min ) .
DDI-DrugBank.d641.s3.e1_DDI-DrugBank.d641.s3.e3 false although ibuprofen ( 400 mg qid ) can be administered with alimta in patients with normal renal function ( creatinine clearance 80 ml/min ) , caution should be used when administering ibuprofen concurrently with alimta to patients with mild to moderate renal insufficiency ( creatinine clearance from 45 to 79 ml/min ) .
DDI-DrugBank.d737.s6
DDI-DrugBank.d737.s6.e0_DDI-DrugBank.d737.s6.e1 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e0_DDI-DrugBank.d737.s6.e2 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e0_DDI-DrugBank.d737.s6.e3 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e0_DDI-DrugBank.d737.s6.e4 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e0_DDI-DrugBank.d737.s6.e5 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e0_DDI-DrugBank.d737.s6.e6 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e0_DDI-DrugBank.d737.s6.e7 true other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e0_DDI-DrugBank.d737.s6.e8 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e0_DDI-DrugBank.d737.s6.e9 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e1_DDI-DrugBank.d737.s6.e2 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e1_DDI-DrugBank.d737.s6.e3 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e1_DDI-DrugBank.d737.s6.e4 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e1_DDI-DrugBank.d737.s6.e5 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e1_DDI-DrugBank.d737.s6.e6 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e1_DDI-DrugBank.d737.s6.e7 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e1_DDI-DrugBank.d737.s6.e8 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e1_DDI-DrugBank.d737.s6.e9 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e2_DDI-DrugBank.d737.s6.e3 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e2_DDI-DrugBank.d737.s6.e4 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e2_DDI-DrugBank.d737.s6.e5 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e2_DDI-DrugBank.d737.s6.e6 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e2_DDI-DrugBank.d737.s6.e7 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e2_DDI-DrugBank.d737.s6.e8 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e2_DDI-DrugBank.d737.s6.e9 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e3_DDI-DrugBank.d737.s6.e4 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e3_DDI-DrugBank.d737.s6.e5 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e3_DDI-DrugBank.d737.s6.e6 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e3_DDI-DrugBank.d737.s6.e7 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e3_DDI-DrugBank.d737.s6.e8 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e3_DDI-DrugBank.d737.s6.e9 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e4_DDI-DrugBank.d737.s6.e5 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e4_DDI-DrugBank.d737.s6.e6 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e4_DDI-DrugBank.d737.s6.e7 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e4_DDI-DrugBank.d737.s6.e8 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e4_DDI-DrugBank.d737.s6.e9 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e5_DDI-DrugBank.d737.s6.e6 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e5_DDI-DrugBank.d737.s6.e7 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e5_DDI-DrugBank.d737.s6.e8 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e5_DDI-DrugBank.d737.s6.e9 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e6_DDI-DrugBank.d737.s6.e7 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e6_DDI-DrugBank.d737.s6.e8 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e6_DDI-DrugBank.d737.s6.e9 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e7_DDI-DrugBank.d737.s6.e8 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e7_DDI-DrugBank.d737.s6.e9 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d737.s6.e8_DDI-DrugBank.d737.s6.e9 false other drugs eliminated via renal secretion : population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system ( e.g. , cimetidine , ranitidine , diltiazem , triamterene , verapamil , quinidine , and quinine ) decreases the oral clearance of pramipexole by about 20 % , while those secreted by the anionic transport system ( e.g. , cephalosporins , penicillins , indomethacin , hydrochlorothiazide , and chlorpropamide ) are likely to have little effect on the oral clearance of pramipexole .
DDI-DrugBank.d765.s2
DDI-DrugBank.d761.s13
DDI-DrugBank.d761.s13.e2_DDI-DrugBank.d761.s13.e1 false therefore , as vitamin k absorption may be decreased with xenical , patients on chronic stable doses of warfarin who are prescribed xenical should be monitored closely for changes in coagulation parameters .
DDI-DrugBank.d761.s13.e2_DDI-DrugBank.d761.s13.e3 true therefore , as vitamin k absorption may be decreased with xenical , patients on chronic stable doses of warfarin who are prescribed xenical should be monitored closely for changes in coagulation parameters .
DDI-DrugBank.d761.s13.e2_DDI-DrugBank.d761.s13.e0 false therefore , as vitamin k absorption may be decreased with xenical , patients on chronic stable doses of warfarin who are prescribed xenical should be monitored closely for changes in coagulation parameters .
DDI-DrugBank.d761.s13.e1_DDI-DrugBank.d761.s13.e3 false therefore , as vitamin k absorption may be decreased with xenical , patients on chronic stable doses of warfarin who are prescribed xenical should be monitored closely for changes in coagulation parameters .
DDI-DrugBank.d761.s13.e1_DDI-DrugBank.d761.s13.e0 false therefore , as vitamin k absorption may be decreased with xenical , patients on chronic stable doses of warfarin who are prescribed xenical should be monitored closely for changes in coagulation parameters .
DDI-DrugBank.d761.s13.e3_DDI-DrugBank.d761.s13.e0 false therefore , as vitamin k absorption may be decreased with xenical , patients on chronic stable doses of warfarin who are prescribed xenical should be monitored closely for changes in coagulation parameters .
DDI-DrugBank.d670.s2
DDI-DrugBank.d629.s0
DDI-DrugBank.d629.s0.e0_DDI-DrugBank.d629.s0.e2 true oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin , resulting in a prolongation of prothrombin time .
DDI-DrugBank.d629.s0.e0_DDI-DrugBank.d629.s0.e1 true oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin , resulting in a prolongation of prothrombin time .
DDI-DrugBank.d629.s0.e2_DDI-DrugBank.d629.s0.e1 false oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin , resulting in a prolongation of prothrombin time .
DDI-DrugBank.d776.s35
DDI-DrugBank.d776.s35.e1_DDI-DrugBank.d776.s35.e2 true short-acting benzodiazepines : following oral administration of midazolam , fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects .
DDI-DrugBank.d776.s35.e1_DDI-DrugBank.d776.s35.e3 false short-acting benzodiazepines : following oral administration of midazolam , fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects .
DDI-DrugBank.d776.s35.e1_DDI-DrugBank.d776.s35.e0 false short-acting benzodiazepines : following oral administration of midazolam , fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects .
DDI-DrugBank.d776.s35.e2_DDI-DrugBank.d776.s35.e3 false short-acting benzodiazepines : following oral administration of midazolam , fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects .
DDI-DrugBank.d776.s35.e2_DDI-DrugBank.d776.s35.e0 false short-acting benzodiazepines : following oral administration of midazolam , fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects .
DDI-DrugBank.d776.s35.e3_DDI-DrugBank.d776.s35.e0 false short-acting benzodiazepines : following oral administration of midazolam , fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects .
DDI-DrugBank.d572.s33
DDI-DrugBank.d689.s3
DDI-DrugBank.d689.s3.e0_DDI-DrugBank.d689.s3.e1 true the pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants .
DDI-DrugBank.d595.s4
DDI-DrugBank.d610.s5
DDI-DrugBank.d636.s3
DDI-DrugBank.d636.s3.e0_DDI-DrugBank.d636.s3.e2 true mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.e0_DDI-DrugBank.d636.s3.e4 true mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.e0_DDI-DrugBank.d636.s3.e5 true mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.e0_DDI-DrugBank.d636.s3.e6 false mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.e0_DDI-DrugBank.d636.s3.e1 true mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.e0_DDI-DrugBank.d636.s3.e3 true mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.e2_DDI-DrugBank.d636.s3.e4 false mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.e2_DDI-DrugBank.d636.s3.e5 false mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.e2_DDI-DrugBank.d636.s3.e6 false mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.e2_DDI-DrugBank.d636.s3.e1 false mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.e2_DDI-DrugBank.d636.s3.e3 false mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.e4_DDI-DrugBank.d636.s3.e5 false mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.e4_DDI-DrugBank.d636.s3.e6 false mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.e4_DDI-DrugBank.d636.s3.e1 false mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.e4_DDI-DrugBank.d636.s3.e3 false mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.e5_DDI-DrugBank.d636.s3.e6 false mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.e5_DDI-DrugBank.d636.s3.e1 false mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.e5_DDI-DrugBank.d636.s3.e3 false mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.e6_DDI-DrugBank.d636.s3.e1 false mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.e6_DDI-DrugBank.d636.s3.e3 false mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d636.s3.e1_DDI-DrugBank.d636.s3.e3 false mephenytoin may also affect the effects of other drugs , which include some steroid medications , warfarin , certain heart medicines , birth control pills , anti-infective medicines , furosemide and theophylline please note that mephenytoin may interact with other drugs that are not listed here .
DDI-DrugBank.d610.s1
DDI-DrugBank.d610.s1.e0_DDI-DrugBank.d610.s1.e1 false no clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir .
DDI-DrugBank.d610.s1.e0_DDI-DrugBank.d610.s1.e2 false no clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir .
DDI-DrugBank.d610.s1.e1_DDI-DrugBank.d610.s1.e2 false no clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir .
DDI-DrugBank.d779.s3
DDI-DrugBank.d627.s3
DDI-DrugBank.d627.s3.e0_DDI-DrugBank.d627.s3.e1 false these effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication ( e.g. , atropine , inhaled ipratropium ) .
DDI-DrugBank.d775.s1
DDI-DrugBank.d775.s1.e0_DDI-DrugBank.d775.s1.e1 true prior administration of succinylcholine can potentiate the neuromuscular blocking effects of nondepolarizing agents .
DDI-DrugBank.d602.s2
DDI-DrugBank.d602.s2.e0_DDI-DrugBank.d602.s2.e1 true caution is recommended when administering doxorubicin with nexavar .
DDI-DrugBank.d728.s2
DDI-DrugBank.d728.s2.e0_DDI-DrugBank.d728.s2.e1 true increases of 5-fu plasma concentrations by approximately 20 % have been observed with doses of 130 mg/m2 eloxatin dosed every 3 weeks .
DDI-DrugBank.d652.s2
DDI-DrugBank.d652.s2.e0_DDI-DrugBank.d652.s2.e1 true the finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously , if at all , in patients receiving monoamine oxi-dase inhibitors .
DDI-DrugBank.d779.s5
DDI-DrugBank.d779.s5.e0_DDI-DrugBank.d779.s5.e1 true when methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity .
DDI-DrugBank.d779.s5.e0_DDI-DrugBank.d779.s5.e2 false when methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity .
DDI-DrugBank.d779.s5.e1_DDI-DrugBank.d779.s5.e2 false when methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity .
DDI-DrugBank.d781.s13
DDI-DrugBank.d585.s2
DDI-DrugBank.d585.s2.e0_DDI-DrugBank.d585.s2.e1 true anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids .
DDI-DrugBank.d709.s3
DDI-DrugBank.d709.s3.e0_DDI-DrugBank.d709.s3.e1 false although such a reaction has not been demonstrated with roxithromycin , concomitant administration of roxithromycin with terfenadine or astemizole is not recommended .
DDI-DrugBank.d709.s3.e0_DDI-DrugBank.d709.s3.e2 false although such a reaction has not been demonstrated with roxithromycin , concomitant administration of roxithromycin with terfenadine or astemizole is not recommended .
DDI-DrugBank.d709.s3.e0_DDI-DrugBank.d709.s3.e3 false although such a reaction has not been demonstrated with roxithromycin , concomitant administration of roxithromycin with terfenadine or astemizole is not recommended .
DDI-DrugBank.d709.s3.e1_DDI-DrugBank.d709.s3.e2 true although such a reaction has not been demonstrated with roxithromycin , concomitant administration of roxithromycin with terfenadine or astemizole is not recommended .
DDI-DrugBank.d709.s3.e1_DDI-DrugBank.d709.s3.e3 true although such a reaction has not been demonstrated with roxithromycin , concomitant administration of roxithromycin with terfenadine or astemizole is not recommended .
DDI-DrugBank.d709.s3.e2_DDI-DrugBank.d709.s3.e3 false although such a reaction has not been demonstrated with roxithromycin , concomitant administration of roxithromycin with terfenadine or astemizole is not recommended .
DDI-DrugBank.d781.s16
DDI-DrugBank.d781.s16.e0_DDI-DrugBank.d781.s16.e1 false however , the extent of biotransformation of perindopril to the active metabolite , perindoprilat , is reduced approximately 43 % , resulting in a reduction in the plasma ace inhibition curve of approximately 20 % , probably clinically insignificant .
DDI-DrugBank.d694.s0
DDI-DrugBank.d694.s0.e0_DDI-DrugBank.d694.s0.e1 false digoxin : there was a slight increase in the area under the curve ( auc , 11 % ) and mean peak drug concentration ( cmax , 18 % ) of digoxin with the co-administration of 100 mg sitagliptin for 10 days .
DDI-DrugBank.d694.s0.e0_DDI-DrugBank.d694.s0.e2 false digoxin : there was a slight increase in the area under the curve ( auc , 11 % ) and mean peak drug concentration ( cmax , 18 % ) of digoxin with the co-administration of 100 mg sitagliptin for 10 days .
DDI-DrugBank.d694.s0.e1_DDI-DrugBank.d694.s0.e2 true digoxin : there was a slight increase in the area under the curve ( auc , 11 % ) and mean peak drug concentration ( cmax , 18 % ) of digoxin with the co-administration of 100 mg sitagliptin for 10 days .
DDI-DrugBank.d776.s32
DDI-DrugBank.d776.s32.e0_DDI-DrugBank.d776.s32.e1 true patients receiving rifabutin and fluconazole concomitantly should be carefully monitored .
DDI-DrugBank.d596.s9
DDI-DrugBank.d596.s9.e3_DDI-DrugBank.d596.s9.e6 false use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol
DDI-DrugBank.d596.s9.e3_DDI-DrugBank.d596.s9.e0 false use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol
DDI-DrugBank.d596.s9.e3_DDI-DrugBank.d596.s9.e1 false use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol
DDI-DrugBank.d596.s9.e3_DDI-DrugBank.d596.s9.e2 false use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol
DDI-DrugBank.d596.s9.e3_DDI-DrugBank.d596.s9.e4 false use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol
DDI-DrugBank.d596.s9.e3_DDI-DrugBank.d596.s9.e5 false use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol
DDI-DrugBank.d596.s9.e6_DDI-DrugBank.d596.s9.e0 false use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol
DDI-DrugBank.d596.s9.e6_DDI-DrugBank.d596.s9.e1 false use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol
DDI-DrugBank.d596.s9.e6_DDI-DrugBank.d596.s9.e2 false use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol
DDI-DrugBank.d596.s9.e6_DDI-DrugBank.d596.s9.e4 false use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol
DDI-DrugBank.d596.s9.e6_DDI-DrugBank.d596.s9.e5 false use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol
DDI-DrugBank.d596.s9.e0_DDI-DrugBank.d596.s9.e1 false use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol
DDI-DrugBank.d596.s9.e0_DDI-DrugBank.d596.s9.e2 false use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol
DDI-DrugBank.d596.s9.e0_DDI-DrugBank.d596.s9.e4 false use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol
DDI-DrugBank.d596.s9.e0_DDI-DrugBank.d596.s9.e5 false use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol
DDI-DrugBank.d596.s9.e1_DDI-DrugBank.d596.s9.e2 false use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol
DDI-DrugBank.d596.s9.e1_DDI-DrugBank.d596.s9.e4 false use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol
DDI-DrugBank.d596.s9.e1_DDI-DrugBank.d596.s9.e5 false use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol
DDI-DrugBank.d596.s9.e2_DDI-DrugBank.d596.s9.e4 false use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol
DDI-DrugBank.d596.s9.e2_DDI-DrugBank.d596.s9.e5 false use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol
DDI-DrugBank.d596.s9.e4_DDI-DrugBank.d596.s9.e5 false use with cholinomimetics and other cholinesterase inhibitors : a synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol
DDI-DrugBank.d710.s7
DDI-DrugBank.d680.s8
DDI-DrugBank.d680.s8.e0_DDI-DrugBank.d680.s8.e1 true because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability ( eg , ketoconazole , ampicillin esters , and iron salts ) .
DDI-DrugBank.d680.s8.e0_DDI-DrugBank.d680.s8.e2 true because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability ( eg , ketoconazole , ampicillin esters , and iron salts ) .
DDI-DrugBank.d680.s8.e0_DDI-DrugBank.d680.s8.e3 true because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability ( eg , ketoconazole , ampicillin esters , and iron salts ) .
DDI-DrugBank.d680.s8.e1_DDI-DrugBank.d680.s8.e2 false because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability ( eg , ketoconazole , ampicillin esters , and iron salts ) .
DDI-DrugBank.d680.s8.e1_DDI-DrugBank.d680.s8.e3 false because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability ( eg , ketoconazole , ampicillin esters , and iron salts ) .
DDI-DrugBank.d680.s8.e2_DDI-DrugBank.d680.s8.e3 false because of profound and long lasting inhibition of gastric acid secretion , pantoprazole may interfere with absorption of drugs where gastric ph is an important determinant of their bioavailability ( eg , ketoconazole , ampicillin esters , and iron salts ) .
DDI-DrugBank.d773.s2
DDI-DrugBank.d773.s2.e1_DDI-DrugBank.d773.s2.e3 false anticoagulants ( such as heparin and vitamin k antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2.e1_DDI-DrugBank.d773.s2.e4 false anticoagulants ( such as heparin and vitamin k antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2.e1_DDI-DrugBank.d773.s2.e5 true anticoagulants ( such as heparin and vitamin k antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2.e1_DDI-DrugBank.d773.s2.e0 false anticoagulants ( such as heparin and vitamin k antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2.e1_DDI-DrugBank.d773.s2.e2 false anticoagulants ( such as heparin and vitamin k antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2.e3_DDI-DrugBank.d773.s2.e4 false anticoagulants ( such as heparin and vitamin k antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2.e3_DDI-DrugBank.d773.s2.e5 false anticoagulants ( such as heparin and vitamin k antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2.e3_DDI-DrugBank.d773.s2.e0 false anticoagulants ( such as heparin and vitamin k antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2.e3_DDI-DrugBank.d773.s2.e2 false anticoagulants ( such as heparin and vitamin k antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2.e4_DDI-DrugBank.d773.s2.e5 false anticoagulants ( such as heparin and vitamin k antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2.e4_DDI-DrugBank.d773.s2.e0 false anticoagulants ( such as heparin and vitamin k antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2.e4_DDI-DrugBank.d773.s2.e2 false anticoagulants ( such as heparin and vitamin k antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2.e5_DDI-DrugBank.d773.s2.e0 false anticoagulants ( such as heparin and vitamin k antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2.e5_DDI-DrugBank.d773.s2.e2 false anticoagulants ( such as heparin and vitamin k antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d773.s2.e0_DDI-DrugBank.d773.s2.e2 false anticoagulants ( such as heparin and vitamin k antagonists ) and drugs that alter platelet function ( such as acetylsalicylic acid , dipyridamole , and gp iib/iiia inhibitors ) may increase the risk of bleeding if administered prior to , during , or after tnkase therapy .
DDI-DrugBank.d689.s0
DDI-DrugBank.d689.s0.e1_DDI-DrugBank.d689.s0.e2 true vasopressors , particularly metaraminol , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all .
DDI-DrugBank.d689.s0.e1_DDI-DrugBank.d689.s0.e0 false vasopressors , particularly metaraminol , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all .
DDI-DrugBank.d689.s0.e2_DDI-DrugBank.d689.s0.e0 false vasopressors , particularly metaraminol , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all .
DDI-DrugBank.d709.s1
DDI-DrugBank.d709.s1.e0_DDI-DrugBank.d709.s1.e1 false concomitant administrations not recommended : - terfenadine and astemizole : certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s1.e0_DDI-DrugBank.d709.s1.e3 false concomitant administrations not recommended : - terfenadine and astemizole : certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s1.e0_DDI-DrugBank.d709.s1.e4 false concomitant administrations not recommended : - terfenadine and astemizole : certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s1.e0_DDI-DrugBank.d709.s1.e2 false concomitant administrations not recommended : - terfenadine and astemizole : certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s1.e1_DDI-DrugBank.d709.s1.e3 false concomitant administrations not recommended : - terfenadine and astemizole : certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s1.e1_DDI-DrugBank.d709.s1.e4 false concomitant administrations not recommended : - terfenadine and astemizole : certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s1.e1_DDI-DrugBank.d709.s1.e2 false concomitant administrations not recommended : - terfenadine and astemizole : certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s1.e3_DDI-DrugBank.d709.s1.e4 false concomitant administrations not recommended : - terfenadine and astemizole : certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s1.e3_DDI-DrugBank.d709.s1.e2 false concomitant administrations not recommended : - terfenadine and astemizole : certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter .
DDI-DrugBank.d709.s1.e4_DDI-DrugBank.d709.s1.e2 false concomitant administrations not recommended : - terfenadine and astemizole : certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter .
DDI-DrugBank.d784.s0
DDI-DrugBank.d784.s0.e0_DDI-DrugBank.d784.s0.e1 true the concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth , constipation , somnolence ( drowsiness ) , and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects .
DDI-DrugBank.d736.s8
DDI-DrugBank.d736.s8.e0_DDI-DrugBank.d736.s8.e0 false potentiation occurs with ganglionic or peripheral adrenergic blocking drugs .
DDI-DrugBank.d736.s8.e0_DDI-DrugBank.d736.s8.e1 false potentiation occurs with ganglionic or peripheral adrenergic blocking drugs .
DDI-DrugBank.d736.s8.e0_DDI-DrugBank.d736.s8.e1 false potentiation occurs with ganglionic or peripheral adrenergic blocking drugs .
DDI-DrugBank.d619.s0
DDI-DrugBank.d619.s0.e0_DDI-DrugBank.d619.s0.e1 true the occurrence of stupor , muscular rigidity , severe agitation , and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine .
DDI-DrugBank.d572.s26
DDI-DrugBank.d670.s9
DDI-DrugBank.d670.s9.e1_DDI-DrugBank.d670.s9.e0 false potential for other drugs to affect invega paliperidone is not a substrate of cyp1a2 , cyp2a6 , cyp2c9 , and cyp2c19 , so that an interaction with inhibitors or inducers of these isozymes is unlikely .
DDI-DrugBank.d737.s8
DDI-DrugBank.d700.s11
DDI-DrugBank.d700.s11.e1_DDI-DrugBank.d700.s11.e0 false therefore , it is recommended that oral contraceptives are co- administered with myfortic with caution and additional birth control methods be considered .
DDI-DrugBank.d633.s5
DDI-DrugBank.d633.s5.e0_DDI-DrugBank.d633.s5.e1 false addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of qrs , qtc , rr , and pr intervals than propafenone alone .
DDI-DrugBank.d633.s5.e0_DDI-DrugBank.d633.s5.e2 false addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of qrs , qtc , rr , and pr intervals than propafenone alone .
DDI-DrugBank.d633.s5.e1_DDI-DrugBank.d633.s5.e2 false addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of qrs , qtc , rr , and pr intervals than propafenone alone .
DDI-DrugBank.d686.s1
DDI-DrugBank.d686.s1.e0_DDI-DrugBank.d686.s1.e1 true therefore , when concomitant use of thiabendazole and xanthine derivatives is anticipated , it may be necessary to monitor blood levels and/or reduce the dosage of such compounds .
DDI-DrugBank.d723.s0
DDI-DrugBank.d723.s0.e0_DDI-DrugBank.d723.s0.e2 false other eye drops or medications such as acetylcholine chloride ( miochol ) and carbachol ( carboptic , isopto carbachol ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0.e0_DDI-DrugBank.d723.s0.e5 true other eye drops or medications such as acetylcholine chloride ( miochol ) and carbachol ( carboptic , isopto carbachol ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0.e0_DDI-DrugBank.d723.s0.e1 false other eye drops or medications such as acetylcholine chloride ( miochol ) and carbachol ( carboptic , isopto carbachol ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0.e0_DDI-DrugBank.d723.s0.e3 false other eye drops or medications such as acetylcholine chloride ( miochol ) and carbachol ( carboptic , isopto carbachol ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0.e0_DDI-DrugBank.d723.s0.e4 false other eye drops or medications such as acetylcholine chloride ( miochol ) and carbachol ( carboptic , isopto carbachol ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0.e2_DDI-DrugBank.d723.s0.e5 false other eye drops or medications such as acetylcholine chloride ( miochol ) and carbachol ( carboptic , isopto carbachol ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0.e2_DDI-DrugBank.d723.s0.e1 false other eye drops or medications such as acetylcholine chloride ( miochol ) and carbachol ( carboptic , isopto carbachol ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0.e2_DDI-DrugBank.d723.s0.e3 false other eye drops or medications such as acetylcholine chloride ( miochol ) and carbachol ( carboptic , isopto carbachol ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0.e2_DDI-DrugBank.d723.s0.e4 false other eye drops or medications such as acetylcholine chloride ( miochol ) and carbachol ( carboptic , isopto carbachol ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0.e5_DDI-DrugBank.d723.s0.e1 false other eye drops or medications such as acetylcholine chloride ( miochol ) and carbachol ( carboptic , isopto carbachol ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0.e5_DDI-DrugBank.d723.s0.e3 false other eye drops or medications such as acetylcholine chloride ( miochol ) and carbachol ( carboptic , isopto carbachol ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0.e5_DDI-DrugBank.d723.s0.e4 false other eye drops or medications such as acetylcholine chloride ( miochol ) and carbachol ( carboptic , isopto carbachol ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0.e1_DDI-DrugBank.d723.s0.e3 false other eye drops or medications such as acetylcholine chloride ( miochol ) and carbachol ( carboptic , isopto carbachol ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0.e1_DDI-DrugBank.d723.s0.e4 false other eye drops or medications such as acetylcholine chloride ( miochol ) and carbachol ( carboptic , isopto carbachol ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d723.s0.e3_DDI-DrugBank.d723.s0.e4 false other eye drops or medications such as acetylcholine chloride ( miochol ) and carbachol ( carboptic , isopto carbachol ) may decrease the effects of suprofen ophthalmic .
DDI-DrugBank.d654.s2
DDI-DrugBank.d654.s2.e1_DDI-DrugBank.d654.s2.e0 false based on in vitro p450 inhibition studies and the low systemic exposure observed following topical application of altabax , retapamulin is unlikely to affect the metabolism of other p450 substrates .
DDI-DrugBank.d632.s1
DDI-DrugBank.d702.s0
DDI-DrugBank.d781.s7
DDI-DrugBank.d633.s9
DDI-DrugBank.d633.s9.e0_DDI-DrugBank.d633.s9.e1 false when phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexitil , lowered mexitil plasma levels have been reported .
DDI-DrugBank.d633.s9.e0_DDI-DrugBank.d633.s9.e2 false when phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexitil , lowered mexitil plasma levels have been reported .
DDI-DrugBank.d633.s9.e0_DDI-DrugBank.d633.s9.e3 true when phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexitil , lowered mexitil plasma levels have been reported .
DDI-DrugBank.d633.s9.e0_DDI-DrugBank.d633.s9.e4 false when phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexitil , lowered mexitil plasma levels have been reported .
DDI-DrugBank.d633.s9.e1_DDI-DrugBank.d633.s9.e2 false when phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexitil , lowered mexitil plasma levels have been reported .
DDI-DrugBank.d633.s9.e1_DDI-DrugBank.d633.s9.e3 true when phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexitil , lowered mexitil plasma levels have been reported .
DDI-DrugBank.d633.s9.e1_DDI-DrugBank.d633.s9.e4 false when phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexitil , lowered mexitil plasma levels have been reported .
DDI-DrugBank.d633.s9.e2_DDI-DrugBank.d633.s9.e3 true when phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexitil , lowered mexitil plasma levels have been reported .
DDI-DrugBank.d633.s9.e2_DDI-DrugBank.d633.s9.e4 false when phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexitil , lowered mexitil plasma levels have been reported .
DDI-DrugBank.d633.s9.e3_DDI-DrugBank.d633.s9.e4 false when phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with mexitil , lowered mexitil plasma levels have been reported .
DDI-DrugBank.d633.s0
DDI-DrugBank.d633.s0.e1_DDI-DrugBank.d633.s0.e0 false since mexitil is a substrate for the metabolic pathways involving cyp2d6 and cyp1a2 enzymes , inhibition or induction of either of these enzymes would be expected to alter mexiletine plasma concentrations .
DDI-DrugBank.d661.s3
DDI-DrugBank.d633.s16
DDI-DrugBank.d633.s16.e1_DDI-DrugBank.d633.s16.e2 false concurrent use of mexitil and theophylline may lead to increased plasma theophylline levels .
DDI-DrugBank.d633.s16.e1_DDI-DrugBank.d633.s16.e0 false concurrent use of mexitil and theophylline may lead to increased plasma theophylline levels .
DDI-DrugBank.d633.s16.e2_DDI-DrugBank.d633.s16.e0 false concurrent use of mexitil and theophylline may lead to increased plasma theophylline levels .
DDI-DrugBank.d666.s4
DDI-DrugBank.d635.s0
DDI-DrugBank.d635.s0.e1_DDI-DrugBank.d635.s0.e0 false other short-acting beta adrenergic aerosol bronchodilators should not be used concomitantly with maxair autohaler because they may have additive effects .
DDI-DrugBank.d706.s0
DDI-DrugBank.d706.s0.e0_DDI-DrugBank.d706.s0.e1 true catecholamine-depleting drugs ( e.g. , reserpine ) may have an additive effect when given with beta-blocking agents .
DDI-DrugBank.d597.s5
DDI-DrugBank.d597.s5.e0_DDI-DrugBank.d597.s5.e1 true concomitant administration of low-dose aspirin with mobic may result in an increased rate of gi ulceration or other complications , compared to use of mobic alone .
DDI-DrugBank.d597.s5.e0_DDI-DrugBank.d597.s5.e2 false concomitant administration of low-dose aspirin with mobic may result in an increased rate of gi ulceration or other complications , compared to use of mobic alone .
DDI-DrugBank.d597.s5.e1_DDI-DrugBank.d597.s5.e2 false concomitant administration of low-dose aspirin with mobic may result in an increased rate of gi ulceration or other complications , compared to use of mobic alone .
DDI-DrugBank.d632.s5
DDI-DrugBank.d632.s5.e0_DDI-DrugBank.d632.s5.e1 false no formal interaction studies have been performed to assess the effect of symlin on the kinetics of oral antidiabetic agents .
DDI-DrugBank.d780.s7
DDI-DrugBank.d780.s7.e1_DDI-DrugBank.d780.s7.e0 false sulfonamides : concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide .
DDI-DrugBank.d780.s7.e1_DDI-DrugBank.d780.s7.e2 true sulfonamides : concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide .
DDI-DrugBank.d780.s7.e1_DDI-DrugBank.d780.s7.e3 false sulfonamides : concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide .
DDI-DrugBank.d780.s7.e0_DDI-DrugBank.d780.s7.e2 false sulfonamides : concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide .
DDI-DrugBank.d780.s7.e0_DDI-DrugBank.d780.s7.e3 false sulfonamides : concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide .
DDI-DrugBank.d780.s7.e2_DDI-DrugBank.d780.s7.e3 false sulfonamides : concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide .
DDI-DrugBank.d633.s1
DDI-DrugBank.d633.s1.e0_DDI-DrugBank.d633.s1.e1 true in a formal , single-dose interaction study ( n = 6 males ) the clearance of mexiletine was decreased by 38 % following the coadministration of fluvoxamine , an inhibitor of cyp1a2 .
DDI-DrugBank.d720.s0
DDI-DrugBank.d742.s11
DDI-DrugBank.d742.s11.e0_DDI-DrugBank.d742.s11.e1 true accordingly , patients should be advised to avoid diazepam and other similar drugs while taking remeron soltab .
DDI-DrugBank.d675.s7
DDI-DrugBank.d675.s7.e1_DDI-DrugBank.d675.s7.e0 false caution should be exercised when methergine ( methylergonovine maleate ) is used concurrently with other vasoconstrictors or ergot alkaloids .
DDI-DrugBank.d675.s7.e1_DDI-DrugBank.d675.s7.e2 true caution should be exercised when methergine ( methylergonovine maleate ) is used concurrently with other vasoconstrictors or ergot alkaloids .
DDI-DrugBank.d675.s7.e1_DDI-DrugBank.d675.s7.e3 false caution should be exercised when methergine ( methylergonovine maleate ) is used concurrently with other vasoconstrictors or ergot alkaloids .
DDI-DrugBank.d675.s7.e0_DDI-DrugBank.d675.s7.e2 true caution should be exercised when methergine ( methylergonovine maleate ) is used concurrently with other vasoconstrictors or ergot alkaloids .
DDI-DrugBank.d675.s7.e0_DDI-DrugBank.d675.s7.e3 true caution should be exercised when methergine ( methylergonovine maleate ) is used concurrently with other vasoconstrictors or ergot alkaloids .
DDI-DrugBank.d675.s7.e2_DDI-DrugBank.d675.s7.e3 false caution should be exercised when methergine ( methylergonovine maleate ) is used concurrently with other vasoconstrictors or ergot alkaloids .
DDI-DrugBank.d713.s2
DDI-DrugBank.d713.s2.e2_DDI-DrugBank.d713.s2.e3 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e2_DDI-DrugBank.d713.s2.e4 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e2_DDI-DrugBank.d713.s2.e5 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e2_DDI-DrugBank.d713.s2.e6 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e2_DDI-DrugBank.d713.s2.e7 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e2_DDI-DrugBank.d713.s2.e8 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e2_DDI-DrugBank.d713.s2.e0 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e2_DDI-DrugBank.d713.s2.e1 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e3_DDI-DrugBank.d713.s2.e4 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e3_DDI-DrugBank.d713.s2.e5 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e3_DDI-DrugBank.d713.s2.e6 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e3_DDI-DrugBank.d713.s2.e7 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e3_DDI-DrugBank.d713.s2.e8 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e3_DDI-DrugBank.d713.s2.e0 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e3_DDI-DrugBank.d713.s2.e1 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e4_DDI-DrugBank.d713.s2.e5 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e4_DDI-DrugBank.d713.s2.e6 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e4_DDI-DrugBank.d713.s2.e7 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e4_DDI-DrugBank.d713.s2.e8 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e4_DDI-DrugBank.d713.s2.e0 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e4_DDI-DrugBank.d713.s2.e1 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e5_DDI-DrugBank.d713.s2.e6 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e5_DDI-DrugBank.d713.s2.e7 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e5_DDI-DrugBank.d713.s2.e8 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e5_DDI-DrugBank.d713.s2.e0 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e5_DDI-DrugBank.d713.s2.e1 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e6_DDI-DrugBank.d713.s2.e7 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e6_DDI-DrugBank.d713.s2.e8 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e6_DDI-DrugBank.d713.s2.e0 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e6_DDI-DrugBank.d713.s2.e1 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e7_DDI-DrugBank.d713.s2.e8 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e7_DDI-DrugBank.d713.s2.e0 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e7_DDI-DrugBank.d713.s2.e1 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e8_DDI-DrugBank.d713.s2.e0 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e8_DDI-DrugBank.d713.s2.e1 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d713.s2.e0_DDI-DrugBank.d713.s2.e1 false drugs eliminated by active tubular secretion : although studies to assess drug-drug interactions with sanctura have not been conducted , sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion ( e.g. digoxin , procainamide , pancuronium , morphine , vancomycin , metformin and tenofovir ) .
DDI-DrugBank.d696.s0
DDI-DrugBank.d696.s0.e0_DDI-DrugBank.d696.s0.e1 true methysergide may reverse the analgesic activity of narcotic analgesics .
DDI-DrugBank.d640.s5
DDI-DrugBank.d640.s5.e1_DDI-DrugBank.d640.s5.e0 false oral anticoagulants : interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect .
DDI-DrugBank.d640.s5.e1_DDI-DrugBank.d640.s5.e2 false oral anticoagulants : interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect .
DDI-DrugBank.d640.s5.e0_DDI-DrugBank.d640.s5.e2 false oral anticoagulants : interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect .
DDI-DrugBank.d578.s10
DDI-DrugBank.d578.s10.e0_DDI-DrugBank.d578.s10.e1 false the effect of methylprednisolone on oral anticoagulants is variable .
DDI-DrugBank.d634.s6
DDI-DrugBank.d743.s10
DDI-DrugBank.d666.s1
DDI-DrugBank.d769.s2
DDI-DrugBank.d769.s2.e3_DDI-DrugBank.d769.s2.e1 false other hdac inhibitors severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of zolinza and other hdac inhibitors ( e.g. , valproic acid ) .
DDI-DrugBank.d769.s2.e3_DDI-DrugBank.d769.s2.e0 false other hdac inhibitors severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of zolinza and other hdac inhibitors ( e.g. , valproic acid ) .
DDI-DrugBank.d769.s2.e3_DDI-DrugBank.d769.s2.e2 false other hdac inhibitors severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of zolinza and other hdac inhibitors ( e.g. , valproic acid ) .
DDI-DrugBank.d769.s2.e1_DDI-DrugBank.d769.s2.e0 false other hdac inhibitors severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of zolinza and other hdac inhibitors ( e.g. , valproic acid ) .
DDI-DrugBank.d769.s2.e1_DDI-DrugBank.d769.s2.e2 true other hdac inhibitors severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of zolinza and other hdac inhibitors ( e.g. , valproic acid ) .
DDI-DrugBank.d769.s2.e0_DDI-DrugBank.d769.s2.e2 false other hdac inhibitors severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of zolinza and other hdac inhibitors ( e.g. , valproic acid ) .
DDI-DrugBank.d777.s2
DDI-DrugBank.d585.s5
DDI-DrugBank.d585.s5.e1_DDI-DrugBank.d585.s5.e0 false anticholinergic drugs may antagonize the effects of drugs that alter gastrointestinal motility , such as metoclopramide .
DDI-DrugBank.d720.s1
DDI-DrugBank.d720.s1.e0_DDI-DrugBank.d720.s1.e2 false because there is a theoretical basis that these effects may be additive , use of ergotamine-containing or ergot-type medications ( like dihydroergotamine or methysergide ) and sumatriptan within 24 hours of each other should be avoided .
DDI-DrugBank.d720.s1.e0_DDI-DrugBank.d720.s1.e3 false because there is a theoretical basis that these effects may be additive , use of ergotamine-containing or ergot-type medications ( like dihydroergotamine or methysergide ) and sumatriptan within 24 hours of each other should be avoided .
DDI-DrugBank.d720.s1.e0_DDI-DrugBank.d720.s1.e4 true because there is a theoretical basis that these effects may be additive , use of ergotamine-containing or ergot-type medications ( like dihydroergotamine or methysergide ) and sumatriptan within 24 hours of each other should be avoided .
DDI-DrugBank.d720.s1.e0_DDI-DrugBank.d720.s1.e1 false because there is a theoretical basis that these effects may be additive , use of ergotamine-containing or ergot-type medications ( like dihydroergotamine or methysergide ) and sumatriptan within 24 hours of each other should be avoided .
DDI-DrugBank.d720.s1.e2_DDI-DrugBank.d720.s1.e3 false because there is a theoretical basis that these effects may be additive , use of ergotamine-containing or ergot-type medications ( like dihydroergotamine or methysergide ) and sumatriptan within 24 hours of each other should be avoided .
DDI-DrugBank.d720.s1.e2_DDI-DrugBank.d720.s1.e4 true because there is a theoretical basis that these effects may be additive , use of ergotamine-containing or ergot-type medications ( like dihydroergotamine or methysergide ) and sumatriptan within 24 hours of each other should be avoided .
DDI-DrugBank.d720.s1.e2_DDI-DrugBank.d720.s1.e1 false because there is a theoretical basis that these effects may be additive , use of ergotamine-containing or ergot-type medications ( like dihydroergotamine or methysergide ) and sumatriptan within 24 hours of each other should be avoided .
DDI-DrugBank.d720.s1.e3_DDI-DrugBank.d720.s1.e4 true because there is a theoretical basis that these effects may be additive , use of ergotamine-containing or ergot-type medications ( like dihydroergotamine or methysergide ) and sumatriptan within 24 hours of each other should be avoided .
DDI-DrugBank.d720.s1.e3_DDI-DrugBank.d720.s1.e1 false because there is a theoretical basis that these effects may be additive , use of ergotamine-containing or ergot-type medications ( like dihydroergotamine or methysergide ) and sumatriptan within 24 hours of each other should be avoided .
DDI-DrugBank.d720.s1.e4_DDI-DrugBank.d720.s1.e1 false because there is a theoretical basis that these effects may be additive , use of ergotamine-containing or ergot-type medications ( like dihydroergotamine or methysergide ) and sumatriptan within 24 hours of each other should be avoided .
DDI-DrugBank.d623.s7
DDI-DrugBank.d732.s4
DDI-DrugBank.d670.s4
DDI-DrugBank.d665.s2
DDI-DrugBank.d584.s9
DDI-DrugBank.d584.s9.e1_DDI-DrugBank.d584.s9.e0 false oral hypoglycemic agents oxandrolone may inhibit the metabolism of oral hypoglycemic agents .
DDI-DrugBank.d584.s9.e1_DDI-DrugBank.d584.s9.e2 true oral hypoglycemic agents oxandrolone may inhibit the metabolism of oral hypoglycemic agents .
DDI-DrugBank.d584.s9.e0_DDI-DrugBank.d584.s9.e2 false oral hypoglycemic agents oxandrolone may inhibit the metabolism of oral hypoglycemic agents .
DDI-DrugBank.d600.s0
DDI-DrugBank.d761.s3
DDI-DrugBank.d761.s3.e1_DDI-DrugBank.d761.s3.e2 true fat-soluble vitamin supplements and analogues : a pharmacokinetic interaction study showed a 30 % reduction in beta-carotene supplement absorption when concomitantly administered with xenical .
DDI-DrugBank.d761.s3.e1_DDI-DrugBank.d761.s3.e0 false fat-soluble vitamin supplements and analogues : a pharmacokinetic interaction study showed a 30 % reduction in beta-carotene supplement absorption when concomitantly administered with xenical .
DDI-DrugBank.d761.s3.e2_DDI-DrugBank.d761.s3.e0 false fat-soluble vitamin supplements and analogues : a pharmacokinetic interaction study showed a 30 % reduction in beta-carotene supplement absorption when concomitantly administered with xenical .
DDI-DrugBank.d585.s1
DDI-DrugBank.d585.s1.e0_DDI-DrugBank.d585.s1.e1 true anticholinergics antagonize the effects of antiglaucoma agents .
DDI-DrugBank.d580.s0
DDI-DrugBank.d739.s11
DDI-DrugBank.d752.s6
DDI-DrugBank.d752.s6.e0_DDI-DrugBank.d752.s6.e1 false inducers of cyp3a4 isozymes : cytochrome p450 inducers , such as rifampin , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased c max and auc of oral midazolam in adult studies .
DDI-DrugBank.d752.s6.e0_DDI-DrugBank.d752.s6.e2 false inducers of cyp3a4 isozymes : cytochrome p450 inducers , such as rifampin , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased c max and auc of oral midazolam in adult studies .
DDI-DrugBank.d752.s6.e0_DDI-DrugBank.d752.s6.e3 true inducers of cyp3a4 isozymes : cytochrome p450 inducers , such as rifampin , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased c max and auc of oral midazolam in adult studies .
DDI-DrugBank.d752.s6.e1_DDI-DrugBank.d752.s6.e2 false inducers of cyp3a4 isozymes : cytochrome p450 inducers , such as rifampin , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased c max and auc of oral midazolam in adult studies .
DDI-DrugBank.d752.s6.e1_DDI-DrugBank.d752.s6.e3 true inducers of cyp3a4 isozymes : cytochrome p450 inducers , such as rifampin , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased c max and auc of oral midazolam in adult studies .
DDI-DrugBank.d752.s6.e2_DDI-DrugBank.d752.s6.e3 true inducers of cyp3a4 isozymes : cytochrome p450 inducers , such as rifampin , carbamazepine , and phenytoin , induce metabolism and caused a markedly decreased c max and auc of oral midazolam in adult studies .
DDI-DrugBank.d588.s10
DDI-DrugBank.d588.s10.e2_DDI-DrugBank.d588.s10.e0 false salicylates and other non-steroidal anti-inflammatory drugs : may decrease the antihypertensive effects of mykrox tablets .
DDI-DrugBank.d588.s10.e2_DDI-DrugBank.d588.s10.e1 false salicylates and other non-steroidal anti-inflammatory drugs : may decrease the antihypertensive effects of mykrox tablets .
DDI-DrugBank.d588.s10.e0_DDI-DrugBank.d588.s10.e1 false salicylates and other non-steroidal anti-inflammatory drugs : may decrease the antihypertensive effects of mykrox tablets .
DDI-DrugBank.d637.s2
DDI-DrugBank.d637.s2.e2_DDI-DrugBank.d637.s2.e3 false interaction with mixed agonist/antagonist opioid analgesics : agonist/antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2.e2_DDI-DrugBank.d637.s2.e4 false interaction with mixed agonist/antagonist opioid analgesics : agonist/antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2.e2_DDI-DrugBank.d637.s2.e5 false interaction with mixed agonist/antagonist opioid analgesics : agonist/antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2.e2_DDI-DrugBank.d637.s2.e0 false interaction with mixed agonist/antagonist opioid analgesics : agonist/antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2.e2_DDI-DrugBank.d637.s2.e1 false interaction with mixed agonist/antagonist opioid analgesics : agonist/antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2.e2_DDI-DrugBank.d637.s2.e6 false interaction with mixed agonist/antagonist opioid analgesics : agonist/antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2.e3_DDI-DrugBank.d637.s2.e4 false interaction with mixed agonist/antagonist opioid analgesics : agonist/antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2.e3_DDI-DrugBank.d637.s2.e5 false interaction with mixed agonist/antagonist opioid analgesics : agonist/antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2.e3_DDI-DrugBank.d637.s2.e0 false interaction with mixed agonist/antagonist opioid analgesics : agonist/antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2.e3_DDI-DrugBank.d637.s2.e1 false interaction with mixed agonist/antagonist opioid analgesics : agonist/antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2.e3_DDI-DrugBank.d637.s2.e6 false interaction with mixed agonist/antagonist opioid analgesics : agonist/antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2.e4_DDI-DrugBank.d637.s2.e5 false interaction with mixed agonist/antagonist opioid analgesics : agonist/antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2.e4_DDI-DrugBank.d637.s2.e0 false interaction with mixed agonist/antagonist opioid analgesics : agonist/antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2.e4_DDI-DrugBank.d637.s2.e1 false interaction with mixed agonist/antagonist opioid analgesics : agonist/antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2.e4_DDI-DrugBank.d637.s2.e6 false interaction with mixed agonist/antagonist opioid analgesics : agonist/antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2.e5_DDI-DrugBank.d637.s2.e0 false interaction with mixed agonist/antagonist opioid analgesics : agonist/antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2.e5_DDI-DrugBank.d637.s2.e1 false interaction with mixed agonist/antagonist opioid analgesics : agonist/antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2.e5_DDI-DrugBank.d637.s2.e6 false interaction with mixed agonist/antagonist opioid analgesics : agonist/antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2.e0_DDI-DrugBank.d637.s2.e1 false interaction with mixed agonist/antagonist opioid analgesics : agonist/antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2.e0_DDI-DrugBank.d637.s2.e6 false interaction with mixed agonist/antagonist opioid analgesics : agonist/antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d637.s2.e1_DDI-DrugBank.d637.s2.e6 false interaction with mixed agonist/antagonist opioid analgesics : agonist/antagonist analgesics ( i.e. , pentazocine , nalbuphine , butorphanol , or buprenorphine ) should not be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic .
DDI-DrugBank.d739.s8
DDI-DrugBank.d739.s8.e0_DDI-DrugBank.d739.s8.e1 false it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as phenobarbital or rifampin , are co-administered with montelukast .
DDI-DrugBank.d739.s8.e0_DDI-DrugBank.d739.s8.e2 true it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as phenobarbital or rifampin , are co-administered with montelukast .
DDI-DrugBank.d739.s8.e1_DDI-DrugBank.d739.s8.e2 true it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as phenobarbital or rifampin , are co-administered with montelukast .
DDI-DrugBank.d779.s16
DDI-DrugBank.d779.s16.e0_DDI-DrugBank.d779.s16.e1 false methyldopa does not interfere with measurement of vma ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert vma to vanillin .
DDI-DrugBank.d779.s16.e0_DDI-DrugBank.d779.s16.e2 false methyldopa does not interfere with measurement of vma ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert vma to vanillin .
DDI-DrugBank.d779.s16.e0_DDI-DrugBank.d779.s16.e3 false methyldopa does not interfere with measurement of vma ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert vma to vanillin .
DDI-DrugBank.d779.s16.e0_DDI-DrugBank.d779.s16.e4 false methyldopa does not interfere with measurement of vma ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert vma to vanillin .
DDI-DrugBank.d779.s16.e1_DDI-DrugBank.d779.s16.e2 false methyldopa does not interfere with measurement of vma ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert vma to vanillin .
DDI-DrugBank.d779.s16.e1_DDI-DrugBank.d779.s16.e3 false methyldopa does not interfere with measurement of vma ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert vma to vanillin .
DDI-DrugBank.d779.s16.e1_DDI-DrugBank.d779.s16.e4 false methyldopa does not interfere with measurement of vma ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert vma to vanillin .
DDI-DrugBank.d779.s16.e2_DDI-DrugBank.d779.s16.e3 false methyldopa does not interfere with measurement of vma ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert vma to vanillin .
DDI-DrugBank.d779.s16.e2_DDI-DrugBank.d779.s16.e4 false methyldopa does not interfere with measurement of vma ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert vma to vanillin .
DDI-DrugBank.d779.s16.e3_DDI-DrugBank.d779.s16.e4 false methyldopa does not interfere with measurement of vma ( vanillylmandelic acid ) , a test for pheochromocytoma , by those methods which convert vma to vanillin .
DDI-DrugBank.d603.s0
DDI-DrugBank.d603.s0.e0_DDI-DrugBank.d603.s0.e1 true when administered concomitantly with proamatine , cardiac glycosides may enhance or precipitate bradycardia , a.v.
DDI-DrugBank.d690.s2
DDI-DrugBank.d781.s3
DDI-DrugBank.d781.s3.e0_DDI-DrugBank.d781.s3.e1 false the rate and extent of perindopril absorption and elimination are not affected by concomitant diuretics .
DDI-DrugBank.d693.s2
DDI-DrugBank.d693.s2.e0_DDI-DrugBank.d693.s2.e1 false daily doses of sulfasalazine 2 g ( maximum 3 g ) and weekly doses of methotrexate 7.5 mg ( maximum 15 mg ) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies .
DDI-DrugBank.d756.s3
DDI-DrugBank.d710.s4
DDI-DrugBank.d633.s8
DDI-DrugBank.d633.s8.e1_DDI-DrugBank.d633.s8.e2 false a variety of antiarrhythmics such as quinidine or propranolol were also added , sometimes with improved control of ventricular ectopy .
DDI-DrugBank.d633.s8.e1_DDI-DrugBank.d633.s8.e0 false a variety of antiarrhythmics such as quinidine or propranolol were also added , sometimes with improved control of ventricular ectopy .
DDI-DrugBank.d633.s8.e2_DDI-DrugBank.d633.s8.e0 false a variety of antiarrhythmics such as quinidine or propranolol were also added , sometimes with improved control of ventricular ectopy .
DDI-DrugBank.d779.s6
DDI-DrugBank.d601.s0
DDI-DrugBank.d601.s0.e4_DDI-DrugBank.d601.s0.e0 false barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e4_DDI-DrugBank.d601.s0.e1 false barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e4_DDI-DrugBank.d601.s0.e2 false barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e4_DDI-DrugBank.d601.s0.e3 false barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e4_DDI-DrugBank.d601.s0.e5 false barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e4_DDI-DrugBank.d601.s0.e6 false barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e4_DDI-DrugBank.d601.s0.e7 false barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e0_DDI-DrugBank.d601.s0.e1 true barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e0_DDI-DrugBank.d601.s0.e2 true barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e0_DDI-DrugBank.d601.s0.e3 true barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e0_DDI-DrugBank.d601.s0.e5 true barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e0_DDI-DrugBank.d601.s0.e6 true barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e0_DDI-DrugBank.d601.s0.e7 true barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e1_DDI-DrugBank.d601.s0.e2 false barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e1_DDI-DrugBank.d601.s0.e3 false barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e1_DDI-DrugBank.d601.s0.e5 false barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e1_DDI-DrugBank.d601.s0.e6 false barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e1_DDI-DrugBank.d601.s0.e7 false barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e2_DDI-DrugBank.d601.s0.e3 false barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e2_DDI-DrugBank.d601.s0.e5 false barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e2_DDI-DrugBank.d601.s0.e6 false barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e2_DDI-DrugBank.d601.s0.e7 false barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e3_DDI-DrugBank.d601.s0.e5 false barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e3_DDI-DrugBank.d601.s0.e6 false barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e3_DDI-DrugBank.d601.s0.e7 false barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e5_DDI-DrugBank.d601.s0.e6 false barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e5_DDI-DrugBank.d601.s0.e7 false barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d601.s0.e6_DDI-DrugBank.d601.s0.e7 false barbiturates may decrease the effectiveness of oral contraceptives , certain antibiotics , quinidine , theophylline , corticosteroids , anticoagulants , and beta blockers .
DDI-DrugBank.d700.s1
DDI-DrugBank.d700.s1.e0_DDI-DrugBank.d700.s1.e1 true it is recommended that myfortic and antacids not be administered simultaneously .
DDI-DrugBank.d597.s25
DDI-DrugBank.d597.s25.e0_DDI-DrugBank.d597.s25.e1 false in vitro , methotrexate did not displace meloxicam from its human serum binding sites .
DDI-DrugBank.d647.s1
DDI-DrugBank.d647.s1.e0_DDI-DrugBank.d647.s1.e1 true streptozocin has been reported to prolong the elimination half-life of doxorubicin and may lead to severe bone marrow suppression ;
DDI-DrugBank.d642.s2
DDI-DrugBank.d656.s0
DDI-DrugBank.d648.s3
DDI-DrugBank.d648.s3.e1_DDI-DrugBank.d648.s3.e0 false if evista is given concurrently with warfarin , prothrombin time should be monitored .
DDI-DrugBank.d576.s3
DDI-DrugBank.d597.s7
DDI-DrugBank.d597.s7.e0_DDI-DrugBank.d597.s7.e1 false cholestyramine : pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50 % .
DDI-DrugBank.d597.s7.e0_DDI-DrugBank.d597.s7.e2 false cholestyramine : pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50 % .
DDI-DrugBank.d597.s7.e1_DDI-DrugBank.d597.s7.e2 true cholestyramine : pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50 % .
DDI-DrugBank.d779.s1
DDI-DrugBank.d762.s1
DDI-DrugBank.d710.s2
DDI-DrugBank.d710.s2.e0_DDI-DrugBank.d710.s2.e1 false acetaminophen : rimantadine hcl , 100 mg , was given twice daily for 13 days to 12 healthy volunteers .
DDI-DrugBank.d615.s1
DDI-DrugBank.d615.s1.e1_DDI-DrugBank.d615.s1.e3 true the effects of anticholinergic drugs , such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine .
DDI-DrugBank.d615.s1.e1_DDI-DrugBank.d615.s1.e0 false the effects of anticholinergic drugs , such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine .
DDI-DrugBank.d615.s1.e1_DDI-DrugBank.d615.s1.e2 false the effects of anticholinergic drugs , such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine .
DDI-DrugBank.d615.s1.e3_DDI-DrugBank.d615.s1.e0 false the effects of anticholinergic drugs , such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine .
DDI-DrugBank.d615.s1.e3_DDI-DrugBank.d615.s1.e2 false the effects of anticholinergic drugs , such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine .
DDI-DrugBank.d615.s1.e0_DDI-DrugBank.d615.s1.e2 false the effects of anticholinergic drugs , such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine .
DDI-DrugBank.d737.s0
DDI-DrugBank.d737.s0.e0_DDI-DrugBank.d737.s0.e1 false carbidopa/levodopa : carbidopa/levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers ( n= 10 ) .
DDI-DrugBank.d737.s0.e0_DDI-DrugBank.d737.s0.e2 false carbidopa/levodopa : carbidopa/levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers ( n= 10 ) .
DDI-DrugBank.d737.s0.e0_DDI-DrugBank.d737.s0.e3 false carbidopa/levodopa : carbidopa/levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers ( n= 10 ) .
DDI-DrugBank.d737.s0.e0_DDI-DrugBank.d737.s0.e4 false carbidopa/levodopa : carbidopa/levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers ( n= 10 ) .
DDI-DrugBank.d737.s0.e1_DDI-DrugBank.d737.s0.e2 false carbidopa/levodopa : carbidopa/levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers ( n= 10 ) .
DDI-DrugBank.d737.s0.e1_DDI-DrugBank.d737.s0.e3 false carbidopa/levodopa : carbidopa/levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers ( n= 10 ) .
DDI-DrugBank.d737.s0.e1_DDI-DrugBank.d737.s0.e4 false carbidopa/levodopa : carbidopa/levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers ( n= 10 ) .
DDI-DrugBank.d737.s0.e2_DDI-DrugBank.d737.s0.e3 false carbidopa/levodopa : carbidopa/levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers ( n= 10 ) .
DDI-DrugBank.d737.s0.e2_DDI-DrugBank.d737.s0.e4 false carbidopa/levodopa : carbidopa/levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers ( n= 10 ) .
DDI-DrugBank.d737.s0.e3_DDI-DrugBank.d737.s0.e4 false carbidopa/levodopa : carbidopa/levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers ( n= 10 ) .
DDI-DrugBank.d711.s0
DDI-DrugBank.d711.s0.e0_DDI-DrugBank.d711.s0.e1 true because tetracyclines have been shown to depress plasma prothrombin activity , patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage .
DDI-DrugBank.d711.s0.e0_DDI-DrugBank.d711.s0.e2 false because tetracyclines have been shown to depress plasma prothrombin activity , patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage .
DDI-DrugBank.d711.s0.e1_DDI-DrugBank.d711.s0.e2 false because tetracyclines have been shown to depress plasma prothrombin activity , patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage .
DDI-DrugBank.d603.s2
DDI-DrugBank.d603.s2.e0_DDI-DrugBank.d603.s2.e1 false the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine
DDI-DrugBank.d603.s2.e0_DDI-DrugBank.d603.s2.e2 false the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine
DDI-DrugBank.d603.s2.e0_DDI-DrugBank.d603.s2.e3 false the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine
DDI-DrugBank.d603.s2.e0_DDI-DrugBank.d603.s2.e4 false the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine
DDI-DrugBank.d603.s2.e0_DDI-DrugBank.d603.s2.e5 true the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine
DDI-DrugBank.d603.s2.e1_DDI-DrugBank.d603.s2.e2 false the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine
DDI-DrugBank.d603.s2.e1_DDI-DrugBank.d603.s2.e3 false the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine
DDI-DrugBank.d603.s2.e1_DDI-DrugBank.d603.s2.e4 false the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine
DDI-DrugBank.d603.s2.e1_DDI-DrugBank.d603.s2.e5 true the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine
DDI-DrugBank.d603.s2.e2_DDI-DrugBank.d603.s2.e3 false the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine
DDI-DrugBank.d603.s2.e2_DDI-DrugBank.d603.s2.e4 false the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine
DDI-DrugBank.d603.s2.e2_DDI-DrugBank.d603.s2.e5 false the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine
DDI-DrugBank.d603.s2.e3_DDI-DrugBank.d603.s2.e4 false the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine
DDI-DrugBank.d603.s2.e3_DDI-DrugBank.d603.s2.e5 false the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine
DDI-DrugBank.d603.s2.e4_DDI-DrugBank.d603.s2.e5 false the use of drugs that stimulate alpha-adrenergic receptors ( e.g. , phenylephrine , pseudoephedrine , ephedrine , phenylpropanolamine or dihydroergotamine ) may enhance or potentiate the pressor effects of proamatine
DDI-DrugBank.d746.s1
DDI-DrugBank.d746.s1.e0_DDI-DrugBank.d746.s1.e1 false monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines .
DDI-DrugBank.d746.s1.e0_DDI-DrugBank.d746.s1.e2 true monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines .
DDI-DrugBank.d746.s1.e1_DDI-DrugBank.d746.s1.e2 true monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines .
DDI-DrugBank.d597.s12
DDI-DrugBank.d597.s12.e0_DDI-DrugBank.d597.s12.e1 false digoxin : meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses .
DDI-DrugBank.d597.s12.e0_DDI-DrugBank.d597.s12.e2 false digoxin : meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses .
DDI-DrugBank.d597.s12.e1_DDI-DrugBank.d597.s12.e2 false digoxin : meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses .
DDI-DrugBank.d623.s5
DDI-DrugBank.d752.s5
DDI-DrugBank.d709.s2
DDI-DrugBank.d640.s10
DDI-DrugBank.d640.s10.e4_DDI-DrugBank.d640.s10.e0 false univasc has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , h2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents .
DDI-DrugBank.d640.s10.e4_DDI-DrugBank.d640.s10.e1 false univasc has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , h2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents .
DDI-DrugBank.d640.s10.e4_DDI-DrugBank.d640.s10.e2 false univasc has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , h2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents .
DDI-DrugBank.d640.s10.e4_DDI-DrugBank.d640.s10.e3 false univasc has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , h2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents .
DDI-DrugBank.d640.s10.e4_DDI-DrugBank.d640.s10.e5 false univasc has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , h2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents .
DDI-DrugBank.d640.s10.e0_DDI-DrugBank.d640.s10.e1 false univasc has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , h2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents .
DDI-DrugBank.d640.s10.e0_DDI-DrugBank.d640.s10.e2 false univasc has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , h2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents .
DDI-DrugBank.d640.s10.e0_DDI-DrugBank.d640.s10.e3 false univasc has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , h2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents .
DDI-DrugBank.d640.s10.e0_DDI-DrugBank.d640.s10.e5 false univasc has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , h2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents .
DDI-DrugBank.d640.s10.e1_DDI-DrugBank.d640.s10.e2 false univasc has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , h2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents .
DDI-DrugBank.d640.s10.e1_DDI-DrugBank.d640.s10.e3 false univasc has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , h2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents .
DDI-DrugBank.d640.s10.e1_DDI-DrugBank.d640.s10.e5 false univasc has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , h2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents .
DDI-DrugBank.d640.s10.e2_DDI-DrugBank.d640.s10.e3 false univasc has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , h2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents .
DDI-DrugBank.d640.s10.e2_DDI-DrugBank.d640.s10.e5 false univasc has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , h2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents .
DDI-DrugBank.d640.s10.e3_DDI-DrugBank.d640.s10.e5 false univasc has been used in clinical trials concomitantly with calcium-channel-blocking agents , diuretics , h2 blockers , digoxin , oral hypoglycemic agents , and cholesterol-lowering agents .
DDI-DrugBank.d734.s1
DDI-DrugBank.d734.s1.e0_DDI-DrugBank.d734.s1.e1 true antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly .
DDI-DrugBank.d781.s17
DDI-DrugBank.d742.s7
DDI-DrugBank.d742.s7.e0_DDI-DrugBank.d742.s7.e1 false alcohol : concomitant administration of alcohol ( equivalent to 60 g ) had a minimal effect on plasma levels of mirtazapine ( 15 mg ) in 6 healthy male subjects .
DDI-DrugBank.d742.s7.e0_DDI-DrugBank.d742.s7.e2 false alcohol : concomitant administration of alcohol ( equivalent to 60 g ) had a minimal effect on plasma levels of mirtazapine ( 15 mg ) in 6 healthy male subjects .
DDI-DrugBank.d742.s7.e1_DDI-DrugBank.d742.s7.e2 true alcohol : concomitant administration of alcohol ( equivalent to 60 g ) had a minimal effect on plasma levels of mirtazapine ( 15 mg ) in 6 healthy male subjects .
DDI-DrugBank.d585.s3
DDI-DrugBank.d585.s3.e1_DDI-DrugBank.d585.s3.e0 false anticholinergic agents may affect gastrointestinal absorption of various drugs , such as slowly dissolving dosage forms of digoxin ;
DDI-DrugBank.d702.s1
DDI-DrugBank.d702.s1.e0_DDI-DrugBank.d702.s1.e1 false these include sympathomimetic bronchodilators , methylxanthines , and oral and inhaled steroids .
DDI-DrugBank.d702.s1.e0_DDI-DrugBank.d702.s1.e2 false these include sympathomimetic bronchodilators , methylxanthines , and oral and inhaled steroids .
DDI-DrugBank.d702.s1.e1_DDI-DrugBank.d702.s1.e2 false these include sympathomimetic bronchodilators , methylxanthines , and oral and inhaled steroids .
DDI-DrugBank.d756.s4
DDI-DrugBank.d756.s4.e0_DDI-DrugBank.d756.s4.e1 true exert particular caution in combining levomepromazine with other anticholinergic drugs ( tricyclic antidepressants and antiparkinsonian-agents ): particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
DDI-DrugBank.d756.s4.e0_DDI-DrugBank.d756.s4.e2 true exert particular caution in combining levomepromazine with other anticholinergic drugs ( tricyclic antidepressants and antiparkinsonian-agents ): particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
DDI-DrugBank.d756.s4.e0_DDI-DrugBank.d756.s4.e3 true exert particular caution in combining levomepromazine with other anticholinergic drugs ( tricyclic antidepressants and antiparkinsonian-agents ): particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
DDI-DrugBank.d756.s4.e1_DDI-DrugBank.d756.s4.e2 false exert particular caution in combining levomepromazine with other anticholinergic drugs ( tricyclic antidepressants and antiparkinsonian-agents ): particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
DDI-DrugBank.d756.s4.e1_DDI-DrugBank.d756.s4.e3 false exert particular caution in combining levomepromazine with other anticholinergic drugs ( tricyclic antidepressants and antiparkinsonian-agents ): particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
DDI-DrugBank.d756.s4.e2_DDI-DrugBank.d756.s4.e3 false exert particular caution in combining levomepromazine with other anticholinergic drugs ( tricyclic antidepressants and antiparkinsonian-agents ): particularly the elderly may develop delirium , high fever , severe obstipation , even ileus and glaucoma .
DDI-DrugBank.d686.s2
DDI-DrugBank.d597.s21
DDI-DrugBank.d640.s3
DDI-DrugBank.d640.s3.e1_DDI-DrugBank.d640.s3.e2 false use of potassium-sparing diuretics ( spironolactone , triamterene , amiloride ) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3.e1_DDI-DrugBank.d640.s3.e3 false use of potassium-sparing diuretics ( spironolactone , triamterene , amiloride ) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3.e1_DDI-DrugBank.d640.s3.e4 false use of potassium-sparing diuretics ( spironolactone , triamterene , amiloride ) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3.e1_DDI-DrugBank.d640.s3.e0 false use of potassium-sparing diuretics ( spironolactone , triamterene , amiloride ) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3.e1_DDI-DrugBank.d640.s3.e5 true use of potassium-sparing diuretics ( spironolactone , triamterene , amiloride ) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3.e2_DDI-DrugBank.d640.s3.e3 false use of potassium-sparing diuretics ( spironolactone , triamterene , amiloride ) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3.e2_DDI-DrugBank.d640.s3.e4 false use of potassium-sparing diuretics ( spironolactone , triamterene , amiloride ) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3.e2_DDI-DrugBank.d640.s3.e0 false use of potassium-sparing diuretics ( spironolactone , triamterene , amiloride ) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3.e2_DDI-DrugBank.d640.s3.e5 false use of potassium-sparing diuretics ( spironolactone , triamterene , amiloride ) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3.e3_DDI-DrugBank.d640.s3.e4 false use of potassium-sparing diuretics ( spironolactone , triamterene , amiloride ) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3.e3_DDI-DrugBank.d640.s3.e0 false use of potassium-sparing diuretics ( spironolactone , triamterene , amiloride ) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3.e3_DDI-DrugBank.d640.s3.e5 false use of potassium-sparing diuretics ( spironolactone , triamterene , amiloride ) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3.e4_DDI-DrugBank.d640.s3.e0 false use of potassium-sparing diuretics ( spironolactone , triamterene , amiloride ) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3.e4_DDI-DrugBank.d640.s3.e5 false use of potassium-sparing diuretics ( spironolactone , triamterene , amiloride ) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d640.s3.e0_DDI-DrugBank.d640.s3.e5 true use of potassium-sparing diuretics ( spironolactone , triamterene , amiloride ) or potassium supplements concomitantly with ace inhibitors can increase the risk of hyperkalemia .
DDI-DrugBank.d773.s0
DDI-DrugBank.d776.s43
DDI-DrugBank.d743.s4
DDI-DrugBank.d743.s4.e0_DDI-DrugBank.d743.s4.e1 true concomitant administration of ketoconazole and terfenadine is contraindicated .
DDI-DrugBank.d735.s5
DDI-DrugBank.d735.s5.e0_DDI-DrugBank.d735.s5.e1 false patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.e0_DDI-DrugBank.d735.s5.e3 false patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.e0_DDI-DrugBank.d735.s5.e4 false patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.e0_DDI-DrugBank.d735.s5.e5 false patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.e0_DDI-DrugBank.d735.s5.e6 false patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.e0_DDI-DrugBank.d735.s5.e2 true patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.e1_DDI-DrugBank.d735.s5.e3 false patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.e1_DDI-DrugBank.d735.s5.e4 false patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.e1_DDI-DrugBank.d735.s5.e5 false patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.e1_DDI-DrugBank.d735.s5.e6 false patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.e1_DDI-DrugBank.d735.s5.e2 true patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.e3_DDI-DrugBank.d735.s5.e4 false patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.e3_DDI-DrugBank.d735.s5.e5 false patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.e3_DDI-DrugBank.d735.s5.e6 false patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.e3_DDI-DrugBank.d735.s5.e2 false patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.e4_DDI-DrugBank.d735.s5.e5 false patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.e4_DDI-DrugBank.d735.s5.e6 false patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.e4_DDI-DrugBank.d735.s5.e2 false patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.e5_DDI-DrugBank.d735.s5.e6 false patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.e5_DDI-DrugBank.d735.s5.e2 false patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d735.s5.e6_DDI-DrugBank.d735.s5.e2 false patients receiving sirolimus or nifedipine in combination with mycamine should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary .
DDI-DrugBank.d627.s1
DDI-DrugBank.d693.s6
DDI-DrugBank.d727.s2
DDI-DrugBank.d727.s2.e0_DDI-DrugBank.d727.s2.e1 true in vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin .
DDI-DrugBank.d727.s2.e0_DDI-DrugBank.d727.s2.e2 true in vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin .
DDI-DrugBank.d727.s2.e1_DDI-DrugBank.d727.s2.e2 false in vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin .
DDI-DrugBank.d642.s0
DDI-DrugBank.d642.s0.e0_DDI-DrugBank.d642.s0.e1 true prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin .
DDI-DrugBank.d716.s2
DDI-DrugBank.d716.s2.e0_DDI-DrugBank.d716.s2.e1 true mazindol may reduce the effects of guanethidine ( ismelin ) .
DDI-DrugBank.d716.s2.e0_DDI-DrugBank.d716.s2.e2 true mazindol may reduce the effects of guanethidine ( ismelin ) .
DDI-DrugBank.d716.s2.e1_DDI-DrugBank.d716.s2.e2 false mazindol may reduce the effects of guanethidine ( ismelin ) .
DDI-DrugBank.d742.s0
DDI-DrugBank.d572.s14
DDI-DrugBank.d776.s23
DDI-DrugBank.d776.s23.e0_DDI-DrugBank.d776.s23.e1 true the combined use of fluconazole at doses of 400 mg or greater with terfenadine is contraindicated .
DDI-DrugBank.d756.s10
DDI-DrugBank.d648.s0
DDI-DrugBank.d648.s0.e0_DDI-DrugBank.d648.s0.e1 false cholestyramine : cholestyramine causes a 60 % reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with evista .
DDI-DrugBank.d648.s0.e0_DDI-DrugBank.d648.s0.e2 false cholestyramine : cholestyramine causes a 60 % reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with evista .
DDI-DrugBank.d648.s0.e0_DDI-DrugBank.d648.s0.e3 false cholestyramine : cholestyramine causes a 60 % reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with evista .
DDI-DrugBank.d648.s0.e1_DDI-DrugBank.d648.s0.e2 true cholestyramine : cholestyramine causes a 60 % reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with evista .
DDI-DrugBank.d648.s0.e1_DDI-DrugBank.d648.s0.e3 true cholestyramine : cholestyramine causes a 60 % reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with evista .
DDI-DrugBank.d648.s0.e2_DDI-DrugBank.d648.s0.e3 false cholestyramine : cholestyramine causes a 60 % reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with evista .
DDI-DrugBank.d573.s2
DDI-DrugBank.d625.s0
DDI-DrugBank.d625.s0.e2_DDI-DrugBank.d625.s0.e3 true  vaccinations with live organism vaccines are not recommended in immunocompromised individuals nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis .
DDI-DrugBank.d625.s0.e2_DDI-DrugBank.d625.s0.e1 false  vaccinations with live organism vaccines are not recommended in immunocompromised individuals nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis .
DDI-DrugBank.d625.s0.e3_DDI-DrugBank.d625.s0.e1 false  vaccinations with live organism vaccines are not recommended in immunocompromised individuals nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis .
DDI-DrugBank.d591.s2
DDI-DrugBank.d591.s2.e0_DDI-DrugBank.d591.s2.e1 true in vivo , the plasma clearance of ropivacaine was reduced by 70 % during coadministration of fluvoxamine ( 25 mg bid for 2 days ) , a selective and potent cyp1a2 inhibitor .
DDI-DrugBank.d590.s3
DDI-DrugBank.d781.s4
DDI-DrugBank.d781.s4.e0_DDI-DrugBank.d781.s4.e1 false the bioavailability of perindoprilat was reduced by diuretics , however , and this was associated with a decrease in plasma ace inhibition .
DDI-DrugBank.d577.s3
DDI-DrugBank.d577.s3.e0_DDI-DrugBank.d577.s3.e1 true sulfamethoxazole may inhibit the hepatic metabolism of phenytoin .
DDI-DrugBank.d680.s4
DDI-DrugBank.d572.s29
DDI-DrugBank.d739.s1
DDI-DrugBank.d739.s1.e0_DDI-DrugBank.d739.s1.e1 false - did not change the pharmacokinetic profile of warfarin ( a substrate of cytochromes p450 2a6 and 2c9 ) or influence the effect of a single 30-mg oral dose of warfarin on prothrombin time or the inr ( international normalized ratio ) .
DDI-DrugBank.d706.s1
DDI-DrugBank.d698.s2
DDI-DrugBank.d698.s2.e0_DDI-DrugBank.d698.s2.e1 true requirements for riboflavin may be increased in patients receiving probenecid .
DDI-DrugBank.d762.s2
DDI-DrugBank.d762.s2.e0_DDI-DrugBank.d762.s2.e1 true therefore , the coadministration of probenecid with meropenem is not recommended .
DDI-DrugBank.d742.s2
DDI-DrugBank.d742.s2.e1_DDI-DrugBank.d742.s2.e0 false drugs affecting hepatic metabolism the metabolism and pharmacokinetics of remeron soltab ( mirtazapine ) orally disintegrating tablets may be affected by the induction or inhibition of drug-metab-olizing enzymes .
DDI-DrugBank.d756.s8
DDI-DrugBank.d751.s1
DDI-DrugBank.d751.s1.e1_DDI-DrugBank.d751.s1.e3 false the use of aggrastat , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone ( see
DDI-DrugBank.d751.s1.e1_DDI-DrugBank.d751.s1.e4 false the use of aggrastat , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone ( see
DDI-DrugBank.d751.s1.e1_DDI-DrugBank.d751.s1.e0 false the use of aggrastat , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone ( see
DDI-DrugBank.d751.s1.e1_DDI-DrugBank.d751.s1.e2 false the use of aggrastat , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone ( see
DDI-DrugBank.d751.s1.e3_DDI-DrugBank.d751.s1.e4 false the use of aggrastat , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone ( see
DDI-DrugBank.d751.s1.e3_DDI-DrugBank.d751.s1.e0 false the use of aggrastat , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone ( see
DDI-DrugBank.d751.s1.e3_DDI-DrugBank.d751.s1.e2 false the use of aggrastat , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone ( see
DDI-DrugBank.d751.s1.e4_DDI-DrugBank.d751.s1.e0 false the use of aggrastat , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone ( see
DDI-DrugBank.d751.s1.e4_DDI-DrugBank.d751.s1.e2 false the use of aggrastat , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone ( see
DDI-DrugBank.d751.s1.e0_DDI-DrugBank.d751.s1.e2 true the use of aggrastat , in combination with heparin and aspirin , has been associated with an increase in bleeding compared to heparin and aspirin alone ( see
DDI-DrugBank.d737.s3
DDI-DrugBank.d737.s3.e0_DDI-DrugBank.d737.s3.e1 false amantadine : population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole ( n= 54 ) .
DDI-DrugBank.d737.s3.e0_DDI-DrugBank.d737.s3.e2 false amantadine : population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole ( n= 54 ) .
DDI-DrugBank.d737.s3.e1_DDI-DrugBank.d737.s3.e2 false amantadine : population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole ( n= 54 ) .
DDI-DrugBank.d781.s6
DDI-DrugBank.d781.s6.e1_DDI-DrugBank.d781.s6.e2 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e1_DDI-DrugBank.d781.s6.e3 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e1_DDI-DrugBank.d781.s6.e4 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e1_DDI-DrugBank.d781.s6.e5 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e1_DDI-DrugBank.d781.s6.e6 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e1_DDI-DrugBank.d781.s6.e7 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e1_DDI-DrugBank.d781.s6.e0 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e2_DDI-DrugBank.d781.s6.e3 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e2_DDI-DrugBank.d781.s6.e4 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e2_DDI-DrugBank.d781.s6.e5 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e2_DDI-DrugBank.d781.s6.e6 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e2_DDI-DrugBank.d781.s6.e7 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e2_DDI-DrugBank.d781.s6.e0 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e3_DDI-DrugBank.d781.s6.e4 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e3_DDI-DrugBank.d781.s6.e5 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e3_DDI-DrugBank.d781.s6.e6 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e3_DDI-DrugBank.d781.s6.e7 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e3_DDI-DrugBank.d781.s6.e0 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e4_DDI-DrugBank.d781.s6.e5 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e4_DDI-DrugBank.d781.s6.e6 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e4_DDI-DrugBank.d781.s6.e7 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e4_DDI-DrugBank.d781.s6.e0 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e5_DDI-DrugBank.d781.s6.e6 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e5_DDI-DrugBank.d781.s6.e7 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e5_DDI-DrugBank.d781.s6.e0 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e6_DDI-DrugBank.d781.s6.e7 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e6_DDI-DrugBank.d781.s6.e0 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d781.s6.e7_DDI-DrugBank.d781.s6.e0 false use of potassium-sparing diuretics ( spironolactone , amiloride , triamterene and others ) , potassium supplements or other drugs capable of increasing serum potassium ( indomethacin , heparin , cyclosporine and others ) can increase the risk of hyperkalemia .
DDI-DrugBank.d716.s5
DDI-DrugBank.d716.s5.e1_DDI-DrugBank.d716.s5.e3 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e1_DDI-DrugBank.d716.s5.e5 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e1_DDI-DrugBank.d716.s5.e7 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e1_DDI-DrugBank.d716.s5.e9 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e1_DDI-DrugBank.d716.s5.e2 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e1_DDI-DrugBank.d716.s5.e4 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e1_DDI-DrugBank.d716.s5.e6 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e1_DDI-DrugBank.d716.s5.e8 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e1_DDI-DrugBank.d716.s5.e0 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e3_DDI-DrugBank.d716.s5.e5 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e3_DDI-DrugBank.d716.s5.e7 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e3_DDI-DrugBank.d716.s5.e9 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e3_DDI-DrugBank.d716.s5.e2 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e3_DDI-DrugBank.d716.s5.e4 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e3_DDI-DrugBank.d716.s5.e6 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e3_DDI-DrugBank.d716.s5.e8 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e3_DDI-DrugBank.d716.s5.e0 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e5_DDI-DrugBank.d716.s5.e7 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e5_DDI-DrugBank.d716.s5.e9 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e5_DDI-DrugBank.d716.s5.e2 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e5_DDI-DrugBank.d716.s5.e4 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e5_DDI-DrugBank.d716.s5.e6 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e5_DDI-DrugBank.d716.s5.e8 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e5_DDI-DrugBank.d716.s5.e0 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e7_DDI-DrugBank.d716.s5.e9 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e7_DDI-DrugBank.d716.s5.e2 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e7_DDI-DrugBank.d716.s5.e4 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e7_DDI-DrugBank.d716.s5.e6 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e7_DDI-DrugBank.d716.s5.e8 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e7_DDI-DrugBank.d716.s5.e0 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e9_DDI-DrugBank.d716.s5.e2 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e9_DDI-DrugBank.d716.s5.e4 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e9_DDI-DrugBank.d716.s5.e6 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e9_DDI-DrugBank.d716.s5.e8 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e9_DDI-DrugBank.d716.s5.e0 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e2_DDI-DrugBank.d716.s5.e4 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e2_DDI-DrugBank.d716.s5.e6 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e2_DDI-DrugBank.d716.s5.e8 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e2_DDI-DrugBank.d716.s5.e0 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e4_DDI-DrugBank.d716.s5.e6 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e4_DDI-DrugBank.d716.s5.e8 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e4_DDI-DrugBank.d716.s5.e0 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e6_DDI-DrugBank.d716.s5.e8 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e6_DDI-DrugBank.d716.s5.e0 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d716.s5.e8_DDI-DrugBank.d716.s5.e0 false before taking this medication , tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( elavil ) , amoxapine ( asendin ) , doxepin ( sinequan ) , nortriptyline ( pamelor ) , imipramine ( tofranil ) , clomipramine ( anafranil ) , protriptyline ( vivactil ) , or desipramine ( norpramin ) .
DDI-DrugBank.d686.s0
DDI-DrugBank.d686.s0.e0_DDI-DrugBank.d686.s0.e1 true thiabendazole may compete with other drugs , such as theophylline , for sites of metabolism in the liver , thus elevating the serum levels of such compounds to potentially toxic levels .
DDI-DrugBank.d602.s4
DDI-DrugBank.d711.s2
DDI-DrugBank.d711.s2.e2_DDI-DrugBank.d711.s2.e3 false absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations .
DDI-DrugBank.d711.s2.e2_DDI-DrugBank.d711.s2.e4 false absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations .
DDI-DrugBank.d711.s2.e2_DDI-DrugBank.d711.s2.e5 false absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations .
DDI-DrugBank.d711.s2.e2_DDI-DrugBank.d711.s2.e0 false absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations .
DDI-DrugBank.d711.s2.e2_DDI-DrugBank.d711.s2.e1 false absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations .
DDI-DrugBank.d711.s2.e3_DDI-DrugBank.d711.s2.e4 false absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations .
DDI-DrugBank.d711.s2.e3_DDI-DrugBank.d711.s2.e5 false absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations .
DDI-DrugBank.d711.s2.e3_DDI-DrugBank.d711.s2.e0 false absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations .
DDI-DrugBank.d711.s2.e3_DDI-DrugBank.d711.s2.e1 false absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations .
DDI-DrugBank.d711.s2.e4_DDI-DrugBank.d711.s2.e5 false absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations .
DDI-DrugBank.d711.s2.e4_DDI-DrugBank.d711.s2.e0 false absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations .
DDI-DrugBank.d711.s2.e4_DDI-DrugBank.d711.s2.e1 false absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations .
DDI-DrugBank.d711.s2.e5_DDI-DrugBank.d711.s2.e0 false absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations .
DDI-DrugBank.d711.s2.e5_DDI-DrugBank.d711.s2.e1 false absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations .
DDI-DrugBank.d711.s2.e0_DDI-DrugBank.d711.s2.e1 false absorption of tetracyclines is impaired by antacids containing aluminum , calcium or magnesium , and iron-containing preparations .
DDI-DrugBank.d588.s14
DDI-DrugBank.d752.s12
DDI-DrugBank.d752.s12.e0_DDI-DrugBank.d752.s12.e1 false no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12.e0_DDI-DrugBank.d752.s12.e2 false no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12.e0_DDI-DrugBank.d752.s12.e3 false no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12.e0_DDI-DrugBank.d752.s12.e4 false no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12.e0_DDI-DrugBank.d752.s12.e5 false no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12.e0_DDI-DrugBank.d752.s12.e6 false no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12.e1_DDI-DrugBank.d752.s12.e2 false no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12.e1_DDI-DrugBank.d752.s12.e3 false no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12.e1_DDI-DrugBank.d752.s12.e4 false no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12.e1_DDI-DrugBank.d752.s12.e5 false no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12.e1_DDI-DrugBank.d752.s12.e6 false no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12.e2_DDI-DrugBank.d752.s12.e3 false no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12.e2_DDI-DrugBank.d752.s12.e4 false no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12.e2_DDI-DrugBank.d752.s12.e5 false no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12.e2_DDI-DrugBank.d752.s12.e6 false no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12.e3_DDI-DrugBank.d752.s12.e4 false no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12.e3_DDI-DrugBank.d752.s12.e5 false no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12.e3_DDI-DrugBank.d752.s12.e6 false no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12.e4_DDI-DrugBank.d752.s12.e5 false no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12.e4_DDI-DrugBank.d752.s12.e6 false no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d752.s12.e5_DDI-DrugBank.d752.s12.e6 false no significant adverse interactions with common premedications ( such as atropine , scopolamine , glycopyrrolate , diazepam , hydroxyzine , and other muscle relaxants ) or local anesthetics have been observed .
DDI-DrugBank.d584.s13
DDI-DrugBank.d752.s3
DDI-DrugBank.d752.s3.e0_DDI-DrugBank.d752.s3.e1 false although not studied , the potent cytochrome p450 3a4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam .
DDI-DrugBank.d752.s3.e0_DDI-DrugBank.d752.s3.e2 true although not studied , the potent cytochrome p450 3a4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam .
DDI-DrugBank.d752.s3.e1_DDI-DrugBank.d752.s3.e2 true although not studied , the potent cytochrome p450 3a4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam .
DDI-DrugBank.d732.s2
DDI-DrugBank.d732.s2.e1_DDI-DrugBank.d732.s2.e0 false concomitant administration of chemet with other chelation therapy , such as cana 2 edta is not recommended .
DDI-DrugBank.d775.s12
DDI-DrugBank.d775.s12.e0_DDI-DrugBank.d775.s12.e1 false while the effects of chronic phenytoin or carbamazepine therapy on the action of mivacron are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher .
DDI-DrugBank.d775.s12.e0_DDI-DrugBank.d775.s12.e2 true while the effects of chronic phenytoin or carbamazepine therapy on the action of mivacron are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher .
DDI-DrugBank.d775.s12.e1_DDI-DrugBank.d775.s12.e2 true while the effects of chronic phenytoin or carbamazepine therapy on the action of mivacron are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher .
DDI-DrugBank.d572.s23
DDI-DrugBank.d700.s14
DDI-DrugBank.d776.s2
DDI-DrugBank.d776.s2.e2_DDI-DrugBank.d776.s2.e3 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e2_DDI-DrugBank.d776.s2.e4 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e2_DDI-DrugBank.d776.s2.e5 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e2_DDI-DrugBank.d776.s2.e6 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e2_DDI-DrugBank.d776.s2.e7 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e2_DDI-DrugBank.d776.s2.e8 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e2_DDI-DrugBank.d776.s2.e9 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e2_DDI-DrugBank.d776.s2.e0 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e2_DDI-DrugBank.d776.s2.e1 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e3_DDI-DrugBank.d776.s2.e4 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e3_DDI-DrugBank.d776.s2.e5 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e3_DDI-DrugBank.d776.s2.e6 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e3_DDI-DrugBank.d776.s2.e7 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e3_DDI-DrugBank.d776.s2.e8 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e3_DDI-DrugBank.d776.s2.e9 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e3_DDI-DrugBank.d776.s2.e0 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e3_DDI-DrugBank.d776.s2.e1 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e4_DDI-DrugBank.d776.s2.e5 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e4_DDI-DrugBank.d776.s2.e6 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e4_DDI-DrugBank.d776.s2.e7 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e4_DDI-DrugBank.d776.s2.e8 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e4_DDI-DrugBank.d776.s2.e9 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e4_DDI-DrugBank.d776.s2.e0 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e4_DDI-DrugBank.d776.s2.e1 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e5_DDI-DrugBank.d776.s2.e6 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e5_DDI-DrugBank.d776.s2.e7 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e5_DDI-DrugBank.d776.s2.e8 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e5_DDI-DrugBank.d776.s2.e9 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e5_DDI-DrugBank.d776.s2.e0 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e5_DDI-DrugBank.d776.s2.e1 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e6_DDI-DrugBank.d776.s2.e7 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e6_DDI-DrugBank.d776.s2.e8 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e6_DDI-DrugBank.d776.s2.e9 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e6_DDI-DrugBank.d776.s2.e0 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e6_DDI-DrugBank.d776.s2.e1 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e7_DDI-DrugBank.d776.s2.e8 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e7_DDI-DrugBank.d776.s2.e9 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e7_DDI-DrugBank.d776.s2.e0 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e7_DDI-DrugBank.d776.s2.e1 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e8_DDI-DrugBank.d776.s2.e9 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e8_DDI-DrugBank.d776.s2.e0 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e8_DDI-DrugBank.d776.s2.e1 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e9_DDI-DrugBank.d776.s2.e0 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e9_DDI-DrugBank.d776.s2.e1 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d776.s2.e0_DDI-DrugBank.d776.s2.e1 false these are described in greater detail below : oral hypoglycemics , coumarin-type anticoagulants , phenytoin , cyclosporine , rifampin , theophylline , terfenadine , cisapride , astemizole , rifabutin , tacrolimus , short-acting benzodiazepines , oral hypoglycemics : clinically significant hypoglycemia may be precipitated by the use of diflucan with oral hypoglycemic agents ;
DDI-DrugBank.d624.s1
DDI-DrugBank.d618.s1
DDI-DrugBank.d618.s1.e0_DDI-DrugBank.d618.s1.e3 false in addition to bleeding associated with heparin and vitamin k antagonists , drugs that alter platelet function ( such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1.e0_DDI-DrugBank.d618.s1.e4 false in addition to bleeding associated with heparin and vitamin k antagonists , drugs that alter platelet function ( such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1.e0_DDI-DrugBank.d618.s1.e2 false in addition to bleeding associated with heparin and vitamin k antagonists , drugs that alter platelet function ( such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1.e0_DDI-DrugBank.d618.s1.e5 true in addition to bleeding associated with heparin and vitamin k antagonists , drugs that alter platelet function ( such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1.e0_DDI-DrugBank.d618.s1.e1 false in addition to bleeding associated with heparin and vitamin k antagonists , drugs that alter platelet function ( such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1.e3_DDI-DrugBank.d618.s1.e4 false in addition to bleeding associated with heparin and vitamin k antagonists , drugs that alter platelet function ( such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1.e3_DDI-DrugBank.d618.s1.e2 false in addition to bleeding associated with heparin and vitamin k antagonists , drugs that alter platelet function ( such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1.e3_DDI-DrugBank.d618.s1.e5 false in addition to bleeding associated with heparin and vitamin k antagonists , drugs that alter platelet function ( such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1.e3_DDI-DrugBank.d618.s1.e1 false in addition to bleeding associated with heparin and vitamin k antagonists , drugs that alter platelet function ( such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1.e4_DDI-DrugBank.d618.s1.e2 false in addition to bleeding associated with heparin and vitamin k antagonists , drugs that alter platelet function ( such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1.e4_DDI-DrugBank.d618.s1.e5 false in addition to bleeding associated with heparin and vitamin k antagonists , drugs that alter platelet function ( such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1.e4_DDI-DrugBank.d618.s1.e1 false in addition to bleeding associated with heparin and vitamin k antagonists , drugs that alter platelet function ( such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1.e2_DDI-DrugBank.d618.s1.e5 false in addition to bleeding associated with heparin and vitamin k antagonists , drugs that alter platelet function ( such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1.e2_DDI-DrugBank.d618.s1.e1 false in addition to bleeding associated with heparin and vitamin k antagonists , drugs that alter platelet function ( such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d618.s1.e5_DDI-DrugBank.d618.s1.e1 false in addition to bleeding associated with heparin and vitamin k antagonists , drugs that alter platelet function ( such as aspirin , dipyridamole , and abciximab ) may increase the risk of bleeding if administered prior to or after retavase therapy .
DDI-DrugBank.d630.s0
DDI-DrugBank.d639.s7
DDI-DrugBank.d762.s3
DDI-DrugBank.d762.s3.e0_DDI-DrugBank.d762.s3.e1 true there is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels ( therapeutic range considered to be 50 to 100 g/ml total valproate ) .
DDI-DrugBank.d762.s3.e0_DDI-DrugBank.d762.s3.e2 false there is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels ( therapeutic range considered to be 50 to 100 g/ml total valproate ) .
DDI-DrugBank.d762.s3.e1_DDI-DrugBank.d762.s3.e2 false there is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels ( therapeutic range considered to be 50 to 100 g/ml total valproate ) .
DDI-DrugBank.d640.s2
DDI-DrugBank.d640.s2.e0_DDI-DrugBank.d640.s2.e2 false potassium supplements and potassium-sparing diuretics : univasc can increase serum potassium because it decreases aldosterone secretion .
DDI-DrugBank.d640.s2.e0_DDI-DrugBank.d640.s2.e1 false potassium supplements and potassium-sparing diuretics : univasc can increase serum potassium because it decreases aldosterone secretion .
DDI-DrugBank.d640.s2.e2_DDI-DrugBank.d640.s2.e1 false potassium supplements and potassium-sparing diuretics : univasc can increase serum potassium because it decreases aldosterone secretion .
DDI-DrugBank.d710.s3
DDI-DrugBank.d584.s2
DDI-DrugBank.d584.s12
DDI-DrugBank.d645.s6
DDI-DrugBank.d645.s6.e0_DDI-DrugBank.d645.s6.e1 true there have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin , however , a causal relationship between lamisil tablets and these changes has not been established .
DDI-DrugBank.d645.s6.e0_DDI-DrugBank.d645.s6.e2 false there have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin , however , a causal relationship between lamisil tablets and these changes has not been established .
DDI-DrugBank.d645.s6.e1_DDI-DrugBank.d645.s6.e2 false there have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin , however , a causal relationship between lamisil tablets and these changes has not been established .
DDI-DrugBank.d597.s30
DDI-DrugBank.d597.s30.e1_DDI-DrugBank.d597.s30.e2 false caution should be used when administering mobic with warfarin since patients on warfarin may experience changes in inr and an increased risk of bleeding complications when a new medication is introduced .
DDI-DrugBank.d597.s30.e1_DDI-DrugBank.d597.s30.e0 false caution should be used when administering mobic with warfarin since patients on warfarin may experience changes in inr and an increased risk of bleeding complications when a new medication is introduced .
DDI-DrugBank.d597.s30.e2_DDI-DrugBank.d597.s30.e0 false caution should be used when administering mobic with warfarin since patients on warfarin may experience changes in inr and an increased risk of bleeding complications when a new medication is introduced .
DDI-DrugBank.d676.s2
DDI-DrugBank.d676.s2.e3_DDI-DrugBank.d676.s2.e4 false because matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline hcl , imipramine hcl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.e3_DDI-DrugBank.d676.s2.e5 false because matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline hcl , imipramine hcl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.e3_DDI-DrugBank.d676.s2.e0 false because matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline hcl , imipramine hcl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.e3_DDI-DrugBank.d676.s2.e1 false because matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline hcl , imipramine hcl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.e3_DDI-DrugBank.d676.s2.e2 false because matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline hcl , imipramine hcl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.e4_DDI-DrugBank.d676.s2.e5 false because matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline hcl , imipramine hcl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.e4_DDI-DrugBank.d676.s2.e0 false because matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline hcl , imipramine hcl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.e4_DDI-DrugBank.d676.s2.e1 false because matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline hcl , imipramine hcl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.e4_DDI-DrugBank.d676.s2.e2 false because matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline hcl , imipramine hcl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.e5_DDI-DrugBank.d676.s2.e0 false because matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline hcl , imipramine hcl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.e5_DDI-DrugBank.d676.s2.e1 false because matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline hcl , imipramine hcl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.e5_DDI-DrugBank.d676.s2.e2 false because matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline hcl , imipramine hcl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.e0_DDI-DrugBank.d676.s2.e1 true because matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline hcl , imipramine hcl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.e0_DDI-DrugBank.d676.s2.e2 true because matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline hcl , imipramine hcl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d676.s2.e1_DDI-DrugBank.d676.s2.e2 false because matulane exhibits some monoamine oxidase inhibitory activity , sympathomimetic drugs , tricyclic antidepressant drugs ( e.g. , amitriptyline hcl , imipramine hcl ) and other drugs and foods with known high tyramine content , such as wine , yogurt , ripe cheese and bananas , should be avoided .
DDI-DrugBank.d613.s2
DDI-DrugBank.d653.s5
DDI-DrugBank.d653.s5.e0_DDI-DrugBank.d653.s5.e1 false this could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn .
DDI-DrugBank.d653.s5.e0_DDI-DrugBank.d653.s5.e2 false this could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn .
DDI-DrugBank.d653.s5.e1_DDI-DrugBank.d653.s5.e2 true this could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn .
DDI-DrugBank.d645.s9
DDI-DrugBank.d645.s9.e2_DDI-DrugBank.d645.s9.e3 false there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9.e2_DDI-DrugBank.d645.s9.e0 false there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9.e2_DDI-DrugBank.d645.s9.e1 false there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9.e2_DDI-DrugBank.d645.s9.e4 false there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9.e2_DDI-DrugBank.d645.s9.e5 false there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9.e2_DDI-DrugBank.d645.s9.e6 false there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9.e3_DDI-DrugBank.d645.s9.e0 false there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9.e3_DDI-DrugBank.d645.s9.e1 false there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9.e3_DDI-DrugBank.d645.s9.e4 false there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9.e3_DDI-DrugBank.d645.s9.e5 false there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9.e3_DDI-DrugBank.d645.s9.e6 false there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9.e0_DDI-DrugBank.d645.s9.e1 false there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9.e0_DDI-DrugBank.d645.s9.e4 false there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9.e0_DDI-DrugBank.d645.s9.e5 false there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9.e0_DDI-DrugBank.d645.s9.e6 false there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9.e1_DDI-DrugBank.d645.s9.e4 false there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9.e1_DDI-DrugBank.d645.s9.e5 false there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9.e1_DDI-DrugBank.d645.s9.e6 false there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9.e4_DDI-DrugBank.d645.s9.e5 false there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9.e4_DDI-DrugBank.d645.s9.e6 false there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d645.s9.e5_DDI-DrugBank.d645.s9.e6 false there is no information available from adequate drug-drug interaction studies with the following classes of drugs : oral contraceptives , hormone replacement therapies , hypoglycemics , theophyllines , phenytoins , thiazide diuretics , beta blockers , and calcium channel blockers .
DDI-DrugBank.d697.s0
DDI-DrugBank.d697.s0.e0_DDI-DrugBank.d697.s0.e1 false interactions for vitamin b1 ( thiamine ): loop diuretics , oral contraceptives , stavudine , tricyclic antidepressants
DDI-DrugBank.d697.s0.e0_DDI-DrugBank.d697.s0.e4 true interactions for vitamin b1 ( thiamine ): loop diuretics , oral contraceptives , stavudine , tricyclic antidepressants
DDI-DrugBank.d697.s0.e0_DDI-DrugBank.d697.s0.e2 true interactions for vitamin b1 ( thiamine ): loop diuretics , oral contraceptives , stavudine , tricyclic antidepressants
DDI-DrugBank.d697.s0.e0_DDI-DrugBank.d697.s0.e3 true interactions for vitamin b1 ( thiamine ): loop diuretics , oral contraceptives , stavudine , tricyclic antidepressants
DDI-DrugBank.d697.s0.e0_DDI-DrugBank.d697.s0.e5 true interactions for vitamin b1 ( thiamine ): loop diuretics , oral contraceptives , stavudine , tricyclic antidepressants
DDI-DrugBank.d697.s0.e1_DDI-DrugBank.d697.s0.e4 true interactions for vitamin b1 ( thiamine ): loop diuretics , oral contraceptives , stavudine , tricyclic antidepressants
DDI-DrugBank.d697.s0.e1_DDI-DrugBank.d697.s0.e2 true interactions for vitamin b1 ( thiamine ): loop diuretics , oral contraceptives , stavudine , tricyclic antidepressants
DDI-DrugBank.d697.s0.e1_DDI-DrugBank.d697.s0.e3 true interactions for vitamin b1 ( thiamine ): loop diuretics , oral contraceptives , stavudine , tricyclic antidepressants
DDI-DrugBank.d697.s0.e1_DDI-DrugBank.d697.s0.e5 true interactions for vitamin b1 ( thiamine ): loop diuretics , oral contraceptives , stavudine , tricyclic antidepressants
DDI-DrugBank.d697.s0.e4_DDI-DrugBank.d697.s0.e2 false interactions for vitamin b1 ( thiamine ): loop diuretics , oral contraceptives , stavudine , tricyclic antidepressants
DDI-DrugBank.d697.s0.e4_DDI-DrugBank.d697.s0.e3 false interactions for vitamin b1 ( thiamine ): loop diuretics , oral contraceptives , stavudine , tricyclic antidepressants
DDI-DrugBank.d697.s0.e4_DDI-DrugBank.d697.s0.e5 false interactions for vitamin b1 ( thiamine ): loop diuretics , oral contraceptives , stavudine , tricyclic antidepressants
DDI-DrugBank.d697.s0.e2_DDI-DrugBank.d697.s0.e3 false interactions for vitamin b1 ( thiamine ): loop diuretics , oral contraceptives , stavudine , tricyclic antidepressants
DDI-DrugBank.d697.s0.e2_DDI-DrugBank.d697.s0.e5 false interactions for vitamin b1 ( thiamine ): loop diuretics , oral contraceptives , stavudine , tricyclic antidepressants
DDI-DrugBank.d697.s0.e3_DDI-DrugBank.d697.s0.e5 false interactions for vitamin b1 ( thiamine ): loop diuretics , oral contraceptives , stavudine , tricyclic antidepressants
DDI-DrugBank.d636.s0
DDI-DrugBank.d636.s0.e1_DDI-DrugBank.d636.s0.e0 false some anticonvulsants may interact with mephenytoin .
DDI-DrugBank.d575.s1
DDI-DrugBank.d609.s0
DDI-DrugBank.d609.s0.e0_DDI-DrugBank.d609.s0.e1 true an inhibitor of cyp2c8 ( such as gemfibrozil ) may increase the auc of rosiglitazone and an inducer of cyp2c8 ( such as rifampin ) may decrease the auc of rosiglitazone .
DDI-DrugBank.d609.s0.e0_DDI-DrugBank.d609.s0.e2 false an inhibitor of cyp2c8 ( such as gemfibrozil ) may increase the auc of rosiglitazone and an inducer of cyp2c8 ( such as rifampin ) may decrease the auc of rosiglitazone .
DDI-DrugBank.d609.s0.e0_DDI-DrugBank.d609.s0.e3 false an inhibitor of cyp2c8 ( such as gemfibrozil ) may increase the auc of rosiglitazone and an inducer of cyp2c8 ( such as rifampin ) may decrease the auc of rosiglitazone .
DDI-DrugBank.d609.s0.e1_DDI-DrugBank.d609.s0.e2 false an inhibitor of cyp2c8 ( such as gemfibrozil ) may increase the auc of rosiglitazone and an inducer of cyp2c8 ( such as rifampin ) may decrease the auc of rosiglitazone .
DDI-DrugBank.d609.s0.e1_DDI-DrugBank.d609.s0.e3 false an inhibitor of cyp2c8 ( such as gemfibrozil ) may increase the auc of rosiglitazone and an inducer of cyp2c8 ( such as rifampin ) may decrease the auc of rosiglitazone .
DDI-DrugBank.d609.s0.e2_DDI-DrugBank.d609.s0.e3 true an inhibitor of cyp2c8 ( such as gemfibrozil ) may increase the auc of rosiglitazone and an inducer of cyp2c8 ( such as rifampin ) may decrease the auc of rosiglitazone .
DDI-DrugBank.d670.s6
DDI-DrugBank.d670.s6.e0_DDI-DrugBank.d670.s6.e3 true given the primary cns effects of paliperidone , invega should be used with caution in combination with other centrally acting drugs and alcohol .
DDI-DrugBank.d670.s6.e0_DDI-DrugBank.d670.s6.e1 false given the primary cns effects of paliperidone , invega should be used with caution in combination with other centrally acting drugs and alcohol .
DDI-DrugBank.d670.s6.e0_DDI-DrugBank.d670.s6.e2 true given the primary cns effects of paliperidone , invega should be used with caution in combination with other centrally acting drugs and alcohol .
DDI-DrugBank.d670.s6.e3_DDI-DrugBank.d670.s6.e1 false given the primary cns effects of paliperidone , invega should be used with caution in combination with other centrally acting drugs and alcohol .
DDI-DrugBank.d670.s6.e3_DDI-DrugBank.d670.s6.e2 false given the primary cns effects of paliperidone , invega should be used with caution in combination with other centrally acting drugs and alcohol .
DDI-DrugBank.d670.s6.e1_DDI-DrugBank.d670.s6.e2 true given the primary cns effects of paliperidone , invega should be used with caution in combination with other centrally acting drugs and alcohol .
DDI-DrugBank.d629.s1
DDI-DrugBank.d629.s1.e1_DDI-DrugBank.d629.s1.e2 false drug interactions should be kept in mind when metrogel ( metronidazole gel ) , 1 % is prescribed for patients who are receiving anticoagulant treatment , although they are less likely to occur with topical metronidazole administration because of low absorption .
DDI-DrugBank.d629.s1.e1_DDI-DrugBank.d629.s1.e0 false drug interactions should be kept in mind when metrogel ( metronidazole gel ) , 1 % is prescribed for patients who are receiving anticoagulant treatment , although they are less likely to occur with topical metronidazole administration because of low absorption .
DDI-DrugBank.d629.s1.e2_DDI-DrugBank.d629.s1.e0 false drug interactions should be kept in mind when metrogel ( metronidazole gel ) , 1 % is prescribed for patients who are receiving anticoagulant treatment , although they are less likely to occur with topical metronidazole administration because of low absorption .
DDI-DrugBank.d771.s2
DDI-DrugBank.d599.s5
DDI-DrugBank.d595.s3
DDI-DrugBank.d736.s2
DDI-DrugBank.d607.s1
DDI-DrugBank.d607.s1.e1_DDI-DrugBank.d607.s1.e0 false drugs which may potentiate the myeloproliferative effects of leukine , such as lithium and corticosteroids , should be used with caution .
DDI-DrugBank.d607.s1.e1_DDI-DrugBank.d607.s1.e2 false drugs which may potentiate the myeloproliferative effects of leukine , such as lithium and corticosteroids , should be used with caution .
DDI-DrugBank.d607.s1.e0_DDI-DrugBank.d607.s1.e2 true drugs which may potentiate the myeloproliferative effects of leukine , such as lithium and corticosteroids , should be used with caution .
DDI-DrugBank.d743.s11
DDI-DrugBank.d743.s11.e0_DDI-DrugBank.d743.s11.e1 false a few spontaneous accounts of qt interval prolongation with ventricular arrhythmia including torsades de pointes , have been reported in patients receiving erythromycin or troleandomycin .
DDI-DrugBank.d770.s2
DDI-DrugBank.d595.s7
DDI-DrugBank.d753.s5
DDI-DrugBank.d599.s7
DDI-DrugBank.d599.s7.e0_DDI-DrugBank.d599.s7.e4 true these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin ) .
DDI-DrugBank.d599.s7.e0_DDI-DrugBank.d599.s7.e1 true these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin ) .
DDI-DrugBank.d599.s7.e0_DDI-DrugBank.d599.s7.e2 true these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin ) .
DDI-DrugBank.d599.s7.e0_DDI-DrugBank.d599.s7.e3 true these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin ) .
DDI-DrugBank.d599.s7.e4_DDI-DrugBank.d599.s7.e1 false these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin ) .
DDI-DrugBank.d599.s7.e4_DDI-DrugBank.d599.s7.e2 false these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin ) .
DDI-DrugBank.d599.s7.e4_DDI-DrugBank.d599.s7.e3 false these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin ) .
DDI-DrugBank.d599.s7.e1_DDI-DrugBank.d599.s7.e2 false these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin ) .
DDI-DrugBank.d599.s7.e1_DDI-DrugBank.d599.s7.e3 false these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin ) .
DDI-DrugBank.d599.s7.e2_DDI-DrugBank.d599.s7.e3 false these data suggest that gh administration may alter the clearance of compounds known to be metabolized by cp450 liver enzymes ( e.g. , corticosteroids , sex steroids , anticonvulsants , cyclosporin ) .
DDI-DrugBank.d598.s2
DDI-DrugBank.d597.s8
DDI-DrugBank.d652.s4
DDI-DrugBank.d776.s11
DDI-DrugBank.d776.s11.e0_DDI-DrugBank.d776.s11.e2 false careful monitoring of phenytoin concentrations in patients receiving diflucan and phenytoin is recommended .
DDI-DrugBank.d776.s11.e0_DDI-DrugBank.d776.s11.e1 false careful monitoring of phenytoin concentrations in patients receiving diflucan and phenytoin is recommended .
DDI-DrugBank.d776.s11.e2_DDI-DrugBank.d776.s11.e1 false careful monitoring of phenytoin concentrations in patients receiving diflucan and phenytoin is recommended .
DDI-DrugBank.d777.s3
DDI-DrugBank.d777.s3.e1_DDI-DrugBank.d777.s3.e0 false in the treatment of acute mi , aspirin , when not otherwise contraindicated , should be administered with streptokinase ( see below ) .
DDI-DrugBank.d585.s0
DDI-DrugBank.d585.s0.e1_DDI-DrugBank.d585.s0.e3 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e1_DDI-DrugBank.d585.s0.e0 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e1_DDI-DrugBank.d585.s0.e2 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e1_DDI-DrugBank.d585.s0.e4 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e1_DDI-DrugBank.d585.s0.e5 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e1_DDI-DrugBank.d585.s0.e6 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e1_DDI-DrugBank.d585.s0.e7 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e1_DDI-DrugBank.d585.s0.e8 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e1_DDI-DrugBank.d585.s0.e9 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e3_DDI-DrugBank.d585.s0.e0 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e3_DDI-DrugBank.d585.s0.e2 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e3_DDI-DrugBank.d585.s0.e4 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e3_DDI-DrugBank.d585.s0.e5 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e3_DDI-DrugBank.d585.s0.e6 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e3_DDI-DrugBank.d585.s0.e7 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e3_DDI-DrugBank.d585.s0.e8 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e3_DDI-DrugBank.d585.s0.e9 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e0_DDI-DrugBank.d585.s0.e2 true the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e0_DDI-DrugBank.d585.s0.e4 true the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e0_DDI-DrugBank.d585.s0.e5 true the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e0_DDI-DrugBank.d585.s0.e6 true the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e0_DDI-DrugBank.d585.s0.e7 true the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e0_DDI-DrugBank.d585.s0.e8 true the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e0_DDI-DrugBank.d585.s0.e9 true the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e2_DDI-DrugBank.d585.s0.e4 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e2_DDI-DrugBank.d585.s0.e5 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e2_DDI-DrugBank.d585.s0.e6 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e2_DDI-DrugBank.d585.s0.e7 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e2_DDI-DrugBank.d585.s0.e8 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e2_DDI-DrugBank.d585.s0.e9 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e4_DDI-DrugBank.d585.s0.e5 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e4_DDI-DrugBank.d585.s0.e6 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e4_DDI-DrugBank.d585.s0.e7 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e4_DDI-DrugBank.d585.s0.e8 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e4_DDI-DrugBank.d585.s0.e9 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e5_DDI-DrugBank.d585.s0.e6 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e5_DDI-DrugBank.d585.s0.e7 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e5_DDI-DrugBank.d585.s0.e8 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e5_DDI-DrugBank.d585.s0.e9 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e6_DDI-DrugBank.d585.s0.e7 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e6_DDI-DrugBank.d585.s0.e8 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e6_DDI-DrugBank.d585.s0.e9 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e7_DDI-DrugBank.d585.s0.e8 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e7_DDI-DrugBank.d585.s0.e9 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d585.s0.e8_DDI-DrugBank.d585.s0.e9 false the following agents may increase certain actions or side effects of anticholinergic drugs : amantadine , antiarrhythmic agents of class i ( e.g. , quinidine ) , antihistamines , antipsychotic agents ( e.g. , phenothiazines ) , benzodiazepines , mao inhibitors , narcotic analgesics ( e.g. , meperidine ) , nitrates and nitrites , sympathomimetic agents , tricyclic antidepressants , and other drugs having anticholinergic activity .
DDI-DrugBank.d752.s7
DDI-DrugBank.d624.s3
DDI-DrugBank.d624.s3.e1_DDI-DrugBank.d624.s3.e2 false tobi should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol .
DDI-DrugBank.d624.s3.e1_DDI-DrugBank.d624.s3.e3 false tobi should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol .
DDI-DrugBank.d624.s3.e1_DDI-DrugBank.d624.s3.e4 false tobi should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol .
DDI-DrugBank.d624.s3.e1_DDI-DrugBank.d624.s3.e0 false tobi should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol .
DDI-DrugBank.d624.s3.e2_DDI-DrugBank.d624.s3.e3 false tobi should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol .
DDI-DrugBank.d624.s3.e2_DDI-DrugBank.d624.s3.e4 false tobi should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol .
DDI-DrugBank.d624.s3.e2_DDI-DrugBank.d624.s3.e0 false tobi should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol .
DDI-DrugBank.d624.s3.e3_DDI-DrugBank.d624.s3.e4 false tobi should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol .
DDI-DrugBank.d624.s3.e3_DDI-DrugBank.d624.s3.e0 false tobi should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol .
DDI-DrugBank.d624.s3.e4_DDI-DrugBank.d624.s3.e0 false tobi should not be administered concomitantly with ethacrynic acid , furosemide , urea , or mannitol .
DDI-DrugBank.d682.s0
DDI-DrugBank.d682.s0.e0_DDI-DrugBank.d682.s0.e2 true sulfoxone may increase the effects of barbiturates , tolbutamide , and uricosurics .
DDI-DrugBank.d682.s0.e0_DDI-DrugBank.d682.s0.e1 true sulfoxone may increase the effects of barbiturates , tolbutamide , and uricosurics .
DDI-DrugBank.d682.s0.e0_DDI-DrugBank.d682.s0.e3 true sulfoxone may increase the effects of barbiturates , tolbutamide , and uricosurics .
DDI-DrugBank.d682.s0.e2_DDI-DrugBank.d682.s0.e1 false sulfoxone may increase the effects of barbiturates , tolbutamide , and uricosurics .
DDI-DrugBank.d682.s0.e2_DDI-DrugBank.d682.s0.e3 false sulfoxone may increase the effects of barbiturates , tolbutamide , and uricosurics .
DDI-DrugBank.d682.s0.e1_DDI-DrugBank.d682.s0.e3 false sulfoxone may increase the effects of barbiturates , tolbutamide , and uricosurics .
DDI-DrugBank.d597.s15
DDI-DrugBank.d653.s0
DDI-DrugBank.d742.s10
DDI-DrugBank.d742.s10.e1_DDI-DrugBank.d742.s10.e0 false however , the impairment of motor skills produced by remeron has been shown to be additive with those caused by diazepam .
DDI-DrugBank.d668.s2
DDI-DrugBank.d668.s2.e1_DDI-DrugBank.d668.s2.e2 false john s wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2.e1_DDI-DrugBank.d668.s2.e3 false john s wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2.e1_DDI-DrugBank.d668.s2.e4 true john s wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2.e1_DDI-DrugBank.d668.s2.e5 false john s wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2.e1_DDI-DrugBank.d668.s2.e0 false john s wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2.e2_DDI-DrugBank.d668.s2.e3 false john s wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2.e2_DDI-DrugBank.d668.s2.e4 false john s wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2.e2_DDI-DrugBank.d668.s2.e5 false john s wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2.e2_DDI-DrugBank.d668.s2.e0 false john s wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2.e3_DDI-DrugBank.d668.s2.e4 false john s wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2.e3_DDI-DrugBank.d668.s2.e5 false john s wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2.e3_DDI-DrugBank.d668.s2.e0 false john s wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2.e4_DDI-DrugBank.d668.s2.e5 false john s wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2.e4_DDI-DrugBank.d668.s2.e0 false john s wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d668.s2.e5_DDI-DrugBank.d668.s2.e0 false john s wort , and certain anticonvulsants ( phenytoin , phenobarbital , carbamazepine ) may induce mifepristone metabolism ( lowering serum levels of mifepristone ) .
DDI-DrugBank.d704.s4
DDI-DrugBank.d704.s4.e1_DDI-DrugBank.d704.s4.e0 false therefore , flomax capsules should be used with caution in combination with cimetidine , particularly at doses higher than 0.4 mg.
DDI-DrugBank.d761.s12
DDI-DrugBank.d761.s12.e0_DDI-DrugBank.d761.s12.e1 false although undercarboxylated osteocalcin , a marker of vitamin k nutritional status , was unaltered with xenical administration , vitamin k levels tended to decline in subjects taking xenical .
DDI-DrugBank.d735.s4
DDI-DrugBank.d735.s4.e0_DDI-DrugBank.d735.s4.e2 false nifedipine auc and cmax were increased by 18 % and 42 % , respectively , in the presence of steady-state mycamine compared with nifedipine alone .
DDI-DrugBank.d735.s4.e0_DDI-DrugBank.d735.s4.e1 true nifedipine auc and cmax were increased by 18 % and 42 % , respectively , in the presence of steady-state mycamine compared with nifedipine alone .
DDI-DrugBank.d735.s4.e2_DDI-DrugBank.d735.s4.e1 false nifedipine auc and cmax were increased by 18 % and 42 % , respectively , in the presence of steady-state mycamine compared with nifedipine alone .
DDI-DrugBank.d698.s1
DDI-DrugBank.d698.s1.e0_DDI-DrugBank.d698.s1.e1 true probenecid - concurrent use decreases gastrointestinal absorption of riboflavin ;
DDI-DrugBank.d658.s0
DDI-DrugBank.d658.s0.e0_DDI-DrugBank.d658.s0.e1 true when administered concurrently , testolactone may increase the effects of oral anticoagulants ;
DDI-DrugBank.d572.s24
DDI-DrugBank.d572.s24.e0_DDI-DrugBank.d572.s24.e3 false multiple dose studies of ezetimibe given in combination with hmg-coa reductase inhibitors ( statins ) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures .
DDI-DrugBank.d572.s24.e0_DDI-DrugBank.d572.s24.e1 false multiple dose studies of ezetimibe given in combination with hmg-coa reductase inhibitors ( statins ) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures .
DDI-DrugBank.d572.s24.e0_DDI-DrugBank.d572.s24.e2 false multiple dose studies of ezetimibe given in combination with hmg-coa reductase inhibitors ( statins ) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures .
DDI-DrugBank.d572.s24.e3_DDI-DrugBank.d572.s24.e1 false multiple dose studies of ezetimibe given in combination with hmg-coa reductase inhibitors ( statins ) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures .
DDI-DrugBank.d572.s24.e3_DDI-DrugBank.d572.s24.e2 false multiple dose studies of ezetimibe given in combination with hmg-coa reductase inhibitors ( statins ) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures .
DDI-DrugBank.d572.s24.e1_DDI-DrugBank.d572.s24.e2 false multiple dose studies of ezetimibe given in combination with hmg-coa reductase inhibitors ( statins ) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures .
DDI-DrugBank.d597.s2
DDI-DrugBank.d597.s2.e2_DDI-DrugBank.d597.s2.e0 false aspirin : concomitant administration of aspirin ( 1000 mg tid ) to healthy volunteers tended to increase the auc ( 10 % ) and cmax ( 24 % ) of meloxicam .
DDI-DrugBank.d597.s2.e2_DDI-DrugBank.d597.s2.e1 false aspirin : concomitant administration of aspirin ( 1000 mg tid ) to healthy volunteers tended to increase the auc ( 10 % ) and cmax ( 24 % ) of meloxicam .
DDI-DrugBank.d597.s2.e0_DDI-DrugBank.d597.s2.e1 false aspirin : concomitant administration of aspirin ( 1000 mg tid ) to healthy volunteers tended to increase the auc ( 10 % ) and cmax ( 24 % ) of meloxicam .
DDI-DrugBank.d653.s1
DDI-DrugBank.d653.s1.e0_DDI-DrugBank.d653.s1.e1 false drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response .
DDI-DrugBank.d653.s1.e0_DDI-DrugBank.d653.s1.e2 false drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response .
DDI-DrugBank.d653.s1.e0_DDI-DrugBank.d653.s1.e3 true drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response .
DDI-DrugBank.d653.s1.e0_DDI-DrugBank.d653.s1.e4 true drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response .
DDI-DrugBank.d653.s1.e1_DDI-DrugBank.d653.s1.e2 false drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response .
DDI-DrugBank.d653.s1.e1_DDI-DrugBank.d653.s1.e3 true drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response .
DDI-DrugBank.d653.s1.e1_DDI-DrugBank.d653.s1.e4 true drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response .
DDI-DrugBank.d653.s1.e2_DDI-DrugBank.d653.s1.e3 true drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response .
DDI-DrugBank.d653.s1.e2_DDI-DrugBank.d653.s1.e4 true drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response .
DDI-DrugBank.d653.s1.e3_DDI-DrugBank.d653.s1.e4 false drugs that induce hepatic enzymes such as phenobarbital , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response .
DDI-DrugBank.d693.s4
DDI-DrugBank.d572.s19
DDI-DrugBank.d647.s2
DDI-DrugBank.d647.s2.e0_DDI-DrugBank.d647.s2.e1 true a reduction of the doxorubicin dosage should be considered in patients receiving zanosar concurrently .
DDI-DrugBank.d676.s0
DDI-DrugBank.d676.s0.e0_DDI-DrugBank.d676.s0.e1 false to minimize cns depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution .
DDI-DrugBank.d676.s0.e0_DDI-DrugBank.d676.s0.e2 false to minimize cns depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution .
DDI-DrugBank.d676.s0.e0_DDI-DrugBank.d676.s0.e3 false to minimize cns depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution .
DDI-DrugBank.d676.s0.e0_DDI-DrugBank.d676.s0.e4 false to minimize cns depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution .
DDI-DrugBank.d676.s0.e1_DDI-DrugBank.d676.s0.e2 false to minimize cns depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution .
DDI-DrugBank.d676.s0.e1_DDI-DrugBank.d676.s0.e3 false to minimize cns depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution .
DDI-DrugBank.d676.s0.e1_DDI-DrugBank.d676.s0.e4 false to minimize cns depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution .
DDI-DrugBank.d676.s0.e2_DDI-DrugBank.d676.s0.e3 false to minimize cns depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution .
DDI-DrugBank.d676.s0.e2_DDI-DrugBank.d676.s0.e4 false to minimize cns depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution .
DDI-DrugBank.d676.s0.e3_DDI-DrugBank.d676.s0.e4 false to minimize cns depression and possible potentiation , barbiturates , antihistamines , narcotics , hypotensive agents or phenothiazines should be used with caution .
DDI-DrugBank.d633.s11
DDI-DrugBank.d633.s11.e1_DDI-DrugBank.d633.s11.e0 false in a formal study , benzodiazepines were shown not to affect mexitil plasma concentrations .
DDI-DrugBank.d781.s0
DDI-DrugBank.d781.s0.e2_DDI-DrugBank.d781.s0.e0 false diuretics : patients on diuretics , and especially those started recently , may occasionally experience an excessive reduction of blood pressure after initiation of aceon tablets therapy .
DDI-DrugBank.d781.s0.e2_DDI-DrugBank.d781.s0.e1 false diuretics : patients on diuretics , and especially those started recently , may occasionally experience an excessive reduction of blood pressure after initiation of aceon tablets therapy .
DDI-DrugBank.d781.s0.e0_DDI-DrugBank.d781.s0.e1 false diuretics : patients on diuretics , and especially those started recently , may occasionally experience an excessive reduction of blood pressure after initiation of aceon tablets therapy .
DDI-DrugBank.d653.s4
DDI-DrugBank.d653.s4.e1_DDI-DrugBank.d653.s4.e0 false corticosteroids may increase the clearance of chronic high dose aspirin .
DDI-DrugBank.d633.s17
DDI-DrugBank.d572.s11
DDI-DrugBank.d572.s11.e0_DDI-DrugBank.d572.s11.e1 false a 104-week dietary carcinogenicity study with ezetimibe was conducted in rats at doses up to 1500 mg/kg/day ( males ) and 500 mg/kg/day ( females ) ( ~20 times the human exposure at 10 mg daily based on auc0 - 24hr for total ezetimibe ) .
DDI-DrugBank.d728.s0
DDI-DrugBank.d665.s3
DDI-DrugBank.d613.s1
DDI-DrugBank.d613.s1.e0_DDI-DrugBank.d613.s1.e1 true in 1984 , drs rimmer and richens at the university of wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy .
DDI-DrugBank.d613.s1.e0_DDI-DrugBank.d613.s1.e2 false in 1984 , drs rimmer and richens at the university of wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy .
DDI-DrugBank.d613.s1.e1_DDI-DrugBank.d613.s1.e2 false in 1984 , drs rimmer and richens at the university of wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy .
DDI-DrugBank.d597.s4
DDI-DrugBank.d597.s4.e1_DDI-DrugBank.d597.s4.e2 true however , as with other nsaids , concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects .
DDI-DrugBank.d597.s4.e1_DDI-DrugBank.d597.s4.e0 false however , as with other nsaids , concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects .
DDI-DrugBank.d597.s4.e2_DDI-DrugBank.d597.s4.e0 false however , as with other nsaids , concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects .
DDI-DrugBank.d717.s2
DDI-DrugBank.d700.s10
DDI-DrugBank.d700.s10.e0_DDI-DrugBank.d700.s10.e1 true however , in a drug-drug interaction study , mean levonorgesterol auc was decreased by 15 % when coadministered with mycophenolate mofetil .
DDI-DrugBank.d596.s6
DDI-DrugBank.d596.s6.e0_DDI-DrugBank.d596.s6.e1 false single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine .
DDI-DrugBank.d596.s6.e0_DDI-DrugBank.d596.s6.e2 false single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine .
DDI-DrugBank.d596.s6.e0_DDI-DrugBank.d596.s6.e3 false single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine .
DDI-DrugBank.d596.s6.e0_DDI-DrugBank.d596.s6.e4 false single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine .
DDI-DrugBank.d596.s6.e1_DDI-DrugBank.d596.s6.e2 false single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine .
DDI-DrugBank.d596.s6.e1_DDI-DrugBank.d596.s6.e3 false single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine .
DDI-DrugBank.d596.s6.e1_DDI-DrugBank.d596.s6.e4 false single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine .
DDI-DrugBank.d596.s6.e2_DDI-DrugBank.d596.s6.e3 false single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine .
DDI-DrugBank.d596.s6.e2_DDI-DrugBank.d596.s6.e4 false single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine .
DDI-DrugBank.d596.s6.e3_DDI-DrugBank.d596.s6.e4 false single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin , warfarin , diazepam , or fluoxetine .
DDI-DrugBank.d653.s3
DDI-DrugBank.d634.s3
DDI-DrugBank.d634.s3.e0_DDI-DrugBank.d634.s3.e1 false digitalis glycosides : serum digitalis levels may be increased when hyperthyroid patients on a stable digitalis glycoside regimen become euthyroid ;
DDI-DrugBank.d716.s0
DDI-DrugBank.d716.s0.e0_DDI-DrugBank.d716.s0.e3 true you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e0_DDI-DrugBank.d716.s0.e5 true you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e0_DDI-DrugBank.d716.s0.e7 true you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e0_DDI-DrugBank.d716.s0.e4 true you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e0_DDI-DrugBank.d716.s0.e6 true you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e0_DDI-DrugBank.d716.s0.e8 true you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e0_DDI-DrugBank.d716.s0.e1 true you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e0_DDI-DrugBank.d716.s0.e2 true you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e3_DDI-DrugBank.d716.s0.e5 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e3_DDI-DrugBank.d716.s0.e7 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e3_DDI-DrugBank.d716.s0.e4 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e3_DDI-DrugBank.d716.s0.e6 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e3_DDI-DrugBank.d716.s0.e8 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e3_DDI-DrugBank.d716.s0.e1 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e3_DDI-DrugBank.d716.s0.e2 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e5_DDI-DrugBank.d716.s0.e7 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e5_DDI-DrugBank.d716.s0.e4 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e5_DDI-DrugBank.d716.s0.e6 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e5_DDI-DrugBank.d716.s0.e8 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e5_DDI-DrugBank.d716.s0.e1 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e5_DDI-DrugBank.d716.s0.e2 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e7_DDI-DrugBank.d716.s0.e4 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e7_DDI-DrugBank.d716.s0.e6 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e7_DDI-DrugBank.d716.s0.e8 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e7_DDI-DrugBank.d716.s0.e1 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e7_DDI-DrugBank.d716.s0.e2 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e4_DDI-DrugBank.d716.s0.e6 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e4_DDI-DrugBank.d716.s0.e8 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e4_DDI-DrugBank.d716.s0.e1 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e4_DDI-DrugBank.d716.s0.e2 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e6_DDI-DrugBank.d716.s0.e8 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e6_DDI-DrugBank.d716.s0.e1 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e6_DDI-DrugBank.d716.s0.e2 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e8_DDI-DrugBank.d716.s0.e1 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e8_DDI-DrugBank.d716.s0.e2 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d716.s0.e1_DDI-DrugBank.d716.s0.e2 false you can not take mazindol if you have taken a monoamine oxidase inhibitor ( maoi ) such as isocarboxazid ( marplan ) , tranylcypromine ( parnate ) , or phenelzine ( nardil ) in the last 14 days .
DDI-DrugBank.d656.s3
DDI-DrugBank.d656.s3.e0_DDI-DrugBank.d656.s3.e1 true it is recommended that plasma lithium levels be monitored when initiating , adjusting and discontinuing feldene .
DDI-DrugBank.d584.s1
DDI-DrugBank.d649.s1
DDI-DrugBank.d649.s1.e1_DDI-DrugBank.d649.s1.e3 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e1_DDI-DrugBank.d649.s1.e4 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e1_DDI-DrugBank.d649.s1.e5 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e1_DDI-DrugBank.d649.s1.e6 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e1_DDI-DrugBank.d649.s1.e7 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e1_DDI-DrugBank.d649.s1.e0 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e1_DDI-DrugBank.d649.s1.e2 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e3_DDI-DrugBank.d649.s1.e4 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e3_DDI-DrugBank.d649.s1.e5 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e3_DDI-DrugBank.d649.s1.e6 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e3_DDI-DrugBank.d649.s1.e7 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e3_DDI-DrugBank.d649.s1.e0 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e3_DDI-DrugBank.d649.s1.e2 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e4_DDI-DrugBank.d649.s1.e5 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e4_DDI-DrugBank.d649.s1.e6 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e4_DDI-DrugBank.d649.s1.e7 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e4_DDI-DrugBank.d649.s1.e0 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e4_DDI-DrugBank.d649.s1.e2 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e5_DDI-DrugBank.d649.s1.e6 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e5_DDI-DrugBank.d649.s1.e7 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e5_DDI-DrugBank.d649.s1.e0 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e5_DDI-DrugBank.d649.s1.e2 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e6_DDI-DrugBank.d649.s1.e7 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e6_DDI-DrugBank.d649.s1.e0 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e6_DDI-DrugBank.d649.s1.e2 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e7_DDI-DrugBank.d649.s1.e0 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e7_DDI-DrugBank.d649.s1.e2 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d649.s1.e0_DDI-DrugBank.d649.s1.e2 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d721.s2
DDI-DrugBank.d721.s2.e1_DDI-DrugBank.d721.s2.e2 false the bioavailability of skelid is increased 2 - 4 fold by indomethacin but is not significantly altered by coadministration of diclofenac .
DDI-DrugBank.d721.s2.e1_DDI-DrugBank.d721.s2.e0 false the bioavailability of skelid is increased 2 - 4 fold by indomethacin but is not significantly altered by coadministration of diclofenac .
DDI-DrugBank.d721.s2.e2_DDI-DrugBank.d721.s2.e0 false the bioavailability of skelid is increased 2 - 4 fold by indomethacin but is not significantly altered by coadministration of diclofenac .
DDI-DrugBank.d588.s2
DDI-DrugBank.d588.s6
DDI-DrugBank.d588.s6.e1_DDI-DrugBank.d588.s6.e0 false corticosteroids or acth : may increase the risk of hypokalemia and increase salt and water retention .
DDI-DrugBank.d584.s6
DDI-DrugBank.d584.s6.e0_DDI-DrugBank.d584.s6.e1 true when oxandrolone therapy is initiated in a patient already receiving treatment with warfarin , the inr or prothrombin time ( pt ) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target inr or pt has been achieved .
DDI-DrugBank.d584.s6.e0_DDI-DrugBank.d584.s6.e2 false when oxandrolone therapy is initiated in a patient already receiving treatment with warfarin , the inr or prothrombin time ( pt ) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target inr or pt has been achieved .
DDI-DrugBank.d584.s6.e1_DDI-DrugBank.d584.s6.e2 false when oxandrolone therapy is initiated in a patient already receiving treatment with warfarin , the inr or prothrombin time ( pt ) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target inr or pt has been achieved .
DDI-DrugBank.d741.s0
DDI-DrugBank.d741.s0.e0_DDI-DrugBank.d741.s0.e2 false in a pharmacokinetic study of 18 chronic hepatitis c patients concomitantly receiving methadone , treatment with peg-intron once weekly for 4 weeks was associated with a mean increase of 16 % in methadone auc ;
DDI-DrugBank.d741.s0.e0_DDI-DrugBank.d741.s0.e1 true in a pharmacokinetic study of 18 chronic hepatitis c patients concomitantly receiving methadone , treatment with peg-intron once weekly for 4 weeks was associated with a mean increase of 16 % in methadone auc ;
DDI-DrugBank.d741.s0.e2_DDI-DrugBank.d741.s0.e1 false in a pharmacokinetic study of 18 chronic hepatitis c patients concomitantly receiving methadone , treatment with peg-intron once weekly for 4 weeks was associated with a mean increase of 16 % in methadone auc ;
DDI-DrugBank.d597.s0
DDI-DrugBank.d597.s0.e0_DDI-DrugBank.d597.s0.e1 false ace inhibitors reports suggest that nsaids may diminish the antihypertensive effect of angiotensin-converting enzyme ( ace ) inhibitors .
DDI-DrugBank.d597.s0.e0_DDI-DrugBank.d597.s0.e2 false ace inhibitors reports suggest that nsaids may diminish the antihypertensive effect of angiotensin-converting enzyme ( ace ) inhibitors .
DDI-DrugBank.d597.s0.e1_DDI-DrugBank.d597.s0.e2 true ace inhibitors reports suggest that nsaids may diminish the antihypertensive effect of angiotensin-converting enzyme ( ace ) inhibitors .
DDI-DrugBank.d710.s1
DDI-DrugBank.d710.s1.e0_DDI-DrugBank.d710.s1.e1 true when a single 100 mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine ( 300 mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ) .
DDI-DrugBank.d710.s1.e0_DDI-DrugBank.d710.s1.e2 false when a single 100 mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine ( 300 mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ) .
DDI-DrugBank.d710.s1.e0_DDI-DrugBank.d710.s1.e3 false when a single 100 mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine ( 300 mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ) .
DDI-DrugBank.d710.s1.e0_DDI-DrugBank.d710.s1.e4 false when a single 100 mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine ( 300 mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ) .
DDI-DrugBank.d710.s1.e1_DDI-DrugBank.d710.s1.e2 false when a single 100 mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine ( 300 mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ) .
DDI-DrugBank.d710.s1.e1_DDI-DrugBank.d710.s1.e3 false when a single 100 mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine ( 300 mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ) .
DDI-DrugBank.d710.s1.e1_DDI-DrugBank.d710.s1.e4 false when a single 100 mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine ( 300 mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ) .
DDI-DrugBank.d710.s1.e2_DDI-DrugBank.d710.s1.e3 false when a single 100 mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine ( 300 mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ) .
DDI-DrugBank.d710.s1.e2_DDI-DrugBank.d710.s1.e4 false when a single 100 mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine ( 300 mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ) .
DDI-DrugBank.d710.s1.e3_DDI-DrugBank.d710.s1.e4 false when a single 100 mg dose of rimantadine hcl was administered one hour after the initiation of cimetidine ( 300 mg four times a day ) , the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18 % ( compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine ) .
DDI-DrugBank.d766.s1
DDI-DrugBank.d766.s1.e0_DDI-DrugBank.d766.s1.e1 true agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole .
DDI-DrugBank.d766.s1.e0_DDI-DrugBank.d766.s1.e2 true agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole .
DDI-DrugBank.d766.s1.e0_DDI-DrugBank.d766.s1.e3 true agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole .
DDI-DrugBank.d766.s1.e0_DDI-DrugBank.d766.s1.e4 true agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole .
DDI-DrugBank.d766.s1.e0_DDI-DrugBank.d766.s1.e5 true agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole .
DDI-DrugBank.d766.s1.e1_DDI-DrugBank.d766.s1.e2 false agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole .
DDI-DrugBank.d766.s1.e1_DDI-DrugBank.d766.s1.e3 false agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole .
DDI-DrugBank.d766.s1.e1_DDI-DrugBank.d766.s1.e4 false agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole .
DDI-DrugBank.d766.s1.e1_DDI-DrugBank.d766.s1.e5 false agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole .
DDI-DrugBank.d766.s1.e2_DDI-DrugBank.d766.s1.e3 false agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole .
DDI-DrugBank.d766.s1.e2_DDI-DrugBank.d766.s1.e4 false agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole .
DDI-DrugBank.d766.s1.e2_DDI-DrugBank.d766.s1.e5 false agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole .
DDI-DrugBank.d766.s1.e3_DDI-DrugBank.d766.s1.e4 false agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole .
DDI-DrugBank.d766.s1.e3_DDI-DrugBank.d766.s1.e5 false agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole .
DDI-DrugBank.d766.s1.e4_DDI-DrugBank.d766.s1.e5 false agents that might be coadministered with trimetrexate in aids patients for other indications that could elicit this activity include erythromycin , rifampin , rifabutin , ketoconazole , and fluconazole .
DDI-DrugBank.d743.s2
DDI-DrugBank.d743.s2.e0_DDI-DrugBank.d743.s2.e1 true pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine , resulting in elevated plasma terfenadine levels .
DDI-DrugBank.d743.s2.e0_DDI-DrugBank.d743.s2.e2 false pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine , resulting in elevated plasma terfenadine levels .
DDI-DrugBank.d743.s2.e1_DDI-DrugBank.d743.s2.e2 false pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine , resulting in elevated plasma terfenadine levels .
DDI-DrugBank.d659.s2
DDI-DrugBank.d659.s2.e1_DDI-DrugBank.d659.s2.e2 false concomitant administration of trental and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals .
DDI-DrugBank.d659.s2.e1_DDI-DrugBank.d659.s2.e3 false concomitant administration of trental and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals .
DDI-DrugBank.d659.s2.e1_DDI-DrugBank.d659.s2.e0 false concomitant administration of trental and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals .
DDI-DrugBank.d659.s2.e2_DDI-DrugBank.d659.s2.e3 false concomitant administration of trental and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals .
DDI-DrugBank.d659.s2.e2_DDI-DrugBank.d659.s2.e0 false concomitant administration of trental and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals .
DDI-DrugBank.d659.s2.e3_DDI-DrugBank.d659.s2.e0 false concomitant administration of trental and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals .
DDI-DrugBank.d690.s4
DDI-DrugBank.d777.s5
DDI-DrugBank.d777.s5.e1_DDI-DrugBank.d777.s5.e0 false the addition of aspirin to streptokinase causes a minimal increase in the risk of minor bleeding ( 3.9 % vs. 3.1 % ) , but does not appear to increase the incidence of major bleeding ( see
DDI-DrugBank.d738.s2
DDI-DrugBank.d725.s0
DDI-DrugBank.d725.s0.e1_DDI-DrugBank.d725.s0.e2 true vasopressors , particularly metaraminol , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all .
DDI-DrugBank.d725.s0.e1_DDI-DrugBank.d725.s0.e0 false vasopressors , particularly metaraminol , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all .
DDI-DrugBank.d725.s0.e2_DDI-DrugBank.d725.s0.e0 false vasopressors , particularly metaraminol , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all .
DDI-DrugBank.d578.s5
DDI-DrugBank.d578.s5.e0_DDI-DrugBank.d578.s5.e1 false drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance .
DDI-DrugBank.d578.s5.e0_DDI-DrugBank.d578.s5.e2 true drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance .
DDI-DrugBank.d578.s5.e1_DDI-DrugBank.d578.s5.e2 true drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance .
DDI-DrugBank.d700.s15
DDI-DrugBank.d603.s4
DDI-DrugBank.d597.s22
DDI-DrugBank.d597.s22.e0_DDI-DrugBank.d597.s22.e1 true patients on lithium treatment should be closely monitored when mobic is introduced or withdrawn .
DDI-DrugBank.d639.s2
DDI-DrugBank.d639.s2.e1_DDI-DrugBank.d639.s2.e2 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e1_DDI-DrugBank.d639.s2.e3 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e1_DDI-DrugBank.d639.s2.e4 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e1_DDI-DrugBank.d639.s2.e5 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e1_DDI-DrugBank.d639.s2.e6 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e1_DDI-DrugBank.d639.s2.e7 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e1_DDI-DrugBank.d639.s2.e8 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e1_DDI-DrugBank.d639.s2.e0 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e2_DDI-DrugBank.d639.s2.e3 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e2_DDI-DrugBank.d639.s2.e4 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e2_DDI-DrugBank.d639.s2.e5 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e2_DDI-DrugBank.d639.s2.e6 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e2_DDI-DrugBank.d639.s2.e7 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e2_DDI-DrugBank.d639.s2.e8 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e2_DDI-DrugBank.d639.s2.e0 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e3_DDI-DrugBank.d639.s2.e4 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e3_DDI-DrugBank.d639.s2.e5 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e3_DDI-DrugBank.d639.s2.e6 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e3_DDI-DrugBank.d639.s2.e7 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e3_DDI-DrugBank.d639.s2.e8 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e3_DDI-DrugBank.d639.s2.e0 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e4_DDI-DrugBank.d639.s2.e5 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e4_DDI-DrugBank.d639.s2.e6 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e4_DDI-DrugBank.d639.s2.e7 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e4_DDI-DrugBank.d639.s2.e8 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e4_DDI-DrugBank.d639.s2.e0 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e5_DDI-DrugBank.d639.s2.e6 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e5_DDI-DrugBank.d639.s2.e7 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e5_DDI-DrugBank.d639.s2.e8 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e5_DDI-DrugBank.d639.s2.e0 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e6_DDI-DrugBank.d639.s2.e7 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e6_DDI-DrugBank.d639.s2.e8 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e6_DDI-DrugBank.d639.s2.e0 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e7_DDI-DrugBank.d639.s2.e8 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e7_DDI-DrugBank.d639.s2.e0 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d639.s2.e8_DDI-DrugBank.d639.s2.e0 false co-administration of sutent with inducers of the cyp3a4 family ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , st. johns wort ) may decrease sunitinib concentrations .
DDI-DrugBank.d779.s12
DDI-DrugBank.d775.s3
DDI-DrugBank.d775.s3.e1_DDI-DrugBank.d775.s3.e2 false the use of mivacron before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied .
DDI-DrugBank.d775.s3.e1_DDI-DrugBank.d775.s3.e0 false the use of mivacron before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied .
DDI-DrugBank.d775.s3.e2_DDI-DrugBank.d775.s3.e0 false the use of mivacron before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied .
DDI-DrugBank.d634.s1
DDI-DrugBank.d776.s18
DDI-DrugBank.d776.s18.e0_DDI-DrugBank.d776.s18.e2 false theophylline : diflucan increases the serum concentrations of theophylline .
DDI-DrugBank.d776.s18.e0_DDI-DrugBank.d776.s18.e1 false theophylline : diflucan increases the serum concentrations of theophylline .
DDI-DrugBank.d776.s18.e2_DDI-DrugBank.d776.s18.e1 false theophylline : diflucan increases the serum concentrations of theophylline .
DDI-DrugBank.d781.s10
DDI-DrugBank.d781.s10.e1_DDI-DrugBank.d781.s10.e0 false use of a diuretic may further increase the risk of lithium toxicity .
DDI-DrugBank.d776.s37
DDI-DrugBank.d776.s37.e1_DDI-DrugBank.d776.s37.e0 false if short-acting benzodiazepines , which are metabolized by the cytochrome p450 system , are concomitantly administered with fluconazole , consideration should be given to decreasing the benzodiazepine dosage , and the patients should be appropriately monitored .
DDI-DrugBank.d776.s37.e1_DDI-DrugBank.d776.s37.e2 false if short-acting benzodiazepines , which are metabolized by the cytochrome p450 system , are concomitantly administered with fluconazole , consideration should be given to decreasing the benzodiazepine dosage , and the patients should be appropriately monitored .
DDI-DrugBank.d776.s37.e0_DDI-DrugBank.d776.s37.e2 false if short-acting benzodiazepines , which are metabolized by the cytochrome p450 system , are concomitantly administered with fluconazole , consideration should be given to decreasing the benzodiazepine dosage , and the patients should be appropriately monitored .
DDI-DrugBank.d753.s3
DDI-DrugBank.d753.s3.e0_DDI-DrugBank.d753.s3.e1 true it has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia .
DDI-DrugBank.d611.s0
DDI-DrugBank.d611.s0.e2_DDI-DrugBank.d611.s0.e1 false other beta adrenergic aerosol bronchodilators should not be used concomitantly with alupent ( metaproterenol sulfate usp ) because they may have additive effects .
DDI-DrugBank.d611.s0.e2_DDI-DrugBank.d611.s0.e0 false other beta adrenergic aerosol bronchodilators should not be used concomitantly with alupent ( metaproterenol sulfate usp ) because they may have additive effects .
DDI-DrugBank.d611.s0.e1_DDI-DrugBank.d611.s0.e0 false other beta adrenergic aerosol bronchodilators should not be used concomitantly with alupent ( metaproterenol sulfate usp ) because they may have additive effects .
DDI-DrugBank.d623.s8
DDI-DrugBank.d720.s3
DDI-DrugBank.d720.s3.e0_DDI-DrugBank.d720.s3.e1 true therefore , the use of sumatriptan succinate tablets in patients receiving mao-a inhibitors is contraindicated .
DDI-DrugBank.d720.s3.e4_DDI-DrugBank.d720.s3.e5 false selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3.e4_DDI-DrugBank.d720.s3.e6 false selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3.e4_DDI-DrugBank.d720.s3.e7 false selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3.e4_DDI-DrugBank.d720.s3.e8 false selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3.e4_DDI-DrugBank.d720.s3.e2 false selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3.e4_DDI-DrugBank.d720.s3.e3 false selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3.e5_DDI-DrugBank.d720.s3.e6 false selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3.e5_DDI-DrugBank.d720.s3.e7 false selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3.e5_DDI-DrugBank.d720.s3.e8 false selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3.e5_DDI-DrugBank.d720.s3.e2 false selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3.e5_DDI-DrugBank.d720.s3.e3 false selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3.e6_DDI-DrugBank.d720.s3.e7 false selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3.e6_DDI-DrugBank.d720.s3.e8 false selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3.e6_DDI-DrugBank.d720.s3.e2 false selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3.e6_DDI-DrugBank.d720.s3.e3 false selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3.e7_DDI-DrugBank.d720.s3.e8 false selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3.e7_DDI-DrugBank.d720.s3.e2 false selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3.e7_DDI-DrugBank.d720.s3.e3 false selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3.e8_DDI-DrugBank.d720.s3.e2 false selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3.e8_DDI-DrugBank.d720.s3.e3 false selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d720.s3.e2_DDI-DrugBank.d720.s3.e3 false selective serotonin reuptake inhibitors ( ssris ) ( e.g. , fluoxetine , fluvoxamine , paroxetine , sertraline ) have been reported , rarely , to cause weakness , hyperreflexia , and incoordination when coadministered with sumatriptan .
DDI-DrugBank.d776.s42
DDI-DrugBank.d628.s6
DDI-DrugBank.d628.s6.e2_DDI-DrugBank.d628.s6.e0 false diprivan injectable emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used neuromuscular blocking agents ( eg , succinylcholine and nondepolarizing muscle relaxants ) .
DDI-DrugBank.d628.s6.e2_DDI-DrugBank.d628.s6.e1 false diprivan injectable emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used neuromuscular blocking agents ( eg , succinylcholine and nondepolarizing muscle relaxants ) .
DDI-DrugBank.d628.s6.e2_DDI-DrugBank.d628.s6.e3 false diprivan injectable emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used neuromuscular blocking agents ( eg , succinylcholine and nondepolarizing muscle relaxants ) .
DDI-DrugBank.d628.s6.e0_DDI-DrugBank.d628.s6.e1 false diprivan injectable emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used neuromuscular blocking agents ( eg , succinylcholine and nondepolarizing muscle relaxants ) .
DDI-DrugBank.d628.s6.e0_DDI-DrugBank.d628.s6.e3 false diprivan injectable emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used neuromuscular blocking agents ( eg , succinylcholine and nondepolarizing muscle relaxants ) .
DDI-DrugBank.d628.s6.e1_DDI-DrugBank.d628.s6.e3 false diprivan injectable emulsion does not cause a clinically significant change in onset , intensity , or duration of action of the commonly used neuromuscular blocking agents ( eg , succinylcholine and nondepolarizing muscle relaxants ) .
DDI-DrugBank.d670.s1
DDI-DrugBank.d737.s5
DDI-DrugBank.d737.s5.e0_DDI-DrugBank.d737.s5.e1 false probenecid : probenecid , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter , did not noticeably influence pramipexole pharmacokinetics ( n= 12 ) .
DDI-DrugBank.d737.s5.e0_DDI-DrugBank.d737.s5.e2 false probenecid : probenecid , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter , did not noticeably influence pramipexole pharmacokinetics ( n= 12 ) .
DDI-DrugBank.d737.s5.e1_DDI-DrugBank.d737.s5.e2 false probenecid : probenecid , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter , did not noticeably influence pramipexole pharmacokinetics ( n= 12 ) .
DDI-DrugBank.d762.s0
DDI-DrugBank.d762.s0.e0_DDI-DrugBank.d762.s0.e1 true probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem .
DDI-DrugBank.d762.s0.e0_DDI-DrugBank.d762.s0.e2 false probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem .
DDI-DrugBank.d762.s0.e1_DDI-DrugBank.d762.s0.e2 false probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem .
DDI-DrugBank.d735.s2
DDI-DrugBank.d735.s2.e1_DDI-DrugBank.d735.s2.e2 false there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2.e1_DDI-DrugBank.d735.s2.e3 false there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2.e1_DDI-DrugBank.d735.s2.e4 false there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2.e1_DDI-DrugBank.d735.s2.e5 false there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2.e1_DDI-DrugBank.d735.s2.e0 false there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2.e2_DDI-DrugBank.d735.s2.e3 false there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2.e2_DDI-DrugBank.d735.s2.e4 false there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2.e2_DDI-DrugBank.d735.s2.e5 false there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2.e2_DDI-DrugBank.d735.s2.e0 false there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2.e3_DDI-DrugBank.d735.s2.e4 false there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2.e3_DDI-DrugBank.d735.s2.e5 false there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2.e3_DDI-DrugBank.d735.s2.e0 false there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2.e4_DDI-DrugBank.d735.s2.e5 false there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2.e4_DDI-DrugBank.d735.s2.e0 false there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics .
DDI-DrugBank.d735.s2.e5_DDI-DrugBank.d735.s2.e0 false there was no effect of a single dose or multiple doses of mycamine on mycophenolate mofetil , cyclosporine , tacrolimus , prednisolone , and fluconazole pharmacokinetics .
DDI-DrugBank.d628.s0
DDI-DrugBank.d628.s0.e2_DDI-DrugBank.d628.s0.e3 false the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics ( eg , morphine , meperidine , and fentanyl , etc . )
DDI-DrugBank.d628.s0.e2_DDI-DrugBank.d628.s0.e4 false the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics ( eg , morphine , meperidine , and fentanyl , etc . )
DDI-DrugBank.d628.s0.e2_DDI-DrugBank.d628.s0.e0 false the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics ( eg , morphine , meperidine , and fentanyl , etc . )
DDI-DrugBank.d628.s0.e2_DDI-DrugBank.d628.s0.e1 false the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics ( eg , morphine , meperidine , and fentanyl , etc . )
DDI-DrugBank.d628.s0.e3_DDI-DrugBank.d628.s0.e4 false the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics ( eg , morphine , meperidine , and fentanyl , etc . )
DDI-DrugBank.d628.s0.e3_DDI-DrugBank.d628.s0.e0 false the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics ( eg , morphine , meperidine , and fentanyl , etc . )
DDI-DrugBank.d628.s0.e3_DDI-DrugBank.d628.s0.e1 false the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics ( eg , morphine , meperidine , and fentanyl , etc . )
DDI-DrugBank.d628.s0.e4_DDI-DrugBank.d628.s0.e0 false the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics ( eg , morphine , meperidine , and fentanyl , etc . )
DDI-DrugBank.d628.s0.e4_DDI-DrugBank.d628.s0.e1 false the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics ( eg , morphine , meperidine , and fentanyl , etc . )
DDI-DrugBank.d628.s0.e0_DDI-DrugBank.d628.s0.e1 true the induction dose requirements of diprivan injectable emulsion may be reduced in patients with intramuscular or intravenous premedication , particularly with narcotics ( eg , morphine , meperidine , and fentanyl , etc . )
DDI-DrugBank.d597.s27
DDI-DrugBank.d597.s27.e0_DDI-DrugBank.d597.s27.e1 false the effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an inr ( international normalized ratio ) between 1.2 and 1.8 .
DDI-DrugBank.d597.s27.e0_DDI-DrugBank.d597.s27.e2 false the effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an inr ( international normalized ratio ) between 1.2 and 1.8 .
DDI-DrugBank.d597.s27.e1_DDI-DrugBank.d597.s27.e2 false the effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an inr ( international normalized ratio ) between 1.2 and 1.8 .
DDI-DrugBank.d638.s5
DDI-DrugBank.d638.s5.e0_DDI-DrugBank.d638.s5.e1 false the safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated .
DDI-DrugBank.d638.s5.e0_DDI-DrugBank.d638.s5.e2 false the safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated .
DDI-DrugBank.d638.s5.e1_DDI-DrugBank.d638.s5.e2 false the safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated .
DDI-DrugBank.d700.s9
DDI-DrugBank.d700.s9.e1_DDI-DrugBank.d700.s9.e0 false oral contraceptives : given the different metabolism of myfortic and oral contraceptives , no drug interaction between these two classes of drug is expected .
DDI-DrugBank.d700.s9.e1_DDI-DrugBank.d700.s9.e2 false oral contraceptives : given the different metabolism of myfortic and oral contraceptives , no drug interaction between these two classes of drug is expected .
DDI-DrugBank.d700.s9.e0_DDI-DrugBank.d700.s9.e2 false oral contraceptives : given the different metabolism of myfortic and oral contraceptives , no drug interaction between these two classes of drug is expected .
DDI-DrugBank.d776.s8
DDI-DrugBank.d776.s8.e0_DDI-DrugBank.d776.s8.e1 true careful monitoring of prothrombin time in patients receiving diflucan and coumarin-type anticoagulants is recommended .
DDI-DrugBank.d680.s9
DDI-DrugBank.d680.s9.e0_DDI-DrugBank.d680.s9.e1 false laboratory tests there have been reports of false-positive urine screening tests for tetrahydrocannabinol ( thc ) in patients receiving most proton pump inhibitors , including pantoprazole .
DDI-DrugBank.d680.s9.e0_DDI-DrugBank.d680.s9.e3 false laboratory tests there have been reports of false-positive urine screening tests for tetrahydrocannabinol ( thc ) in patients receiving most proton pump inhibitors , including pantoprazole .
DDI-DrugBank.d680.s9.e0_DDI-DrugBank.d680.s9.e2 false laboratory tests there have been reports of false-positive urine screening tests for tetrahydrocannabinol ( thc ) in patients receiving most proton pump inhibitors , including pantoprazole .
DDI-DrugBank.d680.s9.e1_DDI-DrugBank.d680.s9.e3 false laboratory tests there have been reports of false-positive urine screening tests for tetrahydrocannabinol ( thc ) in patients receiving most proton pump inhibitors , including pantoprazole .
DDI-DrugBank.d680.s9.e1_DDI-DrugBank.d680.s9.e2 false laboratory tests there have been reports of false-positive urine screening tests for tetrahydrocannabinol ( thc ) in patients receiving most proton pump inhibitors , including pantoprazole .
DDI-DrugBank.d680.s9.e3_DDI-DrugBank.d680.s9.e2 false laboratory tests there have been reports of false-positive urine screening tests for tetrahydrocannabinol ( thc ) in patients receiving most proton pump inhibitors , including pantoprazole .
DDI-DrugBank.d773.s4
DDI-DrugBank.d572.s4
DDI-DrugBank.d596.s5
DDI-DrugBank.d596.s5.e1_DDI-DrugBank.d596.s5.e0 false effect of other drugs on the metabolism of exelon : drugs that induce or inhibit cyp450 metabolism are not expected to alter the metabolism of rivastigmine .
DDI-DrugBank.d775.s0
DDI-DrugBank.d775.s0.e2_DDI-DrugBank.d775.s0.e0 false although mivacron ( a mixture of three stereoisomers ) has been administered safely following succinylcholine-facilitated tracheal intubation , the interaction between mivacron and succinylcholine has not been systematically studied .
DDI-DrugBank.d775.s0.e2_DDI-DrugBank.d775.s0.e1 false although mivacron ( a mixture of three stereoisomers ) has been administered safely following succinylcholine-facilitated tracheal intubation , the interaction between mivacron and succinylcholine has not been systematically studied .
DDI-DrugBank.d775.s0.e0_DDI-DrugBank.d775.s0.e1 false although mivacron ( a mixture of three stereoisomers ) has been administered safely following succinylcholine-facilitated tracheal intubation , the interaction between mivacron and succinylcholine has not been systematically studied .
DDI-DrugBank.d776.s12
DDI-DrugBank.d687.s0
DDI-DrugBank.d687.s0.e0_DDI-DrugBank.d687.s0.e1 true administration of valproic acid decreases oral clearance of temozolomide by about 5 % .
DDI-DrugBank.d640.s7
DDI-DrugBank.d656.s2
DDI-DrugBank.d656.s2.e0_DDI-DrugBank.d656.s2.e4 false plasma levels of piroxicam are depressed to approximately 80 % of their normal values when feldene is administered in conjunction with aspirin ( 3900 mg/day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels .
DDI-DrugBank.d656.s2.e0_DDI-DrugBank.d656.s2.e1 false plasma levels of piroxicam are depressed to approximately 80 % of their normal values when feldene is administered in conjunction with aspirin ( 3900 mg/day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels .
DDI-DrugBank.d656.s2.e0_DDI-DrugBank.d656.s2.e2 false plasma levels of piroxicam are depressed to approximately 80 % of their normal values when feldene is administered in conjunction with aspirin ( 3900 mg/day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels .
DDI-DrugBank.d656.s2.e0_DDI-DrugBank.d656.s2.e3 false plasma levels of piroxicam are depressed to approximately 80 % of their normal values when feldene is administered in conjunction with aspirin ( 3900 mg/day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels .
DDI-DrugBank.d656.s2.e4_DDI-DrugBank.d656.s2.e1 false plasma levels of piroxicam are depressed to approximately 80 % of their normal values when feldene is administered in conjunction with aspirin ( 3900 mg/day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels .
DDI-DrugBank.d656.s2.e4_DDI-DrugBank.d656.s2.e2 false plasma levels of piroxicam are depressed to approximately 80 % of their normal values when feldene is administered in conjunction with aspirin ( 3900 mg/day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels .
DDI-DrugBank.d656.s2.e4_DDI-DrugBank.d656.s2.e3 false plasma levels of piroxicam are depressed to approximately 80 % of their normal values when feldene is administered in conjunction with aspirin ( 3900 mg/day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels .
DDI-DrugBank.d656.s2.e1_DDI-DrugBank.d656.s2.e2 true plasma levels of piroxicam are depressed to approximately 80 % of their normal values when feldene is administered in conjunction with aspirin ( 3900 mg/day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels .
DDI-DrugBank.d656.s2.e1_DDI-DrugBank.d656.s2.e3 false plasma levels of piroxicam are depressed to approximately 80 % of their normal values when feldene is administered in conjunction with aspirin ( 3900 mg/day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels .
DDI-DrugBank.d656.s2.e2_DDI-DrugBank.d656.s2.e3 false plasma levels of piroxicam are depressed to approximately 80 % of their normal values when feldene is administered in conjunction with aspirin ( 3900 mg/day ) , but concomitant administration of antacids has no effect on piroxicam plasma levels .
DDI-DrugBank.d656.s2.e7_DDI-DrugBank.d656.s2.e6 false nonsteroidal anti-inflammatory agents , including feldene , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2.e7_DDI-DrugBank.d656.s2.e5 false nonsteroidal anti-inflammatory agents , including feldene , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d656.s2.e6_DDI-DrugBank.d656.s2.e5 false nonsteroidal anti-inflammatory agents , including feldene , have been reported to increase steady state plasma lithium levels .
DDI-DrugBank.d599.s2
DDI-DrugBank.d721.s0
DDI-DrugBank.d721.s0.e1_DDI-DrugBank.d721.s0.e2 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e1_DDI-DrugBank.d721.s0.e4 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e1_DDI-DrugBank.d721.s0.e5 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e1_DDI-DrugBank.d721.s0.e6 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e1_DDI-DrugBank.d721.s0.e0 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e1_DDI-DrugBank.d721.s0.e3 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e1_DDI-DrugBank.d721.s0.e7 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e2_DDI-DrugBank.d721.s0.e4 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e2_DDI-DrugBank.d721.s0.e5 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e2_DDI-DrugBank.d721.s0.e6 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e2_DDI-DrugBank.d721.s0.e0 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e2_DDI-DrugBank.d721.s0.e3 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e2_DDI-DrugBank.d721.s0.e7 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e4_DDI-DrugBank.d721.s0.e5 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e4_DDI-DrugBank.d721.s0.e6 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e4_DDI-DrugBank.d721.s0.e0 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e4_DDI-DrugBank.d721.s0.e3 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e4_DDI-DrugBank.d721.s0.e7 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e5_DDI-DrugBank.d721.s0.e6 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e5_DDI-DrugBank.d721.s0.e0 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e5_DDI-DrugBank.d721.s0.e3 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e5_DDI-DrugBank.d721.s0.e7 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e6_DDI-DrugBank.d721.s0.e0 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e6_DDI-DrugBank.d721.s0.e3 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e6_DDI-DrugBank.d721.s0.e7 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e0_DDI-DrugBank.d721.s0.e3 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e0_DDI-DrugBank.d721.s0.e7 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d721.s0.e3_DDI-DrugBank.d721.s0.e7 false the bioavailability of skelid is decreased 80 % by calcium , when calcium and skelid are administered at the same time , and 60 % by some aluminum- or magnesium-containing antacids , when administered 1 hour before skelid .
DDI-DrugBank.d665.s7
DDI-DrugBank.d665.s7.e0_DDI-DrugBank.d665.s7.e1 false displacement of penicillin from plasma protein binding sites will elevate the level of free penicillin in the serum .
DDI-DrugBank.d780.s8
DDI-DrugBank.d780.s8.e0_DDI-DrugBank.d780.s8.e1 false acetazolamide : concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine .
DDI-DrugBank.d780.s8.e0_DDI-DrugBank.d780.s8.e2 false acetazolamide : concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine .
DDI-DrugBank.d780.s8.e0_DDI-DrugBank.d780.s8.e3 false acetazolamide : concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine .
DDI-DrugBank.d780.s8.e1_DDI-DrugBank.d780.s8.e2 true acetazolamide : concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine .
DDI-DrugBank.d780.s8.e1_DDI-DrugBank.d780.s8.e3 false acetazolamide : concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine .
DDI-DrugBank.d780.s8.e2_DDI-DrugBank.d780.s8.e3 false acetazolamide : concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine .
DDI-DrugBank.d619.s4
DDI-DrugBank.d619.s4.e1_DDI-DrugBank.d619.s4.e3 false severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and eldepryl and selective serotonin reuptake inhibitors and eldepryl .
DDI-DrugBank.d619.s4.e1_DDI-DrugBank.d619.s4.e0 false severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and eldepryl and selective serotonin reuptake inhibitors and eldepryl .
DDI-DrugBank.d619.s4.e1_DDI-DrugBank.d619.s4.e2 false severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and eldepryl and selective serotonin reuptake inhibitors and eldepryl .
DDI-DrugBank.d619.s4.e3_DDI-DrugBank.d619.s4.e0 false severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and eldepryl and selective serotonin reuptake inhibitors and eldepryl .
DDI-DrugBank.d619.s4.e3_DDI-DrugBank.d619.s4.e2 false severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and eldepryl and selective serotonin reuptake inhibitors and eldepryl .
DDI-DrugBank.d619.s4.e0_DDI-DrugBank.d619.s4.e2 false severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and eldepryl and selective serotonin reuptake inhibitors and eldepryl .
DDI-DrugBank.d773.s1
DDI-DrugBank.d773.s1.e1_DDI-DrugBank.d773.s1.e0 false patients studied in clinical trials of tnkase were routinely treated with heparin and aspirin .
DDI-DrugBank.d773.s1.e1_DDI-DrugBank.d773.s1.e2 false patients studied in clinical trials of tnkase were routinely treated with heparin and aspirin .
DDI-DrugBank.d773.s1.e0_DDI-DrugBank.d773.s1.e2 false patients studied in clinical trials of tnkase were routinely treated with heparin and aspirin .
DDI-DrugBank.d677.s0
DDI-DrugBank.d677.s0.e5_DDI-DrugBank.d677.s0.e0 false phenothiazines are capable of potentiating cns depressants ( e.g. , barbiturates , anesthetics , opiates , alcohol , etc . )
DDI-DrugBank.d677.s0.e5_DDI-DrugBank.d677.s0.e1 false phenothiazines are capable of potentiating cns depressants ( e.g. , barbiturates , anesthetics , opiates , alcohol , etc . )
DDI-DrugBank.d677.s0.e5_DDI-DrugBank.d677.s0.e2 false phenothiazines are capable of potentiating cns depressants ( e.g. , barbiturates , anesthetics , opiates , alcohol , etc . )
DDI-DrugBank.d677.s0.e5_DDI-DrugBank.d677.s0.e3 false phenothiazines are capable of potentiating cns depressants ( e.g. , barbiturates , anesthetics , opiates , alcohol , etc . )
DDI-DrugBank.d677.s0.e5_DDI-DrugBank.d677.s0.e4 false phenothiazines are capable of potentiating cns depressants ( e.g. , barbiturates , anesthetics , opiates , alcohol , etc . )
DDI-DrugBank.d677.s0.e0_DDI-DrugBank.d677.s0.e1 true phenothiazines are capable of potentiating cns depressants ( e.g. , barbiturates , anesthetics , opiates , alcohol , etc . )
DDI-DrugBank.d677.s0.e0_DDI-DrugBank.d677.s0.e2 true phenothiazines are capable of potentiating cns depressants ( e.g. , barbiturates , anesthetics , opiates , alcohol , etc . )
DDI-DrugBank.d677.s0.e0_DDI-DrugBank.d677.s0.e3 true phenothiazines are capable of potentiating cns depressants ( e.g. , barbiturates , anesthetics , opiates , alcohol , etc . )
DDI-DrugBank.d677.s0.e0_DDI-DrugBank.d677.s0.e4 true phenothiazines are capable of potentiating cns depressants ( e.g. , barbiturates , anesthetics , opiates , alcohol , etc . )
DDI-DrugBank.d677.s0.e1_DDI-DrugBank.d677.s0.e2 false phenothiazines are capable of potentiating cns depressants ( e.g. , barbiturates , anesthetics , opiates , alcohol , etc . )
DDI-DrugBank.d677.s0.e1_DDI-DrugBank.d677.s0.e3 false phenothiazines are capable of potentiating cns depressants ( e.g. , barbiturates , anesthetics , opiates , alcohol , etc . )
DDI-DrugBank.d677.s0.e1_DDI-DrugBank.d677.s0.e4 false phenothiazines are capable of potentiating cns depressants ( e.g. , barbiturates , anesthetics , opiates , alcohol , etc . )
DDI-DrugBank.d677.s0.e2_DDI-DrugBank.d677.s0.e3 false phenothiazines are capable of potentiating cns depressants ( e.g. , barbiturates , anesthetics , opiates , alcohol , etc . )
DDI-DrugBank.d677.s0.e2_DDI-DrugBank.d677.s0.e4 false phenothiazines are capable of potentiating cns depressants ( e.g. , barbiturates , anesthetics , opiates , alcohol , etc . )
DDI-DrugBank.d677.s0.e3_DDI-DrugBank.d677.s0.e4 false phenothiazines are capable of potentiating cns depressants ( e.g. , barbiturates , anesthetics , opiates , alcohol , etc . )
DDI-DrugBank.d770.s1
DDI-DrugBank.d661.s1
DDI-DrugBank.d661.s1.e1_DDI-DrugBank.d661.s1.e2 false if zemuron is administered following administration of succinylcholine , it should not be given until recovery from succinylcholine has been observed .
DDI-DrugBank.d661.s1.e1_DDI-DrugBank.d661.s1.e0 false if zemuron is administered following administration of succinylcholine , it should not be given until recovery from succinylcholine has been observed .
DDI-DrugBank.d661.s1.e2_DDI-DrugBank.d661.s1.e0 false if zemuron is administered following administration of succinylcholine , it should not be given until recovery from succinylcholine has been observed .
DDI-DrugBank.d624.s0
DDI-DrugBank.d624.s0.e2_DDI-DrugBank.d624.s0.e0 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e2_DDI-DrugBank.d624.s0.e1 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e2_DDI-DrugBank.d624.s0.e3 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e2_DDI-DrugBank.d624.s0.e4 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e2_DDI-DrugBank.d624.s0.e5 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e2_DDI-DrugBank.d624.s0.e6 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e2_DDI-DrugBank.d624.s0.e7 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e0_DDI-DrugBank.d624.s0.e1 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e0_DDI-DrugBank.d624.s0.e3 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e0_DDI-DrugBank.d624.s0.e4 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e0_DDI-DrugBank.d624.s0.e5 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e0_DDI-DrugBank.d624.s0.e6 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e0_DDI-DrugBank.d624.s0.e7 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e1_DDI-DrugBank.d624.s0.e3 true in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e1_DDI-DrugBank.d624.s0.e4 true in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e1_DDI-DrugBank.d624.s0.e5 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e1_DDI-DrugBank.d624.s0.e6 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e1_DDI-DrugBank.d624.s0.e7 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e3_DDI-DrugBank.d624.s0.e4 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e3_DDI-DrugBank.d624.s0.e5 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e3_DDI-DrugBank.d624.s0.e6 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e3_DDI-DrugBank.d624.s0.e7 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e4_DDI-DrugBank.d624.s0.e5 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e4_DDI-DrugBank.d624.s0.e6 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e4_DDI-DrugBank.d624.s0.e7 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e5_DDI-DrugBank.d624.s0.e6 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e5_DDI-DrugBank.d624.s0.e7 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d624.s0.e6_DDI-DrugBank.d624.s0.e7 false in clinical studies of tobi , patients taking tobi concomitantly with dornase alfa ( pulmozyme , genentech ) , (beta)-agonists , inhaled corticosteroids , other anti-pseudomonal antibiotics , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole .
DDI-DrugBank.d700.s16
DDI-DrugBank.d700.s16.e0_DDI-DrugBank.d700.s16.e1 false interference of mpag hydrolysis may lead to less mpa available for absorption .
DDI-DrugBank.d577.s7
DDI-DrugBank.d637.s0
DDI-DrugBank.d637.s0.e1_DDI-DrugBank.d637.s0.e3 true use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0.e1_DDI-DrugBank.d637.s0.e0 false use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0.e1_DDI-DrugBank.d637.s0.e2 true use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0.e1_DDI-DrugBank.d637.s0.e4 true use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0.e1_DDI-DrugBank.d637.s0.e5 true use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0.e1_DDI-DrugBank.d637.s0.e6 false use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0.e3_DDI-DrugBank.d637.s0.e0 false use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0.e3_DDI-DrugBank.d637.s0.e2 false use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0.e3_DDI-DrugBank.d637.s0.e4 false use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0.e3_DDI-DrugBank.d637.s0.e5 false use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0.e3_DDI-DrugBank.d637.s0.e6 false use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0.e0_DDI-DrugBank.d637.s0.e2 false use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0.e0_DDI-DrugBank.d637.s0.e4 false use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0.e0_DDI-DrugBank.d637.s0.e5 false use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0.e0_DDI-DrugBank.d637.s0.e6 false use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0.e2_DDI-DrugBank.d637.s0.e4 false use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0.e2_DDI-DrugBank.d637.s0.e5 false use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0.e2_DDI-DrugBank.d637.s0.e6 false use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0.e4_DDI-DrugBank.d637.s0.e5 false use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0.e4_DDI-DrugBank.d637.s0.e6 false use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d637.s0.e5_DDI-DrugBank.d637.s0.e6 false use with other central nervous system depressants : the depressant effects of morphine are potentiated by the presence of other cns depressants such as alcohol , sedatives , antihistaminics , or psychotropic drugs .
DDI-DrugBank.d742.s5
DDI-DrugBank.d742.s5.e0_DDI-DrugBank.d742.s5.e1 false while in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes , an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome p450 enzymes , the concomitant use of remeron soltab with most other drugs metabolized by these enzymes has not been formally studied .
DDI-DrugBank.d742.s5.e0_DDI-DrugBank.d742.s5.e2 false while in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes , an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome p450 enzymes , the concomitant use of remeron soltab with most other drugs metabolized by these enzymes has not been formally studied .
DDI-DrugBank.d742.s5.e1_DDI-DrugBank.d742.s5.e2 false while in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes , an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome p450 enzymes , the concomitant use of remeron soltab with most other drugs metabolized by these enzymes has not been formally studied .
DDI-DrugBank.d578.s3
DDI-DrugBank.d578.s3.e0_DDI-DrugBank.d578.s3.e1 true convulsions have been reported with concurrent use of methylprednisolone and cyclosporin .
DDI-DrugBank.d671.s1
DDI-DrugBank.d650.s1
DDI-DrugBank.d652.s6
DDI-DrugBank.d652.s6.e0_DDI-DrugBank.d652.s6.e1 true because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption , insulin dosage or timing of dosage may require adjustment .
DDI-DrugBank.d632.s7
DDI-DrugBank.d632.s7.e1_DDI-DrugBank.d632.s7.e0 false thus , symlin and insulin should not be mixed and must be administered separately .
DDI-DrugBank.d633.s13
DDI-DrugBank.d633.s13.e0_DDI-DrugBank.d633.s13.e1 true concurrent administration of cimetidine and mexitil has been reported to increase , decrease , or leave unchanged mexitil plasma levels ;
DDI-DrugBank.d633.s13.e0_DDI-DrugBank.d633.s13.e2 false concurrent administration of cimetidine and mexitil has been reported to increase , decrease , or leave unchanged mexitil plasma levels ;
DDI-DrugBank.d633.s13.e1_DDI-DrugBank.d633.s13.e2 false concurrent administration of cimetidine and mexitil has been reported to increase , decrease , or leave unchanged mexitil plasma levels ;
DDI-DrugBank.d742.s6
DDI-DrugBank.d596.s3
DDI-DrugBank.d596.s3.e0_DDI-DrugBank.d596.s3.e1 false no pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers .
DDI-DrugBank.d596.s3.e0_DDI-DrugBank.d596.s3.e2 false no pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers .
DDI-DrugBank.d596.s3.e0_DDI-DrugBank.d596.s3.e3 false no pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers .
DDI-DrugBank.d596.s3.e0_DDI-DrugBank.d596.s3.e4 false no pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers .
DDI-DrugBank.d596.s3.e1_DDI-DrugBank.d596.s3.e2 false no pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers .
DDI-DrugBank.d596.s3.e1_DDI-DrugBank.d596.s3.e3 false no pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers .
DDI-DrugBank.d596.s3.e1_DDI-DrugBank.d596.s3.e4 false no pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers .
DDI-DrugBank.d596.s3.e2_DDI-DrugBank.d596.s3.e3 false no pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers .
DDI-DrugBank.d596.s3.e2_DDI-DrugBank.d596.s3.e4 false no pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers .
DDI-DrugBank.d596.s3.e3_DDI-DrugBank.d596.s3.e4 false no pharmacokinetic interaction was observed between rivastigmine and digoxin , warfarin , diazepam , or fluoxetine in studies in healthy volunteers .
DDI-DrugBank.d716.s3
DDI-DrugBank.d737.s7
DDI-DrugBank.d737.s7.e0_DDI-DrugBank.d737.s7.e1 false cyp interactions : inhibitors of cytochrome p450 enzymes would not be expected to affect pramipexole elimination because pramipexole is not appreciably metabolized by these enzymes in vivo or in vitro .
DDI-DrugBank.d779.s7
DDI-DrugBank.d779.s7.e0_DDI-DrugBank.d779.s7.e1 true several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate .
DDI-DrugBank.d779.s7.e0_DDI-DrugBank.d779.s7.e2 true several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate .
DDI-DrugBank.d779.s7.e1_DDI-DrugBank.d779.s7.e2 false several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate .
DDI-DrugBank.d702.s2
DDI-DrugBank.d702.s2.e2_DDI-DrugBank.d702.s2.e0 false however , the co administration of spiriva with other anticholinergic containing drugs ( e.g. , ipratropium ) has not been studied and is therefore not recommended .
DDI-DrugBank.d702.s2.e2_DDI-DrugBank.d702.s2.e1 false however , the co administration of spiriva with other anticholinergic containing drugs ( e.g. , ipratropium ) has not been studied and is therefore not recommended .
DDI-DrugBank.d702.s2.e0_DDI-DrugBank.d702.s2.e1 true however , the co administration of spiriva with other anticholinergic containing drugs ( e.g. , ipratropium ) has not been studied and is therefore not recommended .
DDI-DrugBank.d648.s4
DDI-DrugBank.d710.s5
DDI-DrugBank.d710.s5.e0_DDI-DrugBank.d710.s5.e1 true coadministration with acetaminophen reduced the peak concentration and auc values for rimantadine by approximately 11 % .
DDI-DrugBank.d780.s1
DDI-DrugBank.d675.s0
DDI-DrugBank.d675.s0.e3_DDI-DrugBank.d675.s0.e4 false cyp 3a4 inhibitors ( e.g. macrolide antibiotics and protease inhibitors ) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs ( e.g. dihydroergotamine and ergotamine ) and potent cyp 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
DDI-DrugBank.d675.s0.e3_DDI-DrugBank.d675.s0.e0 false cyp 3a4 inhibitors ( e.g. macrolide antibiotics and protease inhibitors ) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs ( e.g. dihydroergotamine and ergotamine ) and potent cyp 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
DDI-DrugBank.d675.s0.e3_DDI-DrugBank.d675.s0.e1 false cyp 3a4 inhibitors ( e.g. macrolide antibiotics and protease inhibitors ) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs ( e.g. dihydroergotamine and ergotamine ) and potent cyp 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
DDI-DrugBank.d675.s0.e3_DDI-DrugBank.d675.s0.e2 false cyp 3a4 inhibitors ( e.g. macrolide antibiotics and protease inhibitors ) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs ( e.g. dihydroergotamine and ergotamine ) and potent cyp 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
DDI-DrugBank.d675.s0.e4_DDI-DrugBank.d675.s0.e0 false cyp 3a4 inhibitors ( e.g. macrolide antibiotics and protease inhibitors ) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs ( e.g. dihydroergotamine and ergotamine ) and potent cyp 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
DDI-DrugBank.d675.s0.e4_DDI-DrugBank.d675.s0.e1 false cyp 3a4 inhibitors ( e.g. macrolide antibiotics and protease inhibitors ) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs ( e.g. dihydroergotamine and ergotamine ) and potent cyp 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
DDI-DrugBank.d675.s0.e4_DDI-DrugBank.d675.s0.e2 false cyp 3a4 inhibitors ( e.g. macrolide antibiotics and protease inhibitors ) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs ( e.g. dihydroergotamine and ergotamine ) and potent cyp 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
DDI-DrugBank.d675.s0.e0_DDI-DrugBank.d675.s0.e1 false cyp 3a4 inhibitors ( e.g. macrolide antibiotics and protease inhibitors ) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs ( e.g. dihydroergotamine and ergotamine ) and potent cyp 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
DDI-DrugBank.d675.s0.e0_DDI-DrugBank.d675.s0.e2 false cyp 3a4 inhibitors ( e.g. macrolide antibiotics and protease inhibitors ) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs ( e.g. dihydroergotamine and ergotamine ) and potent cyp 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
DDI-DrugBank.d675.s0.e1_DDI-DrugBank.d675.s0.e2 false cyp 3a4 inhibitors ( e.g. macrolide antibiotics and protease inhibitors ) there have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs ( e.g. dihydroergotamine and ergotamine ) and potent cyp 3a4 inhibitors , resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities .
DDI-DrugBank.d572.s15
DDI-DrugBank.d744.s2
DDI-DrugBank.d737.s9
DDI-DrugBank.d585.s4
DDI-DrugBank.d710.s0
DDI-DrugBank.d710.s0.e1_DDI-DrugBank.d710.s0.e2 false : the effects of chronic cimetidine use on the metabolism of rimantadine are not known .
DDI-DrugBank.d669.s0
DDI-DrugBank.d669.s0.e0_DDI-DrugBank.d669.s0.e1 true concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing and anaphylactoid reactions .
DDI-DrugBank.d680.s5
DDI-DrugBank.d680.s5.e1_DDI-DrugBank.d680.s5.e2 true there have been postmarketing reports of increased inr and prothrombin time in patients receiving proton pump inhibitors , including pantoprazole , and warfarin concomitantly .
DDI-DrugBank.d680.s5.e1_DDI-DrugBank.d680.s5.e0 false there have been postmarketing reports of increased inr and prothrombin time in patients receiving proton pump inhibitors , including pantoprazole , and warfarin concomitantly .
DDI-DrugBank.d680.s5.e2_DDI-DrugBank.d680.s5.e0 false there have been postmarketing reports of increased inr and prothrombin time in patients receiving proton pump inhibitors , including pantoprazole , and warfarin concomitantly .
DDI-DrugBank.d780.s4
DDI-DrugBank.d780.s4.e1_DDI-DrugBank.d780.s4.e0 false cns depressant medications : concurrent use of procaine hydrochloride and cns depressant medications may result in additive depressant effects .
DDI-DrugBank.d780.s4.e1_DDI-DrugBank.d780.s4.e2 true cns depressant medications : concurrent use of procaine hydrochloride and cns depressant medications may result in additive depressant effects .
DDI-DrugBank.d780.s4.e0_DDI-DrugBank.d780.s4.e2 false cns depressant medications : concurrent use of procaine hydrochloride and cns depressant medications may result in additive depressant effects .
DDI-DrugBank.d590.s0
DDI-DrugBank.d590.s0.e1_DDI-DrugBank.d590.s0.e2 false coadministration of tritec with clarithromycin resulted in increased plasma ranitidine concentrations ( 57 % ) , increased plasma bismuth trough concentrations ( 48 % ) , and increased 14- hydroxy- clarithromycin plasma concentrations ( 31 % ) .
DDI-DrugBank.d590.s0.e1_DDI-DrugBank.d590.s0.e3 false coadministration of tritec with clarithromycin resulted in increased plasma ranitidine concentrations ( 57 % ) , increased plasma bismuth trough concentrations ( 48 % ) , and increased 14- hydroxy- clarithromycin plasma concentrations ( 31 % ) .
DDI-DrugBank.d590.s0.e1_DDI-DrugBank.d590.s0.e0 false coadministration of tritec with clarithromycin resulted in increased plasma ranitidine concentrations ( 57 % ) , increased plasma bismuth trough concentrations ( 48 % ) , and increased 14- hydroxy- clarithromycin plasma concentrations ( 31 % ) .
DDI-DrugBank.d590.s0.e2_DDI-DrugBank.d590.s0.e3 false coadministration of tritec with clarithromycin resulted in increased plasma ranitidine concentrations ( 57 % ) , increased plasma bismuth trough concentrations ( 48 % ) , and increased 14- hydroxy- clarithromycin plasma concentrations ( 31 % ) .
DDI-DrugBank.d590.s0.e2_DDI-DrugBank.d590.s0.e0 false coadministration of tritec with clarithromycin resulted in increased plasma ranitidine concentrations ( 57 % ) , increased plasma bismuth trough concentrations ( 48 % ) , and increased 14- hydroxy- clarithromycin plasma concentrations ( 31 % ) .
DDI-DrugBank.d590.s0.e3_DDI-DrugBank.d590.s0.e0 false coadministration of tritec with clarithromycin resulted in increased plasma ranitidine concentrations ( 57 % ) , increased plasma bismuth trough concentrations ( 48 % ) , and increased 14- hydroxy- clarithromycin plasma concentrations ( 31 % ) .
DDI-DrugBank.d623.s3
DDI-DrugBank.d591.s0
DDI-DrugBank.d591.s0.e0_DDI-DrugBank.d591.s0.e1 true ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics , since the toxic effects of these drugs are additive .
DDI-DrugBank.d591.s0.e0_DDI-DrugBank.d591.s0.e2 false ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics , since the toxic effects of these drugs are additive .
DDI-DrugBank.d591.s0.e1_DDI-DrugBank.d591.s0.e2 false ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics , since the toxic effects of these drugs are additive .
DDI-DrugBank.d588.s3
DDI-DrugBank.d588.s3.e0_DDI-DrugBank.d588.s3.e3 false alcohol , barbiturates , and narcotics : the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy .
DDI-DrugBank.d588.s3.e0_DDI-DrugBank.d588.s3.e1 false alcohol , barbiturates , and narcotics : the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy .
DDI-DrugBank.d588.s3.e0_DDI-DrugBank.d588.s3.e2 false alcohol , barbiturates , and narcotics : the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy .
DDI-DrugBank.d588.s3.e3_DDI-DrugBank.d588.s3.e1 false alcohol , barbiturates , and narcotics : the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy .
DDI-DrugBank.d588.s3.e3_DDI-DrugBank.d588.s3.e2 false alcohol , barbiturates , and narcotics : the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy .
DDI-DrugBank.d588.s3.e1_DDI-DrugBank.d588.s3.e2 false alcohol , barbiturates , and narcotics : the hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy .
DDI-DrugBank.d597.s26
DDI-DrugBank.d597.s26.e0_DDI-DrugBank.d597.s26.e2 false warfarin : anticoagulant activity should be monitored , particularly in the first few days after initiating or changing mobic therapy in patients receiving warfarin or similar agents , since these patients are at an increased risk of bleeding .
DDI-DrugBank.d597.s26.e0_DDI-DrugBank.d597.s26.e1 false warfarin : anticoagulant activity should be monitored , particularly in the first few days after initiating or changing mobic therapy in patients receiving warfarin or similar agents , since these patients are at an increased risk of bleeding .
DDI-DrugBank.d597.s26.e2_DDI-DrugBank.d597.s26.e1 false warfarin : anticoagulant activity should be monitored , particularly in the first few days after initiating or changing mobic therapy in patients receiving warfarin or similar agents , since these patients are at an increased risk of bleeding .
DDI-DrugBank.d694.s1
DDI-DrugBank.d572.s2
DDI-DrugBank.d572.s2.e1_DDI-DrugBank.d572.s2.e2 false : the safety and effectiveness of ezetimibe administered with fibrates have not been established .
DDI-DrugBank.d624.s2
DDI-DrugBank.d624.s2.e0_DDI-DrugBank.d624.s2.e1 true some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue .
DDI-DrugBank.d624.s2.e0_DDI-DrugBank.d624.s2.e2 false some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue .
DDI-DrugBank.d624.s2.e1_DDI-DrugBank.d624.s2.e2 false some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue .
DDI-DrugBank.d735.s6
DDI-DrugBank.d613.s0
DDI-DrugBank.d613.s0.e0_DDI-DrugBank.d613.s0.e1 true a study published in 2002 found that vigabatrin causes a statistically significant increase in plasma clearance of carbamazepine .
DDI-DrugBank.d604.s1
DDI-DrugBank.d776.s40
DDI-DrugBank.d776.s40.e0_DDI-DrugBank.d776.s40.e1 false the data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel auc values with fluconazole treatment are likely the result of random variation .
DDI-DrugBank.d776.s40.e0_DDI-DrugBank.d776.s40.e2 false the data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel auc values with fluconazole treatment are likely the result of random variation .
DDI-DrugBank.d776.s40.e1_DDI-DrugBank.d776.s40.e2 false the data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel auc values with fluconazole treatment are likely the result of random variation .
DDI-DrugBank.d576.s7
DDI-DrugBank.d580.s1
DDI-DrugBank.d580.s1.e0_DDI-DrugBank.d580.s1.e1 true however , ketoconazole , a potent inhibitor of cytochrome p450 3a4 , may increase plasma levels of mometasone furoate during concomitant dosing .
DDI-DrugBank.d603.s3
DDI-DrugBank.d603.s3.e1_DDI-DrugBank.d603.s3.e0 false proamatine has been used in patients concomitantly treated with salt-retaining steroid therapy ( i.e. , fludrocortisone acetate ) , with or without salt supplementation .
DDI-DrugBank.d650.s0
DDI-DrugBank.d650.s0.e5_DDI-DrugBank.d650.s0.e6 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e5_DDI-DrugBank.d650.s0.e0 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e5_DDI-DrugBank.d650.s0.e1 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e5_DDI-DrugBank.d650.s0.e2 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e5_DDI-DrugBank.d650.s0.e3 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e5_DDI-DrugBank.d650.s0.e4 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e5_DDI-DrugBank.d650.s0.e7 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e6_DDI-DrugBank.d650.s0.e0 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e6_DDI-DrugBank.d650.s0.e1 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e6_DDI-DrugBank.d650.s0.e2 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e6_DDI-DrugBank.d650.s0.e3 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e6_DDI-DrugBank.d650.s0.e4 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e6_DDI-DrugBank.d650.s0.e7 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e0_DDI-DrugBank.d650.s0.e1 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e0_DDI-DrugBank.d650.s0.e2 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e0_DDI-DrugBank.d650.s0.e3 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e0_DDI-DrugBank.d650.s0.e4 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e0_DDI-DrugBank.d650.s0.e7 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e1_DDI-DrugBank.d650.s0.e2 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e1_DDI-DrugBank.d650.s0.e3 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e1_DDI-DrugBank.d650.s0.e4 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e1_DDI-DrugBank.d650.s0.e7 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e2_DDI-DrugBank.d650.s0.e3 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e2_DDI-DrugBank.d650.s0.e4 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e2_DDI-DrugBank.d650.s0.e7 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e3_DDI-DrugBank.d650.s0.e4 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e3_DDI-DrugBank.d650.s0.e7 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d650.s0.e4_DDI-DrugBank.d650.s0.e7 false dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthines ) or metoclopramide , ordinarily should not be administered concurrently with permax ( a dopamine agonist ) ;
DDI-DrugBank.d669.s1
DDI-DrugBank.d669.s1.e0_DDI-DrugBank.d669.s1.e2 false concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1.e0_DDI-DrugBank.d669.s1.e3 false concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1.e0_DDI-DrugBank.d669.s1.e4 false concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1.e0_DDI-DrugBank.d669.s1.e5 false concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1.e0_DDI-DrugBank.d669.s1.e6 false concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1.e0_DDI-DrugBank.d669.s1.e1 false concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1.e2_DDI-DrugBank.d669.s1.e3 false concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1.e2_DDI-DrugBank.d669.s1.e4 false concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1.e2_DDI-DrugBank.d669.s1.e5 false concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1.e2_DDI-DrugBank.d669.s1.e6 false concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1.e2_DDI-DrugBank.d669.s1.e1 false concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1.e3_DDI-DrugBank.d669.s1.e4 false concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1.e3_DDI-DrugBank.d669.s1.e5 false concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1.e3_DDI-DrugBank.d669.s1.e6 false concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1.e3_DDI-DrugBank.d669.s1.e1 false concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1.e4_DDI-DrugBank.d669.s1.e5 false concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1.e4_DDI-DrugBank.d669.s1.e6 false concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1.e4_DDI-DrugBank.d669.s1.e1 false concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1.e5_DDI-DrugBank.d669.s1.e6 false concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1.e5_DDI-DrugBank.d669.s1.e1 false concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d669.s1.e6_DDI-DrugBank.d669.s1.e1 false concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs , such as amphotericin b , aminoglycosides , bacitracin , polymyxin b , colistin , viomycin , or cisplatin , when indicated , requires careful monitoring .
DDI-DrugBank.d618.s0
DDI-DrugBank.d728.s4
DDI-DrugBank.d700.s4
DDI-DrugBank.d606.s1
DDI-DrugBank.d606.s1.e1_DDI-DrugBank.d606.s1.e2 false sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and veratrum alkaloids .
DDI-DrugBank.d606.s1.e1_DDI-DrugBank.d606.s1.e3 false sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and veratrum alkaloids .
DDI-DrugBank.d606.s1.e1_DDI-DrugBank.d606.s1.e0 false sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and veratrum alkaloids .
DDI-DrugBank.d606.s1.e1_DDI-DrugBank.d606.s1.e4 false sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and veratrum alkaloids .
DDI-DrugBank.d606.s1.e2_DDI-DrugBank.d606.s1.e3 false sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and veratrum alkaloids .
DDI-DrugBank.d606.s1.e2_DDI-DrugBank.d606.s1.e0 false sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and veratrum alkaloids .
DDI-DrugBank.d606.s1.e2_DDI-DrugBank.d606.s1.e4 false sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and veratrum alkaloids .
DDI-DrugBank.d606.s1.e3_DDI-DrugBank.d606.s1.e0 false sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and veratrum alkaloids .
DDI-DrugBank.d606.s1.e3_DDI-DrugBank.d606.s1.e4 false sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and veratrum alkaloids .
DDI-DrugBank.d606.s1.e0_DDI-DrugBank.d606.s1.e4 true sympathomimetics may reduce the antihypertensive effects of methyldopa , mecamylamine , reserpine and veratrum alkaloids .
DDI-DrugBank.d761.s4
DDI-DrugBank.d761.s4.e1_DDI-DrugBank.d761.s4.e0 false xenical inhibited absorption of a vitamin e acetate supplement by approximately 60 % .
DDI-DrugBank.d597.s28
DDI-DrugBank.d597.s28.e0_DDI-DrugBank.d597.s28.e1 false in these subjects , meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time .
DDI-DrugBank.d597.s28.e0_DDI-DrugBank.d597.s28.e2 false in these subjects , meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time .
DDI-DrugBank.d597.s28.e1_DDI-DrugBank.d597.s28.e2 false in these subjects , meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time .
DDI-DrugBank.d761.s0
DDI-DrugBank.d761.s0.e0_DDI-DrugBank.d761.s0.e2 false alcohol : in a multiple-dose study in 30 normal weight subjects , coadministration of xenical and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0.e0_DDI-DrugBank.d761.s0.e3 false alcohol : in a multiple-dose study in 30 normal weight subjects , coadministration of xenical and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0.e0_DDI-DrugBank.d761.s0.e4 false alcohol : in a multiple-dose study in 30 normal weight subjects , coadministration of xenical and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0.e0_DDI-DrugBank.d761.s0.e5 false alcohol : in a multiple-dose study in 30 normal weight subjects , coadministration of xenical and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0.e0_DDI-DrugBank.d761.s0.e1 false alcohol : in a multiple-dose study in 30 normal weight subjects , coadministration of xenical and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0.e2_DDI-DrugBank.d761.s0.e3 false alcohol : in a multiple-dose study in 30 normal weight subjects , coadministration of xenical and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0.e2_DDI-DrugBank.d761.s0.e4 false alcohol : in a multiple-dose study in 30 normal weight subjects , coadministration of xenical and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0.e2_DDI-DrugBank.d761.s0.e5 false alcohol : in a multiple-dose study in 30 normal weight subjects , coadministration of xenical and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0.e2_DDI-DrugBank.d761.s0.e1 false alcohol : in a multiple-dose study in 30 normal weight subjects , coadministration of xenical and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0.e3_DDI-DrugBank.d761.s0.e4 false alcohol : in a multiple-dose study in 30 normal weight subjects , coadministration of xenical and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0.e3_DDI-DrugBank.d761.s0.e5 false alcohol : in a multiple-dose study in 30 normal weight subjects , coadministration of xenical and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0.e3_DDI-DrugBank.d761.s0.e1 false alcohol : in a multiple-dose study in 30 normal weight subjects , coadministration of xenical and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0.e4_DDI-DrugBank.d761.s0.e5 false alcohol : in a multiple-dose study in 30 normal weight subjects , coadministration of xenical and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0.e4_DDI-DrugBank.d761.s0.e1 false alcohol : in a multiple-dose study in 30 normal weight subjects , coadministration of xenical and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d761.s0.e5_DDI-DrugBank.d761.s0.e1 false alcohol : in a multiple-dose study in 30 normal weight subjects , coadministration of xenical and 40 grams of alcohol ( e.g. , approximately 3 glasses of wine ) did not result in alteration of alcohol pharmacokinetics , orlistat pharmacodynamics ( fecal fat excretion ) , or systemic exposure to orlistat .
DDI-DrugBank.d608.s4
DDI-DrugBank.d608.s4.e1_DDI-DrugBank.d608.s4.e0 false caution should be used if tolectin is administered concomitantly with methotrexate .
DDI-DrugBank.d776.s13
DDI-DrugBank.d776.s13.e0_DDI-DrugBank.d776.s13.e2 false cyclosporine : diflucan may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment .
DDI-DrugBank.d776.s13.e0_DDI-DrugBank.d776.s13.e1 false cyclosporine : diflucan may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment .
DDI-DrugBank.d776.s13.e2_DDI-DrugBank.d776.s13.e1 false cyclosporine : diflucan may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment .
DDI-DrugBank.d591.s1
DDI-DrugBank.d588.s8
DDI-DrugBank.d588.s8.e3_DDI-DrugBank.d588.s8.e0 false curariform drugs : diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs ( such as tubocurarine ) the most serious effect would be respiratory depression which could proceed to apnea .
DDI-DrugBank.d588.s8.e3_DDI-DrugBank.d588.s8.e1 false curariform drugs : diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs ( such as tubocurarine ) the most serious effect would be respiratory depression which could proceed to apnea .
DDI-DrugBank.d588.s8.e3_DDI-DrugBank.d588.s8.e2 false curariform drugs : diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs ( such as tubocurarine ) the most serious effect would be respiratory depression which could proceed to apnea .
DDI-DrugBank.d588.s8.e0_DDI-DrugBank.d588.s8.e1 false curariform drugs : diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs ( such as tubocurarine ) the most serious effect would be respiratory depression which could proceed to apnea .
DDI-DrugBank.d588.s8.e0_DDI-DrugBank.d588.s8.e2 false curariform drugs : diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs ( such as tubocurarine ) the most serious effect would be respiratory depression which could proceed to apnea .
DDI-DrugBank.d588.s8.e1_DDI-DrugBank.d588.s8.e2 true curariform drugs : diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs ( such as tubocurarine ) the most serious effect would be respiratory depression which could proceed to apnea .
DDI-DrugBank.d638.s1
DDI-DrugBank.d590.s2
DDI-DrugBank.d590.s2.e1_DDI-DrugBank.d590.s2.e2 false coadministration with a high dose of antacid ( 170 meq ) results in a 28 % decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from tritec .
DDI-DrugBank.d590.s2.e1_DDI-DrugBank.d590.s2.e0 false coadministration with a high dose of antacid ( 170 meq ) results in a 28 % decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from tritec .
DDI-DrugBank.d590.s2.e2_DDI-DrugBank.d590.s2.e0 false coadministration with a high dose of antacid ( 170 meq ) results in a 28 % decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from tritec .
DDI-DrugBank.d780.s5
DDI-DrugBank.d780.s5.e0_DDI-DrugBank.d780.s5.e1 false hyaluronidase : hyaluronidase may increase the diffusion rate of procaine hydrochloride , resulting in a decreased time of onset , but an increase in systemic toxicity .
DDI-DrugBank.d780.s5.e0_DDI-DrugBank.d780.s5.e2 false hyaluronidase : hyaluronidase may increase the diffusion rate of procaine hydrochloride , resulting in a decreased time of onset , but an increase in systemic toxicity .
DDI-DrugBank.d780.s5.e1_DDI-DrugBank.d780.s5.e2 true hyaluronidase : hyaluronidase may increase the diffusion rate of procaine hydrochloride , resulting in a decreased time of onset , but an increase in systemic toxicity .
DDI-DrugBank.d654.s3
DDI-DrugBank.d756.s7
DDI-DrugBank.d756.s7.e0_DDI-DrugBank.d756.s7.e1 false caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine .
DDI-DrugBank.d756.s7.e0_DDI-DrugBank.d756.s7.e2 false caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine .
DDI-DrugBank.d756.s7.e0_DDI-DrugBank.d756.s7.e3 true caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine .
DDI-DrugBank.d756.s7.e1_DDI-DrugBank.d756.s7.e2 false caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine .
DDI-DrugBank.d756.s7.e1_DDI-DrugBank.d756.s7.e3 true caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine .
DDI-DrugBank.d756.s7.e2_DDI-DrugBank.d756.s7.e3 true caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine .
DDI-DrugBank.d602.s5
DDI-DrugBank.d743.s8
DDI-DrugBank.d743.s8.e1_DDI-DrugBank.d743.s8.e2 false due to the chemical similarity of other azole-type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.e1_DDI-DrugBank.d743.s8.e3 false due to the chemical similarity of other azole-type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.e1_DDI-DrugBank.d743.s8.e4 false due to the chemical similarity of other azole-type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.e1_DDI-DrugBank.d743.s8.e5 false due to the chemical similarity of other azole-type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.e1_DDI-DrugBank.d743.s8.e6 false due to the chemical similarity of other azole-type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.e1_DDI-DrugBank.d743.s8.e0 false due to the chemical similarity of other azole-type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.e2_DDI-DrugBank.d743.s8.e3 false due to the chemical similarity of other azole-type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.e2_DDI-DrugBank.d743.s8.e4 false due to the chemical similarity of other azole-type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.e2_DDI-DrugBank.d743.s8.e5 false due to the chemical similarity of other azole-type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.e2_DDI-DrugBank.d743.s8.e6 false due to the chemical similarity of other azole-type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.e2_DDI-DrugBank.d743.s8.e0 false due to the chemical similarity of other azole-type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.e3_DDI-DrugBank.d743.s8.e4 false due to the chemical similarity of other azole-type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.e3_DDI-DrugBank.d743.s8.e5 false due to the chemical similarity of other azole-type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.e3_DDI-DrugBank.d743.s8.e6 false due to the chemical similarity of other azole-type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.e3_DDI-DrugBank.d743.s8.e0 false due to the chemical similarity of other azole-type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.e4_DDI-DrugBank.d743.s8.e5 false due to the chemical similarity of other azole-type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.e4_DDI-DrugBank.d743.s8.e6 false due to the chemical similarity of other azole-type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.e4_DDI-DrugBank.d743.s8.e0 false due to the chemical similarity of other azole-type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.e5_DDI-DrugBank.d743.s8.e6 false due to the chemical similarity of other azole-type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.e5_DDI-DrugBank.d743.s8.e0 false due to the chemical similarity of other azole-type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d743.s8.e6_DDI-DrugBank.d743.s8.e0 false due to the chemical similarity of other azole-type antifungal agents ( including fluconazole , metronidazole , and miconazole ) to ketoconazole , and itraconazole , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions .
DDI-DrugBank.d738.s1
DDI-DrugBank.d738.s1.e0_DDI-DrugBank.d738.s1.e1 false patients with congenital or acquired qt prolongation in a study of the effect of solifenacin on the qt interval in 76 healthy women , the qt prolonging effect appeared less with solifenacin 10 mg than with 30 mg ( three times the maximum recommended dose ) , and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose .
DDI-DrugBank.d738.s1.e0_DDI-DrugBank.d738.s1.e2 false patients with congenital or acquired qt prolongation in a study of the effect of solifenacin on the qt interval in 76 healthy women , the qt prolonging effect appeared less with solifenacin 10 mg than with 30 mg ( three times the maximum recommended dose ) , and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose .
DDI-DrugBank.d738.s1.e0_DDI-DrugBank.d738.s1.e3 false patients with congenital or acquired qt prolongation in a study of the effect of solifenacin on the qt interval in 76 healthy women , the qt prolonging effect appeared less with solifenacin 10 mg than with 30 mg ( three times the maximum recommended dose ) , and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose .
DDI-DrugBank.d738.s1.e1_DDI-DrugBank.d738.s1.e2 false patients with congenital or acquired qt prolongation in a study of the effect of solifenacin on the qt interval in 76 healthy women , the qt prolonging effect appeared less with solifenacin 10 mg than with 30 mg ( three times the maximum recommended dose ) , and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose .
DDI-DrugBank.d738.s1.e1_DDI-DrugBank.d738.s1.e3 false patients with congenital or acquired qt prolongation in a study of the effect of solifenacin on the qt interval in 76 healthy women , the qt prolonging effect appeared less with solifenacin 10 mg than with 30 mg ( three times the maximum recommended dose ) , and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose .
DDI-DrugBank.d738.s1.e2_DDI-DrugBank.d738.s1.e3 false patients with congenital or acquired qt prolongation in a study of the effect of solifenacin on the qt interval in 76 healthy women , the qt prolonging effect appeared less with solifenacin 10 mg than with 30 mg ( three times the maximum recommended dose ) , and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose .
DDI-DrugBank.d648.s5
DDI-DrugBank.d648.s5.e0_DDI-DrugBank.d648.s5.e1 false in vitro , raloxifene did not affect the binding of warfarin , phenytoin , or tamoxifen .
DDI-DrugBank.d648.s5.e0_DDI-DrugBank.d648.s5.e2 false in vitro , raloxifene did not affect the binding of warfarin , phenytoin , or tamoxifen .
DDI-DrugBank.d648.s5.e0_DDI-DrugBank.d648.s5.e3 false in vitro , raloxifene did not affect the binding of warfarin , phenytoin , or tamoxifen .
DDI-DrugBank.d648.s5.e1_DDI-DrugBank.d648.s5.e2 false in vitro , raloxifene did not affect the binding of warfarin , phenytoin , or tamoxifen .
DDI-DrugBank.d648.s5.e1_DDI-DrugBank.d648.s5.e3 false in vitro , raloxifene did not affect the binding of warfarin , phenytoin , or tamoxifen .
DDI-DrugBank.d648.s5.e2_DDI-DrugBank.d648.s5.e3 false in vitro , raloxifene did not affect the binding of warfarin , phenytoin , or tamoxifen .
DDI-DrugBank.d572.s17
DDI-DrugBank.d572.s17.e0_DDI-DrugBank.d572.s17.e1 false in oral ( gavage ) fertility studies of ezetimibe conducted in rats , there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats ( ~7 times the human exposure at 10 mg daily based on auc0 - 24hr for total ezetimibe ) .
DDI-DrugBank.d679.s0
DDI-DrugBank.d679.s0.e0_DDI-DrugBank.d679.s0.e1 true preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole .
DDI-DrugBank.d679.s0.e0_DDI-DrugBank.d679.s0.e2 false preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole .
DDI-DrugBank.d679.s0.e1_DDI-DrugBank.d679.s0.e2 false preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole .
DDI-DrugBank.d596.s4
DDI-DrugBank.d596.s4.e0_DDI-DrugBank.d596.s4.e1 false the elevation of prothrombin time induced by warfarin is not affected by administration of exelon .
DDI-DrugBank.d639.s1
DDI-DrugBank.d773.s5
DDI-DrugBank.d599.s1
DDI-DrugBank.d721.s3
DDI-DrugBank.d721.s3.e0_DDI-DrugBank.d721.s3.e1 false the pharmacokinetic parameters of digoxin are not significantly modified by skelid coadministration .
DDI-DrugBank.d584.s7
DDI-DrugBank.d584.s7.e0_DDI-DrugBank.d584.s7.e1 true furthermore , in patients receiving both drugs , careful monitoring of the inr or pt , and adjustment of the warfarin dosage if indicated are recommended when the oxandrolone dose is changed or discontinued .
DDI-DrugBank.d615.s0
DDI-DrugBank.d615.s0.e0_DDI-DrugBank.d615.s0.e2 true triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e0_DDI-DrugBank.d615.s0.e1 true triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e0_DDI-DrugBank.d615.s0.e3 true triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e0_DDI-DrugBank.d615.s0.e4 true triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e0_DDI-DrugBank.d615.s0.e5 true triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e0_DDI-DrugBank.d615.s0.e6 true triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e0_DDI-DrugBank.d615.s0.e7 true triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e2_DDI-DrugBank.d615.s0.e1 false triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e2_DDI-DrugBank.d615.s0.e3 false triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e2_DDI-DrugBank.d615.s0.e4 false triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e2_DDI-DrugBank.d615.s0.e5 false triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e2_DDI-DrugBank.d615.s0.e6 false triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e2_DDI-DrugBank.d615.s0.e7 false triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e1_DDI-DrugBank.d615.s0.e3 false triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e1_DDI-DrugBank.d615.s0.e4 false triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e1_DDI-DrugBank.d615.s0.e5 false triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e1_DDI-DrugBank.d615.s0.e6 false triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e1_DDI-DrugBank.d615.s0.e7 false triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e3_DDI-DrugBank.d615.s0.e4 false triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e3_DDI-DrugBank.d615.s0.e5 false triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e3_DDI-DrugBank.d615.s0.e6 false triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e3_DDI-DrugBank.d615.s0.e7 false triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e4_DDI-DrugBank.d615.s0.e5 false triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e4_DDI-DrugBank.d615.s0.e6 false triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e4_DDI-DrugBank.d615.s0.e7 false triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e5_DDI-DrugBank.d615.s0.e6 false triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e5_DDI-DrugBank.d615.s0.e7 false triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d615.s0.e6_DDI-DrugBank.d615.s0.e7 false triprolidine may enhance the sedative effects of central nervous system depressants including alcohol , barbiturates , hypnotics , narcotic analgesics , sedatives , and tranquillisers .
DDI-DrugBank.d650.s2
DDI-DrugBank.d650.s2.e0_DDI-DrugBank.d650.s2.e1 false because pergolide mesylate is approximately 90 % bound to plasma proteins , caution should be exercised if pergolide mesylate is coadministered with other drugs known to affect protein binding .
DDI-DrugBank.d690.s3
DDI-DrugBank.d690.s3.e0_DDI-DrugBank.d690.s3.e3 false such occurrences have been reported when propoxyphene was administered to patients on antidepressants , anticonvulsants , or warfarin-like drugs .
DDI-DrugBank.d690.s3.e0_DDI-DrugBank.d690.s3.e1 false such occurrences have been reported when propoxyphene was administered to patients on antidepressants , anticonvulsants , or warfarin-like drugs .
DDI-DrugBank.d690.s3.e0_DDI-DrugBank.d690.s3.e2 false such occurrences have been reported when propoxyphene was administered to patients on antidepressants , anticonvulsants , or warfarin-like drugs .
DDI-DrugBank.d690.s3.e3_DDI-DrugBank.d690.s3.e1 false such occurrences have been reported when propoxyphene was administered to patients on antidepressants , anticonvulsants , or warfarin-like drugs .
DDI-DrugBank.d690.s3.e3_DDI-DrugBank.d690.s3.e2 false such occurrences have been reported when propoxyphene was administered to patients on antidepressants , anticonvulsants , or warfarin-like drugs .
DDI-DrugBank.d690.s3.e1_DDI-DrugBank.d690.s3.e2 false such occurrences have been reported when propoxyphene was administered to patients on antidepressants , anticonvulsants , or warfarin-like drugs .
DDI-DrugBank.d616.s2
DDI-DrugBank.d682.s1
DDI-DrugBank.d682.s1.e1_DDI-DrugBank.d682.s1.e3 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e1_DDI-DrugBank.d682.s1.e4 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e1_DDI-DrugBank.d682.s1.e5 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e1_DDI-DrugBank.d682.s1.e6 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e1_DDI-DrugBank.d682.s1.e7 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e1_DDI-DrugBank.d682.s1.e0 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e1_DDI-DrugBank.d682.s1.e2 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e3_DDI-DrugBank.d682.s1.e4 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e3_DDI-DrugBank.d682.s1.e5 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e3_DDI-DrugBank.d682.s1.e6 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e3_DDI-DrugBank.d682.s1.e7 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e3_DDI-DrugBank.d682.s1.e0 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e3_DDI-DrugBank.d682.s1.e2 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e4_DDI-DrugBank.d682.s1.e5 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e4_DDI-DrugBank.d682.s1.e6 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e4_DDI-DrugBank.d682.s1.e7 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e4_DDI-DrugBank.d682.s1.e0 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e4_DDI-DrugBank.d682.s1.e2 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e5_DDI-DrugBank.d682.s1.e6 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e5_DDI-DrugBank.d682.s1.e7 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e5_DDI-DrugBank.d682.s1.e0 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e5_DDI-DrugBank.d682.s1.e2 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e6_DDI-DrugBank.d682.s1.e7 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e6_DDI-DrugBank.d682.s1.e0 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e6_DDI-DrugBank.d682.s1.e2 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e7_DDI-DrugBank.d682.s1.e0 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e7_DDI-DrugBank.d682.s1.e2 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d682.s1.e0_DDI-DrugBank.d682.s1.e2 false it may also interact with thiazides ( increased thrombocytopenia ) , cyclosporine ( increased nephrotoxicity ) , sulfonylurea agents ( increased hypoglycemic response ) , warfarin ( increased anticoagulant effect ) , methotrexate ( decreased renal excretion of methotrexate ) , phenytoin ( decreased hepatic clearance of phenytoin ) .
DDI-DrugBank.d710.s6
DDI-DrugBank.d710.s6.e1_DDI-DrugBank.d710.s6.e0 false aspirin : rimantadine hcl , 100 mg , was given twice daily fro 13 days to 12 healthy volunteers .
DDI-DrugBank.d704.s0
DDI-DrugBank.d704.s0.e0_DDI-DrugBank.d704.s0.e1 false : the pharmacokinetic and pharmacodynamic interactions between flomax capsules and other alpha-adrenergic blocking agents have not been determined .
DDI-DrugBank.d572.s22
DDI-DrugBank.d572.s22.e0_DDI-DrugBank.d572.s22.e1 false in rabbits treated with ezetimibe , an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day ( 150 times the human exposure at 10 mg daily based on auc0 - 24hr for total ezetimibe ) .
DDI-DrugBank.d713.s4
DDI-DrugBank.d766.s4
DDI-DrugBank.d710.s8
DDI-DrugBank.d668.s0
DDI-DrugBank.d668.s0.e0_DDI-DrugBank.d668.s0.e1 false although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by cyp 3a4 , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism ( increasing serum levels of mifepristone ) .
DDI-DrugBank.d668.s0.e0_DDI-DrugBank.d668.s0.e2 false although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by cyp 3a4 , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism ( increasing serum levels of mifepristone ) .
DDI-DrugBank.d668.s0.e0_DDI-DrugBank.d668.s0.e3 false although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by cyp 3a4 , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism ( increasing serum levels of mifepristone ) .
DDI-DrugBank.d668.s0.e0_DDI-DrugBank.d668.s0.e4 false although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by cyp 3a4 , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism ( increasing serum levels of mifepristone ) .
DDI-DrugBank.d668.s0.e1_DDI-DrugBank.d668.s0.e2 false although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by cyp 3a4 , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism ( increasing serum levels of mifepristone ) .
DDI-DrugBank.d668.s0.e1_DDI-DrugBank.d668.s0.e3 false although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by cyp 3a4 , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism ( increasing serum levels of mifepristone ) .
DDI-DrugBank.d668.s0.e1_DDI-DrugBank.d668.s0.e4 true although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by cyp 3a4 , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism ( increasing serum levels of mifepristone ) .
DDI-DrugBank.d668.s0.e2_DDI-DrugBank.d668.s0.e3 false although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by cyp 3a4 , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism ( increasing serum levels of mifepristone ) .
DDI-DrugBank.d668.s0.e2_DDI-DrugBank.d668.s0.e4 true although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by cyp 3a4 , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism ( increasing serum levels of mifepristone ) .
DDI-DrugBank.d668.s0.e3_DDI-DrugBank.d668.s0.e4 true although specific drug or food interactions with mifepristone have not been studied , on the basis of this drug s metabolism by cyp 3a4 , it is possible that ketoconazole , itraconazole , erythromycin , and grapefruit juice may inhibit its metabolism ( increasing serum levels of mifepristone ) .
DDI-DrugBank.d688.s0
DDI-DrugBank.d688.s0.e0_DDI-DrugBank.d688.s0.e1 false pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs .
DDI-DrugBank.d688.s0.e0_DDI-DrugBank.d688.s0.e2 false pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs .
DDI-DrugBank.d688.s0.e1_DDI-DrugBank.d688.s0.e2 false pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs .
DDI-DrugBank.d737.s2
DDI-DrugBank.d737.s2.e0_DDI-DrugBank.d737.s2.e1 false selegiline : in healthy volunteers ( n= 11 ) , selegiline did not influence the pharmacokinetics of pramipexole .
DDI-DrugBank.d737.s2.e0_DDI-DrugBank.d737.s2.e2 false selegiline : in healthy volunteers ( n= 11 ) , selegiline did not influence the pharmacokinetics of pramipexole .
DDI-DrugBank.d737.s2.e1_DDI-DrugBank.d737.s2.e2 false selegiline : in healthy volunteers ( n= 11 ) , selegiline did not influence the pharmacokinetics of pramipexole .
DDI-DrugBank.d739.s15
DDI-DrugBank.d739.s15.e0_DDI-DrugBank.d739.s15.e1 false it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as phenobarbital or rifampin , are co-administered with montelukast .
DDI-DrugBank.d739.s15.e0_DDI-DrugBank.d739.s15.e2 true it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as phenobarbital or rifampin , are co-administered with montelukast .
DDI-DrugBank.d739.s15.e1_DDI-DrugBank.d739.s15.e2 true it is reasonable to employ appropriate clinical monitoring when potent cytochrome p450 enzyme inducers , such as phenobarbital or rifampin , are co-administered with montelukast .
DDI-DrugBank.d572.s3
DDI-DrugBank.d779.s17
DDI-DrugBank.d752.s11
DDI-DrugBank.d623.s4
DDI-DrugBank.d776.s36
DDI-DrugBank.d776.s36.e0_DDI-DrugBank.d776.s36.e1 true this effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously .
DDI-DrugBank.d776.s36.e0_DDI-DrugBank.d776.s36.e2 false this effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously .
DDI-DrugBank.d776.s36.e1_DDI-DrugBank.d776.s36.e2 false this effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously .
DDI-DrugBank.d776.s20
DDI-DrugBank.d776.s20.e2_DDI-DrugBank.d776.s20.e1 false : because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the qtc interval in patients receiving azole antifungals in conjunction with terfenadine , interaction studies have been performed .
DDI-DrugBank.d736.s5
DDI-DrugBank.d736.s5.e1_DDI-DrugBank.d736.s5.e0 false thiazide drugs may increase the responsiveness of tubocurarine .
DDI-DrugBank.d779.s9
DDI-DrugBank.d779.s9.e0_DDI-DrugBank.d779.s9.e1 true coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended .
DDI-DrugBank.d779.s9.e0_DDI-DrugBank.d779.s9.e2 true coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended .
DDI-DrugBank.d779.s9.e1_DDI-DrugBank.d779.s9.e2 false coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended .
DDI-DrugBank.d688.s1
DDI-DrugBank.d688.s1.e0_DDI-DrugBank.d688.s1.e1 true a pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters ( ~36 % for cmax and ~28 % for auc ) of indinavir .
DDI-DrugBank.d688.s1.e0_DDI-DrugBank.d688.s1.e2 false a pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters ( ~36 % for cmax and ~28 % for auc ) of indinavir .
DDI-DrugBank.d688.s1.e1_DDI-DrugBank.d688.s1.e2 false a pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters ( ~36 % for cmax and ~28 % for auc ) of indinavir .
DDI-DrugBank.d572.s7
DDI-DrugBank.d572.s7.e0_DDI-DrugBank.d572.s7.e1 false gemfibrozil : in a pharmacokinetic study , concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold .
DDI-DrugBank.d572.s7.e0_DDI-DrugBank.d572.s7.e2 false gemfibrozil : in a pharmacokinetic study , concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold .
DDI-DrugBank.d572.s7.e1_DDI-DrugBank.d572.s7.e2 false gemfibrozil : in a pharmacokinetic study , concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold .
DDI-DrugBank.d761.s7
DDI-DrugBank.d761.s7.e0_DDI-DrugBank.d761.s7.e3 false nifedipine ( extended-release tablets ): in 17 normal-weight subjects receiving xenical 120 mg three times a day for 6 days , xenical did not alter the bioavailability of nifedipine ( extended-release tablets ) .
DDI-DrugBank.d761.s7.e0_DDI-DrugBank.d761.s7.e1 false nifedipine ( extended-release tablets ): in 17 normal-weight subjects receiving xenical 120 mg three times a day for 6 days , xenical did not alter the bioavailability of nifedipine ( extended-release tablets ) .
DDI-DrugBank.d761.s7.e0_DDI-DrugBank.d761.s7.e2 false nifedipine ( extended-release tablets ): in 17 normal-weight subjects receiving xenical 120 mg three times a day for 6 days , xenical did not alter the bioavailability of nifedipine ( extended-release tablets ) .
DDI-DrugBank.d761.s7.e3_DDI-DrugBank.d761.s7.e1 false nifedipine ( extended-release tablets ): in 17 normal-weight subjects receiving xenical 120 mg three times a day for 6 days , xenical did not alter the bioavailability of nifedipine ( extended-release tablets ) .
DDI-DrugBank.d761.s7.e3_DDI-DrugBank.d761.s7.e2 false nifedipine ( extended-release tablets ): in 17 normal-weight subjects receiving xenical 120 mg three times a day for 6 days , xenical did not alter the bioavailability of nifedipine ( extended-release tablets ) .
DDI-DrugBank.d761.s7.e1_DDI-DrugBank.d761.s7.e2 false nifedipine ( extended-release tablets ): in 17 normal-weight subjects receiving xenical 120 mg three times a day for 6 days , xenical did not alter the bioavailability of nifedipine ( extended-release tablets ) .
DDI-DrugBank.d690.s0
DDI-DrugBank.d690.s0.e0_DDI-DrugBank.d690.s0.e2 true the cns-depressant effect of propoxyphene is additive with that of other cns depressants , including alcohol .
DDI-DrugBank.d690.s0.e0_DDI-DrugBank.d690.s0.e1 true the cns-depressant effect of propoxyphene is additive with that of other cns depressants , including alcohol .
DDI-DrugBank.d690.s0.e2_DDI-DrugBank.d690.s0.e1 false the cns-depressant effect of propoxyphene is additive with that of other cns depressants , including alcohol .
DDI-DrugBank.d668.s4
DDI-DrugBank.d639.s4
DDI-DrugBank.d783.s2
DDI-DrugBank.d763.s7
DDI-DrugBank.d763.s7.e0_DDI-DrugBank.d763.s7.e1 false ondansetron did not increase blood levels of high-dose methotrexate .
DDI-DrugBank.d713.s0
DDI-DrugBank.d713.s0.e0_DDI-DrugBank.d713.s0.e1 true the concomitant use of sanctura with other anticholinergic agents that produce dry mouth , constipation , and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects .
DDI-DrugBank.d596.s1
DDI-DrugBank.d597.s11
DDI-DrugBank.d597.s11.e0_DDI-DrugBank.d597.s11.e1 false cimetidine : concomitant administration of 200 mg cimetidine qid did not alter the single-dose pharmacokinetics of 30 mg meloxicam .
DDI-DrugBank.d597.s11.e0_DDI-DrugBank.d597.s11.e2 false cimetidine : concomitant administration of 200 mg cimetidine qid did not alter the single-dose pharmacokinetics of 30 mg meloxicam .
DDI-DrugBank.d597.s11.e1_DDI-DrugBank.d597.s11.e2 false cimetidine : concomitant administration of 200 mg cimetidine qid did not alter the single-dose pharmacokinetics of 30 mg meloxicam .
DDI-DrugBank.d687.s1
DDI-DrugBank.d677.s1
DDI-DrugBank.d677.s1.e0_DDI-DrugBank.d677.s1.e1 false as well as atropine and phosphorous insecticides .
DDI-DrugBank.d776.s28
DDI-DrugBank.d776.s28.e0_DDI-DrugBank.d776.s28.e1 false astemizole : the use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome p450 system may be associated with elevations in serum levels of these drugs .
DDI-DrugBank.d776.s28.e0_DDI-DrugBank.d776.s28.e2 false astemizole : the use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome p450 system may be associated with elevations in serum levels of these drugs .
DDI-DrugBank.d776.s28.e1_DDI-DrugBank.d776.s28.e2 true astemizole : the use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome p450 system may be associated with elevations in serum levels of these drugs .
DDI-DrugBank.d784.s7
DDI-DrugBank.d784.s7.e2_DDI-DrugBank.d784.s7.e3 false concurrent ingestion of antacid ( 20 ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7.e2_DDI-DrugBank.d784.s7.e4 false concurrent ingestion of antacid ( 20 ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7.e2_DDI-DrugBank.d784.s7.e5 false concurrent ingestion of antacid ( 20 ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7.e2_DDI-DrugBank.d784.s7.e6 false concurrent ingestion of antacid ( 20 ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7.e2_DDI-DrugBank.d784.s7.e0 false concurrent ingestion of antacid ( 20 ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7.e2_DDI-DrugBank.d784.s7.e1 false concurrent ingestion of antacid ( 20 ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7.e3_DDI-DrugBank.d784.s7.e4 false concurrent ingestion of antacid ( 20 ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7.e3_DDI-DrugBank.d784.s7.e5 false concurrent ingestion of antacid ( 20 ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7.e3_DDI-DrugBank.d784.s7.e6 false concurrent ingestion of antacid ( 20 ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7.e3_DDI-DrugBank.d784.s7.e0 false concurrent ingestion of antacid ( 20 ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7.e3_DDI-DrugBank.d784.s7.e1 false concurrent ingestion of antacid ( 20 ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7.e4_DDI-DrugBank.d784.s7.e5 false concurrent ingestion of antacid ( 20 ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7.e4_DDI-DrugBank.d784.s7.e6 false concurrent ingestion of antacid ( 20 ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7.e4_DDI-DrugBank.d784.s7.e0 false concurrent ingestion of antacid ( 20 ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7.e4_DDI-DrugBank.d784.s7.e1 false concurrent ingestion of antacid ( 20 ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7.e5_DDI-DrugBank.d784.s7.e6 false concurrent ingestion of antacid ( 20 ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7.e5_DDI-DrugBank.d784.s7.e0 false concurrent ingestion of antacid ( 20 ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7.e5_DDI-DrugBank.d784.s7.e1 false concurrent ingestion of antacid ( 20 ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7.e6_DDI-DrugBank.d784.s7.e0 false concurrent ingestion of antacid ( 20 ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7.e6_DDI-DrugBank.d784.s7.e1 false concurrent ingestion of antacid ( 20 ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d784.s7.e0_DDI-DrugBank.d784.s7.e1 false concurrent ingestion of antacid ( 20 ml of antacid containing aluminum hydroxide , magnesium hydroxide , and simethicone ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin .
DDI-DrugBank.d739.s4
DDI-DrugBank.d739.s4.e0_DDI-DrugBank.d739.s4.e2 false montelukast at doses of 100 mg daily dosed to pharmacokinetic steady state : - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg .
DDI-DrugBank.d739.s4.e0_DDI-DrugBank.d739.s4.e3 false montelukast at doses of 100 mg daily dosed to pharmacokinetic steady state : - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg .
DDI-DrugBank.d739.s4.e0_DDI-DrugBank.d739.s4.e1 false montelukast at doses of 100 mg daily dosed to pharmacokinetic steady state : - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg .
DDI-DrugBank.d739.s4.e2_DDI-DrugBank.d739.s4.e3 false montelukast at doses of 100 mg daily dosed to pharmacokinetic steady state : - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg .
DDI-DrugBank.d739.s4.e2_DDI-DrugBank.d739.s4.e1 false montelukast at doses of 100 mg daily dosed to pharmacokinetic steady state : - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg .
DDI-DrugBank.d739.s4.e3_DDI-DrugBank.d739.s4.e1 false montelukast at doses of 100 mg daily dosed to pharmacokinetic steady state : - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg .
DDI-DrugBank.d640.s9
DDI-DrugBank.d640.s9.e1_DDI-DrugBank.d640.s9.e2 false other agents : no clinically important pharmacokinetic interactions occurred when univasc was administered concomitantly with hydrochlorothiazide , digoxin , or cimetidine .
DDI-DrugBank.d640.s9.e1_DDI-DrugBank.d640.s9.e3 false other agents : no clinically important pharmacokinetic interactions occurred when univasc was administered concomitantly with hydrochlorothiazide , digoxin , or cimetidine .
DDI-DrugBank.d640.s9.e1_DDI-DrugBank.d640.s9.e0 false other agents : no clinically important pharmacokinetic interactions occurred when univasc was administered concomitantly with hydrochlorothiazide , digoxin , or cimetidine .
DDI-DrugBank.d640.s9.e2_DDI-DrugBank.d640.s9.e3 false other agents : no clinically important pharmacokinetic interactions occurred when univasc was administered concomitantly with hydrochlorothiazide , digoxin , or cimetidine .
DDI-DrugBank.d640.s9.e2_DDI-DrugBank.d640.s9.e0 false other agents : no clinically important pharmacokinetic interactions occurred when univasc was administered concomitantly with hydrochlorothiazide , digoxin , or cimetidine .
DDI-DrugBank.d640.s9.e3_DDI-DrugBank.d640.s9.e0 false other agents : no clinically important pharmacokinetic interactions occurred when univasc was administered concomitantly with hydrochlorothiazide , digoxin , or cimetidine .
DDI-DrugBank.d678.s4
DDI-DrugBank.d678.s4.e1_DDI-DrugBank.d678.s4.e2 false metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity .
DDI-DrugBank.d678.s4.e1_DDI-DrugBank.d678.s4.e0 false metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity .
DDI-DrugBank.d678.s4.e2_DDI-DrugBank.d678.s4.e0 false metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity .
DDI-DrugBank.d636.s1
DDI-DrugBank.d763.s6
DDI-DrugBank.d577.s1
DDI-DrugBank.d577.s1.e0_DDI-DrugBank.d577.s1.e2 true it has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin .
DDI-DrugBank.d577.s1.e0_DDI-DrugBank.d577.s1.e1 false it has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin .
DDI-DrugBank.d577.s1.e2_DDI-DrugBank.d577.s1.e1 false it has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin .
DDI-DrugBank.d709.s0
DDI-DrugBank.d599.s6
DDI-DrugBank.d599.s6.e0_DDI-DrugBank.d599.s6.e1 true limited published data indicate that gh treatment increases cytochrome p450 ( cp450 ) mediated antipyrine clearance in man .
DDI-DrugBank.d735.s3
DDI-DrugBank.d735.s3.e0_DDI-DrugBank.d735.s3.e2 false sirolimus auc was increased by 21 % with no effect on cmax in the presence of steady-state mycamine compared with sirolimus alone .
DDI-DrugBank.d735.s3.e0_DDI-DrugBank.d735.s3.e1 true sirolimus auc was increased by 21 % with no effect on cmax in the presence of steady-state mycamine compared with sirolimus alone .
DDI-DrugBank.d735.s3.e2_DDI-DrugBank.d735.s3.e1 false sirolimus auc was increased by 21 % with no effect on cmax in the presence of steady-state mycamine compared with sirolimus alone .
DDI-DrugBank.d780.s3
DDI-DrugBank.d668.s1
DDI-DrugBank.d668.s1.e0_DDI-DrugBank.d668.s1.e1 false furthermore , rifampin , dexamethasone , st.
DDI-DrugBank.d610.s0
DDI-DrugBank.d610.s0.e0_DDI-DrugBank.d610.s0.e1 false pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine .
DDI-DrugBank.d610.s0.e0_DDI-DrugBank.d610.s0.e2 false pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine .
DDI-DrugBank.d610.s0.e0_DDI-DrugBank.d610.s0.e3 false pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine .
DDI-DrugBank.d610.s0.e0_DDI-DrugBank.d610.s0.e4 false pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine .
DDI-DrugBank.d610.s0.e1_DDI-DrugBank.d610.s0.e2 false pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine .
DDI-DrugBank.d610.s0.e1_DDI-DrugBank.d610.s0.e3 false pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine .
DDI-DrugBank.d610.s0.e1_DDI-DrugBank.d610.s0.e4 false pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine .
DDI-DrugBank.d610.s0.e2_DDI-DrugBank.d610.s0.e3 false pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine .
DDI-DrugBank.d610.s0.e2_DDI-DrugBank.d610.s0.e4 false pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine .
DDI-DrugBank.d610.s0.e3_DDI-DrugBank.d610.s0.e4 false pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine .
DDI-DrugBank.d727.s1
DDI-DrugBank.d727.s1.e0_DDI-DrugBank.d727.s1.e1 true therefore , use of zidovudine in combination with zerit should be avoided .
DDI-DrugBank.d634.s0
DDI-DrugBank.d634.s0.e2_DDI-DrugBank.d634.s0.e0 false anticoagulants ( oral ): the activity of oral anticoagulants may be potentiated by anti-vitamin-k activity attributed to methimazole .
DDI-DrugBank.d634.s0.e2_DDI-DrugBank.d634.s0.e1 false anticoagulants ( oral ): the activity of oral anticoagulants may be potentiated by anti-vitamin-k activity attributed to methimazole .
DDI-DrugBank.d634.s0.e0_DDI-DrugBank.d634.s0.e1 false anticoagulants ( oral ): the activity of oral anticoagulants may be potentiated by anti-vitamin-k activity attributed to methimazole .
DDI-DrugBank.d641.s1
DDI-DrugBank.d775.s2
DDI-DrugBank.d775.s2.e0_DDI-DrugBank.d775.s2.e1 true evidence of spontaneous recovery from succinylcholine should be observed before the administration of mivacron .
DDI-DrugBank.d648.s6
DDI-DrugBank.d648.s6.e1_DDI-DrugBank.d648.s6.e2 false caution should be used when evista is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6.e1_DDI-DrugBank.d648.s6.e3 false caution should be used when evista is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6.e1_DDI-DrugBank.d648.s6.e4 false caution should be used when evista is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6.e1_DDI-DrugBank.d648.s6.e5 false caution should be used when evista is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6.e1_DDI-DrugBank.d648.s6.e6 false caution should be used when evista is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6.e1_DDI-DrugBank.d648.s6.e0 false caution should be used when evista is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6.e2_DDI-DrugBank.d648.s6.e3 false caution should be used when evista is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6.e2_DDI-DrugBank.d648.s6.e4 false caution should be used when evista is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6.e2_DDI-DrugBank.d648.s6.e5 false caution should be used when evista is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6.e2_DDI-DrugBank.d648.s6.e6 false caution should be used when evista is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6.e2_DDI-DrugBank.d648.s6.e0 false caution should be used when evista is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6.e3_DDI-DrugBank.d648.s6.e4 false caution should be used when evista is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6.e3_DDI-DrugBank.d648.s6.e5 false caution should be used when evista is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6.e3_DDI-DrugBank.d648.s6.e6 false caution should be used when evista is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6.e3_DDI-DrugBank.d648.s6.e0 false caution should be used when evista is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6.e4_DDI-DrugBank.d648.s6.e5 false caution should be used when evista is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6.e4_DDI-DrugBank.d648.s6.e6 false caution should be used when evista is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6.e4_DDI-DrugBank.d648.s6.e0 false caution should be used when evista is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6.e5_DDI-DrugBank.d648.s6.e6 false caution should be used when evista is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6.e5_DDI-DrugBank.d648.s6.e0 false caution should be used when evista is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d648.s6.e6_DDI-DrugBank.d648.s6.e0 false caution should be used when evista is coadministered with other highly protein-bound drugs , such as clofibrate , indomethacin , naproxen , ibuprofen , diazepam , and diazoxide .
DDI-DrugBank.d587.s0
DDI-DrugBank.d587.s0.e1_DDI-DrugBank.d587.s0.e3 false since celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) .
DDI-DrugBank.d587.s0.e1_DDI-DrugBank.d587.s0.e4 false since celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) .
DDI-DrugBank.d587.s0.e1_DDI-DrugBank.d587.s0.e5 false since celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) .
DDI-DrugBank.d587.s0.e1_DDI-DrugBank.d587.s0.e0 false since celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) .
DDI-DrugBank.d587.s0.e1_DDI-DrugBank.d587.s0.e2 true since celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) .
DDI-DrugBank.d587.s0.e3_DDI-DrugBank.d587.s0.e4 false since celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) .
DDI-DrugBank.d587.s0.e3_DDI-DrugBank.d587.s0.e5 false since celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) .
DDI-DrugBank.d587.s0.e3_DDI-DrugBank.d587.s0.e0 false since celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) .
DDI-DrugBank.d587.s0.e3_DDI-DrugBank.d587.s0.e2 false since celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) .
DDI-DrugBank.d587.s0.e4_DDI-DrugBank.d587.s0.e5 false since celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) .
DDI-DrugBank.d587.s0.e4_DDI-DrugBank.d587.s0.e0 false since celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) .
DDI-DrugBank.d587.s0.e4_DDI-DrugBank.d587.s0.e2 false since celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) .
DDI-DrugBank.d587.s0.e5_DDI-DrugBank.d587.s0.e0 false since celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) .
DDI-DrugBank.d587.s0.e5_DDI-DrugBank.d587.s0.e2 false since celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) .
DDI-DrugBank.d587.s0.e0_DDI-DrugBank.d587.s0.e2 true since celontin ( methsuximide ) may interact with concurrently administered antiepileptic drugs , periodic serum level determinations of these drugs may be necessary ( eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital ) .
DDI-DrugBank.d641.s5
DDI-DrugBank.d641.s5.e0_DDI-DrugBank.d641.s5.e3 false in the absence of data regarding potential interaction between alimta and nsaids with longer half-lives , all patients taking these nsaids should interrupt dosing for at least 5 days before , the day of , and 2 days following alimta administration .
DDI-DrugBank.d641.s5.e0_DDI-DrugBank.d641.s5.e1 false in the absence of data regarding potential interaction between alimta and nsaids with longer half-lives , all patients taking these nsaids should interrupt dosing for at least 5 days before , the day of , and 2 days following alimta administration .
DDI-DrugBank.d641.s5.e0_DDI-DrugBank.d641.s5.e2 false in the absence of data regarding potential interaction between alimta and nsaids with longer half-lives , all patients taking these nsaids should interrupt dosing for at least 5 days before , the day of , and 2 days following alimta administration .
DDI-DrugBank.d641.s5.e3_DDI-DrugBank.d641.s5.e1 false in the absence of data regarding potential interaction between alimta and nsaids with longer half-lives , all patients taking these nsaids should interrupt dosing for at least 5 days before , the day of , and 2 days following alimta administration .
DDI-DrugBank.d641.s5.e3_DDI-DrugBank.d641.s5.e2 false in the absence of data regarding potential interaction between alimta and nsaids with longer half-lives , all patients taking these nsaids should interrupt dosing for at least 5 days before , the day of , and 2 days following alimta administration .
DDI-DrugBank.d641.s5.e1_DDI-DrugBank.d641.s5.e2 false in the absence of data regarding potential interaction between alimta and nsaids with longer half-lives , all patients taking these nsaids should interrupt dosing for at least 5 days before , the day of , and 2 days following alimta administration .
DDI-DrugBank.d578.s9
DDI-DrugBank.d578.s9.e0_DDI-DrugBank.d578.s9.e1 true aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia .
DDI-DrugBank.d640.s1
DDI-DrugBank.d640.s1.e0_DDI-DrugBank.d640.s1.e1 false the possibility of hypotensive effects with univasc can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with univasc
DDI-DrugBank.d680.s1
DDI-DrugBank.d680.s1.e0_DDI-DrugBank.d680.s1.e1 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e0_DDI-DrugBank.d680.s1.e2 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e0_DDI-DrugBank.d680.s1.e3 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e0_DDI-DrugBank.d680.s1.e4 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e0_DDI-DrugBank.d680.s1.e5 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e0_DDI-DrugBank.d680.s1.e6 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e0_DDI-DrugBank.d680.s1.e7 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e0_DDI-DrugBank.d680.s1.e8 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e0_DDI-DrugBank.d680.s1.e9 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e1_DDI-DrugBank.d680.s1.e2 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e1_DDI-DrugBank.d680.s1.e3 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e1_DDI-DrugBank.d680.s1.e4 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e1_DDI-DrugBank.d680.s1.e5 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e1_DDI-DrugBank.d680.s1.e6 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e1_DDI-DrugBank.d680.s1.e7 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e1_DDI-DrugBank.d680.s1.e8 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e1_DDI-DrugBank.d680.s1.e9 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e2_DDI-DrugBank.d680.s1.e3 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e2_DDI-DrugBank.d680.s1.e4 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e2_DDI-DrugBank.d680.s1.e5 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e2_DDI-DrugBank.d680.s1.e6 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e2_DDI-DrugBank.d680.s1.e7 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e2_DDI-DrugBank.d680.s1.e8 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e2_DDI-DrugBank.d680.s1.e9 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e3_DDI-DrugBank.d680.s1.e4 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e3_DDI-DrugBank.d680.s1.e5 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e3_DDI-DrugBank.d680.s1.e6 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e3_DDI-DrugBank.d680.s1.e7 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e3_DDI-DrugBank.d680.s1.e8 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e3_DDI-DrugBank.d680.s1.e9 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e4_DDI-DrugBank.d680.s1.e5 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e4_DDI-DrugBank.d680.s1.e6 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e4_DDI-DrugBank.d680.s1.e7 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e4_DDI-DrugBank.d680.s1.e8 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e4_DDI-DrugBank.d680.s1.e9 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e5_DDI-DrugBank.d680.s1.e6 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e5_DDI-DrugBank.d680.s1.e7 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e5_DDI-DrugBank.d680.s1.e8 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e5_DDI-DrugBank.d680.s1.e9 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e6_DDI-DrugBank.d680.s1.e7 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e6_DDI-DrugBank.d680.s1.e8 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e6_DDI-DrugBank.d680.s1.e9 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e7_DDI-DrugBank.d680.s1.e8 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e7_DDI-DrugBank.d680.s1.e9 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d680.s1.e8_DDI-DrugBank.d680.s1.e9 false based on studies evaluating possible interactions of pantoprazole with other drugs , no dosage adjustment is needed with concomitant use of the following : theophylline , cisapride , antipyrine , caffeine , carbamazepine , diazepam ( and its active metabolite , desmethyldiazepam ) , diclofenac , naproxen , piroxicam , digoxin , ethanol , glyburide , an oral contraceptive ( levonorgestrel/ethinyl estradiol ) , metoprolol , nifedipine , phenytoin , warfarin , midazolam , clarithromycin , metronidazole , or amoxicillin .
DDI-DrugBank.d610.s6
DDI-DrugBank.d761.s10
DDI-DrugBank.d761.s10.e0_DDI-DrugBank.d761.s10.e3 false pravastatin : in a 2-way crossover study of 24 normal-weight , mildly hypercholesterolemic patients receiving xenical 120 mg three times a day for 6 days , xenical did not affect the pharmacokinetics of pravastatin .
DDI-DrugBank.d761.s10.e0_DDI-DrugBank.d761.s10.e1 false pravastatin : in a 2-way crossover study of 24 normal-weight , mildly hypercholesterolemic patients receiving xenical 120 mg three times a day for 6 days , xenical did not affect the pharmacokinetics of pravastatin .
DDI-DrugBank.d761.s10.e0_DDI-DrugBank.d761.s10.e2 false pravastatin : in a 2-way crossover study of 24 normal-weight , mildly hypercholesterolemic patients receiving xenical 120 mg three times a day for 6 days , xenical did not affect the pharmacokinetics of pravastatin .
DDI-DrugBank.d761.s10.e3_DDI-DrugBank.d761.s10.e1 false pravastatin : in a 2-way crossover study of 24 normal-weight , mildly hypercholesterolemic patients receiving xenical 120 mg three times a day for 6 days , xenical did not affect the pharmacokinetics of pravastatin .
DDI-DrugBank.d761.s10.e3_DDI-DrugBank.d761.s10.e2 false pravastatin : in a 2-way crossover study of 24 normal-weight , mildly hypercholesterolemic patients receiving xenical 120 mg three times a day for 6 days , xenical did not affect the pharmacokinetics of pravastatin .
DDI-DrugBank.d761.s10.e1_DDI-DrugBank.d761.s10.e2 false pravastatin : in a 2-way crossover study of 24 normal-weight , mildly hypercholesterolemic patients receiving xenical 120 mg three times a day for 6 days , xenical did not affect the pharmacokinetics of pravastatin .
DDI-DrugBank.d608.s0
DDI-DrugBank.d608.s0.e0_DDI-DrugBank.d608.s0.e1 false the in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin , and tolmetin does not alter the prothrombin time of normal volunteers .
DDI-DrugBank.d608.s0.e0_DDI-DrugBank.d608.s0.e2 false the in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin , and tolmetin does not alter the prothrombin time of normal volunteers .
DDI-DrugBank.d608.s0.e1_DDI-DrugBank.d608.s0.e2 false the in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin , and tolmetin does not alter the prothrombin time of normal volunteers .
DDI-DrugBank.d715.s1
DDI-DrugBank.d715.s1.e1_DDI-DrugBank.d715.s1.e2 false concurrent use of demser with alcohol or other cns depressants can increase their sedative effects .
DDI-DrugBank.d715.s1.e1_DDI-DrugBank.d715.s1.e0 false concurrent use of demser with alcohol or other cns depressants can increase their sedative effects .
DDI-DrugBank.d715.s1.e2_DDI-DrugBank.d715.s1.e0 false concurrent use of demser with alcohol or other cns depressants can increase their sedative effects .
DDI-DrugBank.d572.s5
DDI-DrugBank.d572.s5.e0_DDI-DrugBank.d572.s5.e1 true co-administration of zetia with fibrates is not recommended until use in patients is studied .
DDI-DrugBank.d656.s1
DDI-DrugBank.d656.s1.e2_DDI-DrugBank.d656.s1.e3 false although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with coumarin-type anticoagulants have been reported with feldene since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin-type anticoagulants and other highly protein-bound drugs .
DDI-DrugBank.d656.s1.e2_DDI-DrugBank.d656.s1.e0 false although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with coumarin-type anticoagulants have been reported with feldene since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin-type anticoagulants and other highly protein-bound drugs .
DDI-DrugBank.d656.s1.e2_DDI-DrugBank.d656.s1.e1 false although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with coumarin-type anticoagulants have been reported with feldene since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin-type anticoagulants and other highly protein-bound drugs .
DDI-DrugBank.d656.s1.e2_DDI-DrugBank.d656.s1.e4 false although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with coumarin-type anticoagulants have been reported with feldene since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin-type anticoagulants and other highly protein-bound drugs .
DDI-DrugBank.d656.s1.e3_DDI-DrugBank.d656.s1.e0 false although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with coumarin-type anticoagulants have been reported with feldene since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin-type anticoagulants and other highly protein-bound drugs .
DDI-DrugBank.d656.s1.e3_DDI-DrugBank.d656.s1.e1 false although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with coumarin-type anticoagulants have been reported with feldene since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin-type anticoagulants and other highly protein-bound drugs .
DDI-DrugBank.d656.s1.e3_DDI-DrugBank.d656.s1.e4 true although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with coumarin-type anticoagulants have been reported with feldene since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin-type anticoagulants and other highly protein-bound drugs .
DDI-DrugBank.d656.s1.e0_DDI-DrugBank.d656.s1.e1 false although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with coumarin-type anticoagulants have been reported with feldene since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin-type anticoagulants and other highly protein-bound drugs .
DDI-DrugBank.d656.s1.e0_DDI-DrugBank.d656.s1.e4 false although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with coumarin-type anticoagulants have been reported with feldene since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin-type anticoagulants and other highly protein-bound drugs .
DDI-DrugBank.d656.s1.e1_DDI-DrugBank.d656.s1.e4 false although this has not occurred in in vitro studies with coumarin-type anticoagulants , interactions with coumarin-type anticoagulants have been reported with feldene since marketing , therefore , physicians should closely monitor patients for a change in dosage requirements when administering feldene to patients on coumarin-type anticoagulants and other highly protein-bound drugs .
DDI-DrugBank.d763.s3
DDI-DrugBank.d763.s3.e0_DDI-DrugBank.d763.s3.e1 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e0_DDI-DrugBank.d763.s3.e2 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e0_DDI-DrugBank.d763.s3.e3 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e0_DDI-DrugBank.d763.s3.e4 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e0_DDI-DrugBank.d763.s3.e5 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e0_DDI-DrugBank.d763.s3.e6 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e0_DDI-DrugBank.d763.s3.e7 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e1_DDI-DrugBank.d763.s3.e2 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e1_DDI-DrugBank.d763.s3.e3 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e1_DDI-DrugBank.d763.s3.e4 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e1_DDI-DrugBank.d763.s3.e5 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e1_DDI-DrugBank.d763.s3.e6 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e1_DDI-DrugBank.d763.s3.e7 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e2_DDI-DrugBank.d763.s3.e3 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e2_DDI-DrugBank.d763.s3.e4 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e2_DDI-DrugBank.d763.s3.e5 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e2_DDI-DrugBank.d763.s3.e6 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e2_DDI-DrugBank.d763.s3.e7 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e3_DDI-DrugBank.d763.s3.e4 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e3_DDI-DrugBank.d763.s3.e5 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e3_DDI-DrugBank.d763.s3.e6 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e3_DDI-DrugBank.d763.s3.e7 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e4_DDI-DrugBank.d763.s3.e5 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e4_DDI-DrugBank.d763.s3.e6 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e4_DDI-DrugBank.d763.s3.e7 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e5_DDI-DrugBank.d763.s3.e6 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e5_DDI-DrugBank.d763.s3.e7 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d763.s3.e6_DDI-DrugBank.d763.s3.e7 false phenytoin , carbamazepine , and rifampicin : in patients treated with potent inducers of cyp3a4 ( i.e. , phenytoin , carbamazepine , and rifampicin ) , the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased .
DDI-DrugBank.d776.s33
DDI-DrugBank.d776.s33.e0_DDI-DrugBank.d776.s33.e1 false tacrolimus : there have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered .
DDI-DrugBank.d776.s33.e0_DDI-DrugBank.d776.s33.e2 false tacrolimus : there have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered .
DDI-DrugBank.d776.s33.e1_DDI-DrugBank.d776.s33.e2 true tacrolimus : there have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered .
DDI-DrugBank.d597.s10
DDI-DrugBank.d627.s4
DDI-DrugBank.d627.s4.e0_DDI-DrugBank.d627.s4.e1 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e0_DDI-DrugBank.d627.s4.e2 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e0_DDI-DrugBank.d627.s4.e3 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e0_DDI-DrugBank.d627.s4.e4 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e0_DDI-DrugBank.d627.s4.e5 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e0_DDI-DrugBank.d627.s4.e6 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e0_DDI-DrugBank.d627.s4.e7 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e0_DDI-DrugBank.d627.s4.e9 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e0_DDI-DrugBank.d627.s4.e8 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e1_DDI-DrugBank.d627.s4.e2 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e1_DDI-DrugBank.d627.s4.e3 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e1_DDI-DrugBank.d627.s4.e4 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e1_DDI-DrugBank.d627.s4.e5 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e1_DDI-DrugBank.d627.s4.e6 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e1_DDI-DrugBank.d627.s4.e7 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e1_DDI-DrugBank.d627.s4.e9 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e1_DDI-DrugBank.d627.s4.e8 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e2_DDI-DrugBank.d627.s4.e3 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e2_DDI-DrugBank.d627.s4.e4 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e2_DDI-DrugBank.d627.s4.e5 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e2_DDI-DrugBank.d627.s4.e6 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e2_DDI-DrugBank.d627.s4.e7 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e2_DDI-DrugBank.d627.s4.e9 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e2_DDI-DrugBank.d627.s4.e8 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e3_DDI-DrugBank.d627.s4.e4 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e3_DDI-DrugBank.d627.s4.e5 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e3_DDI-DrugBank.d627.s4.e6 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e3_DDI-DrugBank.d627.s4.e7 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e3_DDI-DrugBank.d627.s4.e9 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e3_DDI-DrugBank.d627.s4.e8 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e4_DDI-DrugBank.d627.s4.e5 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e4_DDI-DrugBank.d627.s4.e6 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e4_DDI-DrugBank.d627.s4.e7 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e4_DDI-DrugBank.d627.s4.e9 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e4_DDI-DrugBank.d627.s4.e8 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e5_DDI-DrugBank.d627.s4.e6 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e5_DDI-DrugBank.d627.s4.e7 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e5_DDI-DrugBank.d627.s4.e9 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e5_DDI-DrugBank.d627.s4.e8 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e6_DDI-DrugBank.d627.s4.e7 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e6_DDI-DrugBank.d627.s4.e9 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e6_DDI-DrugBank.d627.s4.e8 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e7_DDI-DrugBank.d627.s4.e9 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e7_DDI-DrugBank.d627.s4.e8 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d627.s4.e9_DDI-DrugBank.d627.s4.e8 false while no formal drug interaction studies have been performed , the following concomitant drugs were used in at least 10 % of patients in either or both sj grens efficacy studies : acetylsalicylic acid , artificial tears , calcium , conjugated estrogens , hydroxychloroquine sulfate , ibuprofen , levothyroxine sodium , medroxyprogesterone acetate , methotrexate , multivitamins , naproxen , omeprazole , paracetamol , and prednisone .
DDI-DrugBank.d572.s31
DDI-DrugBank.d597.s17
DDI-DrugBank.d597.s17.e0_DDI-DrugBank.d597.s17.e1 false furosemide : single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of meloxicam .
DDI-DrugBank.d676.s1
DDI-DrugBank.d781.s9
DDI-DrugBank.d776.s41
DDI-DrugBank.d776.s41.e0_DDI-DrugBank.d776.s41.e1 true while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism .
DDI-DrugBank.d776.s41.e0_DDI-DrugBank.d776.s41.e2 true while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism .
DDI-DrugBank.d776.s41.e0_DDI-DrugBank.d776.s41.e3 false while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism .
DDI-DrugBank.d776.s41.e0_DDI-DrugBank.d776.s41.e4 false while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism .
DDI-DrugBank.d776.s41.e0_DDI-DrugBank.d776.s41.e5 false while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism .
DDI-DrugBank.d776.s41.e1_DDI-DrugBank.d776.s41.e2 false while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism .
DDI-DrugBank.d776.s41.e1_DDI-DrugBank.d776.s41.e3 false while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism .
DDI-DrugBank.d776.s41.e1_DDI-DrugBank.d776.s41.e4 false while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism .
DDI-DrugBank.d776.s41.e1_DDI-DrugBank.d776.s41.e5 false while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism .
DDI-DrugBank.d776.s41.e2_DDI-DrugBank.d776.s41.e3 false while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism .
DDI-DrugBank.d776.s41.e2_DDI-DrugBank.d776.s41.e4 false while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism .
DDI-DrugBank.d776.s41.e2_DDI-DrugBank.d776.s41.e5 false while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism .
DDI-DrugBank.d776.s41.e3_DDI-DrugBank.d776.s41.e4 false while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism .
DDI-DrugBank.d776.s41.e3_DDI-DrugBank.d776.s41.e5 false while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism .
DDI-DrugBank.d776.s41.e4_DDI-DrugBank.d776.s41.e5 false while there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism .
